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Abstract 
 
Fungal Aspergillus species cause invasive and chronic disease in humans and other animals, 
mostly due to the ubiquitous Aspergillus fumigatus, and triazole therapeutics are the first line 
antifungal defence. However, in the past decade there has been a global increase in disease due 
to “cryptic” Aspergillus species, and azole resistance development amongst A. fumigatus and 
cryptic Aspergillus species has complicated treatment. In particular, fungal infections due to 
Aspergillus viridinutans species complex (AVSC) members are being increasingly reported in 
human and veterinary medicine. Invasive upper respiratory tract infection due to A. felis in cats 
has been the most commonly reported syndrome. Although the first member of the complex, 
A. viridinutans sensu stricto was discovered in Australia in 1954, the ecological niche and 
prevalence of other Aspergillus viridinutans species complex members in Australia, including 
A. felis, has not been investigated. Additionally, the most common Aspergillus species causing 
avian aspergillosis, commonly affected animal species, in Australia is unknown. The 
prevalence of and risk of exposure to azole resistant A. fumigatus (ARAF) due to cyp51A 
mutations in clinical and environmental isolates in Australia is also largely unknown. This 
thesis investigates cryptic and common Aspergillus species belonging to A. section Fumigati; 
their prevalence in Australia and virulence factors affecting the efficacy of the most commonly 
used antifungal therapeutics, triazole therapeutics. 
 
An environmental investigation for cryptic fungal species, with a focus on AVSC members in 
the Australian environment is documented, and the discovery of a new fungal species within 
the AVSC is described. Soil and air (Merck Millipore MAS-100 air sampler) samples were 
collected from yards and gardens of 8 Australian homes where cats diagnosed with aspergillosis 
due to Aspergillus viridinutans species complex members lived (NSW 5, Vic 2, ACT 1), and 
from the Mornington Peninsula region in VIC, where A. viridinutans sensu stricto was 
originally isolated in the 1950’s. Soil samples were diluted, heat treated, and soil and air 
samples were cultured on specialised agar for up to 3 weeks at 37 oC. Cultures with 
morphological features consistent with Aspergillus species underwent DNA extraction, PCR 
and sequencing of the internal transcribed spacer (ITS) region and partial beta tubulin gene 
(BenA) for species identification. Isolates belonging to the AVSC then underwent further 
characterisation including growth on multiple agar types and at varying temperatures, PCR and 
sequencing of the calmodulin (CalM), minichromosome maintenance factor 7 (MCM7), actin 
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and RNA polymerase II genes (RPB2) as well as extrolite extraction and analysis. Of 104 
isolates recovered, 61% were A. fumigatus, 9% were AVSC members and 30% were other 
Aspergillus species, including 6 known human and animal pathogenic species (A. fischeri, A. 
thermomutatus, A. lentulus, A. laciniosus, A. fumisynnematus and A. hiratsukae). AVSC 
members were not isolated from the home environments of cats; however A. felis-clade isolates 
were recovered from the Mornington Peninsula (Frankston, Victoria) where a new fungal 
species belonging to the complex was also isolated, named A. frankstonensis. Although the 
prevalence of other cryptic and pathogenic Aspergillus species was common, the risk of direct 
environmental exposure to AVSC members in areas where humans and cats co-habitate in 
Australia is low, and they appear to have a particular environmental niche in Frankston, 
Victoria. 
 
The most common cause of avian aspergillosis amongst captive birds in Australia is also 
described. Thirty fungal isolates from 30 birds with confirmed avian aspergillosis were 
received from zoological parks (NSW 23, SA 3), poultry farms (NSW 3) and private practice 
(Qld 1). All cultures had morphological features consistent with Aspergillus species and 
underwent DNA extraction, PCR and sequencing of the ITS region and partial BenA gene for 
identification to species level. A. fumigatus is identified as the most common cause of avian 
aspergillosis in captive birds in Australia (87%). A. restrictus is also identified here for the first 
time as a cause of avian aspergillosis. A. flavus and A. nidulans were also agents of disease. 
Cryptic Aspergillus species were not found to cause disease in captive birds in Australia. 
 
The prevalence of azole resistance amongst A. fumigatus isolates from clinical (human and 
veterinary) and environmental (agricultural and domestic) samples in Australia is documented 
over two studies. The first study investigated antifungal susceptibility profiles in veterinary 
isolates of A. fumigatus from dogs (n=46) and cats (n=4) with fungal rhino-sinusitis in Australia 
(n=33), the USA (n=10) and Belgium (n=7). Itraconazole resistance was detected in one 
Australian isolate sampled from a dog in the early 1990’s. Cyp51A sequencing of this isolate 
revealed the F46Y single point mutation; however this mutation has not been confirmed to 
confer azole resistance. There was a low prevalence of ARAF in Australian, USA and Belgium 
veterinary isolates, and no evidence of emerging azole resistant A. fumigatus in veterinary 
isolates. The second study investigates azole resistance amongst both Australian clinical and 
environmental isolates. The identities of 354 A. fumigatus isolates (185 environmental [64 azole 
exposed, 121 azole naïve], 21 veterinary [14 avian, 5 canine, 2 feline] and 148 human clinical 
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isolates) were confirmed by sequencing of the partial BenA gene and isolates screened for azole 
susceptibility using a commercial test kit (VIPcheck™). Antifungal susceptibility was tested 
for any isolates demonstrating resistance (n=8) as well as non-resistant controls (n=192) using 
a commercially available microdilution assay (Sensititre™ YeastOne™ YO10), which 
confirmed azole resistance in three isolates of human origin. Cyp51A sequencing of resistant 
isolates revealed the cyp51A tandem repeat (TR) and single point mutation TR34/L98H in one 
multi-azole resistant isolate, and two itraconazole and posaconazole resistant isolates 
harbouring the G54R single point mutation. The prevalence of ARAF in Australia was low, 
detected in only 0.85% of all isolates tested (3/354), and was associated with mutations in the 
cyp51A gene. 
 
Investigation of antifungal susceptibility testing and amplification of the cyp51A gene in cryptic 
AVSC members is described. A total of 56 AVSC isolates of both environmental (n=26), 
clinical (7 human and 19 veterinary) and unknown (n=4) origins were examined. DNA 
extraction and amplification of the cyp51A gene using novel degenerate primers, mircobroth 
dilution antifungal testing (CLSI reference method (n=37)) and cyp51A crystal structure protein 
modelling based on Saccharomyces cerevisiae were performed. CLSI testing detected very 
high minimum inhibitory concentrations (MICs) to azoles in 84% of isolates. Compared to the 
wild-type A. fumigatus cyp51A gene, high rates of cyp51A mutations were detected in the 
cohort. Cyp51A protein homology modelling of mutations unique to isolates with high 
minimum inhibitory concentrations to azole drugs tested (G138C/T215S; S197C/Q340R; 
A63S/L327P/V396A; A103T/V101L/A234V/I360V/V428I/G505R/Q423D/F478V) did not 
significantly change the overall protein structure to confer resistance. 
 
This program of research has furthered our understanding of the epidemiology of common and 
cryptic pathogenic Aspergillus species causing disease in humans and other animals in 
Australia, including aspects of disease pathogenesis in cats, and causes of treatment failure, 
including mechanisms of azole resistance in A. fumigatus and cryptic species of the AVSC. Key 
findings include a moderate risk of exposure to known pathogenic and cryptic Aspergillus 
species, but a low risk of exposure to AVSC members in indoor and outdoor domestic 
environments in Australia; an environmental niche for AVSC members in Frankston, Australia; 
the discovery of a new cryptic A. sect. Fumigati species within the AVSC, A. frankstonensis 
present at least in Australia and has demonstrated high minimum inhibitory concentration 
values to triazole drugs; A. fumigatus as the most common cause of avian aspergillosis in 
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Australia with no cryptic species infections identified; A. restrictus as a pathogenic agent of 
avian aspergillosis; a low prevalence of ARAF amongst Australian isolates from clinical (human 
and veterinary) and environmental origins; cyp51A sequencing in cryptic AVSC members; and 
antifungal susceptibility profiles of AVSC members. This research represents an important step 
in our understanding of one-health Aspergillus species pathogens from clinical and 
environmental settings, namely the importance of screening for both cryptic and azole resistant 
A. sect. Fumigati species. 
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Chapter 1. Introduction 
 
1.1 Introduction 
 
Aspergillosis, an infection with Aspergillus fungal species, can present as a variety of disease 
forms from non-invasive localised to invasive focal or invasive disseminated infections. 
Antifungal azole drugs are first line therapeutics for this disease. In the past 20 years 
discoveries in the field of mycology have furthered our knowledge of pathogenic Aspergillus 
species and the efficacy of first line of defence azole therapeutics. These discoveries helped 
highlight some of the causes of treatment failure amongst aspergillosis patients. 
 
Advances in molecular identification techniques and polyphasic taxonomy have led to the 
recognition of previously unknown and unrecognised Aspergillus species as opportunistic 
pathogens (Hong et al., 2005, Samson et al., 2007, Samson et al., 2014). This advancement has 
identified “cryptic” Aspergillus species, previously mistakenly identified as Aspergillus 
fumigatus, as a cause of disease in humans and other animal species. Correct identification of 
cryptic species is important as cryptic species infections are often associated with invasive 
disease unresponsive to common antifungal therapies, with a high mortality rate (Alhambra et 
al., 2008, Vinh et al., 2009a, Vinh et al., 2009b, Coelho et al., 2011, Barrs et al., 2013, 
Alastruey-Izquierdo et al., 2014), particularly cryptic species belonging to the Aspergillus 
viridinutans species complex (AVSC). These fungi cause invasive disease in humans (Balajee 
et al., 2006, Alcazar-Fuoli et al., 2008, Vinh et al., 2009a, Vinh et al., 2009b, Sugui et al., 2010, 
Posteraro et al., 2011, Coelho et al., 2011, Gyotoku et al., 2012, Andersen et al., 2012, 
Escribano et al., 2013, Barrs et al., 2013, Peláez et al., 2013, Alastruey-Izquierdo et al., 2013, 
Sugui et al., 2014, Nováková et al., 2014, Tamiya et al., 2015) and interestingly are the most 
commonly reported cause of invasive sino-orbital aspergillosis in cats, with most cases reported 
in Australia and due to the AVSC member A. felis (Barrs et al., 2012, Barrs et al., 2013). This 
disease in cats has a high mortality rate, with the largest study reporting a 92% mortality rate 
(Barrs et al., 2012). Although studies have documented the discovery of A. felis in the 
environment in several global locations (Barrs et al., 2013, Nováková et al., 2014, Gonçalves 
et al., 2016), its prevalence, and those of other AVSC and cryptic Aspergillus species in 
Australia, is largely unknown. 
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Cryptic species are not however the only threat to aspergillosis treatment and prognosis. Since 
first reported in 1997 (Denning DW et al., 1997), azole resistant A. fumigatus isolates have 
been increasingly identified amongst clinical and environmental isolates throughout the world. 
This is particularly concerning as antifungal therapeutic choices are limited, with azoles being 
one of the few approved oral antifungal treatments available for aspergillosis (Patterson et al., 
2016). While azole resistant A. fumigatus has been reported in isolates from Australian human 
patients (Kidd et al., 2015), no large-scale surveillance studies have investigated clinical and 
environmental isolates of A. fumigatus. 
 
My research began as a yearlong research project I completed as an undergraduate Bachelor of 
Veterinary Science student. Under the supervision of a Small Animal Medicine Specialist, 
Professor Vanessa Barrs, I began researching the most common cause of aspergillosis amongst 
dogs in Australia using molecular fungal identification techniques. Over the course of the year 
this project developed into a multicentre international collaboration, and my interest in 
veterinary research and fungal pathogens in animals and humans was only further enhanced. I 
was exposed to clinical examination and investigation of dogs and cats with aspergillosis 
performed at the University Veterinary Teaching Hospital Sydney and was able to assist with 
diagnosis through application of my newly acquired technical skills. My project determined 
that the most common cause of upper respiratory tract aspergillosis in dogs was A. fumigatus, 
and that the rate of cryptic species causing infection in dogs was interestingly much lower (2%) 
than that of cats, where 65% of upper respiratory tract aspergillosis infections involve the sino-
orbital structures, and 100% of these reported sino-orbital infections are caused by cryptic 
Aspergillus species (Talbot et al., 2014, Barrs and Talbot, 2014). The marked differences in 
disease presentation I had seen between dogs and cats, differences in the aetiological agent of 
infection, and poor clinical outcomes experienced by both groups cemented my desire to 
continue research into the pathogenesis of this disease, focusing on the pathogen-environment 
interaction, and why antifungal therapies may not be curative. 
 
The overall objective of my research was to determine the prevalence of common and cryptic 
Aspergillus one-health pathogens in Australia, the environmental niche of specific agents of 
aspergillosis in cats in Australia (particularly AVSC members) and antifungal susceptibility 
patterns in clinical and environmental A. sect. Fumigati isolates (particularly A. fumigatus and 
AVSC members). Specific aims were to investigate the environmental prevalence of cryptic 
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Aspergillus species in Australia (Chapter 3), aetiological agent/s of avian aspergillosis in 
captive birds in Australia (Chapter 4), the prevalence of azole resistant A. fumigatus amongst 
Australian environmental and clinical isolates (Chapters 5, 6) and to further examine azole 
susceptibility profiles and potential causes of high minimum inhibitory concentrations (MICs) 
to antifungal azoles in the cryptic AVSC members (Chapter 7). To achieve this, I collected 
environmental (Chapters 3 and 6) and clinical (Chapters 4 - 6) Aspergillus species isolates from 
multiple locations in Australia. I also spent four months at the Westerdijk Institute in the 
Netherlands where I accessed their collection of AVSC isolates, for further examination. 
 
In Chapter 3, an environmental investigation for cryptic Aspergillus species in Australia is 
described. The specific aim of this study was to investigate the Australian environmental 
prevalence of cryptic Aspergillus species causing infection in cats (members of the AVSC), as 
most global reports of feline upper respiratory tract aspergillosis (URTA) were from Australia, 
and the risk of environmental exposure to animals including humans was unknown; so the 
investigation included sampling air and substrates from the homes of cats with confirmed 
URTA. Additionally, samples were collected from a nature reserve in Frankston, Victoria, 
Australia because this was where the founding member of this complex, A. viridinutans, was 
discovered in the 1950s. Aspergillus species isolated from samples were identified based on 
phenotypic and molecular methods. This revealed common and cryptic pathogenic Aspergillus 
species were common in domestic Australian environments, but interestingly AVSC members 
were only isolated from Frankston. To further characterise the AVSC isolates I found in the 
Australian environment I visited the Westerdijk Institute in Utrecht, the Netherlands, funded 
by an Endeavour Research Fellowship from the Australian Government. There further 
analysing the isolates using polyphasic taxonomy with Professor Robert Samson and Dr Jos 
Houbraken, I discovered a novel fungal species within the AVSC, A. frankstonensis. 
 
This visit also allowed me to further examine all AVSC isolates in the Westerdijk culture 
collection in addition to my own (from Chapter 3) and to investigate potential defence 
mechanisms. Clinical investigations had shown that infections due to these species were often 
non-responsive to antifungal azole therapies and it was hypothesised this could be due to 
mutations in the cyp51A gene as has been increasingly detected in A. fumigatus species. This 
included amplification of the cyp51A gene (the target gene of azole drugs), and several novel 
cyp51A mutations discovered are described in Chapter 7. I also  
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visited Professor Jens Frisvad of the Technical University of Denmark to use high-performance 
liquid chromatography (HPLC) to analyse the secondary metabolite profiles of my new species 
(Chapter 3). Kindly, the Westerdijk Institute shared their AVSC isolates and upon my return to 
Australia I tested antifungal susceptibilities using a commercial microbroth dilution method 
commonly used in Australian Mycology Reference Laboratories (Sensititre™ YeastOne™ 
YO8, TREK Diagnostic Systems Ltd., OH, USA), while colleagues in Europe performed the 
Clinical Laboratory Standards Institute (CLSI) antifungal susceptibility testing method to 
compare results (Clinical Laboratory Standards Institute (CLSI), 2017). I also received an 
isolate from an Australian human patient in this time from Dr Sarah Kidd, SA Pathology, 
Adelaide, SA, Australia, which I identified as A. felis (a member of the AVSC), and so the isolate 
was added to the study. High MICs to azoles were detected in most isolates on CLSI testing, 
(84 %) but only two had cyp51A mutations previously associated with resistance in A. fumigatus 
species. This led to further collaboration at the University of Sydney with Professor David 
Hibbs and his PhD student Ms Felcia Lai into cyp51A protein modelling to determine the 
potential significance of these and other mutations only seen amongst isolates with high azole 
MIC values on CLSI testing. This study concluded that mutations in AVSC cyp51A did not 
significantly change the overall protein structure to confer resistance. This study also presents 
antifungal susceptibility testing results for AVSC against luliconazole, with low MIC values 
reported for this different class antifungal drug. Chapter 7 describes the findings of this 
investigation. 
 
The prevalence of azole resistance in A. fumigatus was examined initially in a study focusing 
on isolates from canine and feline URTA. This study included Australian, North American 
(USA) and Belgian isolates and is detailed in Chapter 5. Multi- azole resistance was detected 
in an Australian canine isolate from the early 1990s; however cyp51A analysis only revealed 
one mutation, F46Y, which has been associated with both resistant and wild-type (susceptible) 
isolates of A. fumigatus, making its significance undetermined. The environmental cryptic 
species investigation (Chapter 3) had recovered many A. fumigatus isolates and, following the 
publication by Dr Sarah Kidd in 2015 that identified the presence of azole resistance amongst 
Australian human clinical isolates, the idea of screening for azole resistance amongst my 
environmental isolates developed. It progressed into a multi-centre collaboration with 
Infectious Disease Specialist Dr Sharon Chen’s group at CIMID, Westmead Hospital, NSW, 
Australia for which I collected and 
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processed veterinary (including isolates from Chapter 4) and environmental (samples from 
agriculture, viticulture, hospital grounds, and a selection of isolates from domiciles and the 
nature reserve from Chapter 3) isolates of A. fumigatus, and Dr Chen’s group screened human 
clinical isolates of A. fumigatus. The results of this study described in Chapter 6 revealed a low 
prevalence of azole resistance in Australia (2%) which was only detected in isolates from 
human patients. This provided the opportunity to collaborate with Professor Hibbs’ group again 
to model the mutations found in human clinical isolates, detailed in Chapter 6. 
 
Throughout my investigation I received prospective isolates from clinical cases of avian 
aspergillosis. Chapter 4 describes the findings of this investigation into avian aspergillosis 
amongst captive birds in Australia. This study revealed the most common cause of aspergillosis 
in Australian captive birds is A. fumigatus (87%), with no cryptic species identified amongst 
the isolates. Aspergillus fumigatus isolates from this study were also screened for azole 
resistance in Chapter 6. This study also reports for the first time A. restrictus as a fungal 
pathogen in birds. 
 
Chapter 8 includes a discussion of the research findings from Chapters 3 - 7 and 
recommendations for future research on aspergillosis in humans and other animals, 
highlighting the need for continued surveillance for both cryptic species and azole resistance 
amongst clinical and environmental Aspergillus isolates. 
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Chapter 2. Literature Review 
 
2.1 Aspergillosis: a one health infectious disease 
 
2.1.1 Aspergillosis and its host species 
 
Aspergillosis is the infection of a host by an opportunistic fungal pathogen of the genus 
Aspergillus. It is a one health infectious disease, causing a range of conditions in a variety of 
animal species including humans, including acute and chronic, non-invasive and invasive 
forms. Infection is most commonly attributed to fungi in Aspergillus section Fumigati, and 
most frequently to the fungus Aspergillus fumigatus sensu stricto (Vanden Bossche et al., 1988, 
Bodey and Vartivarian, 1989, Kurup and Kumar, 1991, Dixon and Walsh, 1992, Latgé et al., 
1997, Balajee et al., 2009b, Alastruey-Izquierdo et al., 2013, Negri et al., 2014), a ubiquitous 
saprophyte common in soil, compost and spread via air (Mullins et al., 1976, Mullins et al., 
1984, Vanden Bossche et al., 1988, Pitt, 1994, Haines, 1995). Aspergillosis is primarily a 
disease of the respiratory tract, generally following inhalation of environmental spores (Latgé, 
1999). Aspergillosis develops when the host’s immune system cannot remove Aspergillus 
spores due to either an overwhelming fungal load and/ or immunosuppression. Aspergillosis 
causes significant morbidity amongst infected hosts, with a high mortality rate in invasive 
aspergillosis (IA), presenting diagnostic and treatment challenges to clinicians. 
 
Aspergillosis has been most widely reported in humans, where invasive disease most commonly 
affects immunocompromised individuals. Immunocompromise can be secondary to other 
diseases (e.g. acquired immunodeficiency virus, leukaemia) or immunosuppressive therapies 
(e.g. corticosteroids, chemotherapy) (Nash et al., 1997, Denning, 1998, Meersseman et al., 
2004, Shaukat et al., 2005, Chamilos et al., 2006, Stergiopoulou et al., 2007, Segal and Romani, 
2009, Balajee et al., 2009b, Neofytos et al., 2009, Kontoyiannis et al., 2010, Pappas et al., 
2010). Chronic pulmonary aspergillosis (CPA) is most commonly reported in patients with 
current or prior lung disease, including cystic fibrosis (CF), tuberculosis and asthma (Laufer et 
al., 1984, Greenberger and Patterson, 1988, Denning, 2009, Nam et al., 2010, Denning et al., 
2011b, Denning et al., 2016). In humans, the disease has no identified predilection for age or 
gender. 
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Natural infection includes reports in land and marine mammals, birds and reptiles. Disease is 
most commonly reported in stressed or immunocompromised captive birds exposed to high 
environmental burdens of fungal spores, attributed to husbandry practices and facility location 
(Balseiro et al., 2005, Burco et al., 2012, Neumann, 2016). Various avian species have been 
reported to be affected, with no species predilection. This is similar to horses, where host 
immunosuppression predisposes to aspergillosis associated with different diseases including 
neoplasia, endocrinopathies and enteritis (Hattel et al., 1991, Carrasco et al., 1996). In contrast, 
breed predilections have been identified in dogs and cats indicating a genetic factor in disease 
susceptibility. In dogs, infection occurs most commonly in medium or long nosed breeds 
(mesaticephalic or dolicocephalic) (Peeters and Clercx, 2007), whereas in cats short-nosed 
breeds of oriental descent are over represented (Barrs et al., 2015). Additionally, aspergillosis 
often affects systemically immunocompetent, young to middle-aged canine and feline patients 
(Sharp et al., 1991, Barrs and Talbot, 2014). Reports of aspergillosis in ruminants are mostly 
associated with increased environmental burdens, particularly contaminated feed, with 
increased disease susceptibility in recently calved and early lactating cows (Puntenney et al., 
2003). Naturally occurring aspergillosis is reported in many other species including rhinoceros, 
dolphins, whales, rabbits, turtles, tortoises, snakes, chuckwallas, crocodiles and non-human 
primates (Scott, 1930, Frye and Dutra, 1974, Tappe et al., 1984, Joseph et al., 1986, Domingo 
et al., 1992, Buenviaje et al., 1994, Reidarson et al., 1998, Woods et al., 1999, Miller et al., 
2004, Myers et al., 2009, Prahl et al., 2011, Delaney et al., 2013, Bryant et al., 2016, Allizond 
et al., 2016, Cassle et al., 2016, Groch et al., 2018), mostly due to host immune-compromise and 
poor husbandry. 
 
2.1.2 Forms and agents of disease 
 
Invasive and non-invasive forms of aspergillosis occur (Table 1). Locally or systemically 
invasive infections have a high mortality rate as they often lead to dissemination of the fungus 
via the circulatory system. Localised disease is often chronic and usually confined to the upper 
and/or lower respiratory tract. Most of the wide-ranging types of Aspergillus diseases  
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in natural infections have also been reported in humans, including respiratory, otic, ocular, 
cutaneous and disseminated disease (Latgé, 1999, Parize et al., 2009, Chrdle et al., 2012, 
Denning et al., 2016, Patterson et al., 2016, Chowdhary et al., 2017). 
 
In humans, aspergillosis can present as allergic, chronic or invasive disease mostly involving 
the respiratory system. Allergic Aspergillus conditions include severe asthma with fungal 
sensitisation and allergic bronchopulmonary aspergillosis (ABPA) (Chowdhary et al., 2017). 
CPA, mostly in immunocompetent patients, has been associated with ABPA, cystic fibrosis and 
other chronic granulomatous diseases such as tuberculosis (Laufer et al., 1984, Greenberger and 
Patterson, 1988, Denning, 2009, Nam et al., 2010, Denning et al., 2011b, Denning et al., 2016). 
IA, however, mostly affects severely immunocompromised, including transplant patients (solid 
organ and haematopoietic stem cell transplant patients) and patients on immunosuppressive 
therapies, such as corticosteroids and chemotherapy (Nash et al., 1997, Denning, 1998, 
Meersseman et al., 2004, Shaukat et al., 2005, Hope et al., 2005, Chamilos et al., 2006, 
Stergiopoulou et al., 2007, Segal and Romani, 2009, Balajee et al., 2009b, Neofytos et al., 2009, 
Kontoyiannis et al., 2010, Pappas et al., 2010). The recently described Aspergillus bronchitis 
occurs in patients with cystic fibrosis, bronchiectasis, lung transplant recipients and patients in 
intensive care units on mechanical ventilation (Chrdle et al., 2012). 
 
Localised (invasive and non-invasive) and disseminated (invasive) infections have been 
reported in captive and companion animal species. The respiratory tract is mostly affected in 
dogs, cats, birds and horses, where bronchopulmonary, sino-nasal and sino-orbital infections 
are described, as well as air sacculitis in birds and guttural pouch infection in horses (Ainsworth 
and Rewell, 1949, Cook, 1968, Burr, 1981, Harvey, 1984, Dyar et al., 1984, Southard, 1987, 
Lane, 1989, Sharp et al., 1991, Tsai et al., 1992, Tasker et al., 1999, Cork et al., 1999, Willis et 
al., 1999, Hamilton et al., 2000, des Lions et al., 2000, Zonderland et al., 2002, Akan et al., 
2002, Kim et al., 2003, Perez et al., 2003, Peeters et al., 2005, Whitney et al., 2005, Balseiro et 
al., 2005, Vestappen and Dorrestein, 2005, Tell, 2005, Mathews and Sharp, 2006, Johnson et 
al., 2006, Nardoni et al., 2006, Peeters and Clercx, 2007, Barrs et al., 2007, Xavier et al., 2007, 
Meler et al., 2008, Kano et al., 2008, Zafra et al., 2008, Kendall et al., 2008, Billen et al., 2009a, 
Day, 2009, Cacciuttolo et al., 2009, Barachetti et al., 2009, Sharman et al., 2010, Smith and 
Hoffman, 2010, Sato and Itagaki, 2010, Adamama- Moraitou et al., 2011, Ito et al., 2011, 
Hazell et al., 2011, Arne et al., 2011, Barrs et al., 2012, Dobesova et al., 2012, Kano et al., 2013, 
Barrs et al., 2013, Barrs et al., 2014, Barrs et al., 2015, 
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Tamborini et al., 2016, de Souto et al., 2016, Neumann, 2016). Infection of the reproductive 
system is common in cows, including mastitis and placentitis, a cause of mycotic abortion 
(Knudtson and Kirkbride, 1992, Pérez et al., 1998, Las Heras et al., 2000, Puntenney et al., 
2003, Garcia et al., 2004). The most frequently reported infections in reptiles are cutaneous 
(Frye and Dutra, 1974, Jacobson et al., 2000, Miller et al., 2004, Girling and Fraser, 2009), and 
in marine mammals, encephalitis is described (Domingo et al., 1992, Dagleish et al., 2006, 
Barley et al., 2007, Dagleish et al., 2008). Other forms of disease are reported in many species 
including otologic (Coyner, 2010, Prahl et al., 2011), dermatologic (Chute et al., 1955, 
Mohammed et al., 1980, Tappe et al., 1984, Abrams et al., 2001, Suedmeyer et al., 2002), ocular 
(Pickett et al., 1985, Beckman et al., 1994, Hoppes et al., 2000, Abrams et al., 2001, Sansom et 
al., 2005, Labelle et al., 2009, Dalton and Ainsworth, 2011, Wada et al., 2013), gastrointestinal 
(Jensen et al., 1994, Puntenney et al., 2003) and musculoskeletal systems (van Veen et al., 1999, 
Cortes et al., 2005, Olias et al., 2010, Simpson, 2011, Barnett et al., 2011), and disseminated 
infection (Scott, 1930, Sautter et al., 1955, Schiefer, 1965, Pakes et al., 1967, Weiland, 1970, 
McCausland, 
1972, Bolton and Brown, 1972, Stokes, 1973, Vogler and Wagner, 1975, Fox et al., 1978, 
Köhler et al., 1978, Kirkpatrick, 1982, Migaki, 1983, Pickett et al., 1985, Ossent, 1987, Severo 
et al., 1989, Jensen et al., 1990, Burk et al., 1990, Reidarson et al., 1999, Pérez et al., 1999, 
Adamama-Moraitou et al., 2001, Throne Steinlage et al., 2003, Hope et al., 2005, Martin et al., 
2007, Schultz et al., 2008, Hunter and Nation, 2011, Hazell et al., 2011, Dégi et al., 2011, 
Jurczynski et al., 2012, Zhang et al., 2012, Abdo et al., 2012, Groch et al., 2018). 
 
Historically A. fumigatus has been the most frequently identified cause of aspergillosis in 
humans. Traditionally, fungal cultures were identified in the clinical setting based on 
morphology following mycelial and/ or conidial growth on agar. Other methods included 
identifying fungal elements such as conidia on cytological examination of bodily fluids and 
aspirates or identifying fungal spores and inflammatory cells on histopathology (McClenny, 
2005). 
 
The introduction of molecular identification techniques in the past 20 years has demonstrated 
that morphological identification alone often cannot distinguish between similar species of 
Aspergillus (Hong et al., 2005, Samson et al., 2007, Balajee et al., 2007, Balajee et al., 2009a, 
Lamoth, 2016). These are the so-called “cryptic” Aspergillus species. Retrospective and 
prospective epidemiological studies employing molecular 
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techniques for clinically relevant Aspergillus isolates identified new and existing Aspergillus 
fungal species as opportunistic pathogens. While A. fumigatus is still the most common cause 
of aspergillosis in humans, 18 other A. sect. Fumigati species are now reported as pathogens 
(Guarro et al., 2002, Sutton et al., 2002, Balajee et al., 2005a, Balajee et al., 2005b, Balajee et 
al., 2006, Alhambra et al., 2008, Balajee et al., 2009b, Vinh et al., 2009a, Vinh et al., 2009b, 
Sugui et al., 2010, Posteraro et al., 2011, Coelho et al., 2011, Gyotoku et al., 2012, Alastruey-
Izquierdo et al., 2013, Barrs et al., 2013, Peláez et al., 2013, Toskova et al., 2013, Malejczyk et 
al., 2013, Sugui et al., 2014, Negri et al., 2014, Alvarez-Pérez et al., 2014, Khare et al., 2014, 
Frisvad and Larsen, 2016). Molecular identification also identified A. fumigatus as the most 
common cause of sino-nasal infection in cats and dogs; however sino-orbital infection in cats 
is mostly due to members of the Aspergillus viridinutans species complex (AVSC) (Kano et 
al., 2008, Barrs et al., 2012, Barrs et al., 2013, Kano et al., 2013, Barrs et al., 2014). Traditional 
morphological identification is reported for most other animal- associated Aspergillus species, 
with molecular identification studies lacking for many. 
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Table 1. Types of aspergillosis reported in natural infections  
 
 
Host Invasive disease Non-invasive disease 
Human Invasive pulmonary aspergillosis, 
disseminated, invasive bronchial 
aspergillosis, chronic invasive pulmonary 
aspergillosis (necrotising, cavitary, fibrosing), 
acute/ chronic invasive sinusitis, sino-orbital 
aspergillosis, cerebral aspergillosis, CNS 
aspergillosis, chronic granulomatous sinusitis, 
cardiovascular aspergillosis, osteomyelitis, 
septic arthritis, endopthalmitis, renal 
aspergillosis, orchitis, prostatic aspergillosis, 
pelvic aspergillosis, gastrointestinal 
aspergillosis 
Aspergilloma (“fungus ball”) 
of the sinus, lung or kidney, 
allergic bronchopulmonary 
aspergillosis, chronic 
pulmonary aspergillosis, 
keratitis, scleritis, cutaneous 
aspergillosis 
Canine Disseminated, bronchopulmonary, sino- 
orbital aspergillosis 
Sino-nasal aspergillosis, 
otomycosis 
Feline Sino-orbital aspergillosis, bronchopulmonary 
aspergillosis, disseminated 
Sino-nasal aspergillosis, 
ulcerative keratomycosis 
Avian Invasive pulmonary aspergillosis, 
disseminated, spondylitis, articular 
aspergillosis (hip joint), pulmonary 
aspergilloma 
Air-sacculitis, blepharitis, 
keratitis, keratoconjunctivitis, 
dermatitis, omphalitis, nasal 
aspergillosis 
Equine Invasive pulmonary aspergillosis, encephalitis Guttural pouch mycosis, sino- 
nasal aspergillosis, keratitis 
Bovine Mycotic placentitis, bronchopulmonary, 
gastroenteritis, mastitis, lymphadenitis 
 
Non-human 
primate 
Disseminated  
Reptile Disseminated, bronchopulmonary dermatitis, keratitis 
Marine mammal Disseminated, encephalitis, otitis media/ otits 
interna, invasive pulmonary aspergillosis 
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2.1.3 Diagnosis 
 
Ante-mortem diagnosis of aspergillosis can be challenging for clinicians with patients often 
presenting with non-specific clinical signs. Following a history and presentation that alerts the 
clinician to the possibility of fungal infection, several tests can confirm or support a diagnosis 
of aspergillosis. Sometimes however, diagnosis is only achieved post-mortem. 
 
In human patients, diagnosis is based on imaging (radiographs, computed tomography (CT), 
magnetic resonance imaging (MRI), bronchoscopy), observation of fungal hyphae in tissue 
biopsy or fluid sampling and analysis (sputum, bronchoalveolar lavage (BAL) fluid, 
cerebrospinal fluid, lesion aspirates), with or without positive fungal culture, serology 
(galactomannan and β-D-glucan assay) and histopathology (Patterson et al., 2016). More 
recently, molecular detection of Aspergillus fungi in sputum has proven more sensitive than 
sputum culture to diagnose aspergillosis in cystic fibrosis patients (Guegan et al., 2018). The 
sensitivity and specificity of serological tests for aspergillosis varies within and between patient 
populations and for antigen versus antibody tests. Results from the β-D-glucan antigen test can 
support a positive culture; however sensitivity and specificity varies greatly amongst IA 
patients with haematologic malignancies (Odabasi et al., 2004, Kawazu et al., 2004, Ostrosky-
Zeichner et al., 2005, Pickering et al., 2005, Obayashi et al., 2008, Koo et al., 2009). Another 
antigen test, galactomannan, is most useful to diagnose IA in patients with haematopoietic cell 
transplants or haematologic malignancies (Mennink-Kersten et al., 2004, Marr et al., 2005). 
Aspergillus antibody detection is useful in immunocompetent patients with aspergilloma, 
ABPA or CPA, due to the significant humoral response to Aspergillus antigen (Latgé, 1999, 
Barton et al., 2008, Guitard et al., 2012, Ohba et al., 2012). Antibodies are usually detected via 
gel antibody-antigen complexes with the predominant precipitation of immunoglobulin G 
(IgG), achieved by immunodiffusion or counter-immunoelectrophoresis or via enzyme linked 
immunosorbent assay (ELISA) to detect IgG (Page et al., 2015). 
 
Non-specific clinical signs can make ante-mortem veterinary diagnosis difficult and diagnosis is 
often post-mortem via observing fungal plaques or granulomas in tissues, confirmed by 
histopathology and positive fungal culture. 
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Definitive ante-mortem diagnostic tests depend on host species but include imaging 
(radiographs, CT scans, endoscopy), positive culture from biopsy, cytology and histopathology 
(Jenkins, 1991, Redig, 1994, Phalen, 2000, Jones and Orosz, 2000, Saunders and van Bree, 
2003, Saunders et al., 2004, Schultz et al., 2008, Barrs et al., 2012, Barrs et al., 2014). Serology 
also has limited diagnostic success in animals, dependent on the immunocompetence of the 
host, but is useful in some species, including antigen and antibody testing in some avian species 
with respiratory or disseminated aspergillosis, and antigen testing in dogs with disseminated 
IA (Jones and Orosz, 2000, Deem, 2003, Billen et al., 2009b, Cray et al., 2009a, Cray et al., 
2009b, Franca et al., 2012, Garcia et al., 2012). In cats and dogs with SNA or SOA, antibody 
detection can be useful with a demonstrated sensitivity and specificity >90% in cats, and 
specificity >90% and sensitivity >76% in dogs (Barrs et al., 2015, Taylor et al., 2016, Billen et 
al., 2009b). Positive culture of Aspergillus from non-sterile sites must be supported by 
additional diagnostic tests. 
 
Mycology researchers use a polyphasic taxonomic approach to analyse species’ relatedness and 
describe new species. This includes morphological analysis (macro and micro morphological 
features), growth conditions / characteristics (agar types, temperatures of growth, degree of 
sporulation), phylogenetic analysis of multiple genes (multi-locus sequencing) and secondary 
metabolite profiling of fungal specimens (Hong et al., 2005, Samson et al., 2007). The most 
commonly targeted genes for phylogeny are the ITS, BenA and calmodulin genes, with RPB2, 
actin, TSR1, elongation factor and MCM7 also used (White et al., 1990, Glass and Donaldson, 
1995, Hong et al., 2005, Sugui et al., 2014). This full array of laboratory techniques is rarely 
available to identify species in a fungal culture in the clinical setting. Traditional morphological 
methods are still the main identification method in reference laboratories; however adding at 
least molecular identification of fungal isolates when a cryptic species is suspected or when 
antifungal susceptibility profiling returns high or resistant results is becoming more common. 
Amplification of the ITS region for identification to species complex level and either the 
calmodulin or partial beta- tubulin genes for identification to species level are the most 
commonly targeted genes and are recommended by the International Society for Human and 
Animal Mycology (ISHAM) (Powers-Fletcher and Hanson, 2016). Some centres also use 
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matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) for 
species level identification (Lestrade et al., 2016). 
 
2.1.4 Treatment and prognosis 
 
Most A. sect. Fumigati species are resistant to certain azole drugs (fluconazole, ketoconazole) 
and 5-flucytosine C. They are, however, generally susceptible to the newer classes of triazole 
drugs (posaconazole, voriconazole), echinocandins (caspofungin, anidulafungin and 
micafungin) and amphotericin-B. Some cryptic species are less susceptible to triazoles 
(Alcazar-Fuoli et al., 2008, Escribano et al., 2013, Alastruey-Izquierdo et al., 2014). 
 
Azole antifungal therapeutics are the first line treatment of aspergillosis. Azoles target the 
production of sterol synthesis, an important component of the fungal cell membrane and fungal 
cell growth (Hargrove et al., 2015). Azole drug selection depends on the form of disease (i.e. 
invasive vs localized, non-invasive), when performed (e.g. in patients unresponsive to therapy), 
and in vitro antifungal susceptibility results (Patterson et al., 2016). Additionally, drug 
withholding periods for production animals, cost and availability affect treatment choice, and 
with advanced disease euthanasia is often inevitable. Prognostic factors include the fungal 
species causing infection, its antifungal susceptibilities, disease form and location, and the 
host’s immune response (Verweij et al., 2015, Patterson et al., 2016). 
 
Removing fungal balls from humans with chronic fungal rhinosinusitis via endoscopic surgery 
generally resolves infection (Uri et al., 2003). The triazole drugs itraconazole, voriconazole, 
posaconazole and isavuconazole are the oral drugs of choice for treating invasive and chronic 
forms of aspergillosis in humans, and posaconazole, voriconazole and isavuconazole are also 
available as intravenous preparations (Patterson et al., 2016, Ullmann et al., 2018). 
Voriconazole and isavuconazole are the first-line treatments of choice for IA (Walsh et al., 
2008, Patterson et al., 2016, Ullmann et al., 2018). Other non-triazole intravenous drugs 
(liposomal amphotericin B and echinocandins) are usually only suitable for IA cases that do 
not respond to azole therapy (i.e. salvage therapy), where azoles cannot be administered, or, as 
for liposomal amphotericin B, as the first-line treatment of IA in neonates and where a high 
prevalence of 
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ARAf is known for an area or institution (Lestrade et al., 2016, Patterson et al., 2016, Ullmann 
et al., 2018). 
 
IA, however, carries a high mortality rate of 28.5% to 50% (Bitar et al., 2014, Verweij et al., 
2015). Many factors contributed to this mortality rate, including delays in diagnosis due to a 
lack of rapid and reliable diagnostic tests, and co-morbidities. Triazole treatment has reduced 
the mortality rate for IA to 19-20% (Neofytos et al., 2009, Verweij et al., 2015, Maertens et al., 
2016). However, mortality rates of up to 88% are reported due to the emergence of azole-
resistant A. fumigatus (ARAf) strains (van der Linden et al., 2011, Steinmann et al., 2015). One 
Dutch study reported a high rate of ARAf in ICU patients with IA, with a 100% mortality rate 
(Russcher et al., 2014). Consequently, in areas (including regions and institutions / 
departments) where the prevalence of azole resistant strains of A. fumigatus is considered high 
(>10%), recommended alternate treatments include voriconazole and echinocandin 
combination therapy or liposomal amphotericin B monotherapy (Verweij et al., 2015). 
 
Azole treatment for aspergillosis can be topical (imidazole class drugs enilconazole, 
clotrimazole, miconazole), systemic (triazole class drugs itraconazole, voriconazole, 
posaconazole), or both and used as monotherapy or combined with other antifungal drugs, 
including amphotericin B, terbinafine and echinocandins. Additionally, these drugs can be used 
without azoles as monotherapy or in combination (Seyedmousavi et al., 2015). Long term azole 
therapy is used in patients with chronic infections. Surgical debridement of fungal plaques and 
granulomas is also performed in cases of avian, canine and feline infections, and, in 
combination with topical azole application, is the current recommended treatment for dogs and 
cats with non-invasive sino-nasal aspergillosis (SNA), with systemic therapy only 
recommended when topical azoles cannot be administered (e.g. severe lysis of the cribriform 
plate) (Goodall et al., 1984, Zonderland et al., 2002, Tomsa et al., 2003, Claeys et al., 2006, 
Xavier et al., 2007, Furrow and Groman, 2009, Billen et al., 2010, Barrs et al., 2012, Tamborini 
et al., 2016, Stengel, 2017, Vedrine and Fribourg-Blanc, 2018). Medical and surgical therapies 
are required in horses with guttural pouch aspergillosis to prevent arterial haemorrhage (Church 
et al., 1986, Léveillé et al., 2000, Lepage and Piccot-Crezollet, 2005, Delfs et al., 2009). 
Generally, for all animal species, disseminated invasive aspergillosis carries a poor to grave 
prognosis; however, a high rate of treatment failure is also seen in localised, even non-invasive 
conditions, such as canine SNA where a mortality rate of 13% has 
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been reported and up to 70% of dogs require multiple treatments to achieve therapeutic success 
(Sharman et al., 2010). The pharmacokinetics of antifungal drugs have not been established for 
many animal species, and recommended doses have often come from few case reports. 
 
2.2 Aspergillus viridinutans complex species 
 
2.2.1 Background 
 
Cryptic species are difficult to distinguish from more commonly identified fungi based on 
morphological analysis alone. Within A. sect. Fumigati this term refers to isolates 
morphologically similar to A. fumigatus. They are of medical importance and have been 
identified in prevalence studies as agents causing disease in human and veterinary patients. 
Many cryptic species infections are associated with high antifungal susceptibility profiles and 
less favourable prognoses. Thus, accurately identifying cryptic Aspergillus species is important 
for clinical treatment and determining prognosis. 
 
The following paper is a literature review of the AVSC, a group of cryptic fungi in A. sect. 
Fumigati. It investigates this group’s association with human and animal disease, 
environmental niches, and virulence traits (physiology, secondary metabolite production and 
antifungal susceptibility profiles) that can contribute to pathogenesis. This fungal group is 
important medically as most of the AVSC species have been associated with invasive disease 
in humans and animals that is refractory to treatment and is mostly fatal. This article reviews 
the current literature on members of the AVSC. 
 
2.2.2 Publication 
 
The following publication has been re-formatted here to suit the style of this thesis. The 
publication’s in-text references remain in the style required by the journal (superscript number 
form) and the publication associated tables, figures, references and supplementary data follow 
the main text. This research is presented in its original publication form in Appendix 1. A list 
of all other references referred to in this chapter outside of section 2.2.2 Publication can be 
found at the chapter’s end (see 2.4 References). 
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Talbot JJ, Barrs VR. One-health pathogens in the Aspergillus viridinutans complex. Medical 
Mycology. Volume 56, Issue 1, 1 January 2018, Pages 1–12, 
https://doi.org/10.1093/mmy/myx016. 
 
Abstract 
 
Cryptic species in Aspergillus section Fumigati are increasingly recognised as pathogens in 
humans and animals. The A. viridinutans complex (AVC) has recently expanded to comprise 
10 species, of which six are known to be pathogenic, including A. udagawae, A. felis, A. 
pseudofelis, A. parafelis, A. pseudoviridinutans, and A. wyomingensis. They cause locally 
invasive and disseminated invasive disease syndromes, including chronic pulmonary 
aspergillosis and invasive aspergillosis in humans, invasive fungal rhinosinusitis in cats, and 
disseminated invasive aspergillosis in dogs. In contrast to A. fumigatus, AVC species are 
characterized by higher minimum inhibitory concentrations (MICs) of antifungal drugs and the 
infections they cause are typically more chronic and more refractory to therapy. This review, 
of relevance for one-health practitioners, explores the history of the AVC as well as current 
phylogenetic relationships, secondary metabolite production, environmental distribution, 
clinical syndromes, and antifungal susceptibility patterns. 
 
Introduction 
 
Aspergillus section Fumigati contains 63 species, 19 of which are known human and veterinary 
pathogens (Fig. 1).1,2 Since the implementation of polyphasic taxonomical methods for fungal 
identification, there has been a striking increase in the number of cryptic and newly discovered 
species of medical importance within the section. Cryptic species can be defined as isolates of 
closely related fungal species that are indistinguishable on classical morphological features but 
can be identified to species level using molecular techniques.3 The most common cryptic 
species in section Fumigati associated with clinical  disease  in  humans  are  A. lentulus,4– 18A. 
thermomutatus,11,19,20 and members of the A. viridinutans complex (AVC).6,21–26 Of the 10 
species within this complex, six have been identified by multi-locus sequencing as pathogens 
in humans and animals including A. udagawae, A. felis, A. pseudofelis, A. parafelis, A. 
pseudoviridinutans, and A. wyomingensis. They cause locally invasive and disseminated 
invasive disease syndromes, have increased resistance to commonly used antifungal therapies, 
and are associated with high mortality rates.4,21–27 Although A. viridinutans sensu stricto has 
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been reported as a pathogen, this is questionable as isolates in these reports were identified 
using morphological methods or only one gene was sequenced for phylogeny.25–30 Some of 
these isolates have since been definitively identified and confirmed to be other species within 
the complex.4,24,25,31 Three other species within the AVC, A. aureoles, A. arcoverdensis, and 
A. siamensis have been isolated from environmental samples only and their pathogenic 
potential is not known.31–36 This review explores the history of the AVC and highlights the need 
for medical and veterinary practitioners to be aware of this important group of closely related 
fungi. Morphological features, secondary metabolite production, current phylogenetic 
relationships, clinical syndromes, and antifungal susceptibility patterns of the ten currently 
accepted members are discussed. 
 
Species in the A. viridinutans complex and their characteristics 
 
 
There  are  currently  ten  accepted  species  within  the  AVC:  A. viridinutans  sensu  stricto, 
A. udagawae, A. felis, A. wyomingensis, A. aureolus, A. parafelis, A. pseudofelis, 
A. pseudoviridinutans, A. siamensis, and A. arcoverdensis (Fig. 1).4,24,31,32,34–39Aspergillus 
viridinutans sensu stricto was discovered in 1954 in the Australian environment.39 This was 
shortly followed by the discovery of Aspergillus aureolus,32 previously known as Sartorya 
aureola,40Neosartorya aureola41 and A. aureoluteus.42 It was not until the mid-1990s that 
another species, Neosartorya udagawae (now A. udagawae) was described and added to the 
complex.34 In recent years the complex has further expanded. Since 2013 seven more species 
have been described, largely attributed to advances in polyphasic taxonomy, which utilizes 
morphologic, physiologic, and molecular characteristics to determine isolate speciation and 
phylogeny.37,43 
 
Nomenclature changes 
 
In 2011 the International Association for Plant Taxonomy (IAPT) adopted changes to the rules 
for naming fungi. A one fungus–one name approach was adopted, enforcing the adoption of 
the same genus name for teleomorph (sexual) and anamorph (asexual) types of a species.44 This 
meant the sexual state of fungi previously known as Neosartorya was to be replaced with 
Aspergillus. Changes were also made around the Latin designation of a species epithet. The 
termination of a name is dependent on whether the epithet is based on gender, geography, if 
there is an existing Latin name and species basionyms, as per Chapter III, Section 4 to Chapter 
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IX, Section 2 of the International Code of Nomenclature for algae, fungi, and plants.44 In cases 
Where the names of species had been changed from their original name over time, names 
reverted to the original name. Thus, Neosartorya udagawae became Aspergillus udagawae, 
while Aspergillus aureolus maintained its basionym with no other variations. 
 
Species in the AVC share some common morphological features. They are typically slow 
growing, slow to sporulate and thermophilic with optimal growth between 35° and 
42°C.4,24,31,32,34–39Aspergillus aureolus and A. siamensis are the only homothallic species in the 
complex.31,36 
 
Mating genotype and phenotype has been determined for A. felis, A. wyomingensis, A. 
udagawae, and A. parafelis.4,24,31 Mating genotype, but not phenotype, has been confirmed in 
A. viridinutans sensu stricto, A. pseudofelis, A. pseudoviridinutans, and A. arcoverdensis.4,31,35 
Fertile interspecies matings have been reported between A. parafelis with A. fumigatus sensu 
stricto, A. viridinutans sensu stricto, A. felis, A. pseudoviridinutans and A. wyomingensis, and 
also between A. pseudofelis with A. felis.4 
 
It is difficult to distinguish AVC species from other species in section Fumigati based on 
morphological features alone. Although members possess characteristic “nodding heads” on 
cytological examination (Fig. 2), this feature occurs in some other section Fumigati species.31 
The inability to grow at 50°C can be exploited as a practical method in clinical laboratories to 
distinguish cryptic species in section Fumigati from A. fumigatus sensu stricto.4,24,31 
Distinguishing between species within the AVC is also difficult based on anamorph and 
teleomorph morphological features. The gold standard for identification is through the addition 
of molecular identification to morphological techniques. 
 
Molecular identification 
 
Phylogenetic relationships within the AVC have been determined by comparative sequence 
analysis of multiple loci including the internal transcribed spacer region (ITS), beta-tubulin 
(benA), calmodulin (caM), rodlet A (rodA), minichromosome maintenance factor (Mcm7), a 
pre-RNA processing protein (Tsr1), and the second largest unit of RNA polymerase II 
(RPB2).4,24,31,42,43,45–49 Comparative multilocus sequence analysis is the gold standard for 
molecular identification although no one gene is currently accepted as a stand-alone method 
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for identification. 33,38 The most commonly used genes that have been used for species 
descriptions are benA and caM. 4,24,31,35,36 
 
Secondary metabolites 
 
Determination of secondary metabolites may be useful to predict pathogenicity where only 
environmental isolates exist for a species.1 Viriditoxin is a secondary metabolite produced by 
all species in the AVC.1,50 The role of viriditoxin in disease pathogenesis is unknown, since it 
is produced by both known pathogens and species of unknown pathogenicity. However, one 
study demonstrated lethality in mice following intraperitoneal administration (LD50 of 2.8 mg), 
as well as the ability to inhibit growth of several bacterial species (Corynebacterium, Bacillus, 
and Streptococcus).50,51 Viriditoxin is also produced by one other species in section Fumigati, 
Aspergillus denticulate.52Aspergillus brevipes was also reported to produce viriditoxin; 
however, this was since confirmed to be present in a mixed culture with A. viridinutans sensu 
stricto.37,53,54 
 
A number of novel bioactive compounds have been discovered through secondary metabolite 
extraction of AVC species. Some extrolites have demonstrated anti-cancer and antibacterial 
properties. 50,55–58 Recent investigations into secondary metabolite extracts from environmental 
A. felis isolates demonstrated in vitro activity against Paracoccidiodes brasiliensis PB18.58 
Extracts from a range of fungal genera were tested, with isolates of A. felis and A. udagawae 
demonstrating the greatest activity against P. brasiliensis PB18. Using reversed-phase HPLC, 
A. felis extracts were identified as pyripyropene A, aspochalasin E, and cytochalasins 
(rosellichalasin, cytochalasin Kasp, and cytochalasin E) as well as a number of unknown 
compounds. Rosellichalasin and cytochalasin E have proven cytotoxic activity against human 
tumour cells lines,59 while aspochalasin E is active against the cancer cells murine melanoma 
B16-F10 and human colon carcinoma HCT-116 cells.60 Secondary metabolites produced from 
clinical and environmental isolates of both A. udagawae and A. viridinutans sensu stricto 
include fumigaclavine C, helvolic acid, methyl-sulochrin, pyripyropene A and E and 
trypacidin. Aspergillus udagawae also produces fumigaclavine A and fumiquinazoline F/G, 
while A. viridinutans sensu stricto also produces fumagillin, fumitremorgins A and C, and 
pyripyropenes O and S.61 However, in the study that characterized these secondary metabolites, 
the  clinical  isolates  listed  with   BenA  and  CaM  sequences  available  on  GenBank62      (A. 
udagawae IFM 5058, IFM 51744, IFM 53867, IFM 53868, IFM 54303; A. viridinutans 
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IFM 54303), only had identity similarities with BenA and CaM markers for A. udagawae 
(AF132226, AB748566) and A. viridinutans sensu stricto (AF134779, DQ534162)38 type 
strains of 97–99%.61 Therefore, additional comparative gene sequence analyses may be 
necessary for definitive species identification of these isolates. 
 
Recently  MALDI-ToF  mass  spectrometry  has  been  utilized  for  rapid  identification  of 
Aspergillus sp., including differentiation of A. fumigatus sensu stricto from the cryptic species 
A. lentulus.63 More work is required for accurate identification of species within the AVC. 
However, this is a promising technique that is already used in clinical microbiology laboratories 
worldwide. 
 
Identification of isolates in the clinical laboratory 
 
Given the clinical management implications, clinical microbiologists can utilize specific 
laboratory techniques to increase recognition of cryptic species in section Fumigati. 
Knowledge of the correct fungal species is clinically relevant due to in vitro and in vivo 
antifungal resistance to commonly used therapeutics associated with some cryptic species 
infections.7,8,19,64,65 Accurate identification is also essential for epidemiological studies to 
ascertain the prevalence of cryptic species infections in hospital populations.19,64,65 While 
polyphasic taxonomy is the gold standard for species delimitation, this is not practical in the 
time crucial setting of clinical disease. Accurate identification of clinical isolates causing 
aspergillosis can be achieved using comparative sequence analysis of the partial BenA and CaM 
genes in laboratories where molecular techniques are available.4,24,31,35,36 Initial isolation on 
malt extract agar at 37°C is suggested as these species will generally sporulate within 7 days 
on this medium for microscopic analysis and DNA extraction.24 The presence of a `nodding 
head’ (Fig. 2) should alert clinical mycologists to the possibility of an AVC species; however, 
other section Fumigati isolates have also been reported to share this feature.31 The incubation 
of an isolate at 50°C is usually sufficient to distinguish most isolates of A. fumigatus, which is 
thermoresistant, from AVC species, which generally do not grow at temperatures higher than 
42–45°C.3,24,31,32,34–39 Slow sporulation of an isolate and high MIC values of antifungals should 
alert clinicians and laboratory mycologists to the possibility of cryptic species infection, and 
trigger molecular testing for definitive species identification. In addition to comparative 
sequence analysis, multiplex polymerase chain reaction (PCR) and restriction fragment length 
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polymorphism (RFLP) are other molecular techniques with potential application for 
identification of clinical isolates.6,66,67 
 
Environmental prevalence 
 
Aspergillus viridinutans complex species have been isolated from a range of habitats, and most 
appear to have worldwide distribution, including North and South America, Europe, Africa, 
Northeast Asia, and Asia-Pacific (Table 1). Four species in the AVC (A. arcoverdensis, A. 
aureolus, A. siamensis and A. viridinutans sensu stricto) have only been found in the 
environment and are of unknown pathogenic status.32,34–36,39,68 The other six species have been 
isolated from both environmental and clinical samples. Environmental isolates have been 
sourced predominantly from soil, as well as food, air, animal faeces, and desert rocks. 
Aspergillus felis has been isolated from a variety of substrates, reflecting the ability of this 
organism to survive in a range of environments, and it appears to be globally distributed.24,31,55 
To date Only small numbers of A. parafelis, A. pseudofelis, and A. pseudoviridinutans have 
only been reported, and their environmental distribution is unknown (Table 1). Aspergillus 
arcoverdensis has been isolated from arid, semi-desert soil, and forest soil, demonstrating 
widespread distribution and an ability to survive in diverse environments.35 The diverse range 
of environments inhabited by members of this complex, coupled with their potential for 
virulence, highlights the importance for medical and veterinary practitioners to be aware of 
these species. 
 
Clinical disease and antifungal resistance 
 
Cases of aspergillosis due to AVC species are being increasingly reported amongst human and 
veterinary patients, reflecting the importance of a One-Health approach to these mycoses 
(Table 2). Six species are recognized as pathogens: A. udagawae, A. felis, A. wyomingensis, A. 
pseudofelis, A. parafelis, and A. pseudoviridinutans.2,4,21,24 Previous reports included 
A. viridinutans sensu stricto as a cause of disease in people; however, multilocus molecular 
analysis  of  these  strains  revealed  they  were  A. felis,  A.  parafelis,  A.  pseudofelis,  or 
A. pseudoviridinutans.4,24–27 
 
These infections fall within the scope of disease due to `cryptic’ Aspergillus species in section 
Fumigati. In recent studies where multilocus comparative sequence analysis was used for 
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identification, the prevalence of cryptic Aspergillus sp. infections in section Fumigati among 
human patients was 3–5%.8,19,64 One European study examined 162 Aspergillus section 
Fumigati strains from hospitals in Spain and identified six cryptic section Fumigati species 
causing aspergillosis (3.7%), including one AVC species.64 The Transplant-Associated 
Infection Surveillance Network and the American Centers for Disease Control and Prevention, 
Atlanta investigated cryptic species prevalence among transplant recipients with invasive 
aspergillosis (n = 216) and showed that 68% of isolates were from section Fumigati, amongst 
which there was a cryptic species prevalence of 5%. Aspergillus udagawae caused 2% of 
section Fumigati infections overall, and 37.5% of cryptic A. section Fumigati sp. infections.8 
Another study of 133 Aspergillus sp. isolates from human patients in Brazil showed 19% were 
cryptic species in section Fumigati but none belonged to the AVC.19 
 
In section Fumigati, cryptic species infections in humans are most commonly caused by 
A. lentulus,4–18A. udagawae, 6,21–23A. thermomutatus,11,19,20  and A. felis.24,25  Two other species 
A. fumigatiaffini11 and A. novofumigatus14,26 have been isolated from clinical specimens, 
however further evidence to support their role as pathogens is required. Further prevalence data 
are also needed in the veterinary field, since there are few molecular based studies. One study 
found no cryptic species in section Fumigati in dogs with non-invasive fungal rhinosinusitis, 
which is the most common anatomic form of aspergillosis in this host.69 This is in contrast to 
the high prevalence of cryptic section Fumigati species isolated from cases of fungal 
rhinosinusitis in cats (72%, n = 33/46), of which the majority (81%, n = 29/36) were AVC 
species.2,24,70–74 clinical disease in dogs and cats occurs most commonly in systemically 
immunocompetent animals. Information gleaned from naturally infected animal hosts can be 
used to further knowledge across human and veterinary medicine, including agents of disease, 
their virulence, antifungal susceptibilities, disease progression, and management. 
 
Human infections 
 
Human infections caused by the AVC have been reported in Spain, Portugal, the Czech 
Republic, Italy, Norway, the United States, and Japan. The most common presentation is 
chronic invasive pulmonary aspergillosis in immunosuppressed patients, which can become 
disseminated.4,21,24,26,27Aspergillus felis, A. parafelis, and A. udagawae have been isolated from 
such  cases.4,21,24   One  patient  with  leukaemia  and  A.  felis infection  was  coinfected  with 
A. novofumigatus.26 Another case, caused by A. parafelis, was characterized by chronic spread 
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of infection across anatomical planes, including cervical and thoracic lymph nodes, lungs, and 
pleura.4,27 In addition, invasive pulmonary aspergillosis due to A. udagawae has a more chronic 
disease course than that caused by A. fumigatus sensu stricto.21Aspergillus udagawae has also 
been reported to cause localised bronchial infection in an elderly immunosuppressed patient,22 
acute respiratory distress syndrome (ARDS) in a middle-aged immunocompetent patient,75 and 
a severe corneal infection.23 In a study investigating the prevalence of cryptic species among 
US and European reference laboratory collections of isolates morphologically identified as 
A. fumigatus, RFLP analysis, and multilocus sequence typing identified A. udagawae from 
brain, sputum, BAL, and lung samples.11 
 
Other clinical isolates obtained from patients include A. pseudofelis from sputum and a nail, 
A. parafelis from oropharyngeal exudates, A. pseudoviridinutans from a mediastinal lymph 
node,4 and A. udagawae from a nail.31 The identity of some clinical isolates, reported to be 
A. udagawae or A. viridinutans sensu stricto, is likely to be inaccurate for at least some isolates, 
since some were based on nucleotide homology of <99% with available, most closely related 
type strain sequences, or only one gene region was sequenced or the sequence was not 
submitted to GenBank.62 Such isolates require further identification, especially in light of the 
number of recently discovered new species in the A. viridinutans complex.6,14,21,29,61,64,76–77 
 
Animal infections 
 
The most commonly described syndrome caused by the AVC is sino-orbital aspergillosis 
(SOA) in cats, a form of chronic invasive fungal rhinosinusitis. Disease has been reported in 
three geographical regions: Europe, Asia, and Australia.24,71–73 Infection is most commonly 
caused by A. felis, but A. udagawae and A. wyomingensis have also been isolated from affected 
cats.2,24,72,73 While A. viridinutans sensu stricto was reported as a cause of feline infection, this 
is doubtful as its identity was based on sequencing of the partial beta-tubulin gene only and the 
closest match using the GenBank BLAST tool62 was 99%.73 Previous isolates showing a similar 
percentage homology to other members of this complex have been demonstrated to be different 
species.4,24,31,71 
 
Feline SOA carries a poor prognosis and is often fatal.24,70,71 Cats typically present with signs 
of an orbital mass (exophthalmos, prolapse of the nictitating membrane (third eyelid), exposure 
keratitis and conjunctival hyperaemia), and signs or a recent history of nasal disease (sneezing, 
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nasal discharge, epistaxis). Extension of disease beyond the orbit often results in an oral mass 
or ulcer in the pterygopalatine fossa and paranasal soft tissue swelling. Mild mandibular 
lymphadenopathy is also common. In advanced disease, neurological signs including 
hyperaesthesia and seizures may be present.24,70,71 Infection due to A. felis has also been 
reported in a dog with disseminated invasive aspergillosis.24 
 
It is currently unclear why A. felis is a major fungal pathogen of cats but is rarely involved in 
human or canine aspergillosis. Interestingly, in cats infection occurs in apparently systemically 
immunocompetent individuals, whereas human and canine infections have occurred in 
immunocompromised patients.2 Around 40% of affected cats are pure-breeds of Persian lineage 
and have a brachycephalic facial conformation with foreshortening of the skull and anterior 
rotation of the nasal bones.70 Infection may be more likely in cats due to an environmental 
exposure factor (e.g., their exposure to fungal spores in the environment may be secondary to 
a particular feline behaviour such as burying faeces) and/or genetic factors such as a deficient 
innate immune response (e.g., problems with local immune factors).78 
 
Antifungal therapy 
 
The current recommended primary therapy for invasive aspergillosis in humans is 
voriconazole, with isavuconazole and amphotericin B acceptable as alternatives for treatment 
failures.79 Given AVC species can have high MICs of voriconazole,4,21–26 patient management 
can be greatly impacted by the failure to recognise the aetiological agent, leading to treatment 
failure and protracted illness. Therefore, correct identification of the species causing invasive 
aspergillosis is crucial for optimal patient treatment. 
 
The optimal treatment for cats with SOA caused by A. viridinutans complex species is yet to 
be identified. Most treated cats have been euthanased due to disease progression despite 
aggressive antifungal therapy using itraconazole or posaconazole as monotherapy or combined 
with amphotericin B, or with amphotericin B and terbinafine.71 A benefit of adding exenteration 
to the treatment regime has not been demonstrated. Voriconazole can have serious adverse 
effects on cats and cannot be used for first line therapy.71,80,81 The echinocandin caspofungin 
was effective in one case that failed therapy with triazoles and amphotericin B.71 
 
Antifungal resistance 
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Azole resistance amongst Aspergillus species is an increasing global problem and can be 
primary (inherent) or secondary (acquired). Mutations in the cyp51A gene are associated with 
secondary azole resistance amongst human clinical isolates of A. fumigatus.82–85 Cyp51A 
mutations have not yet been investigated in AVC species. The draft genome sequence of 
A. udagawae has been recently released and may help identify regions that contribute to 
resistance mechanisms.86 
 
Resistance mechanisms have been investigated for another cryptic A. section Fumigati species, 
A. lentulus.87,88 These studies concluded that the cyp51A mechanisms conferring resistance for 
A. lentulus differ from that of A. fumigatus. A three-dimensional protein model was used to 
explore interactions between cyp51A and voriconazole.88 When A. fumigatus and A. lentulus 
cyp51A proteins were compared, a difference in the BC loop of the protein led to differences 
in the BC loop lock-up of voriconazole, which could account for differences in antifungal 
susceptibility profiles between these two species. The prevalence of acquired versus inherent 
resistance mechanisms amongst AVC species is unknown. Epidemiological cut-off values 
(ECVs) for antifungal susceptibility testing have not yet been established for this complex. The 
MICs of all classes of antifungal drugs are often higher in AVC species compared to ECVs 
established for A. fumigatus (Table 3).89–91In vitro and in vivo resistance to triazoles in human 
patients with AVC infections, have resulted in treatment failure.6,11,21,23,26,27 One patient with 
chronic invasive pulmonary aspergillosis due to A. parafelis infection failed to respond to 
itraconazole initially, had a partial response to posaconazole, then relapsed during voriconazole 
therapy.4,27 Combination therapy with posaconazole and caspofungin was also unsuccessful, 
and the patient died. Antifungal susceptibility testing of the infecting A. parafelis isolate 
obtained at post mortem demonstrated high MIC values of voriconazole (4 μg/ml) and 
itraconazole (>16 μg/ml).4,27 
 
Another patient with leukaemia and invasive pulmonary aspergillosis due to A. felis was treated 
using combination therapy with voriconazole, caspofungin and amphotericin B. The patient 
had a mixed infection with other Aspergillus sp. (initially A. calidoustus and A. novofumigatus, 
then A. novofumigatus and A. felis) and died. All infecting isolates had high MICs of 
voriconazole (4–8 μg/ml).24–26 
 
High MICs of amphotericin B, itraconazole and voriconazole have been observed among 
A. udagawae isolates from clinical infections when compared to A. fumigatus, via microbroth 
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dilution methods.21 Clinically, infections were also refractory to therapy, with longer infection 
duration observed among chronic granulomatous disease (CGD) patients with IA due to 
A. udagawae (mean duration 35 weeks) compared to CGD patients with IA due to A. fumigatus 
(mean duration 5.5 weeks).21 High MICs of amphotericin B and voriconazole have also been 
observed in other reports of invasive infection due to A. udagawae.6 In an ocular A. udagawae 
infection, therapy with itraconazole tablets and ophthalmic drops failed to clear the infection 
and the eye was exenterated. The isolate had a high MIC of voriconazole (8 μg/ml) but appeared 
to be susceptible to itraconazole based on a low MIC value (0.25 μg/ml).23 
 
High MICs of itraconazole, voriconazole, and ravuconazole and susceptibility to amphotericin 
B and echinocandins were reported for two clinical isolates of A. viridinutans11 that were later 
revealed to be A. pseudofelis (NRRL 62902) and A. parafelis (NRRL 62900).4 
 
Other cases of human infection due to A. udagawae that were treated successfully with triazoles 
had high MIC values of nonazole antifungals. In One case of bronchial aspergillosis, decreased 
susceptibility to amphotericin B compared to A. fumigatus sensu stricto was observed.22 In a 
patient with A. udagawae infection causing ARDS, treatment with amphotericin B and 
methylprednisone was unsuccessful, although no antifungal susceptibility testing was 
performed in this case.75 
 
The extended spectrum triazole isavuconazole has been tested against one environmental and 
nine clinical isolates of A. udagawae.92 Many of the isolates demonstrated decreased 
susceptibility to itraconazole (Mode MIC 1 μg/ml, geometric mean 0.660 μg/ml) and 
voriconazole (Mode MIC of 1 μg/ml, geometric mean 0.812 μg/ml) but increased susceptibility 
to isavuconazole (Mode MIC 0.125 μg/ml, geometric mean 0.100 μg/ml). This drug shows 
promise for clinical treatment of invasive aspergillosis due to A. udagawae. The susceptibility 
of other species in the AVC to isavuconazole is yet to be determined. 
 
Antifungal susceptibilities of A. felis isolates from cats have been reported, with generally low 
MICs for amphotericin B and echinocandins. Some isolates had high MICs of triazoles, and 
cross-resistance to triazoles was also observed.4,24 Results of antifungal susceptibility testing 
should inform antifungal selection in treatment of individual cats. Infecting isolates can be 
readily cultured from clinical biopsies of sinonasal mucosa or orbital masses on commercial 
media, for example, Sabouraud's dextrose agar or malt extract agar at 37°C.71 
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The Aspergillus viridinutans complex contains many clinically relevant species and recently 
discovered species of unknown pathogenicity. Known pathogenic species in the complex can 
affect both human and animal patients, reflecting the scope for a One-Health approach to 
disease investigation. Human and veterinary clinicians should be aware of the emerging threat 
members of this complex pose to susceptible patients. Knowledge of their epidemiology is 
important for exposure risk assessment and differential diagnoses. Their seemingly global 
distribution further highlights the need for clinician awareness. Members of this complex share 
some morphological and physiological characteristics and relatedness is confirmed by 
phylogeny based on combined multi-locus sequence analysis. Given that members of the 
A. viridinutans complex have seemingly inherent resistance to commonly used triazole 
antifungal therapeutics and infections usually have a poor to grave clinical prognosis, it is 
important to correctly identify agents of disease through polyphasic taxonomy and to perform 
antifungal susceptibility testing. This will assist both human and veterinary practitioners with 
prognosis assessment and case management. 
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Publication Figures 
 
 
 
Figure 1. Phylogenetic tree depicting species in the Aspergillus viridinutans complex and 
pathogenic species in section Fumigati based on BenA and CaM DNA sequences of type 
strains.4,54 All pathogenic species are set in bold. Nonpathogenic species are in blue font. Three 
pathogenic species in section Fumigati: A. beijingensis, A. qizutongii, and A. wangduanlii were 
not included since BenA and CaM sequence data are not available. The evolutionary history 
was inferred by using the maximum likelihood method based on the Kimura 2-parameter 
model94 with 1,000 bootstrap replicates.95 The tree with the highest log likelihood (−3539.8604) 
is shown. The percentage of trees in which the associated taxa clustered together is shown next 
to the branches for values >70%. A discrete Gamma distribution was used to model 
evolutionary rate differences among sites (five categories +G, parameter = 0.8578). The tree is 
drawn to scale, with branch lengths measured in the number of substitutions per site. 
Evolutionary analyses were conducted in MEGA6.96 
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Figure 2. Nodding conidial head typical of Aspergillus viridinutans complex species. A. 
parafelis isolate ×100 light microscopy image. 
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Publication tables 
 
Table 1. Environmental Aspergillus viridinutans complex isolates. 
 
Species Sources Geographic region Publications 
A. arcoverdensis (n = 11) Semi-desert soil Brazil (n = 11) Matsuzawa et al. 201535 
A. aureolus (n = 6) Soil Ghana (n = 2), Liberia (n = 1), Brazil (n = 2), 
unknown (n = 1) 
Fennell and Raper 195532; Raper and Fennell 
196533; Horie et al. 199534; Nováková et al. 
201431 
A. felis (n = 12) Indoor air 
Soil 
Food 
Germany (n = 1), USA (n = 4), Sri Lanka (n = 
2), India (n = 1), Czech Republic (n = 1), Japan 
(n = 1), 
Barrs et al. 201324; Nováková et al. 201431; 
Gonçalves et al. 201655 
 Pinus caribea Chile (n = 1), Zambia (n = 1)  
 Rocks   
A. siamensis (n = 3) Coastal forest 
soil 
Thailand (n = 3) Eamvijarn et al. 201336 
A. udagawae (n = 57) Soil 
Rocks 
USA (n = 53), Brazil (n = 3) Chile (n = 1) Hong et al. 201093; Horie et al. 199534; 
Nováková et al. 201431; Gonçalves et al. 
201655 
A. viridinutans sensu 
stricto (n = 3) 
Rabbit dung 
Sandy podzol 
Soil 
Australia (n = 3) McLennan et al. 195439; Katz et al. 200528,a 
A. wyomingensis (n = 14) Soil USA (n = 12) China (n = 1) Russia (n = 1) Nováková et al. 201431; Varga et al. 200066 
 
a Identification questionable: nucleotide homology < 99% with type strain sequence. 
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Table 2. Published clinical cases caused by Aspergillus viridinutans complex species where molecular sequencing techniques were used in addition 
to morphological identification.a 
 
 
Fungal species Host Origin Source Publication Gene 
sequenced 
A. felis (n = 14) Cat Australia Retrobulbar 
mass 
Barrs et al. 201324 ITS, BenA, 
CaM 
    Katz et al. 200528 Alkaline 
protease, 
BenA, ITS 
A. felis (n = 1) Dog Australia Vitreous humor Barrs et al. 201324 ITS, BenA, 
CaM 
A. felis (n = 1) Cat UK Retrobulbar 
mass 
Barrs et al. 201324 ITS, BenA, 
CaM 
A. felis (n = 1) Cat Australia Thoracic mass Barrs et al. 201324 ITS, BenA, 
CaM 
A. felis (n = 1) Cat Australia Sino-nasal 
cavity 
Barrs et al. 201324 ITS, BenA, 
CaM 
A. felis (n = 1) Human Spain Sputum, BAL Barrs et al. 201324 ITS, BenA, 
CaM 
    Peláez et al. 201326  
A. felis (n = 1) Human Portugal Lung Barrs et al. 201324Coelho et al. 201127 ITS, BenA, 
CaM, rodA 
A. felis (n = 1) Human Japan Thigh bone 
abscess 
Novakova et al. 201488 BenA, CaM 
A. parafelis (n = 1) Human Portugal Lung Sugui et al. 20144 BenA, CaM, 
MCM7, RPB2, 
TSR1 
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A. parafelis (n = 1) Human Spain Oropharyngeal 
exudate 
Sugui et al. 20144Alcazar-Fuoli et al. 200811 BenA, CaM, 
MCM7, RPB2, 
TSR1, rodA 
A. pseudofelis (n = 1) Human Spain Nail Sugui et al. 20144Alcazar-Fuoli et al. 200811 BenA, CaM, 
MCM7, RPB2, 
TSR1, rodA 
A. pseudofelis (n = 1) Human Spain Sputum Sugui et al. 20144 BenA, CaM, 
MCM7, RPB2, 
TSR1 
A. pseudoviridinutans (n = 1) Human USA Lymph node Sugui et al. 20144Vinh et al. 200929 BenA, CaM, 
MCM7, RPB2, 
TSR1 
A. udagawae (n = 1) Human Japan BAL fluid Gyotoku et al. 201222 BenAa 
A. udagawae (n = 1) Human USA BAL fluid Farrell et al. 201475 ITS, BenA, 
CaM 
A. udagawae (n = 1) Human Italy Cornea Posteraro et al. 201123 ITS, BenA, 
CaM 
A. udagawae (n = 4) Human USA Lung Vinh et al. 200921 ITS, BenA, 
rodA 
A. udagawae (n = 1) Human Czech 
Republic 
Nail Novakova et al. 201431 CaMa 
A. udagawae (n = 2) Human USA Lung Sugui et al. 201076 BenA, rodA 
A. udagawae (n = 3) Human Japan Unknown Tamiya et al. 201561 BenA, CaM 
A. udagawae (n = 1) Human Japan BAL fluid Tamiya et al. 201561 BenA, CaM 
A. udagawae (n = 1) Human Japan Ocular bulb Tamiya et al. 201561 BenA, CaM 
A. udagawae (n = 3) Human USA BAL fluid Balajee et al. 20066 BenA, rodA, 
RFLPa 
A. udagawae (n = 1) Human USA Lung Balajee et al. 20066 BenA, rodA, 
RFLPa 
A. udagawae (n = 2) Human Unknown Unknown Balajee et al. 20066 BenA, rodA, 
RFLPa 
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A. udagawae (n = 1) Human Unknown Brain Balajee et al. 20066 BenA, rodA, 
RFLPa 
A. udagawae (n = 2) Human Spain Unknown Escribano et al. 201314 BenAa 
A. udagawae (n = 1) Cat Australia Sinonasal cavity Barrs et al. 20142 BenA, CaM 
A. udagawae (n = 1) Cat Australia Respiratory tract Barrs et al. 201324 
Katz et al. 200528 
ITS, BenA, 
CaMAlkaline 
protease, 
BenA, ITS 
A. udagawae (n = 1) Cat USA Retrobulbar 
mass 
Barrs et al. 20142 CaMa 
A. udagawae (n = 2) Cat Japan Retrobulbar 
mass 
Kano et al. 2008, 201372,73 ITS, BenAa 
A. udagawae (n = 3) Human USA Lung Balajee et al. 20098 ITS, BenAa 
A. viridinutans (n = 1) Human Japan Cornea Shigeyasu 201230 BenAa 
A. viridinutans (n = 1) Human Japan Unknown Tamiya et al. 201561 BenA, CaMa 
A. viridinutans (n = 1) Human Japan Lung Tamiya et al. 201561 BenA, CaMa 
A. viridinutans (n = 1) Human USA Lung Vinh et al. 200929 ITS, BenA, 
rodAa 
A. viridinutans (n = 1) Human Spain Unknown Alastruey-Izquierdo et al. 201364 ITS, BenAa 
A. viridinutans (n = 1) Human Spain Unknown Escribano et al. 201314 BenAa 
A. viridinutans (n = 1) Human Norway Brain Andersen et al. 201277 ITSa 
A. wyomingensis (n = 1) Cat Australia Retrobulbar 
mass 
Barrs et al. 20142 ITS, BenA 
a Identification questionable: nucleotide homology <99% with type strain sequence, no GenBank sequence available or only one gene sequenced. 
BAL = Bronchoalveolar lavage. 
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Table 3. Antifungal susceptibility profiles reported for clinical isolates of Aspergillus viridinutans complex species and one environmental isolate 
(A. viridinutans) based on CLSI M38-A2,4,11,21–23,26,27 EUCAST and Sensititre YO10 broth microdilution methods.24 
Drug (ECV μg/ml 
for wild-type 
A. fumigatus sensu 
stricto) 
Species Number of isolates tested MIC/MEC range (μg/ml) MIC/MEC Geometric Mean 
(μg/ml) 
Amphotericin B* 
(2)89 
A. felis4,24,26 15 0.25–1 0.55 
 A. parafelis4,11,27 5 0.37–2 0.99 
 A. pseudofelis4 2 2 2.00 
 A. pseudoviridinutans4 2 2 2.00 
 A. udagawae6,21–23 14 0.125–4 1.53 
 A. viridinutans4 1 0.25 0.25 
Itraconazole* 
(0.25)90 
A. felis4,24,26 15 0.03–8 0.31 
 A. parafelis4 5 14.4–>16 15.17 
 A. pseudofelis4 2 >16 >16.00 
 A. pseudoviridinutans4 2 2–>16 5.65 
 A. udagawae6,21–23 14 0.125–4 0.48 
 A. viridinutans4 1 1 1.00 
Voriconazole* (1)90 A. felis4,24,26 15 0.25–8 1.45 
 A. parafelis4 5 4–8 5.28 
 A. pseudofelis4 2 8 8.00 
 A. pseudoviridinutans4 2 2–8 4.00 
 A. udagawae6,21–23 14 0.25–>16 1.12 
 A. viridinutans4 1 1 1.00 
Posaconazole* 
(0.25)90 
A. felis24,26 14 0.03–4 0.14 
 A. parafelis4 3 0.25–0.41 0.29 
 A. udagawae21,23 5 0.25–0.5 0.33 
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Terbinafine* A. felis24 13 0.25 0.25 
 A. parafelis4 2 0.75–1.2 0.95 
 A. udagawae21 4 0.25–1 0.40 
Caspofungin† (1)91 A. felis24,26 14 0.008–2 0.06 
 A. parafelis4 3 <0.016–1 0.82 
 A. udagawae6,21,23 12 0.015–0.5 0.05 
Anidulafungin† A. felis24,26 14 0.015–<0.03 0.02 
 A. parafelis4 1 <0.016 <0.02 
 A. udagawae23 1 0.016 0.02 
Micafungin† A. felis24,26 14 0.008–<0.03 0.01 
 A. parafelis4 2 0.03–2 0.07 
 A. udagawae21–23 6 <0.015–0.25 0.25 
Fluconazole* A. udagawae23 1 >256 >256.00 
*MIC, minimum inhibitory concentration; †MEC, minimum effective concentration. 
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2.2.3 Conclusions 
 
The AVSC is a medically important group of cryptic fungi found in a variety of environments. 
Although not all member species have been identified as pathogenic, continued surveillance 
for these cryptic species amongst clinical isolates is warranted to identify patients at higher risk 
of treatment failure and to monitor pathogenicity within the complex. 
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Since this review, the antifungal susceptibility data of a large group of AVSC isolates have been 
published (Lyskova et al., 2018). The recent study, published in February of 2018, compared 
the in vitro microbroth dilution antifungal susceptibility methods of EUCAST (EUCAST, 
2017) and Sensititre™ YeastOne™ (Thermo Scientific Trek Diagnostic Systems, USA on 
environmental and clinical AVSC isolates (n=90) for triazoles (voriconazole, posaconazole, 
itraconazole), amphotericin B and echinocandins (anidulafungin, micafungin and 
caspofungin). The study included isolates of A. udagawae, A. felis, A. wyomingensis, A. 
arcoverdensis, A. pseudoviridinutans, A. aureolus, A. siamensis, A. viridinutans, as well as 
isolates from a suspected new species, temporarily called A. acrensis (Lyskova et al., 2018) 
(the species description for A. acrensis sp. nov. was recently accepted for publication (Hubka 
et al., 2018)). EUCAST testing returned low MICs of posaconazole and MECs of 
echinocandins for most AVSC isolates, and compared to EUCAST testing, the Sensititre™ 
YeastOne™ method could not detect elevated MICs of itraconazole in AVSC isolates. Overall 
the study found an agreement between the two in vitro methods of 67% (when Sensititre™ 
YeastOne™ results were read at 48 hours) to 82% (when read at 72 hours) (Lyskova et al., 
2018). 
 
2.3 Azole resistance in Aspergillus fumigatus and the cyp51A gene 
 
2.3.1 Triazole antifungals and the cyp51 gene 
 
Triazole antifungal drugs are commonly used to control or prevent fungal infections in medical 
patients (human and veterinary), and fungal contamination of agricultural crops and 
manufactured materials (Figure 1) (Chowdhary et al., 2017). 
 
Cyp51 is a cytochrome P450 enzyme gene family required for sterol biosynthesis, and is 
maintained across biological kingdoms, including bacteria, fungi and humans (Hargrove et al., 
2015). In fungi it encodes for the demethylation of lanosterol to ergosterol and is important for 
maintaining the membrane permeability and function of fungal cell walls (Hargrove et al., 
2015). There have been two paralogue Cyp51 genes identified in A. fumigatus, cyp51A and 
cyp51B (Mellado et al., 2001). Both genes encode the cytochrome P450 sterol 14α-demethylase, 
the target protein for antifungal azole drugs that inhibit the formation of sterol precursors and 
cause the accumulation of 14α-methylated precursors by preventing the binding and oxidation 
of substrates at the P450 active site (Hargrove et al., 2015). Cyp51A 
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is thought to be induced by the presence of azoles whereas cyp51B is thought to be 
constitutively expressed, and both genes share an amino acid similarity of 59% (Hargrove et 
al., 2015). 
 
Medical triazoles used to treat aspergillosis in humans include itraconazole, voriconazole, 
posaconazole and isavuconazole. Agriculturally applied triazole de-methylation inhibitors 
(DMIs) with similar chemical structure and protein docking mechanisms to these include 
propiconazole, tebuconazole, epoxiconazole, difenoconazole and bromuconazole (Snelders et 
al., 2012). 
 
Figure 1. The applications of azole therapeutics to medical, veterinary and agricultural 
industries. 
 
 
 
 
 
2.3.2 Antifungal susceptibility testing 
 
In the clinical laboratory, 48-hour incubation microbroth dilution testing is used to determine 
the susceptibility phenotype of A. fumigatus to a number of antifungal drug classes; including 
minimum inhibitory concentrations (MICs) to azoles and amphotericin B where the MIC is 
read at 100% inhibition of visual growth; and minimum effective concentrations 
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(MECs) to echinocandins where the MEC is read as the lowest drug concentration associated 
with compact (shorter and smaller) hyphal forms compared to the hyphal growth in the positive 
control well (long and unbranched) (Clinical Laboratory Standards Institute (CLSI), 2017, 
EUCAST, 2017). These results are then interpreted to determine the susceptibility or resistance 
of an isolate. Currently two standards are widely accepted for testing, the European Committee 
for Antibiotic Susceptibility Testing (EUCAST) and Clinical Laboratory Standards Institute 
(CLSI) M38 (formerly M38-A2) testing methods (EUCAST, 2017, Clinical Laboratory 
Standards Institute (CLSI), 2017). No interpretive breakpoints have yet been resolved for 
filamentous fungi for the CLSI method, and this includes A. fumigatus. Instead epidemiological 
cut-off values (ECVs) have been developed based on wild-type A. fumigatus isolate 
susceptibility profiles for detecting azole resistance (Rodriguez-Tudela et al., 2008, Verweij et 
al., 2009a, Pfaller et al., 2009, Espinell-Ingroff et al., 2010, Espinel-Ingroff et al., 2013, Clinical 
Laboratory Standards Institute (CLSI), 2017). Proposed breakpoints have been recommended 
for EUCAST testing based on knowledge of azole therapeutic drug actions, and A. fumigatus in 
vivo and in vitro susceptibility results, and these have also been applied to CLSI result 
interpretation (Table 2) (Verweij et al., 2009a, Wiederhold et al., 2016, EUCAST, 2017). 
 
Commercially available testing kits have also been developed for rapid use, including the strip 
diffusion tests Etest® (produced by bioMérieux SA, France) and Liofilchem® MIC Strip Test 
(Liofilchem, Roseto degli Abruzzi, Italy), Sensititre™ YeastOne™ (colorimetric microbroth 
dilution testing produced by Thermo Scientific Trek Diagnostic Systems, USA) and Vitek® 2 
(an automated antifungal susceptibility testing system produced by bioMérieux SA, France). 
While the Sensititre™ YeastOne™ kits have been demonstrated to yield similar results to the 
CLSI M38 standard for Aspergillus fumigatus, this test and Vitek® 2 have only been approved 
for testing yeast, not mould fungal species in Europe (Meletiadis et al., 2002, Alastruey- 
Izquierdo et al., 2015, Mello et al., 2017). The Sensititre™ YeastOne™ test is used by the 
Australian National Reference Laboratory in Medical Mycology following the preparation 
standards set for moulds in the CLSI M38 method, as CLSI or EUCAST methods are not 
routinely available in the region (Ellis, 2017, Kidd et al., 2017, Clinical Laboratory Standards 
Institute (CLSI), 2017). The reliability of the E-test® to detect resistance has not been 
validated, with multiple studies reporting varied results on its usefulness in comparison to broth 
microdilution testing (Meletiadis et al., 2002, Ozkutuk et al., 2008, Lamoth and Alexander, 
2015, Arendrup et al., 2017a). A recently accepted manuscript comparing E-test® and the 
EUCAST microbroth dilution method using A. fumigatus clinical isolates from the University 
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Hospital Münster, Germany, found similar results for both methods for itraconazole, 
voriconazole and posaconazole (Idelevich et al., 2018). The same study also compared the 
Liofilchem® MIC Strip Test with EUCAST testing, and while itraconazole and voriconazole 
results were similar, the MIC Test Strip produced much lower agreement for posaconazole. 
Liofilchem® MIC Strip Test did however have good agreement with EUCAST for 
isavuconazole (Idelevich et al., 2018), also supported by another recent study looking at this 
testing method for A. fumigatus isolates (Arendrup et al., 2017a); however, studies on this test 
are limited. Recently, the development of an azole screening test called the VIPcheck™ (Balis 
Laboratorium V.O.F., Boven Leeuwen, the Netherlands) test has proven useful and will be 
discussed later in this chapter. 
 
Table 2. Proposed breakpoints (mg/L) for EUCAST (EUCAST, 2017) and CLSI (Espinell- 
Ingroff et al., 2010, Clinical and Laboratory Standards Institute (CLSI), 2018) antifungal 
susceptibility testing. 
 
 
Testing 
 
Method 
Itraconazole 
 
(mg/L) 
Voriconazole 
 
(mg/L) 
Posaconazole 
 
(mg/L) 
Isavuconazole 
 
(mg/L) 
EUCAST <1 (S) 
 
>1 – 2 (I) 
 
>2 (R) 
< 1 (S) 
 
>1 – 2 (I) 
 
>2 (R) 
< 0.125 (S) 
 
>0.125 – 0.25 (I) 
 
>0.25 (R) 
<1 (S) 
 
>1 (R) 
CLSI 1 (ECV) 1 (ECV) 0.5 (ECV) 1 (ECV) 
S= susceptible; I= intermediate; R= resistant; ECV= epidemiological cut-off value 
 
 
 
2.3.3 The development and global spread of azole resistance 
 
Acquired defence mechanisms are virulence factors that fungi develop in response to 
environmental pressures for survival. These acquired or adaptive defence mechanisms enable 
fungi to survive antifungal treatments and present another challenge in the global battle against 
antimicrobial resistance. The main acquired defence mechanism of concern amongst 
Aspergillus species is the development of azole resistance. Since first reported in the late 1990s, 
the number of triazole resistant A. fumigatus isolates amongst human patients has 
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increased globally, particularly in the past decade (Denning et al., 1997, Chryssanthou, 1997, 
Snelders et al., 2008, Howard et al., 2009, Bueid et al., 2010, Lockhart et al., 2011, van der 
Linden et al., 2011, Mortensen et al., 2011a, Morio et al., 2012, Burgel et al., 2012, van der 
Linden et al., 2013, Bader et al., 2013, Seyedmousavi et al., 2013, van der Linden et al., 2015, 
Lestrade et al., 2016, Mohammadi et al., 2016, Zhao et al., 2016). This presents challenges for 
patient treatments as there are few approved alternate antifungal drug classes available. 
 
The epidemiology of ARAf varies depending on the country, region and hospital patient group. 
Hospital and reference laboratory studies on A. fumigatus from human clinical patients from 
around the world have shown an azole-resistance prevalence of 7.9% in Taiwan (Wu et al., 
2015), 6.6% in Pakistan (Perveen et al., 2016), 9.1% to 13.8% in Japan (Tashiro et al., 2012a, 
Tashiro et al., 2012b, Toyotome et al., 2016), 1.8% to 1.9% in India (Chowdhary et al., 2012a, 
Chowdhary et al., 2015), 3.2 to 4.2% in Iran (Seyedmousavi et al., 2013, Mohammadi et al., 
2016), 12.5% in one small study from Kuwait (Ahmad et al., 2015), 4.9% in the United States 
(Pham et al., 2014), and up to 28% in the United Kingdom (Bueid et al., 2010) and 26% in the 
Netherlands (van der Linden et al., 2015). The prevalence of ARAf has been most widely 
investigated in Europe, particularly Western Europe (van der Linden et al., 2015). 
 
A. fumigatus can reproduce sexually, asexually or by parasexual means. Sexual reproduction 
results in genetic variation via meiotic recombination that may enhance a resistant phenotype, 
asexual reproduction enables fast propagation of a spontaneous mutation and parasexual 
recombination can also increase genetic variation via diploidisation allowing mitotic 
recombination (Verweij et al., 2016, Zhang et al., 2017). Asexual and parasexual processes 
occur in A. fumigatus and most likely contribute to development and spread of azole resistance 
in human hosts (Verweij et al., 2016), the former being most common and thought to be 
associated with lung cavity aspergillomas and the latter with IA (Snelders et al., 2008, Verweij 
et al., 2016, Meis et al., 2016). 
 
The increasing global prevalence of ARAf isolates (Figure 2) threatens successful treatment of 
aspergillosis patients and is a global public health concern. 
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Figure 2. World map with regions where azole resistant Aspergillus fumigatus has been 
detected in animals (blue) (Beernaert et al., 2009, Ziolkowska et al., 2014), humans (red) 
(Verweij et al., 1998, Verweij et al., 2002, Snelders et al., 2008, Howard et al., 2009, Mortensen 
et al., 2010, Klaassen et al., 2010, Bueid et al., 2010, Alanio et al., 2011, Mortensen et al., 
2011a, Mortensen et al., 2011b, van der Linden et al., 2011, Lockhart et al., 2011, Burgel et al., 
2012, Morio et al., 2012, Chowdhary et al., 2012a, Tashiro et al., 2012b, Tashiro et al., 2012a, 
Seyedmousavi et al., 2013, van der Linden et al., 2013, Bader et al., 2013, Pham et al., 2014, 
Choukri et al., 2015, van der Linden et al., 2015, Wu et al., 2015, Ahmad et al., 2015, 
Mohammadi et al., 2016, Mushi et al., 2016, Zhao et al., 2016, Alanio et al., 2016, Perveen et 
al., 2016, Wiederhold et al., 2016, Toyotome et al., 2016), and the environment (green) 
(Snelders et al., 2009, Mortensen et al., 2010, Chowdhary et al., 2012b, Badali et al., 2013, van 
der Linden et al., 2013, Chowdhary et al., 2014b, Prigitano et al., 2014, Ahmad et al., 2014, 
Sharma et al., 2015, Bader et al., 2015, Kano et al., 2015, Le Pape et al., 2016, Jeanvoine et al., 
2017, Zhang et al., 2017, Hurst et al., 2017, Tangwattanachuleeporn et al., 2017, Ren et al., 
2017, Santoro et al., 2017). 
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2.3.4 Cyp51A mechanisms of azole resistance 
 
In moulds the cyp51A gene encodes ergosterol synthesis via the conversion of the cytochrome 
P450 enzyme lanosterol14-alpha demethylase, an important step in the biosynthetic pathway. 
Azole drugs target this enzyme, inhibiting the catalytic function of 14-alpha demethylase thus 
preventing ergosterol formation, leading to the accumulation of sterol precursors (Snelders et 
al., 2010, Hargrove et al., 2015, Liu et al., 2016). The main azole resistance mechanism is 
thought to be due to mutations in this gene, achieved by either inhibiting access to the haem 
protein or by causing instability in the protein complex via gene over-expression or single point 
mutations, leading to structural changes that inhibit drug binding to the enzyme. 
 
The main mechanisms of cyp51A mediated azole resistance include tandem repeats in the 
promoter region of the gene and/or alterations in the cyp51A gene (i.e. point mutations). 
Environmental acquired mutations include single point mutations most often in combination 
with a tandem repeat, whereas patient acquired resistance is usually only associated with point 
mutations (Meis et al., 2016). The TR34/L98H and TR46/Y121F/T289A mutations are thought 
to be environmentally acquired (Snelders et al., 2009, Verweij et al., 2009b, Mortensen et al., 
2010, Vermeulen et al., 2012, van der Linden et al., 2013) and there is evidence of geographical 
spread of environmentally induced resistance spores in some regions (e.g. from the Netherlands 
to other European, African and Asian countries) (Snelders et al., 2008, Verweij et al., 2009b, 
Camps et al., 2012a, Snelders et al., 2012, Vermeulen et al., 2012, van der Linden et al., 2013, 
Chowdhary et al., 2014b, Hagiwara et al., 2016). The most commonly identified resistance 
mechanism, TR34/L8H, has been demonstrated to infer pan-azole resistance, while the 
TR46/Y121F/T289A resistance mechanism leads to voriconazole resistance (Mann et al., 2003, 
Camps et al., 2011, Rodriguez-Tudela et al., 2008, van der Linden et al., 2013, Chowdhary et 
al., 2013). Other tandem repeat and tandem repeat / single point mutation combinations have 
been described. The TR53 mechanism was reported in a paediatric patient from the Netherlands 
with osteomyelitis due to A. fumigatus. The patient had chronic granulomatous disease and had 
been on itraconazole prophylactically. The isolate, sampled in 2006, was itraconazole and 
voriconazole resistant (Hodiamont et al., 2009). A recently published report from the 
Netherlands looking at environmental and clinical isolates found new tandem repeats and single 
point mutations associated with azole resistance, including the TR46
3/ 
Y121F/M172I/T289A/G448S and TR46
4 /Y121F/M172I/T289A/G448S (Zhang et al., 2017). 
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Single point mutations are commonly seen in patients with chronic aspergillosis on long-term 
azole therapy and while 59 single point mutations have been identified, only a small number 
have been demonstrated to correlate directly with azole resistance (Weber et al., 2017). The 
single point mutation G54 has been associated with cross resistance to itraconazole and 
posaconazole (Mann et al., 2003, Camps et al., 2012b, Chowdhary et al., 2014b). The mutation 
G138 has been associated with itraconazole and voriconazole resistance (Howard et al., 2006, 
Chowdhary et al., 2014b). Both G54 and G138 have also been associated with pan-azole 
resistance (Howard et al., 2006, Garcia-Effron et al., 2008, Wiederhold et al., 2016). The 
mutation G448 is associated with voriconazole resistance and M220 with reduced susceptibility 
to triazoles with varying patterns reported (Mann et al., 2003, Mellado et al., 2004, Chen et al., 
2005, Howard et al., 2006, Howard et al., 2009, Bellete et al., 2010, Peláez et al., 2012). A 
number of other mutations have been reported amongst both azole-susceptible and azole-
resistant A. fumigatus isolates, sometimes in association with single point mutations that confer 
resistance, and sometimes on their own, including F46Y, N248T/K, D255E, E427K and M172V 
(Howard et al., 2009, Snelders et al., 2010, Escribano et al., 2011, Alanio et al., 2012, Buied et 
al., 2013, Prigitano et al., 2014, Kidd et al., 2015, Lavergne et al., 2015, Abdolrasouli et al., 
2015, Shalhoub et al., 2015, Liu et al., 2015). 
 
A. fumigatus cyp51A protein homology models were developed to help predict the significance 
of mutations in the gene that might be related to azole resistance (Xiao et al., 2004, Snelders et 
al., 2010, Alcazar-Fuoli et al., 2011, Fraczek et al., 2011, Hargrove et al., 2015, Liu et al., 2016, 
Nash and Rhodes, 2017). These have been designed based on bacterial (Mycobacterium 
tuberculosis) (Xiao et al., 2004, Snelders et al., 2010), human (Homo sapiens) (Fraczek et al., 
2011) and more recently fungal (Saccharomyces cerevisiae) (Alcazar- Fuoli et al., 2011, Liu et 
al., 2016) cyp51A protein structures that have similarities with A. fumigatus cyp51A protein of 
29%, 38% and 50% respectively. Most recently a model of A. fumigatus cyp51A has been 
constructed based on the crystal structure of the A. fumigatus cyp51B gene (Hargrove et al., 
2015). This demonstrated the highest similarity of 59%. The model has since been used to 
demonstrate how the TR34/L98H mechanism causes pan-azole resistance (Nash and Rhodes, 
2017). 
 
The cyp51A gene has been amplified in few Aspergillus species, including A. fumigatus, A. flavus 
(Mellado et al., 2001) and A. lentulus (Mellado et al., 2011). More recently the whole genome sequence 
of one AVSC species A. udagawae was released (Kusuya et al., 2015), 
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including the cyp51A region; however, analysis of this region is not reported. The cyp51A gene 
has not been amplified in any other AVSC species. Thus, whether the reported high antifungal 
MICs in AVSC species are due to cyp51A mediated resistance mechanisms is unknown. 
 
2.3.5 Clinical and environmental azole resistance development mechanisms 
 
The rise and spread of ARAf has been linked to the use of azole class drugs in agriculture and 
the clinical setting (Figure 3). In medical patients, resistance has been linked to previous 
exposure to azole class antifungal drugs, either through agricultural practices using azole-based 
fungicides on crops (i.e. fungicide-driven resistance) (van der Linden et al., 2011), or the 
repeated use of azole therapeutics clinically (i.e. ‘in-patient’ resistance development seen 
amongst CPA, ABPA and CF patients) (Vermeulen et al., 2013, van der Linden et al., 2015). 
Fungicide-driven resistance appears to be the most commonly acquired mechanism of ARAf, 
with two-thirds of ARAf patients having no previous exposure to azole therapeutics (van der 
Linden et al., 2011, Meis et al., 2016). Demethylation inhibitors (DMIs) are azole-class 
fungicides used commonly in agriculture for several decades to protect crops from fungal 
disease and ensure food safety (Russell, 2005, Lago et al., 2014, Hollomon, 2017). DMIs are 
also used in the horticulture, wood and textile industries (Snelders et al., 2009, Hollomon, 
2017). In the Australian agricultural industry DMIs are used regularly to control non-
Aspergillus fungal diseases in plants, including rust and mildew; however, since A. fumigatus 
is ubiquitous, it would be regularly exposed to DMIs (Lago et al., 2014). Azoles can survive in 
soil for prolonged periods, contributing to resistance development (Mortensen et al., 2010). 
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Figure 3. Timeline showing the introduction of triazole DMIs for agricultural use (green) 
(Russell, 2005, Price et al., 2015) and the development of azole resistance in clinical isolates 
(red) (Snelders et al., 2008, Howard et al., 2009, Bueid et al., 2010, Kidd et al., 2015). 
Abbreviations: DMI, demethylase inhibitors; ITC, itraconazole; VRC, voriconazole; POS, 
posaconazole; ISA, isavuconazole; ARAf azole-resistant Aspergillus fumigatus; NL, the 
Netherlands; UK, United Kingdom. 
 
 
 
2.3.6 Azole resistance in A. fumigatus clinical isolates 
 
Detection of ARAf is important as it can lead to disease progression in patients and poor clinical 
outcomes (van der Linden et al., 2015), with an increased mortality rate amongst patients with 
azole-resistant IA (van der Linden et al., 2011, Steinmann et al., 2015). One Dutch study 
reported a high rate of ARAf in ICU patients with IA, with a 100% mortality rate (Russcher et 
al., 2014). In the clinical setting antifungal susceptibility testing and/or failure of the patient to 
respond to therapy alert the clinician to ARAf. More recently rapid DNA testing for azole 
resistance and Aspergillus species confirmation in clinical BAL samples has been developed, 
detecting the most commonly prevalent mutations (TR34/L98H, T289A and Y121F) and 
isolates of A. fumigatus, A. terreus and Aspergillus species in clinical isolates (AsperGenius®, 
PathoNostics, Maastricht, NL) (Chong et al., 2015, Chong et al., 2016, White et al., 2017, 
Chong et al., 2017, Montesinos et al., 2017, Schauwvlieghe et al., 2017). 
 
ARAf has increased in prevalence throughout the world since the early 2000s, with some 
regions now reporting a prevalence in human clinical isolates as high as 20-26% (Bueid et al., 
2010, van der Linden et al., 2015). Prevalence is highest in Western Europe, but 
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varies between regions and countries and within hospital populations. Surveillance studies on 
clinical isolates from Europe, North America, Africa, the Middle East and Asia demonstrate a 
prevalence of 0 – 26%, depending on the disease syndrome and subsequent azole exposure of 
the sample population (Verweij et al., 1998, Verweij et al., 2002, Snelders et al., 2008, Howard 
et al., 2009, Mortensen et al., 2010, Klaassen et al., 2010, Bueid et al., 2010, Alanio et al., 2011, 
Mortensen et al., 2011a, Mortensen et al., 2011b, van der Linden et al., 2011, Lockhart et al., 
2011, Burgel et al., 2012, Morio et al., 2012, Chowdhary et al., 2012a, Tashiro et al., 2012a, 
Tashiro et al., 2012b, Seyedmousavi et al., 2013, van der Linden et al., 2013, Bader et al., 2013, 
Pham et al., 2014, Choukri et al., 2015, van der Linden et al., 2015, Ahmad et al., 2015, 
Mohammadi et al., 2016, Mushi et al., 2016, Zhao et al., 2016, Alanio et al., 2016, Wiederhold 
et al., 2016, Toyotome et al., 2016, Perveen et al., 2016) (see Table 3 for summary of prevalence 
studies). Azole resistance has been demonstrated to be widespread in Europe (van der Linden 
et al., 2015). 
 
2.3.7 Early investigations into azole-resistance in A. fumigatus clinical isolates 
 
Itraconazole resistance in isolates of A. fumigatus from human clinical patients was first 
reported in 1997 (Denning et al., 1997). Using the macrobroth dilution technique, Denning et 
al. (1997) found resistance to itraconazole (MICs >16 mg/L) in three isolates from two patients 
diagnosed with IA. Both patients were from California, the United States of America, and 
samples had been collected in 1987 (Patient 1) and 1989 (Patient 2). Both patients had been 
treated with itraconazole for IA (Denning et al., 1997). Then, only itraconazole and 
amphotericin B were licensed for therapy in human patients so this news prompted further 
prevalence studies and the screening for resistance in individual case reports. Shortly after this 
publication, another study investigating antifungal susceptibility of Aspergillus species clinical 
isolates from hospital patients in Sweden found a prevalence of 3.7% ARAf (itraconazole) in 
107 isolates of A. fumigatus, with all three patients from whom ARAf were isolated being on 
itraconazole therapy (Chryssanthou, 1997). 
 
2.3.8 Prevalence of azole-resistant A. fumigatus in the Netherlands 
 
Initial prevalence studies in the Netherlands demonstrated that ARAf was uncommon. A study 
of 130 clinical isolates and 20 environmental A. fumigatus isolates from a University Hospital 
in Nijmegen showed a low prevalence of ARAf of 0.7% (1/150 isolates) with only one 
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voriconazole resistant clinical isolate (Verweij et al., 1998); however, later phylogenetic studies 
showed this isolate was the cryptic species A. lentulus (Hong et al., 2010). Another ARAf 
prevalence study in the Netherlands, tested 170 A. fumigatus isolates from 1945 to 1998 from 
114 patients at 21 different hospitals (Verweij et al., 2002) for susceptibility to itraconazole 
and voriconazole using the NCCLS M38-P and E-test methods. It showed a low prevalence of 
azole resistance during this period (3/170 isolates, 1.8%). All three resistant isolates were from 
the same lung-transplant recipient on itraconazole therapy for respiratory tract aspergillosis. All 
other isolates tested were susceptible to itraconazole, and all isolates were susceptible to 
voriconazole (Verweij et al., 2002). 
 
The first ARAf report in 1997 (Denning et al., 1997) and the initial prevalence studies of 
clinical A. fumigatus isolates in the Netherlands indicated that ARAf was uncommon (Verweij 
et al., 1998, Verweij et al., 2002). However, reports of clinical cases increased throughout the 
first decade of the 2000’s and additional prevalence studies of retrospective cases demonstrated 
an increase in ARAf. This prompted further investigations from different countries to 
determine the extent of the problem. Initially the TR34/L98H mutation was identified as the 
cause of ARAf; however, with more cases and studies, more cyp51A resistance mechanisms 
conferring resistance were discovered, although TR34/L98H remains the most common 
mutation (Verweij et al., 2007). 
 
The highest number of prevalence studies of ARAf among human clinical isolates have been 
performed in the Netherlands, with prevalence rates ranging from 1.8% to 26% (Verweij et al., 
2002, Snelders et al., 2008, Klaassen et al., 2010, van der Linden et al., 2011, van der Linden 
et al., 2013, van der Linden et al., 2015). Between 64% and 71% of patients in the Netherlands 
with ARAf due to environmental resistance mechanisms had no prior treatment with azole 
drugs (van der Linden et al., 2011, van der Linden et al., 2013). A prevalence of 5.3% 
itraconazole resistance was found in clinical A. fumigatus isolates collected from seven 
University Medical Centres from 2007 to 2009 (van der Linden et al., 2011). The most common 
mutation was TR34/L98H and most ARAf isolates were from azole-naïve patients (64%). Other 
mutations included G54W (itraconazole and posaconazole resistant), P216L (itraconazole 
resistant), F219I (itraconazole resistant), and F46Y, G89G, M172V, N248T, D255E, L358L, 
E427K, C454C (itraconazole and voriconazole resistant). Resistant isolates 
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were most common amongst patients with haematologic or oncologic conditions (van der 
Linden et al., 2011). 
 
Another study investigating clinical isolates from hospital patients received at the Radboud 
University Nijmegen Medical Center in the Netherlands, collected from 1994 to 2007, found a 
prevalence of ARAf of 2.6% (32/1219 hospital patients), with the first resistant isolate detected 
in 1998, and the remainder post 2000, increasing in prevalence yearly from 1.7% to 6% 
(Snelders et al., 2008). Most of these resistant isolates had the cyp51A TR34/L98H mutation 
(n=30); one had the single point mutation M220V and one had no cyp51A mutations. The 
patient population varied with the highest incidence of itraconazole resistance reported from 
haematology (25%), oncology (15.6%), and lung disease (cystic fibrosis, chronic obstructive 
pulmonary disease) (15.6%) patients (Snelders et al., 2008). This study also included isolates 
from 28 other medical centres in the Netherlands from 1994 to 2006, finding an ARAf 
prevalence of 12.8% (13/101 patients), and patient isolates from Belgium, France, Sweden, 
Norway, United Kingdom (isolate had originated in the US) and Greece from 1994 to 2002, 
with a prevalence of 1.9% (6/317 isolates). Cyp51A mutations were found in one isolate each 
from France (M220R), Sweden (M220I) and Norway (TR34/L98H) and in 10 isolates from the 
Netherlands (M220I (n=1), TR34/L98H-S297T-F495I (n=1), TR34/L98H-S297T (n=1) and 
TR34/L98H (n=7)) 
(Snelders et al., 2008). 
 
A lower prevalence of 2% ARAf (itraconazole) was found in other studies from the Netherlands 
(Klaassen et al., 2010; Verweij et al., 2002). Verweij et al. (2002) looked at isolates collected 
from 1945 to 1998 and only found resistance in isolates collected after 1990. A more widespread 
rate of ARAf of 6.8% (63/921 patients) was found in clinical isolates of A. fumigatus collected 
from 2009 to 2011 from eight university hospitals in the Netherlands (van der Linden et al., 
2013). Amongst the resistant isolates, 74.6% (47/63) had multi-azole resistance and the TR34- 
L98H mechanism, 20.6% (13/63) had voriconazole resistance and the TR46/Y121F/T289A, 
with one isolate additionally having the M172I and G448S substitutions, and 4.7% (3/63) had 
no cyp51A mutations. Interestingly, isolates with the TR46/Y121F/T289A mechanism were also 
found to be tebuconazole resistant (van der Linden et al., 2013). 
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A national survey undertaken in 2015 investigating azole resistance rates in clinical isolates 
from eight University Medical Centres and eight non-academic teaching hospitals in the 
Netherlands reported a prevalence of ARAf of between 2% and 30%, with an average resistance 
rate of 5% (Lestrade et al., 2016). High risk wards included haematology units, where azole 
drugs itraconazole, voriconazole and posaconazole were used for prophylaxis. Of the centres, 
81.3% used voriconazole as the primary first-line therapy for treating patients with IA, with 
87.5% using liposomal amphotericin B when ARAf was diagnosed. Another recent study 
investigating the prevalence of ARAf in patients with haematological malignancies presenting 
to the Radboud University Medical Center from 2006 – 2012 found a lower resistance rate 
(overall 1.2%, 5/432 patients), including a low voriconazole resistance rate of 0.5% (Lestrade 
et al., 2018). 
 
2.3.9 Prevalence of azole-resistant A. fumigatus in the United Kingdom 
 
A United Kingdom study of 519 isolates collected from patients with aspergillosis from 1992 
to 2007 found an overall prevalence of ARAf of 7% (Howard et al., 2009). While the first 
ARAf isolate was from 1999, a significant increase in prevalence was observed in isolates from 
2004 (5% ARAf) to 2007 (17% ARAf). Two isolates had the TR34/L98H mechanism and were 
pan-azole resistant, while several non-synonymous single point mutations were associated with 
resistance. This included mutations conferring itraconazole only resistance (P216L), 
itraconazole and voriconazole resistance (F46Y/M172V/E427K, 
F46Y/M172V/E427K/N248T/D255E, H147Y, Y431C, G434C, G448S/H147Y (and in the  
case of this last mutation combination, one case also of posaconazole resistance)), itraconazole 
and posaconazole resistance (G54E/R/V), voriconazole and posaconazole resistance (M220K), 
voriconazole and variable posaconazole resistance (M220T) and pan-azole resistance (G138C) 
(Howard et al., 2009). This high prevalence continued, and in 2010 a combined prevalence of 
28% (64/230 isolates) was reported amongst human derived clinical A. fumigatus isolates 
submitted to the Mycology Reference Centre Manchester, United Kingdom from 2008-2009 
(Bueid et al., 2010). The incidence of ARAf increased from 14% in isolates from 2008 to 20% 
in isolates from 2009. Susceptibility testing was performed using the EUCAST method. Most 
of these ARAf isolates were multi-azole resistant (50/64, 78%), with voriconazole resistance 
less common (2/64, 3%). Itraconazole resistance was most common, detected in 97% (62/64) 
of isolates. Cyp51A sequencing revealed mutations in 67% of ARAf isolates, including     
M220I/K/V/R/W,     A284T, the F46Y/G89G/M172V/L358L/E427K/C454C 
92 
 
 
combination, and the F46Y/G89G/M172V/L358L/E427K/C454C/N248T/D255E 
combination. The remaining 43% had wild-type cyp51A, suggesting other mechanisms were 
responsible for resistance in this group (Bueid et al., 2010). Another study from the United 
Kingdom investigating azole susceptibility (itraconazole, voriconazole and posaconazole) of 
colonies of A. fumigatus from aspergillomas of three patients with CPA found azole-resistant 
isolates in one patient, and a mixture of azole-susceptible and azole-resistant isolates in another. 
The patient with only azole-resistant isolates had cyp51A mutations, including M220K and 
M220T (Howard et al., 2013). 
 
2.3.10 Multi-centre international surveillance studies 
 
The ARTEMIS surveillance program was established to detect global ARAf trends, with 100 
participating medical centres around the world (Lockhart et al., 2011). It included a large ARAf 
prevalence study on 497 isolates of A. fumigatus from 2008 to 2009 from 62 medical centres 
worldwide. Testing susceptibility to itraconazole, voriconazole and posaconazole using the 
CLSI M38-A2 method showed a prevalence of ARAf of 5.8% (29/497) with resistant isolates 
from China (n=24), the Czech Republic (n=2), Portugal (n=1), the United States (n=1) and 
Brazil (n=1). Eight isolates from China with itraconazole resistance harboured the TR34/L98H 
mutation plus the mutations S297T and F495I, and interestingly these isolates did not display 
cross- resistance to voriconazole, as is typical of isolates harbouring the TR34/L98H mutation. 
Additionally, not all resistant isolates had cyp51A mutations, and the mutations 
F47Y/M172V/N248T/D255E/E427K were seen amongst susceptible wild-type isolates as well 
as isolates with elevations in MICs for posaconazole. This study was the first to document 
ARAf due to TR34/L98H outside of Europe, in clinical isolates from China (Lockhart et al., 
2011). This study also included antifungal susceptibility data for three Australian derived 
isolates, all with wild-type ECVs and cyp51A sequences (Lockhart et al., 2011). 
 
A recent international study involving medical centres from 19 countries (18 European and 4 
non-European sites) found a prevalence of ARAf in isolates of A. fumigatus of 3.2 %, with 47 
A. fumigatus isolates demonstrating itraconazole resistance (van der Linden et al., 2015). The 
TR34/L98H was the most common resistance mechanism, and was found amongst isolates from 
Austria, Belgium, Denmark, France, Italy and the Netherlands. Other mechanisms reported 
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included the TR46/Y121F/T289A from the Netherlands, F46Y/M172G with TR34/L98H from 
Belgium, G54W with TR34/L98H from France, F46Y/M172G from Sweden and from the 
United Kingdom the mutations P381R/D481E, L77V/L399I/D481E, M220I, M220R, G54R, 
G54E and G54W were found (van der Linden et al., 2015). 
 
2.3.11 Prevalence of azole- resistant A. fumigatus in patients with cystic fibrosis and 
haematologic disorders in France, Denmark and Germany 
 
An ARAf prevalence rate of 0.9% - 8% has been reported amongst clinical isolates from 
France, higher amongst patients with CF, and lower amongst patients with haematological 
disorders. This may be because azole treatments in haematology patients are generally shorter 
than the lengthy treatments for chronic lung conditions. One study investigating 118 isolates of 
A. fumigatus collected from 89 patients with haematological malignancies and probable or 
proven IA from 2006 to 2009 found an ARAf prevalence of 0.9% (Alanio et al., 2011). One 
isolate had high itraconazole MICs and the G432S mutation. The patient was naïve to azole 
treatment. The same group reported results at the same institution for A. fumigatus isolates 
recovered from 2012 - 2014 from French patients with probable or proven IA, demonstrating a 
similar low prevalence of ARAf of 1.5% (1/68 isolates) (Alanio et al., 2016). The resistant 
isolate harboured the TR34/L98H resistance mechanism (de Fontbrune et al., 2014). Most 
isolates came from patients with haematologic malignancies. Another study found a resistance 
rate of 1.8% (3/165 isolates) amongst patients with chronic respiratory disease 
(immunocompetent and immunocompromised patients) attending two tertiary hospitals in 
2012, with all three resistant isolates demonstrating pan-azole resistance and the TR34 /L98H 
resistance mechanism (Choukri et al., 2015). Recent itraconazole exposure was also associated 
with high ARAf in another study investigating patients with CF (Burgel et al., 2012). The study 
investigated ARAf amongst French CF patients in isolates collected from 2010 to 2011, finding 
a prevalence of 4.6% (6/131 isolates). All six isolates had reduced susceptibility to itraconazole 
and posaconazole, and 3/6 had reduced susceptibility to voriconazole. Five of the isolates were 
from patients that had received itraconazole therapy within the preceding three years, and four 
of these had cyp51A mutations reported including G54E, M220I, M220R and TR34/L98H. The 
remaining resistant isolate was from an azole-naïve patient and harboured the TR34/L98H 
resistance mechanism. It was proposed that the high prevalence of ARAf in CF patients was 
due to the use of prolonged courses of itraconazole for treating ABPA amongst this cohort 
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(Burgel et al., 2012). Another study screening for ARAf in respiratory samples from patients 
at risk of respiratory aspergillosis found ARAf in 1/19 isolates (5.3%) (Zhao et al., 2016). The 
isolate had pan-azole resistance and the TR34/L98H resistance mechanism was found on 
cyp51A analysis. The patient had been on posaconazole therapy for one year (Zhao et al., 2016). 
An even higher prevalence of itraconazole resistance of 8% was reported in another study of 
French CF patients (4/50 patients), with isolates collected from 2010 to 2011 (Morio et al., 
2012). Cyp51A resistance mechanisms found included TR34/L98H (n = 5, multi-azole resist), 
M220T (n = 4, itraconazole and posaconazole resistance) and G54R (n = 1, itraconazole and 
posaconazole resistance). Three isolates from one patient were shown to be genetically distinct 
(Morio et al., 2012). 
 
A study from Denmark examining ARAf in CF patients found a prevalence of resistance to 
itraconazole of 4.5% (6/133 isolates) (Mortensen et al., 2011a). Five of the resistant isolates 
had cyp51A mutations (M220K; TR34/L98H; TR34/L98H-S297T-F495I, M220I-V101F and 
Y431C). 
 
A German study investigating ARAf found a prevalence of 3.2% (17/527 isolates) amongst 
clinical patients, with the highest prevalence detected amongst CF patients (5.2%) (Bader et 
al., 2013). Reported cyp51A resistance mechanisms included TR34/L98H (itraconazole 
resistant), G54W (itraconazole and posaconazole resistant), M220I (itraconazole resistant) and 
F219C (itraconazole resistant). 
 
2.3.12 Prevalence studies of azole-resistant A. fumigatus external to Western Europe 
 
The USA 
 
Although the first reported isolates of ARAf were sampled from the USA in the 1980s, further 
investigations into the prevalence of ARAf in the USA were more recent. In 2014 a study 
investigated azole resistance amongst 1026 A. fumigatus isolates collected from 22 states 
between 2011-2013, and of 51 isolates (51/1026, 4.9%) with MICs above the ECV, only one 
isolate with an azole resistance associated cyp51A mutation M220I was identified (Pham et al., 
2014). The isolate had an elevated MIC for itraconazole (reported as >32 mg/L). Seventeen 
other isolates with elevated MICs had other mutations not recognised to be associated with 
resistance. Interestingly the most commonly reported azole resistance 
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associated cyp51A mutation, TR34/L98H was not recovered (Pham et al., 2014). Another US 
study performed in 2016 targeted clinical isolates with high azole MICs and found numerous 
cyp51A single point mutations as well as tandem repeats in the promoter region of the gene 
(Wiederhold et al., 2016). Mechanisms associated with itraconazole resistance included 
TR34/L98H, M220V/I/K, G54R/E, G138S/C, G448S and F219S; with voriconazole resistance 
G448S (V); with cross resistance to itraconazole and voriconazole G448S; and with cross 
resistance to itraconazole and posaconazole TR46/Y121F/T289A and G54W/R (Wiederhold et 
al., 2016). 
 
India 
 
ARAf was first reported in India in 2012 in human patients suspected of having 
bronchopulmonary aspergillosis, following a screening of 103 A. fumigatus isolates from 85 
patients collected from 2005 to 2010 (Chowdhary et al., 2012a). Susceptibility to itraconazole, 
posaconazole, voriconazole and isavuconazole was tested. An ARAf prevalence of 1.9% was 
reported (2/103 isolates), with multiple triazole resistance and TR34/L98H mutations confirmed 
in both isolates. Microsatellite typing demonstrated divergence from Dutch ARAf isolates with 
the same mutation. Both patients were naïve to azole therapeutics (Chowdhary et al., 2012a). 
Another study investigating A. fumigatus isolates from one Indian hospital during 2011 to 2014 
found a similar prevalence of ARAf of 1.8% (12/685 isolates) (Chowdhary et al., 2015). Eleven 
of the ARAf isolates were pan-azole resistant, and one demonstrated resistance to itraconazole 
and posaconazole. Of the pan-azole resistant isolates, 10 harboured the TR34/L98H mutation, 
while one had the mutations F46Y/D255E/M172V. The remaining multi- azole resistant isolate 
harboured the G54E mutation. Microsatellite genotyping of the TR34/L98H isolates 
demonstrated a unique genotype compared to TR34/L98H isolates from China, the Middle East 
and Europe. Additionally, all 12 resistant isolates were also resistant to the azole fungicides 
bromuconazole, cyproconazole, difenoconazole, epoxiconazole, penconazole, tebuconazole, 
triadimefon, hexaconazole and tricyclazole (Chowdhary et al., 2015). 
 
Iran 
 
ARAf has been reported in Iran. An investigation of 124 clinically relevant isolates of A. 
fumigatus collected from human patients from 2003-2009 revealed a prevalence of ARAf of 
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3.2% (4/124), with the first azole resistant isolate from 2005 (Seyedmousavi et al., 2013). The 
TR34/L98H mutation was found in three of four resistant isolates, with no cyp51A resistance 
mechanisms detected in one isolate. ARAf isolates were from patients with pulmonary 
aspergillosis (n=3) and allergic bronchopulmonary aspergillosis (n=1). Microsatellite 
genotyping of the isolates showed they were genetically distinct from European strains 
(Seyedmousavi et al., 2013). A second study from Iran investigated the prevalence of ARAf in 
clinical isolates from Iran and found a similar prevalence of 3.5% (6/172 A. fumigatus isolates) 
(Mohammadi et al., 2016). The six isolates were resistant to itraconazole and voriconazole and 
harboured the TR34/L98H mechanism. Microsatellite genotyping revealed these isolates had 
distinct genotypes to other Iranian and Dutch isolates harbouring the TR34/L98H mechanism 
(Mohammadi et al., 2016). 
 
Taiwan 
 
A study of A. fumigatus isolates collected from two hospitals in Taiwan from 2011 to 2014 
demonstrated a prevalence of ARAf of 6.5% (2/31 patients) (Wu et al., 2015). The three ARAf 
isolates were recovered from respiratory samples from two patients with pulmonary 
aspergillosis, and both were azole-naïve. Both isolates demonstrated multi-azole resistance to 
itraconazole, voriconazole and posaconazole and were also cross resistant to tebuconazole and 
penconazole, two azole fungicides used in agriculture. Cyp51A sequencing demonstrated all 
three isolates harboured the TR34/L98H mutation, and microsatellite genotyping showed one 
isolate was closely related to ARAf isolates harbouring the same mutation from the 
Netherlands, India, Iran and Australia, while the other two isolates clustered with other wild- 
type isolates included in the study, being genetically distinct from ARAf isolates found 
elsewhere in the world (Wu et al., 2015). 
 
Japan 
 
A study of isolates collected from 1994 to 2010 in one hospital in Japan reported a prevalence 
of ARAf of 13.8% (27/196 A. fumigatus isolates), and cyp51A G54E/W/R mutations were 
found in 14 isolates with resistance to itraconazole (n=9) and posaconazole (n=5) (Tashiro et 
al., 2012b). A selection of these isolates demonstrated acquired resistance due to the G54E 
mutation in one isolate from a CPA patient where, compared to earlier azole susceptible 
isolates, following itraconazole therapy, itraconazole and 
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posaconazole resistance and the mutation had developed (Tashiro et al., 2012a). Another study 
from Japan examining clinical and environmental isolates of A. fumigatus for ARAf found a 
prevalence of 9.1% (2/22 isolates) at one hospital amongst isolates collected from 2013 to 2015. 
Resistance to voriconazole was detected in all ARAf isolates, and one was found to harbour 
the G448S mutation. This isolate was sampled from a patient that had been treated with 
voriconazole for 85 days. Interestingly an earlier isolate collected prior to voriconazole 
treatment in this patient was azole susceptible (Toyotome et al., 2016). 
 
Tanzania 
 
A Tanzanian study investigating azole resistance amongst clinical isolates of fungi causing 
suppurative otitis media found five isolates of A. fumigatus all resistant to itraconazole with 
reduced susceptibility to posaconazole and voriconazole and harbouring the TR34/L98H 
mutation (Mushi et al., 2016). 
 
Poland 
 
In Poland Nawrot et al., 2018 found ARAf in 5/121 A. fumigatus clinical isolates (4.1%), with 
all isolates harbouring the TR34/L98H mechanism and demonstrating itraconazole resistance. 
Four of these isolates had cross-resistance to posaconazole and one isolate had cross-resistance 
to voriconazole (Nawrot et al., 2018). 
 
Australia 
 
There are limited azole resistance surveillance studies on Australian A. fumigatus isolates, with 
a resistance rate of 0% (van der Linden et al., 2015) to 2.2% (Kidd et al., 2015). In a study by 
Kidd and others (2015), cyp51A sequencing of resistant A. fumigatus isolates found the 
environmentally acquired resistance mechanism TR34/ L98H in two isolates, and single point 
mutations in four isolates (G54R, F46Y, Y431S, G448S respectively). Other single point 
mutations associated with the periphery of the protein were considered likely insignificant in 
terms of azole resistance (M172V, N248T, D255E, and E427K). Three resistant isolates had no 
cyp51A mutations. This study noted that one of the isolates harbouring the TR34/L98H mutation 
was potentially contracted in Europe; however, microsatellite typing 
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showed no relatedness to European or the other Australian isolates (Kidd et al., 2015). The 
other isolate could have been acquired from suburban Sydney. The authors called for further 
Australia-wide surveillance studies (Kidd et al., 2015). 
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Table 3. Summary of isolate details from clinical prevalence studies investigating azole resistant Aspergillus fumigatus. 
 
 
Study Country No. 
hospitals 
No. 
isolates 
tested 
No. isolates 
yielding Af (%) 
No. isolates yielding 
ARAf/Total Af isolates 
tested (%) 
No. patients with 
ARAf/Total patients 
with Af 
Chryssanthou 1997 Sweden NS 122 107/122 (87.7%) 4/107 (3.7%) NS 
Verweij et al., 2002 The Netherlands 21 170 170/170 (100%) 3/170 (1.8%) 1/114 (0.9%) 
Snelders et al., 2008 The Netherlands 1 1219 1219/1219 (100%) 41/1219 (3.4%) 32/1219 (2.6%) 
Snelders et al., 2008 The Netherlands 28 147 147/147 (100%) 22/147 (14.9%) 13/101 (12.8%) 
Snelders et al., 2008 Belgium, France, 
Sweden, Norway, United 
Kingdom#, Greece 
NS 317 317/317 (100%) 6/317 (1.9%) NS 
Howard et al., 2009 United Kingdom NS 519 519/519 (100%) 34/519 (6.6%) NS 
Klaassen et al., 
2010 
The Netherlands 14 209 209/209 (100%) 4/209 (1.9%) 4/209 (1.9%) 
Buied et al., 2010 United Kingdom NS 230 230/230 (100%) 64/230 (27.8%) NS 
Alanio et al., 2011 France 1 118 118/118 (100%) 1/118 (0.85%) 1/89 (1.12%) 
Lockhart et al., 
2011 
Multi-centre international 
(ARTEMIS) 
62 497 497/497 (100%) 29/497 (5.8%) NS 
Mortensen et al., 
2011a 
Denmark 1 133 NS NS 6/133 (4.5%) 
Mortensen et al., 
2011b 
Denmark 4 NS NS NS 2/112 (1.8%) 
van der Linden et 
al., 2011b 
The Netherlands 7 2062 1792/2062 (86.9%) 82/1792 (4.6%) 63/1192 (5.3%) 
100 
 
 
 
Morio et al., 2012 France 1 85 85/85 (100%) 9/85 (10.6%) 4/50 (8%) 
Burgel et al., 2012 France 1 131 285/285 (100%) 6/285 (2.1%) 6/131 (4.6%) 
Chowdhary et al., 
2012a 
India 1 103 103/103 (100%) 2/103 (1.9%) 2/85 (2.35%) 
Tashiro et al., 2012b Japan 1 196 196/196 (100%) 27/196 (13.8%) NS 
Bader et al., 2013 Germany NS 527 527/527 (100%) 17/527 (3.2%) NS 
Seyedmousavi et al., 
2013 
Iran NS 124 124/124 (100%) 4/124 (3.2%) NS 
van der Linden et 
al., 2013 
The Netherlands 7 1315 1315/1315 (100%) NS 63/921 (6.8%) 
Pham et al., 2014 USA NS 1026 1026/1026 (100%) 51/1026 (4.9%) NS 
Ahmed et al., 2015 Kuwait NS 16 16/16 (100%) 2/16 (12.5%) NS 
Choukri et al., 2015 France 2 165 165/165 (100%) 3/165 (1.8%) 3/134 (2.2%) 
Chowdhary et al., 
2015 
India 2117 1 685/2117 (32.4%) 12/685 (1.8%) NS 
Kidd et al., 2015 Australia NS 418 414/418 (99%) 9/414 (2.17%) NS 
van der Linden et 
al., 2015 
Multi-centre international 
(SCARE-network) 
22 3788 NS NS 46/1450 (3.2%) 
Wu et al., 2015 Taiwan 2 38 38/38 (100%) 3/38 (7.9%) 2/31 (6.5%) 
Mohammadi et al., 
2016 
Iran NS 172 172//172 (100%) 6/172 (3.5%) 6/142 (4.23%) 
Perveen et al., 2016* Pakistan NS 210 210/210 (100%) 14/210 (6.6%) NS 
Mushi et al., 2016 Tanzania 1 54 5/54 (9.3%) 5/5 (100%) 5/44 (11.4%) 
Alanio et al., 2016 France 1 68 68/68 (100%) 1/68 (1.5%) NS 
Zhao et al., 2016 France 1 20 19/20 (95%) 1/19 (5.3%) NS 
Toyotome et al., 
2016 
Japan 1 22 22/22 (100%) 2/22 (9.1%) NS 
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Lestrade et al., 2018 The Netherlands 1 25 25/25 (100%) 5/25 (20%) 5/432 (1.2%) 
Nawrot et al., 2018 Poland NS 121 121/121 (100%) 5/121 (4.1%) 5/109 (4.6%) 
Abbreviations: Af, Aspergillus fumigatus; ARAf, azole resistant Aspergillus fumigatus; NS, not stated. *abstract only
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2.3.13 Individual case reports of azole-resistant A. fumigatus 
 
Individual cases of ARAf have been reported throughout the world. 
 
Phenotypic and genotypic changes in serial isolates of A. fumigatus from a pulmonary 
tuberculosis patient with pulmonary aspergillosis in China receiving itraconazole therapy (Chen 
et al., 2005) demonstrated a change in in vitro MICs for itraconazole within six months of 
commencing treatment, from 0.25 mg/L prior to commencing therapy, to >16 mg/L. Two 
months after treatment stopped, the MIC had reduced again to 0.5 mg/L. Therapy was re-started 
and three more isolates were obtained over four to seven months, with a return to elevated MICs 
of >16 mg/L (Chen et al., 2005). Cyp51A gene sequencing was performed on all four resistant 
isolates, and the single point mutation M220I was identified in the first resistant isolate, with 
G54R identified in the remaining three resistant isolates. Internal transcribed spacer (ITS) 
region and random amplified polymorphic DNA (RAPD) assay genotyping demonstrated all 
isolates were identical, indicating they were likely the same A. fumigatus strain responding to 
different conditions induced through the disease course and treatment (Chen et al., 2005). 
However, other studies have since demonstrated co-infection with azole susceptible and azole 
resistant strains of A. fumigatus (de Valk et al., 2007, Kolwijck et al., 2016). 
 
Multi-azole resistance was reported in a United Kingdom patient treated with itraconazole for 
over three years then voriconazole for over a year for cavitary aspergillosis with aspergillomas 
(Howard et al., 2006). Six isolates of  
A. fumigatus, collected over 17 months following prolonged treatment with both drugs, 
consistently demonstrated high MICs of itraconazole and voriconazole. Cyp51A sequencing on 
the first two isolates revealed the G138C mutation. The patient then received caspofungin for 
over 12 months until dying of respiratory failure attributed to infection (Howard et al., 2006). 
 
A Belgian patient with multiple myeloma (Vermeulen et al., 2012) and mould-active azole-
naïve was diagnosed with pulmonary IA. CLSI M38-A2 protocol susceptibility testing showed 
the sampled isolate was voriconazole resistant (>16 mg/L) and had elevated MICs for 
itraconazole (4 mg/L) and 
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posaconazole (1 mg/L) (Vermeulen et al., 2012). The patient was initially treated with an azole 
antifungal as part of a double-blinded clinical trial but was withdrawn from the trial following 
poor clinical response and started on liposomal amphotericin B. IA then spread to involve the 
eye and brain and the patient died. The isolate harboured the TR46/Y121F/T289A mutation. 
This mutation, first discovered in 2011 in clinical A. fumigatus isolates from the Netherlands 
(Camps et al., 2011), is associated with higher MICs of voriconazole compared to itraconazole, 
which contrasts with the TR34/L98H mutation that generally has higher MICs for itraconazole 
(Vermeulen et al., 2012). 
 
The TR46/Y121F/T298H cyp51A resistance mechanism was also identified in two case reports 
from French patients (Lavergne et al., 2015, Lavergne et al., 2017). One reported itraconazole 
and voriconazole resistance in a CF patient with a history of itraconazole and voriconazole 
exposure and found the same mutation in soil isolates from a wheat field in the region but not 
close to the patient’s home (Lavergne et al., 2015). The other report, which described a patient 
with IA infected by an A. fumigatus isolate with high MICs of itraconazole and voriconazole, 
found genotypically identical isolates at the patient’s home (garden and house) four months 
after the patient had died (Lavergne et al., 2017). The patient lived in an agricultural region, 
and nearby crops found ARAf harbouring the TR34/L98H mutation, with a high prevalence of 
ARAf noted of 19% (38/200 A. fumigatus isolates) (Lavergne et al., 2017). The 
TR46/Y121F/T289A resistance mechanism has also been reported associated with voriconazole 
resistance in patients from Denmark (Astvad et al., 2014), Germany (Fischer et al., 2014), Spain 
(Peláez et al., 2015) and Japan (Hagiwara et al., 2016). 
 
ARAf was first described in a German patient in 2012 (Rath et al., 2012). The patient had been 
diagnosed with aspergilloma and was treated with oral voriconazole for nine months prior to 
presentation for lung lobectomy due to treatment failure. ARAf was recovered from a sputum 
sample, with resistance to itraconazole (>16mg/L) and voriconazole (4mg/L), and intermediate 
susceptibility to voriconazole (0.5 mg/L), with the mutation TR34/L98H identified on cyp51A 
sequencing (Rath et al., 2012). A second report from the same year described an acute myeloid 
leukaemia patient with IA also due to ARAf. The patient had been on a short course of 
posaconazole treatment (14 days) when the pan-azole resistant sample was isolated. The isolate 
also harboured the TR34/L98H mutation (Hamprecht et al., 2012). 
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The first Spanish case of ARAf due to the TR34/L98H mechanism was also isolated from a 
patient with IA on long-term azole therapy (Mellado et al., 2013). This patient also had chronic 
myeloid leukaemia and had received an allogeneic hematopoietic cell transplantation. Multiple 
isolates of A. fumigatus were obtained from the patient during treatment. Initially the first 
isolate was susceptible to azole therapeutics, however in vitro testing on a second isolate 
collected after nine months of azole therapy (one month itraconazole and eight months 
voriconazole therapy) demonstrated resistance, and a third azole resistant A. nidulans isolate 
was collected after twelve months of voriconazole therapy (Mellado et al., 2013). It is unknown 
if resistant isolates were due to chronic therapy or if different strains of azole-susceptible and 
azole-resistant A. fumigatus and A. nidulans were already present in the patient (i.e. acquired 
environmentally) and azole treatment selected for the latter. The environmentally associated 
cyp51A mutation TR34/L98H was, however, found in the resistant A. fumigatus isolate. The 
authors suggested that any patient on long-term azole therapy should have regular isolate 
sampling and antifungal susceptibility testing performed to monitor for the development of 
azole resistance (Mellado et al., 2013). 
 
A patient from Japan on long-term itraconazole therapy for pulmonary aspergillosis with 
itraconazole resistance harboured a G54 cyp51A mutation (Tashiro and Izumikawa, 2016), and 
the TR34/L98H mutation was also found in an azole-naïve cancer patient from Japan being 
treated for pulmonary aspergillosis (Toyotome et al., 2017). The TR34/L98H mechanism has 
also been found in azole-naïve and azole-exposed IA patients in Denmark (Astvad et al., 2014). 
 
Most recently ARAf has also been reported in South America (Argentina) in a human patient 
with no previous azole exposure suffering fungal keratitis. The isolate was itraconazole 
resistant and harboured the G54E mutation (Leonardelli et al., 2017). 
 
2.3.14 Antifungal susceptibility profiles in infections involving multiple A. fumigatus 
genotypes 
 
Multiple genotypes of A. fumigatus have been isolated from infected lung lesions, further 
complicating successful disease control (de Valk et al., 2007). Different azole profiles (resistant 
and susceptible) have been identified in isolates of A. fumigatus collected at the same time from 
the same patient. This may be due to environmentally acquired infection or from azole-therapy 
induced selection. 
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Voriconazole resistant and susceptible A. fumigatus coinfection was reported amongst patients 
in the Netherlands (Kolwijck et al., 2016). One patient with signs of respiratory and renal 
insufficiency, that was started on voriconazole therapy but died of multiorgan failure within 24 
hours of presentation to an ICU unit, had two pan-azole resistant isolates harbouring the 
TR34/L98H mutation (from BAL and left lung tissue), and one isolate that was azole susceptible 
(tissue right lung) with wild-type cyp51A. Another patient with IA that presented with 
pneumonia following renal transplantation for diabetic nephropathy was treated with 
voriconazole after culturing a voriconazole susceptible A. fumigatus isolate from a BAL sample 
(Kolwijck et al., 2016). Ten days after commencing therapy, two bronchial aspirate samples 
were cultured, one being susceptible to voriconazole with wild-type cyp51A, the other being a 
voriconazole-resistant A. fumigatus isolate sampled harbouring the TR46/Y121F/T289A 
mutation. The patient died after just over a month of therapy with voriconazole and 
anidulafungin, and at autopsy wild-type cyp51A isolates were sampled from multiple 
pulmonary nodules, one renal lesion and a cavitary pulmonary lesion in the right lung lobe, 
which also demonstrated voriconazole susceptibility on in vitro antifungal susceptibility testing 
(Kolwijck et al., 2016). A third immunocompromised post-renal transplant patient with IA had 
a voriconazole-susceptible A. fumigatus isolate sampled from BAL and was started on 
voriconazole, however therapy was stopped after only six days as evidence of IA was deemed 
to be limited based on galactomannan and CT scan results. However, follow up CT scan 
confirmed lesions typical of IA, with voriconazole-resistant A. fumigatus with the TR34/L98H 
mutation isolated from sputum sample, and the patient was switched to liposomal amphotericin 
B. Follow-up sputum sampling nine days later cultured voriconazole-susceptible A. fumigatus 
from sputum. Anidulafungin was also added to the treatment regime, however the patient re- 
presented with delirium and an MRI revealed two brain lesions, with frontotemporal cerebral 
lobe biopsy showing large B-cell lymphoma and a voriconazole-resistant A. fumigatus isolate 
with TR34/L98H mutation was also cultured from brain biopsy tissue; the patient died two 
weeks later (Kolwijck et al., 2016). These cases highlight the difficulties in treating 
aspergillosis in areas where azole resistant A. fumigatus are prevalent. The authors suggested 
that in regions where environmental isolates of A. fumigatus have identified cyp51A mutations, 
co-infection with azole-susceptible and azole-resistant isolates should be anticipated and 
necessitate the close monitoring of IA patients that have recovered azole-susceptible A. 
fumigatus isolates. They also questioned the use of azole monotherapy in regions with the 
environmental mutations TR34/L98H and TR46/Y121F/T289A (Kolwijck et al., 2016). 
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The array of available antifungal therapeutics is limited and azole drugs are of vital importance 
for prophylaxis and treatment of aspergillosis in human patients, making the spread of ARAf 
throughout the world a major concern for the medical community, and necessitating ongoing 
surveillance for resistance. 
 
2.3.15 Environmental antifungal use and the development of azole resistance 
 
Antifungal pesticides are used on agricultural crops throughout the world to protect from 
spoilage and prevent substantial economic losses and shortage of supply. Globally azole 
fungicides (DMIs) are used for this purpose. These drugs are closely related to the medical 
triazoles used to treat aspergillosis. European cereal production is heavily reliant on the use of 
fungicides for agriculture, being one of the biggest users worldwide (Kuck and Russell, 2006). 
 
Environmentally acquired mutations are most commonly reported amongst clinical isolates of 
A. fumigatus, and their presence in the environment has been associated with the use of azole 
fungicides in agriculture (Snelders et al., 2009, van der Linden et al., 2011, Snelders et al., 
2012). Agricultural use of low-cost and broad spectrum azole fungicides is a global practice 
for food safety and protection of crops against plant fungal pathogens such as rusts and mildews 
(Price et al., 2015). Azole fungicides, including epoxiconazole, tebuconazole, bromuconazole, 
difenconazole, propiconazole and metconazole, in use since the 1990s, are structurally similar 
to those used for medical therapies (Snelders et al., 2009, Snelders et al., 2012). They are the 
most commonly used agricultural fungicides in Europe (Snelders et al., 2012, Price et al., 2015, 
Meis et al., 2016) and they have been demonstrated to induce cross-resistance to medical 
triazole drugs in laboratory tests (Snelders et al., 2009, Snelders et al., 2012). Studies from 
Europe have demonstrated this agricultural azole fungicide application has led to mutations in 
the cyp51A gene causing azole-resistance in A. fumigatus isolates. It has been demonstrated 
that the TR34/L98H mutation arose in the late-1990s from the agricultural application of azoles, 
with the allele spreading throughout the world’s population of A. fumigatus (Snelders et al., 
2009, Verweij et al., 2009b, Chowdhary et al., 2013). The ability for A. fumigatus isolates with 
prolonged exposure to agricultural azoles to develop resistance due to cyp51A mutations to 
medical azoles has also been demonstrated in the laboratory setting (Ren et al., 2017). 
 
ARAf is thought to develop through the long-term use of azole therapy leading to selection 
pressure for azole resistant A. fumigatus, or from environmentally acquired azole resistant 
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strains of A. fumigatus (Stensvold et al., 2012). The TR34/L98H mechanism is the most 
commonly reported cause of ARAf, being found in both azole-naïve and azole-exposed 
patients. For this reason this mode of resistance is thought to be environmentally acquired. The 
development and spread of environmentally acquired ARAf has been linked to the use of DMI 
fungicides for crop protection. Five commonly used DMIs have been demonstrated to have 
similar mechanisms of action against A. fumigatus as medical triazoles - epoxiconazole, 
bromuconazole, propiconazole, tebuconazole and difenconazole. All these DMIs were in use in 
the Netherlands prior to the report of the first TR34/L98H mutation in the late 1990s (Snelders 
et al., 2009, Snelders et al., 2012). Other cyp51A resistance mechanisms that are thought to be 
environmentally acquired include the TR46/Y121F/T289A and G54 (van der Linden et al., 
2013, Sharma et al., 2015). An investigation into the exposure concentrations for DMIs in their 
various applications in the health, agricultural and materials industries demonstrated the highest 
exposure concentrations occur during medical therapy and treatments applied to wood, certain 
fruits and seeds, with greatly lowered exposure rates (up to 100 times lower) when DMIs are 
applied to crops (Gisi, 2014). Thus on the basis that medical treatment is prolonged and fruit 
and seed applications tend to only occur once per season, the study concluded the likeliest 
source of resistance development is medical treatments (Gisi, 2014). However for azole-naïve 
patients, environmental origin of ARAf is more plausible.  
 
Environmental ARAf have been isolated in Europe, Asia, North and South America and Africa, 
with a prevalence of between 0 – 91%, and the majority of reported mutations due to 
TR34/L98H (Table 4). Studies that have screened for ARAf in the environment have 
investigated air, soil, organic debris and composts (Snelders et al., 2009, Mortensen et al., 2010, 
Chowdhary et al., 2012b, Badali et al., 2013, van der Linden et al., 2013, Chowdhary et al., 
2014b, Prigitano et al., 2014, Chowdhary et al., 2014a, Ahmad et al., 2014, Sharma et al., 2015, 
Bader et al., 2015, Kano et al., 2015, Le Pape et al., 2016, Toyotome et al., 2016, Jeanvoine et 
al., 2017, Zhang et al., 2017, Hurst et al., 2017, Tangwattanachuleeporn et al., 2017, Ren et al., 
2017, Santoro et al., 2017). Environmental investigations from the Netherlands have 
demonstrated a high prevalence of ARAf in the environment. One study reported a 7% (20/297 
environmental indoor and outdoor isolates) prevalence of itraconazole resistance, and the 
TR34/L98H mechanism was found in 86% of isolates that underwent cyp51A sequencing (13/15 
isolates) (Snelders et al., 2009). Microsatellite genotyping of these isolates found they clustered 
with Dutch clinical ARAf strains harbouring the same mutation (TR34/L98H). Clinical and 
environmental isolates were also tested for resistance to DMIs, demonstrating tebuconazole 
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and metconazole resistance in itraconazole resistant isolates (Snelders et al., 2009). Another 
study screening for azole resistant isolates found a total of 140 ARAf isolates from indoor and 
outdoor air samples taken at hospitals and patient domiciles, with 90% (126) of these 
harbouring the TR34/L98H mechanism and 10% (14) the TR46/Y121F/T289A mechanism (van 
der Linden et al., 2013). Another study found a high prevalence of ARAf in composts treated 
with azoles (91%, 41/45 isolates) compared to azole free compost (2%, 1/50 isolates) (Zhang 
et al., 2017). Of these ARAf compost isolates, 80% had the cyp51A mechanism 
TR46/Y121F/T289A, 2% had TR46/Y121F/M172I/T289A/G448S and 9% had a novel 
mechanism associated with pan-azole resistance, TR46
3/Y121F/M172I/T289A/G448S (Zhang 
et al., 2017). 
 
A French study investigating the prevalence of ARAf in 20 French sawmills, found a 3% 
prevalence in substrate samples (20/600 samples) (Jeanvoine et al., 2017). A total of 24 ARAf 
strains were isolated, with 83% (20/24) harbouring the TR34/L98H mechanism, two strains with 
TR34/L98H/S297T/F495I, one with P216L and one with no mutations or promoter region 
changes. Seventeen of 24 ARAf isolates were taken from eight sawmills that used DMIs 
propiconazole and tebuconazole to treat wood via dipping in azole tanks, with 14/17 of these 
isolates sampled from tank areas (Jeanvoine et al., 2017). 88% (21/24 isolates) were pan-azole 
resistant to itraconazole, voriconazole, posaconazole and isavuconazole, and were also resistant 
to tebuconazole and propiconazole. One strain had itraconazole resistance only, another 
itraconazole and posaconazole resistant, and one had resistance to itraconazole, posaconazole 
and isavuconazole with intermediate voriconazole susceptibility. The authors also found a 
significant increase in ARAf isolates from sawmills that used both propiconazole and 
tebuconazole DMIs (Jeanvoine et al., 2017). 
 
An Italian study investigating the presence of ARAf in environmental soil isolates from 
vineyards, gardens and agricultural crops found a high prevalence of 13%, with 6/47 samples 
growing ARAf isolates (Prigitano et al., 2014). Nine ARAf isolates were obtained and all had 
high MICs for itraconazole and posaconazole, and seven isolates also had elevated MICs for 
voriconazole. Cyp51A sequencing revealed seven isolates carried the TR34/L98H mechanism, 
one isolate had a number of single point mutations including F46Y/M172V/N248T/D255E and 
the remaining isolate had no mutations or changes to the promoter region of the cyp51A gene 
(Prigitano et al., 2014). Another study examining environmental isolates from Italy, Spain and 
Hungary found no ARAf in compost and silage samples tested for susceptibility to the DMIs 
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epoxiconazole and difenconazole, the medical triazole posaconazole and the veterinary azole 
enilconazole (Santoro et al., 2017). Only one isolate from green compost in Hungary showed 
reduced susceptibility to posaconazole, and no cyp51A mutations commonly associated with 
azole resistance were found amongst 15 isolates tested (Santoro et al., 2017). 
 
An Indian study investigating environmental soil and air isolates found a prevalence of ARAf 
of 5% (24/486 samples) (Chowdhary et al., 2012b). Resistant isolates grew from soil from tea 
gardens, cotton trees, rice paddy fields, hospital garden flower pots, soil containing bird 
droppings and air from hospital ward. Isolates demonstrated pan-azole resistance and all had 
the TR34/L98H gene, and were demonstrated to be genetically identical on microsatellite testing 
(Chowdhary et al., 2012b). A study from Thailand looking at azole resistance in agricultural 
environmental isolates of A. fumigatus found a prevalence of 3.3% (10/308) 
(Tangwattanachuleeporn et al., 2017). All the isolates were resistant to itraconazole, with 8/10 
isolates carrying the TR34/L98H Cyp51A mutation and two isolates also showed posaconazole 
resistance and carried the G54R mutation, while one isolate also had resistance to voriconazole 
(Tangwattanachuleeporn et al., 2017). An Iranian study investigating ARAf in soil from 
hospital surroundings found a prevalence rate of 3.3%, and all carried the TR34/L98H mutation 
(Badali et al., 2013). The isolates were found to be related to Dutch and Indian clinical and 
environmental ARAf isolates that also harboured the TR34/L98H mechanism (Badali et al., 
2013). Interestingly, a study from Japan investigating air samples from a pumpkin farm where 
tetraconazole was used twice a year for 15 years found a prevalence of ARAf isolates of 0% 
(Kano et al., 2015), and a second study from Japan investigating soil isolates from farms where 
tetraconazole and tebuconazole were used also found an ARAf prevalence of 0% (Toyotome 
et al., 2016). 
 
A recent study from China found an ARAf prevalence of 4.1% (3/73 isolates) in greenhouse 
agricultural soil (Ren et al., 2017). Two of the resistant isolates demonstrated voriconazole 
resistance and had the TR46/Y121F/T289A mechanism, and one isolate with itraconazole 
resistance had the TR34/L98H/S297T/F495I mechanism (Ren et al., 2017). A Tanzanian study 
found ARAf in 13.9% of environmental isolates of soil and woody debris from the grounds of 
a medical centre, with 11/15 isolates carrying the TR34/L98H mutation (pan-azole resistance) 
and 4/15 the TR46/Y121F/T289A mutation (high MICs of voriconazole and isavuconazole) 
(Chowdhary et al., 2014b). Interestingly the genotype for the TR46/Y121F/T289A strains was 
identical to Dutch clinical isolates harbouring the same mutation, while the TR34/L98H 
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mutation was identical to a clinical isolate from India (Chowdhary et al., 2014b). More recently 
tulip plant bulbs imported from the Netherlands to Ireland were noted to harbour ARAf isolates, 
and ARAf isolates with the TR34/L98H mutation and the TR46/Y121F/T289A mutation were 
also found in the environment (soil, compost and air) in Ireland (Dunne et al., 2017), and as 
mentioned above, at the home of a patient with ARAf in France (Lavergne et al., 2017). The 
TR34/L98H mutation has also been isolated from compost of azole sprayed peanut crops in the 
USA (Hurst et al., 2017). In France ARAf with the mutation TR34/L98H has been isolated from 
the environment of sawmills, with a significant link made between the number of ARAf strains 
and the quantity of propiconazole fungicide present (Jeanvoine et al., 2017). A Danish study 
reported an ARAf prevalence of 11% (4/38 A. fumigatus isolates) in soil samples from hospital 
surroundings and flowerbeds, all harbouring the TR34/L98H mechanism (Mortensen et al., 
2010). The same study also investigated soil samples from Spain and Austria, with no ARAf 
found (Mortensen et al., 2010). 
 
In a letter to the Editor, a research group screening for ARAf on itraconazole or voriconazole 
supplemented agar amongst soil samples from flower fields and greenhouses in Colombia 
identified 20 A. fumigatus resistant strains (Le Pape et al., 2016). Cyp51A sequencing revealed 
diverse genotypic resistance mechanisms, including TR34/L98H (n=1), TR46/Y121F/T289A 
(n=17) and TR53 (n=1), while one isolate had wild-type cyp51A (Le Pape et al., 2016). A more 
recent study published by the same group investigating itraconazole and voriconazole 
resistance in soil isolates of A. fumigatus from Colombian flower fields and flower beds found 
a prevalence of ARAf of 9.3% (8/86 soil samples) and the resistance mechanisms 
TR46/Y121F/T289A (associated with itraconazole and voriconazole resistance), TR34/L98H 
and TR53 (associated with itraconazole resistance only) were also found. Soil samples were 
examined for fungicide residues and the DMIs tetraconazole, penconazole, tebuconazole and 
difenconazole were found in flower crop soil, with no residues identified in public gardens soil 
samples (Alvarez-Moreno et al., 2017). 
 
Single point mutations in G54 leading to amino acid changes have been associated with 
resistance to itraconazole and posaconazole, and were originally thought to develop in patients 
on azole therapy. However a recent study reported this mutation (G54E) in environmental 
isolates collected in India (20% of ARAf isolates tested), Tanzania (46.4% of ARAf isolates 
tested) and Romania (30.4% of ARAf isolates tested) (Sharma et al., 2015). These isolates 
demonstrated resistance to itraconazole, posaconazole and the agricultural fungicides 
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penconazole, bromuconazole, difenconazole, epoxiconazole, cyproconazole, triadimefon, 
tricyclazole, tebuconazole and hexaconazole. They were susceptible to voriconazole, 
isavuconazole and the fungicide metconazole. Genotype analysis showed most G54E resistant 
isolates from Romania and Tanzania were identical, and all Tanzanian isolates were identical. 
These were distinct from Dutch clinical isolates harbouring this mutation (Sharma et al., 2015). 
The one Indian isolate with the G54E mutation demonstrated a distinct genotype to all other 
isolates examined. The authors of this study suggested long term exposure to agricultural 
fungicides likely led to selection for resistant phenotype and genotype in the environment. This 
study found an overall prevalence of ARAf in Tanzania, Romania and India of 26.4% (28/106), 
24.2% (23/95) and 9.6% (5/52) respectively (Sharma et al., 2015). 
 
A study on environmental isolates from indoor and outdoor hospital areas in Kuwait found pan-
azole resistance to itraconazole, voriconazole and posaconazole in 8/115 A. fumigatus isolates 
(7%) (Ahmad et al., 2014). All isolates harboured the TR34/L98H mechanism and microsatellite 
typing revealed three distinct groups of isolates, one group clustering with clinical and 
environmental isolates from India. There was no clustering of Kuwait isolates with Iranian, 
Asian or European isolates (Ahmad et al., 2014). Another Kuwait study examining triazole 
susceptibility (itraconazole, posaconazole and voriconazole) of environmental (n=50) and 
clinical (n=16) Aspergillus fumigatus isolates from single colonies demonstrated a mix of azole 
resistance and azole susceptible strains in serial dilutions of single colonies form three isolates 
(1 environmental, 2 clinical) (Ahmad et al., 2015). All resistant strains carried the TR34/L98H 
mutation. This demonstrated that A. fumigatus colonies could potentially be made up of 
different conidia (Ahmad et al., 2015). 
 
Another tandem repeat in the cyp51A gene of 53 base pairs has been identified in an A. 
fumigatus isolate from a patient with chronic granulomatous disease receiving itraconazole 
prophylaxis (Hodiamont et al., 2009). This patient developed osteomyelitis due to A. fumigatus, 
and the recovered isolate was resistant to itraconazole and voriconazole, with reduced 
susceptibility to posaconazole (Hodiamont et al., 2009). This 53bp mutation has also been 
found in Colombian environmental isolates of A. fumigatus that were resistant to itraconazole 
(Le Pape et al., 2016, Alvarez-Moreno et al., 2017). 
 
To date there have been no environmental prevalence investigations for ARAf in Australia. 
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The apparent migration of ARAf from the Netherlands throughout Europe and into Asia and 
Africa is a public health concern that should be monitored globally. 
 
Table 4. Summary of sample and isolate details from environmental prevalence studies 
investigating azole resistant Aspergillus fumigatus. 
 
 
Study Country Substrate No. 
samples 
tested 
No. samples 
yielding AF 
(%) 
No. samples 
yielding 
ARAf/Total 
samples 
tested (%) 
No. ARAf 
isolates/Total 
AF isolates 
(%) 
Snelders et 
al., 2009 
The 
Netherlands 
Soil, compost, seeds, 
leaves 
79 49/79 (62%) 10/49 (20%) NS 
Snelders et 
al., 2009 
The 
Netherlands 
Hospital indoor air and 
water 
248 248/248 
(100%) 
5/248 (2%) 5/248 (2%) 
van der 
Linden et 
al., 2013 
The 
Netherlands 
Air from hospitals and 
domiciles 
21 NS 18/21 (86%) NS 
Zhang et al., 
2017 
The 
Netherlands 
Azole-exposed compost 6 6/6 (100%) NS 41/45 (91%) 
Zhang et al., 
2017 
The 
Netherlands 
Azole-naive compost 6 6/6 (100%) NS 1/50 (2%) 
Mortensen 
et al., 2010 
Austria Soil, compost 50  
144/185 (78%) 
0/49 (0%) 0 
Mortensen 
et al., 2010 
Denmark Soil, compost 76 4/76 (5%) 4/55 (7%) 
Mortensen 
et al., 2010 
Spain Soil, compost 59 0/59 (0%) 0 
Bader et al., 
2015 
Germany Soil 455 NS NS 55/452 (12%) 
Jeanvoine et 
al., 2017 
France Air in 20 sawmills 200 91/200 (46%) 0/200 (0%) 0 
Jeanvoine et 
al., 2017 
France Sawmill substrates in 20 
sawmills 
600 279/600 (47%) 20/600 (3%) 24/150 (16%) 
Prigitano et 
al., 2014 
Italy Soil from vineyards, 
agricultural crops, 
gardens, compost from 
garden centre and flower 
pots 
47 29/47 (62%) 6/47 (12.8%) NS 
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Santoro et 
al., 2017 
Italy Compost 56 NS NS 0/5 (0%) 
Santoro e et 
al., 2017 
Spain Compost 56 NS NS 0/20 (0%) 
Santoro et 
al., 2017 
Hungary Compost 56 NS NS 0/8 (0%) 
Badali et al., 
2013 
Iran Garden soil 150 NS 5/150 (3%) 5/41 (12%) 
Ahmad et 
al., 2014 
Kuwait Air, water and cotton 
swabs from 
indoor/outdoor 
environments, soil 
362 115/362 (32%) NS 8/115 (7%) 
Ahmad et 
al., 2015 
Kuwait Soil sample, hospital door 
swabs 
50 50/50 (100%) 1/50 (2%) 1/50 (2%) 
Chowdhary 
et al., 2014 
Tanzania Soil, woody debris 30 29/30 (97%) 6/30 (20%) 15/108 (14%) 
Sharma et 
al., 2015 
Tanzania Soil, woody debris 30  
73/81 (90%) 
10/30 (33%) 28/106 (26%) 
Sharma et 
al., 2015 
Romania Soil, woody debris 27 5/27 (19%) 23/95 (24%) 
Sharma et 
al., 2015 
India Soil, woody debris 24 5/24 (21%) 5/52 (9.6%) 
Chowdhary 
et al., 2012 
India Soil from crops, garden 
beds, flower pots, hospital 
gardens, containing bird 
droppings, air from 
hospital ward 
486 201/486 (41%) 24/486 (5%) 44/630 (7%) 
Chowdhary 
et al., 2014 
India Soil from agricultural 
crop and flower beds 
105 37/105 (35%) NS 14/126 (11%) 
Kano et al., 
2015 
Japan Air from azole-treated 
pumpkin farm 
50 NS 0/50 (0%)  
0/50 (0%) 
Toyotome et 
al., 2016 
Japan Soil from azole-treated 
farms 
11 11/11 (100%) 0/11 (0%) 0/91 (0%) 
Tangwattan- 
achuleeporn 
et al., 2017 
Thailand Soil 308 99/308 (32%) 10/308 (3%) 10/99 (10%) 
Ren et al., 
2017 
China Greenhouse soil 144 64/144 (44%) 3/144 (2%) 3/73 (4%) 
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Le Pape et 
al., 2016* 
Colombia Soil, flower fields and 
greenhouses 
38 20/38 (53%) 20/20 
(100%)# 
NS 
Hurst et al., 
2017 
USA Azole-treated peanut crop 
debris, soil 
34 8/34 (24%) NS 38/200 (19%) 
Abbreviations: ARAf, azole resistant Aspergillus fumigatus; AF Aspergillus fumigatus; NS not 
stated. *Letter to the Editor; #selected resistant A. fumigatus isolates for the study. 
 
 
2.3.16 Rapid diagnosis of azole-resistant A. fumigatus strains in the clinical setting 
 
More rapid methods of screening for azole resistance in the clinical setting are being introduced 
to identify resistant cases faster, including azole screening tests and molecular screening tests 
targeting cyp51A mutations that are well-known to confer azole resistance. 
 
In recent years the VIPcheck™ (AMT Plates (Balis Laboratorium V.O.F., Boven Leeuwen, the 
Netherlands) testing kit has been developed commercially in the Netherlands and demonstrated 
to be sensitive and specific for quick in-house screening of isolates against the most commonly 
used antifungal azole drugs itraconazole, voriconazole and posaconazole (van der Linden et 
al., 2009, van der Linden et al., 2013, van der Linden et al., 2015). The plate has four agar 
wells, with three containing itraconazole, voriconazole and posaconazole and one antifungal- 
free growth control well. Clinical testing of the kit has been performed as part of a national 
surveillance program in the Netherlands, where A. fumigatus isolates were screened for 
resistance using the kit and any positive isolates were sent for further testing at the National 
Mycology Reference Laboratory for further confirmation with microbroth dilution antifungal 
susceptibility testing and cyp51A gene sequencing (Lestrade et al., 2016). The test has been 
demonstrated to be a valuable screening test, with a reported sensitivity and specificity of 99% 
for detecting ARAf due to TR34/L98H, G54, M220 and TR46/Y121F/T289A (van der Linden 
et al., 2013, Lestrade et al., 2016, Arendrup et al., 2017b). The screening plate has the potential 
benefits of early ARAf detection for more appropriate therapeutic selection and increased 
ARAf screening made possible by this easy to use test could help uncover the true 
epidemiology of ARAf (Arendrup et al., 2017b). 
 
Targeted PCR assays have been developed to identify specific resistance associated mutations 
in A. fumigatus samples, including the resistance mechanisms TR34/L98H, and single point 
mutations. Molecular screening for ARAf was first successfully performed with a novel mixed- 
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format real-time PCR assay looking for the specific single point mutations L98, G54, M220 
and G138 and the promoter region (Klaassen et al., 2010). A total of 209 clinically relevant A. 
fumigatus isolates were tested for ARAf using the CLSI M38-A2 method. Four isolates 
demonstrated multi-azole resistance to itraconazole, voriconazole, posaconazole and 
isavuconazole. The TR34/L98H resistance mechanism was identified in all four resistant 
isolates in this study. This study also determined a low ARAf prevalence rate of 1.9% (4/209) 
amongst patients in the Netherlands (Klaassen et al., 2010). Another study developed a rapid 
real-time PCR method for detection of G54 mutations conferring resistance in A. fumigatus 
isolates (Balashov et al., 2005). 
 
Molecular technology has made screening for ARAf without a positive culture possible. A high 
prevalence of cyp51A mutations (55.1%) were found in sputum samples from patients with 
chronic fungal disease that were culture negative but had Aspergillus DNA on PCR (Denning 
et al., 2011a). TR34/L98H was detected in 75% (6/8) of patients with ABPA and the M220K 
(n=2) and M220R (n=2) mutations were detected in 50% (12/24) of patients with CPA 
(Denning et al., 2011a). More recently the AsperGenius® (PathoNostics, Maastricht, NL) assay 
has been demonstrated to be useful for identifying common azole mutations (TR34/L98H, 
T289A, Y121F) and Aspergillus species in BAL fluid (sensitivity 80% to 88.9%, specificity 
80% to 93.3%, positive predictive value 72.7% to 80%, negative predictive value 87% to 
93.3%), serum (sensitivity 78.6%, specificity 100%) and with varying reliability in plasma 
(sensitivity 80% to 100%, specificity 50 to 77.8%) (Chong et al., 2015, Chong et al., 2016, 
White et al., 2017, Chong et al., 2017, Montesinos et al., 2017, Schauwvlieghe et al., 2017). 
 
2.3.17 Azole-resistant A. fumigatus in veterinary patients 
 
There are few reports of A. fumigatus triazole resistance in the veterinary literature (Table 5). 
Studies on samples from domestic and wild birds and their environments in Europe and Asia 
have reported a resistance prevalence of 0 to 35.7% (Beernaert et al., 2009, Wang et al., 2014), 
however not all studies have investigated resistance mechanisms. One study found azole- 
resistant phenotypes amongst birds previously treated with itraconazole, however no cyp51A 
sequencing was performed (Beernaert et al., 2009). Another study looking at samples from 
poultry farms in France, where the imidazole parconazole had been used prophylactically, and 
China, where the poultry farm was azole naïve, found no azole resistant isolates. However on 
cyp51A sequencing nine single point mutations were found, including F46Y, M172V, N248T, 
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N248K, D255E, E427K, A116R, E130D, Q131H (Wang et al., 2014). A Polish study using the 
CLSI M44 disk diffusion and M38-A2 microbroth dilution testing standards found a high 
prevalence of 14.1% itraconazole resistance in A. fumigatus isolates form domestic geese, 
however cyp51A sequence analysis was not performed and no other resistance mechanisms 
were investigated or determined (Ziolkowska et al., 2014). Interestingly the avian isolates also 
demonstrated concomitant resistance to imidazoles and amphotericin B (Ziolkowska et al., 
2014). 
 
Table 5. Summary of veterinary studies investigating prevalence of azole-resistant strains of 
A. fumigatus 
 
 
Country 
(Publication) 
Animal 
Species 
Sample site No. A. 
fumigatus 
isolates 
Antifungal 
susceptibility 
testing method 
ARAf 
prevalence 
Cyp51A 
alterations 
Belgium, the 
Netherlands 
(Beernaert et 
al., 2009) 
Domestic 
and wild 
avian 
species 
Not 
specified 
59 Broth micro- 
dilution (CLSI 
M38-A2) 
6.8% Not tested 
France, 
China (Wang 
et al., 2014) 
Domestic 
Guinea 
fowl, 
turkeys and 
chickens, 
other avian 
species 
Pharyngeal 
swabs, 
laboratory 
collection 
isolates 
from birds 
with 
aspergillosis 
175 (124 
France, 
51 China) 
Etest 
(BioMerieux, 
Lyon, 
France), CLSI 
M38-A2 
0% F46Y 
M172V 
N248T 
N248K 
D255E 
E427K 
A116R 
E130D 
Q131H 
Poland 
(Ziolkowska 
et al., 2014) 
Domestic 
geese 
Oral swabs, 
environment 
85 Disk diffusion 
(CLSI M44) 
Broth micro- 
dilution (CLSI 
M38-A2) 
14.1% Not tested 
 
 
 
2.3.18 Cyp51A homology modelling 
 
A. fumigatus cyp51A homology models have explored the impact of amino acid changes 
(mutations) on azole drug interaction with the conserved cyp51A target protein site. As the 
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crystal structure of the A. fumigatus cyp51A gene has not yet been characterised, existing 
homology models have based on cyp51A crystal structures of other species, including bacteria 
(M. tuberculosis), humans (H. sapiens) and non-Aspergillus fungi (S. cerevisiae), all with 
varying percentage similarities to A. fumigatus cyp51A. These models offer predictions of the 
significance of A. fumigatus mutations (Lewis et al., 1999, Xiao et al., 2004, Zhao et al., 2007, 
Sheng et al., 2009, Snelders et al., 2010, Fraczek et al., 2011, Liu et al., 2016). The recent 
modelling of the A. fumigatus cyp51B gene, a paralogue gene of cyp51A that also conserves 
metabolic roles of 14-alpha-demethylase, demonstrated the closest percentage similarity with 
wild-type A. fumigatus cyp51A to date (Hargrove et al., 2015, Nash and Rhodes, 2017). 
 
Homology modelling has shown there are two ligand access channels to the active site of the 
cyp51A protein (the haem centre), and it is thought azole drugs utilise these channels to gain 
access to the target site (Snelders et al., 2010). Therefore mutations occurring close to the target 
protein have been determined to be more likely to affect azole docking access, and protein 
structural stability and amino acid changes occurring near the access channel openings are 
thought to disrupt azole molecules from docking to the protein, thereby enabling azole 
resistance (Snelders et al., 2010). Mutations on the less conserved periphery of the protein are 
less likely to be associated with azole resistance (Snelders et al., 2010). 
 
A study using the cyp51A crystal structure of M. tuberculosis (a 28% similarity to A. fumigatus 
cyp51A) concluded that mutations in G54, G138, M220 and L98H were all located close to one 
of the protein’s two ligand access channels and so likely interfered with azole molecule docking 
(Snelders et al., 2010). Other mutations located peripherally did not change the protein’s 
structural integrity and did not interact with azole drugs, including F46Y, N248T, M172V, 
L358L, E427K and D255E (Snelders et al., 2010). Another study then used the human cyp51A 
protein to develop a model for A. fumigatus (Fraczek et al., 2011). The human cyp51A protein 
had a higher similarity of 41% and demonstrated mutations at G54 and M220 could block 
binding channel access for the long-chain azoles itraconazole and posaconazole, and G448, 
positioned adjacent to the haem, could alter its position in the protein. The model could not 
demonstrate how L98H could alter its structure (Fraczek et al., 2011). A recent study using 
cyp51A modelling based on the fungus S. cerevisiae (similarity of 50% with A. fumigatus 
cyp51A protein) found mutations at L98, M220 and Y431 decrease binding affinity of azoles 
to the protein, and L98 and G432 mutations reduce protein stability (Liu et al., 2016). This 
study also observed that some mutations associated with azole resistance increased rather than 
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decreased protein model stability, including G54, G138, H147, G432 and F495 (Liu et al., 
2016). To date, the A. fumigatus cyp51B model with the closest percentage similarity to A. 
fumigatus cyp51A (59%) has only been used to demonstrate how the L98H mutation confers 
resistance, determining the histidine substitution forms hydrogen bonds with neighbouring 
polar side chains that decreases the active site surface, potentially interfering with the azole 
drug binding process (Nash and Rhodes, 2017). 
 
Protein homology modelling offers a prediction of the significance of A. fumigatus cyp51A 
mutations that is limited by its similarity to cyp51A in other biological species and potential 
differences in functionality to other cyp51 genes in the same species. 
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Chapter 3. Australian environmental investigation for cryptic and 
pathogenic Aspergillus species and discovery of a novel species, 
Aspergillus frankstonensis 
 
3.1 Introduction 
 
This first study investigates how cats are exposed to the most common agent of feline upper 
respiratory tract aspergillosis Aspergillus felis in the Australian environment. Prior to this 
study, the majority of A. felis isolates had originated from clinical patients (5 human and 18 
veterinary (1 dog, 17 cats)) (Barrs et al., 2013), with only a small number of environmental 
isolates located (one from an indoor air sample, four from soil in the USA, one each from soil 
in India, Zambia and the Czech Republic, one from a pine tree in Sri Lanka and one from food 
in Japan) (Barrs et al., 2013, Nováková et al., 2014). Interestingly, although the majority of 
clinical isolates of A. felis had originated in Australia (17/18) (Barrs et al., 2013), no isolates 
had yet been discovered in the Australian environment. Therefore an Australian environmental 
investigation was considered an important step in better understanding the pathogenesis of this 
disease and how cats are potentially exposed to infection by cryptic Aspergillus species. 
Additionally, given the ability of this fungus to cause disease in humans as well as animals, the 
prevalence of this species within the Australian environment was of relevance to both the 
veterinary and medical communities. 
 
3.2 Premise 
 
The publication in this chapter includes research into the environmental niche of A. felis and 
other opportunistic pathogenic cryptic species in the A. viridinutans species complex and A. 
section Fumigati in Australia. 
 
This study utilised fungal environmental isolation techniques, including soil and air sampling. 
These substrates were selected as the most likely sources of A. felis based on previous 
environmental isolates (Barrs et al., 2013, Nováková et al., 2014). Agar type (dichloran rose- 
bengal agar with chloramphenicol (DRBC) and malt extract agar supplemented with 
chloramphenicol (MEASC), soil processing and incubation temperatures were chosen to favour 
growth of Aspergillus viridinutans species complex (AVSC) members, with the 
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inclusion of a heating diluted soil step to activate ascospores potentially in the soil (Houbraken 
and Samson, 2006, Kidd et al., 2009, Samson et al., 2010, Nováková et al., 2014). 
Morphological identification methods were then used to select Aspergillus species and 
molecular identification methods were used to identify genus and species level via 
amplification of the ITS region and partial beta-tubulin gene (White et al., 1990, Glass and 
Donaldson, 1995). Following this, other substrates were also tested, including cat food (dry 
commercial food) and different cat litter substrates. 
 
This investigation spanning 2014 to 2016 included sampling locations along the east coast of 
Australia. For sample collection I visited the homes of cats that had been infected with 
aspergillosis, the majority of whom had succumbed to the disease. I developed a survey for the 
owner to complete regarding their cat’s habits and husbandry related items (see Appendix 1). 
On arrival at their homes I discussed with owners their cat’s case, habits and own 
environmental niches within their properties to attempt to narrow down collection sites. 
 
During the investigation I recovered Aspergillus isolates whose species identity could not be 
resolved based on ITS and partial beta-tubulin sequencing due to low percentage homology on 
BLAST analysis of the sequences and further phylogenetic analysis of the isolates was 
required. I performed this at the Westerdijk Institute in the Netherlands, funded by an 
Endeavour Research Fellowship from the Australian Government under the supervision of Dr 
Jos Houbraken and Dr Robert Samson. Based on morphological analysis (measurements and 
description of growth on multiple agar types at different temperatures), further phylogeny 
evaluation (amplification of partial calmodulin, RPB2 and actin genes and the MCM7 gene 
using novel primers, with Mr Bayes and RAxML phylogenetic analysis in concordance with 
the genealogical concordance phylogenetic species recognition rules) and exometabolite 
analysis under the supervision of Dr Jens Frisvad at the Technical University of Denmark, I 
further characterise a suspected novel species as well as other AVSC isolates I had sampled 
from the Australian environment (Smedsgaard, 1997, Hong et al., 2005, Stamatakis, 2006, 
Nielsen et al., 2011, Ronquist et al., 2011, Sugui et al., 2014). At the Westerdijk Institute I had 
the added opportunity to examine AVSC clinical and environmental isolates within their 
Mycobank collection and was able to perform further sequencing of these isolates to include in 
the phylogenetic analysis when assessing the potential new species. 
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A bank of important isolates from this investigation have been deposited into the Mycobank 
private collection of Professor Vanessa Barrs at the University of Sydney as well as to the 
Westerdijk Institute public collection and Technical University of Denmark collection. 
 
This paper represents the discovery of not only the prevalence of Aspergillus species in 
Australian domestic dwellings, but also the discovery of a novel species belonging to the AVSC 
in Australia, A. frankstonensis sp. nov. . 
 
3.3 Publication 
 
The following publication has been re-formatted here to suit the style of this thesis. The 
publication’s in-text references remain in the style required by the journal (number bracket 
form) and the publication associated tables, figures, references and supplementary data follow 
the main text. This research is presented in its original publication form in Appendix 2. A list 
of all other references referred to in this chapter outside of section 3.3 Publication can be found 
at the chapter’s end (see 3.5 References). 
 
Talbot JJ, Houbraken J, Frisvad JC, Samson RA, Kidd SE, Pitt J, Lindsay S, Beatty JA, Barrs 
VR. Discovery of Aspergillus frankstonensis sp. nov. during environmental sampling for 
animal and human fungal pathogens. PLoS ONE. 2017; 12(8): e0181660. 
https://doi.org/10.1371/journal.pone.0181660. 
 
Abstract 
 
Invasive fungal infections (IFI) due to species in Aspergillus section Fumigati (ASF), including 
the Aspergillus viridinutans species complex (AVSC), are increasingly reported in humans and 
cats. The risk of exposure to these medically important fungi in Australia is unknown. Air and 
soil was sampled from the domiciles of pet cats diagnosed with these IFI and from a nature 
reserve in Frankston, Victoria, where Aspergillus viridinutans sensu stricto was discovered in 
1954. Of 104 ASF species isolated, 61% were A. fumigatus sensu stricto, 9% were AVSC (A. 
felis-clade and A. frankstonensis sp. nov.) and 30% were other species (30%). Seven pathogenic 
ASF species known to cause disease in humans and animals (A. felis-clade, A. fischeri, A. 
thermomutatus, A. lentulus, A. laciniosus A. fumisynnematus, A. hiratsukae) comprised 25% of 
isolates overall. AVSC species were only isolated from Frankston soil where they were 
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abundant, suggesting a particular ecological niche. Phylogenetic, morphological and 
metabolomic analyses of these isolates identified a new species, A. frankstonensis that is 
phylogenetically distinct from other AVSC species, heterothallic and produces a unique array 
of extrolites, including the UV spectrum characterized compounds DOLD, RAIMO and 
CALBO. Shared morphological and physiological characteristics with other AVSC species 
include slow sporulation, optimal growth at 37˚C, no growth at 50˚C, and viriditoxin 
production. Overall, the risk of environmental exposure to pathogenic species in ASF in 
Australia appears to be high, but there was no evidence of direct environmental exposure to 
AVSC species in areas where humans and cats cohabitate. 
 
Introduction 
 
Aspergillosis is an opportunistic respiratory or systemic disease affecting a range of 
mammalian, avian and reptile hosts globally. It is most commonly caused by fungi belonging 
to Aspergillus section Fumigati (ASF), of which 19 of 63 described species are known to be 
pathogenic [1, 2]. The saprophytic, ubiquitous fungus Aspergillus fumigatus sensu stricto is the 
most common cause of aspergillosis overall. However, other species within the section, 
including members of the Aspergillus viridinutans species complex (AVSC) are increasingly 
recognized as emerging causes of invasive fungal infections (IFI). Currently, of the 10 accepted 
species in the AVSC, six are known pathogens including A. udagawae, A. felis, A. 
wyomingensis, A. pseudoviridinutans, A. parafelis and A. pseudofelis [2–8]. 
 
Aspergillus felis, A. wyomingensis and A. udagawae cause an invasive form of fungal 
rhinosinusitis in systemically immunocompetent cats called sino-orbital aspergillosis [2, 4]. 
Infection is often fatal, with high MICs of azole antifungals recorded in vitro and clinical 
resistance in vivo [4, 9]. Aspergillus felis has been isolated from clinical samples in humans, 
cats, dogs and birds, demonstrating a broad range of susceptible hosts [4]. While feline sino- 
orbital aspergillosis has been reported in diverse geographic regions including Europe, the 
United States and Japan, the majority of cases are from Australia [4, 10]. Other, less common 
causes of feline fungal rhinosinusitis include A. fumigatus s. str., A. thermomutatus (syn. N. 
pseudofischeri), A. fischeri, A. lentulus and A. niger species complex [9–13]. 
 
Aspergillus felis was first isolated from infected cats in Australia [4]. It has since been isolated 
from environmental samples from the USA and from other countries with low to no disease 
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incidence, in soil (Czech Republic, India, Zambia) [14], Caribbean Pine (Sri Lanka) [14], 
indoor air (Germany) [4] and on desert rocks in Chile [15]. The environmental prevalence of 
A. felis and other pathogenic species in section Fumigati in Australia has not been investigated, 
so environmental risk factors for exposure are unknown. 
 
Here we report the findings of an investigation to determine if ASF species causing IFI in cats 
could be isolated from the home environments of cats with these infections. We also collected 
environmental samples from the region where A. viridinutans s. str. was first recovered and 
discovered a novel species, Aspergillus frankstonensis sp. nov. 
 
Materials and methods 
Sampling and isolation 
With the permission of private land owners, as per the University of Sydney Human Ethics 
Approval (project number 2014/980), soil and air samples were collected from yards and 
gardens where eight cats previously diagnosed with SOA due to A. udagawae (n = 2), A. felis 
(n = 5) and A. wyomingensis (n = 1) were domiciled (5 in New South Wales (NSW), 2 in 
Victoria (VIC), 1 in the Australian Capital Territory (ACT). These locations included urban (n 
= 6), rural (n = 1) and semi-rural (n = 1) properties. Samples were also collected from municipal 
nature reserves in the coastal town of Frankston in the Mornington Peninsula region, VIC, 
where A. viridinutans s. str. was originally isolated in soil and rabbit dung [16]. Permission to 
sample was granted by the Frankston City Council. Field studies did not involve endangered 
or protected species. 
 
A minimum of two air samples were collected at each site directly onto dichloran rose-bengal 
agar (DRBC) (Thermo Scientific, Thebarton, Australia) using a Merck Millipore MAS-100 
NT1 air sampler (Merck KGaA, Darmstadt, Germany) at a rate of 100L/minute [17]. Ten soil 
samples, including garden and lawn soils (sandy and loamy) and mulches (sugar cane, wood 
chip and straw hay) were collected at each site to a depth of 10 cm and stored at 4˚C. Isolation 
of fungi from soil was achieved by 10−1 to 10−4 serial dilutions with sterile water. The 
resulting dilutions were transferred to a Whirlpak1 (Nasco) homogenizer bag, heated at 75˚C 
for 30 min, and 0.1 mL was inoculated onto DRBC [14, 18]. Additionally, 17 representative 
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samples of different soil types from each location were processed using the same method 
without heat treatment. 
 
Samples of commercial cat litter substrates, including the same brands used by cats in the study 
(recycled paper pellets, clumping clay, recycled timber pellets and silica crystals), 
commercially available dry cat food samples were also tested in the same manner. 
 
Air samples were incubated in the dark for up to three weeks at 37˚C. Treated soil samples 
were cultured on DRBC and malt extract agar supplemented with chloramphenicol (MEASC) 
[19] for up to three weeks at 37˚C. Fungal colonies were sub-cultured onto malt extract agar 
(MEA) (Thermo Scientific Oxoid Microbiology Products, Thebarton, Australia; Landsmeer, 
Netherlands) [19] for further analysis. 
 
Identification of environmental isolates 
 
For environmental isolates with gross macro- and microscopic morphological features 
consistent with Aspergillus spp. (excluding Aspergillus section Nigri species), amplification 
and sequencing of the ITS region and partial β-tubulin (BenA) gene was performed for species 
identification as previously described [20, 21]. A BLAST [22] search on GenBank was 
performed with the newly generated sequences, which were also aligned with Aspergillus 
references sequences (Samson et al. 2014) using MEGA version 6 software [23]. Phylogenetic 
analysis was performed using the maximum likelihood discrete method (tree searching method 
of 1000 replicate trees) and bootstrapping to determine the statistical support of the nodes. 
 
Phylogenetic analysis of AVSC isolates. Nine environmental isolates identified in the AVSC 
were further examined based on molecular studies and phylogenetic analysis results of less 
than 100% match for A. felis (n = 7) and A. viridinutans (n = 2) ITS and BenA sequences. 
Additional molecular analysis was performed by sequencing partial calmodulin (CaM), actin 
(Act) and RNA polymerase II second largest subunit (RPB2) genes as previously described [8, 
24]. Specific primers targeting the minichromosome maintenance factor gene (Mcm7) were 
developed based on previously published primers [8]: MCM7-709F_Fum ACTCGTGTCTCG 
GACGTCAAACC (forward) and MCM7-1348R_Fum 
GATTTGGCRACACCAGGATCACCCAT (reverse). For comparative analysis, these genes 
were also sequenced for AVSC members in the CBS-KNAW collection and for a new clinical 
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isolate from the USA from a cat with SOA (see Table 1). Phylogenetic and molecular 
evolutionary analyses were conducted using Randomised Axelerated Maximum Likelihood 
(RAxML) and Bayesian methods [25, 26]. 
 
Phenotypic species differentiation. The physiology and macro- and micromorphology of the 
two isolates demonstrated to be phylogenetically distinct from other AVSC species (CBS 
142234 and CBS 142233) were studied. Isolates were grown at 25˚C on Czapek yeast agar 
(CYA) [19], Czapek yeast agar with 5% NaCl (CYAS) [27], yeast extract sucrose agar (YES) 
[19], MEA, oatmeal agar (OAT), creatine sucrose agar (CREA) [19], dichloran 18% glycerol 
agar (DG18) [28] for seven days. For temperature growth testing isolates were also grown on 
CYA at 30˚C, 37˚C, 45˚C and 50˚C for seven days. 
 
Extrolite analysis. Extrolite extraction was performed on the two phylogenetically distinct 
isolates after growth on CYA and YES agar at 25˚C and 37˚C for 7 days. Three agar plugs 
were extracted according to the agar plug extraction method of Smedsgaard [29]. Extracts were 
analysed using UHPLC-DAD (Dionex Ultramate 3000 UHPLC) and compounds were 
identified against an internal database of UV spectra and literature [30]. Extrolite standards 
were available as reported by Nielsen et al. [30]. 
 
Antifungal susceptibility testing. Antifungal susceptibility testing was performed on all AVSC 
environmental isolates, and the clinical isolate, using Sensititre YeastOne YO8 microdilution 
trays (Trek Diagnostic Systems, Thermo Fisher Scientific, Scoresby, Australia) to assess the 
minimum inhibitory concentration (MIC) values of posaconazole (POS), itraconazole (ITZ), 
voriconazole (VCZ), fluconazole (FLU), ketoconazole (KCZ), amphotericin B (AMB), and 
minimum effective concentration (MEC) of caspofungin (CSP) as previously described [31]. 
 
Mating type analysis. Mating type for all AVSC environmental isolates was determined by 
targeting the MAT1-1 and MAT1-2 genes [4]. Mating experiments were also performed on 
isolates with opposite mating types of the same species where available, or with other members 
of the AVSC where unavailable, on OAT and MEA in the dark at 30˚C. Ascospore viability 
tests were performed by rupturing ascomata, suspending ascospores in 0.05% Tween 80 and 
heating at 70˚C for 60 min. After heating, 100 μL of the ascospore suspension was plated on 
2% MEA and incubated at 28˚C for 24 h [32]. To act as a negative control, the same treatment 
was also applied to the conidia of paired parental strains from the mating plate. Scanning 
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electron microscopy was performed on all ascospores (Emitech 550K Sputter coater JEOL 
6480LA). 
 
Nomenclature. The electronic version of this article in Portable Document Format (PDF) in a 
work with an ISSN or ISBN will represent a published work according to the International 
Code of Nomenclature for algae, fungi, and plants, and hence the new names contained in the 
electronic publication of a PLOS article are effectively published under that Code from the 
electronic edition alone, so there is no longer any need to provide printed copies. 
 
In addition, new names contained in this work have been submitted to MycoBank from where 
they will be made available to the Global Names Index. The unique MycoBank number can be 
resolved and the associated information viewed through any standard web browser by 
appending the MycoBank number contained in this publication to the prefix http://www. 
mycobank.org/MB/. The online version of this work is archived and available from the 
following digital repositories: PubMed Central, LOCKSS. 
 
Results 
 
Sequence-based identification 
 
Overall 104 ASF species were isolated from all sites including 61% (n = 64) A. fumigatus s. 
str., 9% (n = 9) AVSC (A. felis-clade and A. frankstonensis sp. nov.) and 30% (n = 31) other 
ASF species (see S2 Table, S1 Fig) (Genbank accession numbers: KY808753-KY808856 
(ITS); KY808591- KY808694 (BenA)). Pathogenic ASF species (A. A. felis-clade (n = 7), A. 
fischeri (n = 6), A. thermomutatus (n = 1), A. lentulus (n = 2), A. laciniosus (n = 2), A. 
fumisynnematus (n = 4), A. hiratsukae (n = 1) comprised 25% of isolates overall. AVSC species 
were only isolated from Frankston soil where they were abundant and comprised 41% of 
isolates from that site. 
 
Aspergillus isolates were only recovered from three of the nine sampled locations when no heat 
treatment was used. Isolated species included A. fumigatus s. str. (Kealba, n = 1), A. hiratsukae 
(Frankston, n = 1; Amaroo, n = 1). Aspergillus fumigatus s. str. was also isolated from recycled 
paper cat litter. No Aspergillus species were isolated from other cat litter types and dry food 
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tested. The clinical isolate from the cat in the US (Table 1) was phylogenetically closely related 
to the type of A. parafelis, CBS 140762, in the A. felis-clade. 
 
Phylogeny. The length of the datasets were BenA 422 basepairs (bp), CaM 485 bp, Act 379 bp, 
RPB2 831 bp and Mcm7 450 bp. Phylogenetic analysis of combined BenA, CaM, Act, RPB2 
and Mcm7 data (2567 bp) confirmed seven isolates belong in the A. felis-clade, related to the 
type of A. parafelis CBS 140762, and two isolates were most closely related to, but 
phylogenetically distinct from A. viridinutans s. str. (Figs 1 and 2). These two isolates had 
identical sequences and are described as a new species below, A. frankstonensis sp. nov. 
 
The individual and combined phylogenies (BenA, CaM, RPB2, Act, Mcm7) show that the 9 
isolates from Frankston soil are accommodated in the AVSC and ASF (Figs 1 and 2). Two of 
these isolates (CBS 142233, CBS 142234) were most closely related to A. viridinutans s. str. 
in all trees, with bootstrap support (bs) >70% in four of the six trees generated (RPB2 71% bs; 
Act 95% bs; BenA 74% bs; combined 100% bs). This was also supported by Bayesian method 
posterior probability values (RPB2 0.99 pp; Act 1.00 pp; BenA 0.97 pp; combined 1.00 pp). 
Aspergillus arcoverdensis takes a basal position to those two species with high statistical 
support (bs 100%, 1.00 pp). These sequences of CBS 142234 and CBS 142233 are different 
from the other species in AVSC and ASF, with the genetic change seen in the distance of the 
horizontal branch. For both these isolates the percentage difference at ITS, BenA, CaM, RPB2, 
Act and Mcm7 were 99%, 96%, 98%, 99%, 98% and 98% respectively when compared with A. 
viridinutans s. str. (NRRL 4365). A BLAST analysis did not show a 100% similarity match on 
GenBank for either of these isolates, and the highest similarities were with the type strain for 
A. viridinutans s. str. The remaining seven Frankston soil isolates (DTO 341-F2, DTO 341-E6, 
DTO341-E4, DTO 341-E5, DTO 341-F1, DTO 341-E9, DTO 341-E8) were also shown to be 
accommodated in the AVSC and ASF. The results of the analysis of the combined dataset (Fig 
1) showed that these isolates were with high statistical support (99% bs, 1.00 pp) most closely 
related to the type of A. parafelis CBS 140762. The individual and combined phylogenies also 
showed that isolate CBS 458.75 is accommodated in the AVSC, most closely related to A. 
pseudoviridinutans isolates in five of the six trees generated (Act 70% bs, 0.96 pp; CaM 96% 
bs, 1.00 pp; Mcm7 89% bs 1.00 pp; RPB2 91% bs, 0.98 pp; combined 100% bs, 1.00 pp). 
Isolates DTO 131-E4, DTO 131-E5 and DTO 131-G1 formed a separate clade to other A. felis 
isolates in the Act (98% bs, 1.00 pp), Mcm7 (86% bs, <0.95 pp), RPB2 (<70% bs, 0.96 pp) and 
combined trees (89%, 1.00 pp). The BenA tree showed DTO 131-G1 and DTO 131-E5 were in 
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the same clade (100% bs, 1.00 pp) and basal to the A. felis-clade, while DTO 131-E4 was more 
closely related to the type of A. felis (CBS 130245) (70% bs, 0.99 pp). In the CaM tree, DTO 
131-E4 and DTO 131-G1 were in the same clade (100% bs, 1.00 pp) but their position in the 
A. felis-clade was unresolved, and DTO 131-E5 was positioned in a clade with moderate 
statistical support (73% bs, < 0.95 pp) related to the types for A. pseudofelis (CBS 140763) and 
A. felis (CBS 130245). 
 
Taxonomy 
 
Morphological and physiological characterization 
 
Species description of A. frankstonensis (CBS 142233 = DTO 341-E7 = IBT 34172; CBS 
142234 = DTO 341-F3 = IBT 34204) 
 
Aspergillus frankstonensis Talbot et al 2017, sp. nov. MycoBank 819986. Fig 3. 
 
Etymology. Named after Frankston, Australia, the collection location of the type strain. This 
town in Victoria, Australia was also the location where Aspergillus viridinutans s. str. was first 
isolated [16]. 
 
Diagnostic characteristics. Aspergillus frankstonensis belongs in Aspergillus subgenus 
Fumigati section Fumigati and is phenotypically similar to other members of the AVSC as it 
is generally slow to sporulate and thermophilic. The species is phylogenetically most closely 
related to A. viridinutans s. str. but differs from this species by its ability to sporulate well at 
37˚C and grow at 45˚C. 
 
Specimen examined. Australia (latitude 38.1414˚S, longitude 145.1225˚E), from soil, 
collection date May 7th 2015, J. Talbot & V. Barrs, (holotype CBS-H-22969, culture ex-type 
CBS 142233 = DTO 341-E7; Australia, identical collection information as CBS 142233, CBS 
142234 = DTO 341-F3). 
 
Description (Fig 3) 
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Colony diam, 7 days, 25˚C (mm): CYA 30–43; MEA 28–34; YES 42–55; DG18 40–45; CYAS 
18–22; OAT 40–43; DG18 20–24; CREA 10–27, poor growth, no acid production. Other 
incubation temperatures: CYA 30˚C 42–53; CYA 37˚C 45–56; CYA 45˚C 25; CYA 50˚C no 
growth; optimum growth temperature 37˚C, maximum between 45 and 50˚C. 
 
Macromorphology: CYA 25˚C, 7 days: colony sulcate, radiating and concentric patterns; 
sporulation moderate; colony texture velvety to floccose; conidia yellow-green in centre of 
colony, dull green towards edge; non-sporulating edge 2 mm; mycelium white to yellow; 
soluble pigment present, yellow; exudate present as yellow droplets; margin regular; reverse 
yellow. 
 
MEA 25˚C, 7 days: colony slightly raised, sulcate, radiating; sporulation poor; colony texture 
velvety to floccose; mycelium white to pale yellow; conidia pale to bright green; exudate 
present as clear to yellow droplets; reverse yellow to orange. YES 25˚C, 7 days: colony sulcate; 
sporulation moderate; mycelium white; conidia en masse pale-dull green; non-sporulating edge 
3 mm; soluble pigments orange; exudate absent; reverse brown and yellow. DG18 25˚C, 7 
days: colony sulcate; sporulation moderate, conidia dull green, mycelium white with pink tinge; 
soluble pigment present, pink to yellow; exudate absent, reverse yellow to brown. OA 25˚C, 7 
days: colony elevated; sporulation moderate; colony texture floccose; mycelium white; conidia 
pale green; soluble pigment absent; exudate absent; sclerotia absent; reverse yellow. 
Micromorphology: Conidial heads columnar, uniseriate. Stipes hyaline, smooth walled, 
 
60–130 × 4–5 μm. Vesicles subglobose, up to 12.5 μm in diameter. Phialides ampulliform, 6– 
8 × 2–3 μm, covering *75% of the head. Conidia globose, smooth, hyaline 2 × 2–3 μm; average 
width/length = 0.95, n = 40; Hülle cells absent. 
 
Occurrence. This species has been found in the soil at a recreational reserve, Upper Sweetwater 
Creek Reserve in Frankston, Victoria, Australia, 38.1580˚ S, 145.1350˚ E. 
 
Genbank accession numbers: CBS 142233: KY808756 (ITS); KY808594 (BenA); KY808724 
(CaM); KY808948 (RPB2); KY808549 (Act); KY808901 (Mcm7). CBS 142234: 
KY808761(ITS); 
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KY808599 (BenA); KY808729 (CaM); KY808953 (RPB2); KY808554 (Act); KY808906 
(Mcm7). 
 
Secondary metabolite production 
 
Both isolates produced viriditoxin, apolar indole-alkaloids and three new compounds given the 
temporary names of DOLD, RAIMO and CALBO, based on their unique UV spectra. The 
CALBO compounds had an absorption maximum at 343 nm quite similar to calbistrins. One 
of the isolates (CBS 142234) was also observed to produce two chrysogine precursors, a unique 
apolar indol alkaloid and an additional three new compounds given the temporary names of 
OKAM, USOC and COT based on their UV spectra. The other isolate (CBS 142233) produced 
aszonapyrone A & B, a chrysogine precursor, apolar indolalkaloids and an additional two 
compounds given the temporary name of HITO and BRUDA. Aspergillus frankstonensis shares 
viriditoxin production with A. viridinutans, and aszonapyrones with several Aspergillus section 
Fumigati species. 
 
Antifungal susceptibilities 
 
Antifungal susceptibility results are summarized in Table 2 for two A. frankstonensis isolates 
and seven A. felis-clade isolates (6 environmental, 1 clinical). There was no observed activity 
of ITZ against one environmental A. felis-clade isolate. 
 
Mating type analysis 
 
Both isolates of A. frankstonensis sp. nov. were MAT1-2. All pairings with MAT1-2 isolates 
of other AVSC species were negative (supplementary Table 2). Both mating types MAT1-1 (n 
= 5) and MAT1-2 (n = 2) were found amongst A. felis-clade environmental isolates. Positive 
intra-species and inter-species matings between opposite mating types (Table 3) produced 
clusters of white to creamish cleistothecia along the barrage zone that contained lenticular 
ascospores with two prominent equatorial crests and an echinulate convex surface. Ascospores 
from three A. felis-clade intra-species and one inter- species pairing with A. felis were fertile 
and from one pairing with A. wyomingensis were infertile (Fig 4). No growth was seen from 
parental strains. 
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Taxonomic notes 
 
Aspergillus frankstonensis has some unique morphological characteristics that can be used to 
further distinguish it from its closest AVSC relatives (including A. viridinutans s. str., A. 
arcoverdensis and A. udagawae). Grossly, when grown on CYA at 25˚C in the dark for 7 days, 
A. frankstonensis has a smaller colony diameter than A. arcoverdensis and A. udagawae (A. 
frankstonensis 30–43 mm; A. arcoverdensis 56–58 mm; A. udagawae 82–85 mm), and a larger 
colony diameter than A. viridinutans (28–40 mm) [14, 33]. On MEA A. frankstonensis has pale 
to bright green conidia on white to pale yellow mycelium, whereas its closely related species 
range from yellowish white (A. arcoverdensis) to gray green (A. viridinutans) to dull green (A. 
udagawae) [33]. Microscopically, the conidial head of A. frankstonensis (60– 130 × 4–5 μm) 
differs in size compared to A. arcoverdensis (82–110 × 22.5–30 μm), A. viridinutans (50 × 30 
μm) and A. udagawae (95–145 × 20–50 μm) [33]. It differs from A. fumigatus by its inability 
to grow at 50˚C. 
 
Discussion 
 
Our findings suggest that human and animal exposure to pathogenic Aspergillus species in 
Australia is not uncommon since 25% of all ASF isolates were pathogenic species. As 
expected, the predominant Aspergillus species isolated was A. fumigatus s. str. and this species 
remains the most common cause of aspergillosis in humans and animals. However, the 
incidence of aspergillosis due to other species in ASF is increasing, reported between 3 to 5% 
of aspergillosis cases in human patients [34–38]. 
 
In soil from residential environments we found the human and animal pathogens A. fumigatus, 
A. fischeri, A. laciniosus, A. lentulus, A. fumisynnematus, A. hiratsukae and A. thermomutatus 
(syn. N. pseudofischeri). Four of these (A. fumigatus, A. fischeri, A. lentulus and A. 
thermomutatus) cause IFI in cats [4, 10]. Isolation of these known feline pathogens from soil 
in areas cats had access to supports that the source of feline infections is environmental. A. felis 
conidia have also been found in air [4], making infection of cats possible via disruption of soil 
or wind dispersal, such as could occur through the natural feline behaviours of digging, sniffing 
and grooming. Given that infection often occurs in brachycephalic purebred cats of Persian 
lineage [4, 9], an immunogenetic defect may predispose cats to disease [10, 39]. 
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Interestingly, we only isolated AVSC species from soil from Frankston, but not from residential 
environments, cat litter or cat food. A. viridinutans s. str., was discovered in Frankston in 1954 
in rabbit dung and sandy soil [16]. This suggests a possible ecological niche for AVSC species 
at this site associated with faunae, flora and associated soils [40], or local processes such as 
bush regeneration and back-burning which may remove competing microbiota [41, 42]. AVSC 
species have been found to be abundant in other specific regions, including a coal mining 
reclamation site in Wyoming, USA [14]. 
 
The most abundant AVSC species isolated from Frankston were in the A-felis-clade, closely 
related to the type of A. parafelis, CBS 140762, which is a clinical isolate from the 
oropharyngeal exudate of a human [8]. Here, we also identified another closely related isolate, 
OHIGB6-A1, which was cultured from a cat with sino-orbital aspergillosis. 
 
Our soil isolation technique was adapted from two previous studies [14, 18]. As A. felis is a 
heterothallic species producing heat resistant ascospores, we aimed to recover activated 
ascospores by heat treating soil. Soil processed without heat did not recover any members of 
the AVSC. Thus, the ascospores of these species are present in soil and heat activation appears 
to be an important surveillance technique for heterothallic AVSC species. 
 
Following their polyphasic taxonomical analysis of 11 AVSC isolates, Sugui et al (2014) 
described three phylogenetically closely related but separate species within the A. felis-clade; 
the already described A. felis [4] and two new species, A. parafelis and A. pseudofelis. We 
investigated the phylogenetic relationships of 56 clinical and environmental AVSC isolates 
(Fig 1). Our phylogenetic data, based on the single gene and a combined dataset of six genes 
demonstrated that A. felis and A. pseudofelis are the same species. The distinctiveness of A. 
parafelis is questionable due to the positioning of a clade of previously described A. felis 
isolates DTO 131 E4, DTO 131-E5 and DTO 131-G1 [4]. These isolates have in the combined 
dataset a basal position to the A. felis-clade, but the position of these isolates in the single gene 
phylogenies isn’t congruent. This data indicates that A. parafelis is also conspecific with A. 
felis, when the gene concordance phylogenetic species recognition concept is applied. This is 
supported by mating experiments and isolates from different lineages are all able to mate [8]. 
We demonstrated fertile mating between A. felis (DTO 131-F4) and an A. felis-clade isolate 
(DTO 341-E6), which is closely related to the type strain for A. parafelis (CBS 140762). 
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Our phylogenetic data also showed that isolate CBS 458.75 is phylogenetically most closely 
related to A. pseudoviridinutans. Investigation into exometabolite production will further 
determine the relationship, however preliminary studies have shown CBS 458.75 is able to 
produce some of the same exometabolites that A. pseudoviridinutans strains (DTO 303-A1, 
NRRL 6106) produce, including antafumicins, clavatols, fumigatin, VERN and pseurotins. 
 
Here we reported the discovery of a new AVSC species, A. frankstonensis, which is of 
unknown pathogenicity. However, the ability to sporulate at 37˚C indicate pathogenic potential 
[1]. Although MICs of most antifungals tested were generally low, one A. frankstonensis isolate 
had a high MIC of VCZ (4 ug/mL). 
 
We performed AVSC inter-species mating experiments on A. frankstonensis sp. nov. as other 
AVSC members have been reported to mate with other species in the complex [8]. A. 
frankstonensis inter-species mating were negative, further confirming its status as a distinct 
species. Intraspecies mating tests could not be performed as we had only one mating type for 
A. frankstonensis. Heterothallism (sexual reproduction) allows genetic recombination and has 
the potential to increase fitness. This may be beneficial for adaptation to environmental 
conditions, and may also contribute to drug resistance [43]. Interestingly, the majority of the 
19 known pathogenic fungi from the genus Aspergillus are also heterothallic, with the 
exception of some doubtful species, A. beijingensis, A. qizutongi and A. wanduanglii [44]. 
However, many heterothallic species of unknown pathogenicity also exist. 
 
Recent studies have demonstrated that the small molecule extrolite (secondary metabolite), 
profiles of ASF species can determine the relatedness and identification of a species [45], and 
may also predict the potential pathogenicity of a new species where only environmental isolates 
have been discovered [1]. Extrolite production by AVSC environmental isolates in this study 
shared similarities with other members in the complex. All isolates were shown to produce 
viriditoxin, which is produced by all other members of the AVSC and one other ASF species 
[1], therefore its link to pathogenicity is unknown. The only other ASF species reported to 
produce viriditoxin is A. denticulatus [46]. There were some secondary metabolite differences 
between the two A. frankstonensis sp. nov. isolates from Frankston soil. One isolate produced 
aszonapyrones and chrysogine precursors which may be associated with pathogenicity [47, 48]. 
Aszonapyrones have antibacterial properties [47]; and chrysogine is an alkaloid [48]. There 
was a notable difference in the degree of sporulation between the two isolates with one 
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demonstrating poor sporulation. This may account for the differences in extrolite profiles. 
However, phylogenetically they are the same species with no nucleotide differences between 
them, based on a number of targeted genes. Novel extrolites were also produced by these 
isolates, some of which were shared. These unique extrolites may be produced for fungal 
competitiveness in the primary habitat of this fungal species. Further analysis of the novel 
compounds and secondary metabolite profiling of other members of the AVSC will be 
undertaken by the authors for further comparison between environmental and pathogenic 
strains. 
 
Conclusions 
 
The risk of exposure to pathogenic species in ASF in Australia appears to be high. The risk of 
direct environmental exposure to the AVSC in areas where humans and cats co-habitate in 
Australia, however appears to be low. There was no evidence of an environmental reservoir of 
these organisms in the homes of any cats diagnosed with aspergillosis. Detection of AVSC 
organisms from only one location suggests a niche for these species that favours specific 
environmental conditions. A. frankstonensis sp. nov is an interesting new species in ASF that 
is closely related to known human and animal pathogens and possesses some virulent 
characteristics including growth at 37˚C and a high MIC of voriconazole. It also produces 
unique secondary metabolites that require further investigation. 
 
Acknowledgments 
 
The authors wish to thank Martin Meijer and Tineke van Doorn at Westerdijk Fungal 
Biodiversity Institute, Utrecht, the Netherlands for technical assistance. 
 186 
 
 
 
Publication Figures 
 
Figure 1. Aspergillus viridinutans species complex combined phylogenetic tree. Tree based on 
sequencing of Mcm7, BenA, Act, RPB2, CaM genes (phylogeny model Kimura 2, gamma 
distribution, 1000 bootstrap replicates with Bayesian method posterior probability values in 
italics). Isolates previously described as A. felis, A. parafelis and A. pseudofelis are listed here 
under the one grouping “A. felis-clade”. 
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Figure 2. Aspergillus viridinutans species complex individual gene phylogenetic trees. All phylogenies made with gamma distribution 
and 1000 bootstrap replicates with Bayesian method posterior probability values in italics. A = Act (phylogeny model General Time 
Reversible); B = BenA (phylogeny model Kimura 2); C = CaM (phylogeny model Tamura-Nei); D = Mcm7 (phylogeny model Kimura 
2); E = RPB2 (phylogeny model General Time Reversible). 
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Figure 3. Aspergillus frankstonensis CBS 142233; CBS 142234. (A) Colonies grown at 25˚C for 
7 days, from left to right (top row) CYA, YES, MEA, CYAS, OA; middle row CYA reverse, YES 
reverse, MEA reverse, DG18, CREA; bottom CYA grown at 30˚C, 37˚C, 45˚C, 50˚C. (B) Conidia 
(C—D) Conidiophores (E) Hyphae. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Ascospores from mating experiments with A. felis-clade isolates. A = A. felis-clade 
(DTO 341-E6) X A. felis-clade (DTO 341-E5); B = A. felis-clade (DTO 341-E6) X A. 
wyomingensis (CCF 4416; C = A. felis-clade (DTO 341-F2) X A. felis (DTO 131-E3). 
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Publication Tables 
 
Table 1. Isolates included in phylogenetic analysis of the Aspergillus viridinutans complex. 
 
Identification 
number 
Species name Source Location ITS BenA Cam RPB2 Actin MCM7 
DTO 006-A3 A. udagawae soil USA KY808735 KY808572 KY808696 KY808908 KY808509 KY808858 
DTO 019-D7 A. udagawae unknown unknown KY808737 KY808573 KY808697 KY808909 KY808510 KY808859 
DTO 019-D8 A. udagawae unknown unknown KY808738 KY808574 KY808698 KY808910 KY808511 KY808860 
DTO 019-F2 A. arcoverdensis soil Australia KY808747 KY808575 KY808699 KY808911 KY808512 KY808861 
DTO 050-F1, 
CBS 127.56T, 
NRRL 4365 
A. viridinutans rabbit dung Australia EF669978 AF134779 DQ534162 EF669765 DQ094862 KY808862 
DTO 331-G6, 
CBS 105.55T, 
DTO 052-C8, 
NRRL 2244 
A. aureolus soil Ghana EF669950 EF669808 KY808720 KY808943 DQ094861 KY808895 
DTO 131-E3 A. felis cat, RBM Australia JX021671 KY808576 KY808701 KY808912 KY808513 KY808863 
DTO 131-E4 A. felis cat, RBM Australia JX021673 JX021692 KY808702 KY808913 KY808514 KY808864 
DTO 131-E6, 
CBS 130244 
A. felis cat, RBM Australia JX021675 JX021694 JX021717 KY808915 KY808516 KY808866 
DTO 131-E5 A. felis cat, RBM Australia JX021674 JX021693 JX021719 KY808914 KY808515 KY808865 
DTO 131-E9 A. felis cat, RBM Australia JX021676 JX021696 KY808703 KY808916 KY808517 KY808867 
DTO 131-F1 A. felis cat, RBM Australia JX021677 JX021697 KY808704 KY808917 KY808518 KY808868 
DTO 131-F2 A. felis cat, RBM Australia JX021678 JX021698 KY808705 KY808918 KY808519 KY808869 
DTO 131-F3 A. felis cat, RBM Australia JX021679 JX021699 KY808706 KY808919 KY808520 KY808870 
DTO 131-F4, 
CBS 130245T 
A. felis cat, RBM Australia J X021685 JX021700 JX021715 KY808920 KY808521 KY808871 
DTO 131-F6 A. felis cat, RBM Australia JX021680 JX021702 JX021721 KY808921 KY808522 KY808872 
DTO 131-F9, 
CBS 130246 
A. felis cat, SNC Australia JX021681 JX021704 JX021724 KY808922 KY808523 KY808873 
DTO 131-G1 A. felis cat, RBM Australia JX021682 JX021705 JX021725 KY808923 KY808524 KY808874 
DTO 131-G2, 
CBS 130247 
A. felis cat, RBM Australia JX021683 JX021706 JX021726 KY808924 KY808525 KY808875 
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DTO 131-G3, 
CBS 130248 
A. felis cat, RBM Australia JX021684 JX021707 JX021727 KY808925 KY808526 KY808876 
DTO 155-G2 A. wyomingensis cat, RBM Australia JX021685 JX021709 KY808707 KY808927 KY808527 KY808878 
DTO 155-G3, 
CBS 130249 
A. felis dog, VH Australia JX021686 JX021711 JX021713 KY808928 KY808528 KY808879 
DTO 157-D7, 
CBS 114217T 
A. udagawae soil Brazil AB250781 AF132226 AB748566 KY808929 KY808529 KY808880 
DTO 157-D8, 
CBS 114218 
A. udagawae soil Brazil AB250782 AB248303 AY689373 KY808930 KY808530 KY808881 
DTO 159-C9, 
CBS 130250 
A. felis-clade cat, RBM United 
Kingdom 
JX021689 JX021712 JX021714 KY808931 KY808531 KY808882 
DTO 166-D6 A. udagawae cat Australia KY808740 KY808579 KY808710 KY808932 KY808532 KY808883 
DTO 175-H3 A. sp. surface 
water 
Portugal KY808741 KY808580 KY808711 KY808933 KY808533 KY808884 
DTO 176-F1 A. felis air Germany KY808742 KY808581 KC305168 KY808934 KY808534 KY808885 
DTO 278-B6, 
CBS 137452T 
A. siamensis soil Thailand - KY808582 AB776704 KY808712 KY829134 KY808886 
DTO 278-B7, 
CBS 137453 
A. aureolus soil Brazil KY808743 KY808583 KY808713 KY808935 KY808535 KY808887 
DTO 283-D3 A. udagawae soil Thailand KY808744 KY808584 KY808714 KY808936 KY808536 KY808888 
DTO 303-A1 A. 
pseudoviridinutans 
Pinus 
caribea 
(pine tree) 
Sri Lanka KY808745 KY808585 KY808715 KY808937 KY808537 KY808889 
DTO 308-H6 A. udagawae soil Turkey KY808746 KY808586 KY808716 KY808938 KY808539 KY808890 
DTO 316-C8 A. felis/ A. 
conversis 
CBS culture 
contaminant 
The 
Netherlands 
KY808750 KY808587 KY808717 KY808939 KY808540 KY808891 
DTO 316-F7, 
CBS 139187T 
A. arcoverdensis semi-desert 
soil 
Brazil KY808748 AB818845 AB818856 KY808940 KY808541 KY808892 
DTO 316-F9, 
CBS 139188 
A. arcoverdensis unknown Brazil KY808749 KY808588 KY808718 KY808941 KY808542 KY808893 
DTO 327-G4 A. viridinutans human 
patient 
The 
Netherlands 
KY808751 KX903288 KY808719 KY808942 KY808543 KY808894 
DTO 332-B1, 
CBS 135456T 
A. wyomingensis coal mine 
reclamation 
site soil 
Glenrock, 
USA 
HG324081 KY808589 KY808721 HF937378 KY808544 KY808896 
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NRRL 6106, 
DTO 342-I3, 
CBS 
140764 
A. 
pseudoviridinutans 
unknown Unknown - AF134778 KJ914709 KY808965 KY808566 KJ914726 
NRRL 62900, 
CM-3147, 
DTO 
342-I4, CBS 
140762T 
A. felis-clade human, 
OPE 
Spain - KJ914692 KJ914702 KY808966 KY808567 KJ914720 
NRRL 62901, 
CM-5623, 
DTO 
342-I5, CBS 
140765 
A. felis-clade human, 
lungs 
Portugal - KJ914693 KJ914703 KY808967 KY808568 KJ914721 
NRRL 62902, 
CM-4518, 
DTO 
342-I6, CBS 
140766 
A. felis-clade human, nail Spain - KJ914696 KJ914704 KY808968 KY808569 KJ914722 
NRRL 62903, 
CM-6087, 
DTO 
342-I7, CBS 
140763T 
A. felis-clade human, 
sputum 
Spain - KJ914697 KJ914705 KY808969 KY808570 KJ914723 
NRRL 62904, 
NIHAV1, 
DTO 
304-I5, CBS 
140396T 
A. 
pseudoviridinutans 
human, 
lung 
USA - GQ144441 GQ144442 KJ914730 KY808538 KJ914727 
DTO 341-E8 A. felis-clade woodland 
soil 
Frankston, 
Australia 
KY808757 KY808595 KY808725 KY808949 KY808550 KY808902 
DTO 341-E9 A. felis-clade woodland 
soil 
Frankston, 
Australia 
KY808758 KY808596 KY808726 KY808950 KY808551 KY808903 
DTO 341-F1 A. felis-clade woodland 
soil 
Frankston, 
Australia 
KY808759 KY808597 KY808727 KY808951 KY808552 KY808904 
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DTO 341-E6 A. felis-clade woodland 
soil 
Frankston, 
Australia 
KY808755 KY808593 KY829133 KY808947 KY808548 KY808900 
DTO341-E4 A. felis-clade woodland 
soil 
Frankston, 
Australia 
KY808753 KY808591 KY808723 KY808945 KY808546 KY808898 
DTO 341-F2 A. felis-clade woodland 
soil 
Frankston, 
Australia 
KY808760 KY808598 KY808728 KY808952 KY808553 KY808905 
DTO 341-E5 A. felis-clade woodland 
soil 
Frankston, 
Australia 
KY808754 KY808592 KY829132 KY808946 KY808547 KY808899 
OHIG B6-A1 A. felis-clade cat, RBM Connecticut, 
USA 
KY808857 KY808695 KY808734 KY808970 KY808571 KY808907 
DTO 341-E7, 
CBS 142233, 
IBT 
34172 T 
A. frankstonensis 
sp. nov. 
woodland 
soil 
Frankston, 
Australia 
KY808756 KY808594 KY808724 KY808948 KY808549 KY808901 
DTO 341-F3, 
CBS 142234, 
IBT 
34204 
A. frankstonensis 
sp. nov. 
woodland 
soil 
Frankston, 
Australia 
KY808761 KY808599 KY808729 KY808953 KY808554 KY808906 
DTO 341-E3, 
CBS 142231 
A. udagawae cat, RBM Kealba, 
Australia 
KY808752 KY808590 KY808722 KY808944 KY808545 KY808897 
DTO 153- 
A1*, CBS 
458.75 
A. sp. soil India KY808736 AY685178 HG426048 KY808926 DQ094853 KY808877 
T = Type strain; CBS ID number culture collection of the Westerdijk Fungal Biodiversity Institute, the Netherlands; DTO in-house 
collection ID number at Westerdijk Institute, the Netherlands; NRRL ID number Agricultural Research Service Culture Collection, 
USA; OHIG ID number One Health Infectious Disease Research Group Collection, University of Sydney, Australia; RBM = retrobulbar 
mass; SNC = sino-nasal cavity; VH = vitreous humor; OPE = oropharyngeal exudates. * = This isolate was included in this study as 
previous in-house sequence analysis showed close phylogenetic relatedness to members of this complex. - = no sequence or accession 
number available. 
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Table 2. Antifungal susceptibility results for two A. frankstonensis isolates, six A. felis-clade isolates from environmental soil and one 
A. felis-clade clinical isolate (cat). MIC/MEC (μg/mL) values reflect the number of isolates within the specific cut-off value. 
 
 
Drug Species MIC/MEC (μg/mL) distribution among tested isolates 
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 >16 GM 
AMB* A. frankstonensis    1   1      0.35 
A. felis-clade       1 5 1    2.00 
ITZ* A. frankstonensis    1  1       0.24 
A. felis-clade       4 2    1 1.26 
VCZ* A. frankstonensis       1  1    2.00 
A. felis-clade       1 2 4    2.69 
POS* A. frankstonensis     1 1       0.35 
A. felis-clade      1 6      0.90 
CSP† A. frankstonensis 1 1           0.02 
A. felis-clade 5 1 1          0.02 
*MIC, minimum inhibitory concentration; †MEC, minimum effective concentration; GM, geometric mean 
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Table 3. Intra- and interspecific mating results among environmental A. felis-clade isolates. 
 MAT1-1 strain 
A. felis-clade A. felis-clade A. felis-clade A. felis-clade A. felis-clade A. felis A. felis 
MAT1-2 strain DTO 341-F1 DTO 341-E6 DTO 341-E4 DTO 341-E8 DTO 341-E9 DTO 131-E3 DTO 131-E5 
A. felis-clade 
DTO 341-F2 
+ +* - - + + + 
A. felis-clade 
DTO 341-E5 
+* +* - - - - - 
A. felis 
DTO 131-E4 
- +* + - - - - 
A. wyomingensis 
CCF 4416 
- + - - - - - 
A. frankstonensis 
DTO 341-F3 
- - - - - - - 
- no cleistothecia or ascospores; + cleistothecia production; *fertile ascospores 
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S1 Figure. Phylogenetic trees of 104 environmental isolates and type strains for A. section 
Fumigati based on BenA sequencing (phylogeny model Kimura 2, gamma distribution, 1000 
bootstrap replicates). 
 203  
 
 
 204  
 
 205 
 
 
S1 Table. Aspergillus sect. Fumigati species isolated from air and diluted, heat-treated soil from eight Australian properties where cats 
were domiciled with confirmed feline upper respiratory tract aspergillosis due to AVSC and one National Park site. (#), number of 
isolates found at property. 
Property 1 
(Leichhardt, NSW) 
Property 2 (Lane 
Cove, NSW) 
Property 3 (Anna 
Bay, NSW) 
Property 4 (Russel 
Lea, NSW) 
Property 5 
(Amaroo, ACT) 
Property 6 
(Miranda, 
NSW) 
Property 7 
(Lara, VIC) 
Property 8 (Kealba, 
VIC) 
Reserve site 
(Frankston, VIC) 
A. fumigatus (5) 
A. fischeri (5) 
A. laciniosus (2) 
A. fumigatus (4) 
A. lentulus (1) 
A. fumigatus (1) 
A. fumisynnematus (4) 
A. fennelliae (1) 
A. fumigatus (3) 
A. fischeri (1) 
A. lentulus (1) 
A. laciniosus (1) 
A. marvanovae (3) 
A. nishimurae (6) 
A. laciniosus (2) 
A. hiratsukae (1) 
A. fumigatus 
(6) 
A. fumigatus (5) A. thermomutatus (1) 
A. fumigatus (27) 
A. marvanovae (2) 
A. fumigatus (13) 
A. felis-clade (7) 
A. frankstonensis 
(2) 
 
S2 Table. AVSC species isolates that were paired with A. frankstonensis sp. nov. DTO 341-F3 (MAT1-2). 
 
Mating type Species ID number 
MAT1-1 A. felis-clade DTO 341-F1 
MAT1-1 A. felis-clade DTO 341-E6 
MAT1-1 A. felis-clade DTO 341-E4 
MAT1-1 A. felis-clade DTO 341-E8 
MAT1-1 A. felis-clade DTO 341-E9 
MAT1-1 A. felis DTO 131-E3 
MAT1-1 A. felis DTO 131-E5 
MAT1-1 A. viridinutans IFM 47045 
MAT1-1 A. udagawae IFM 46972 
MAT1-1 A. arcoverdensis IFM 61334 
MAT1-1 A. felis-clade NRRL 62901 
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3.4 Conclusions 
 
The publication in this chapter demonstrates the variety of Aspergillus species pathogens 
isolated from Australian soil and air from areas where humans and animals cohabitate. I showed 
a high incidence of pathogenic species other than A. fumigatus in samples from domestic 
environments, including isolates known to cause feline aspergillosis. 
 
Invasive fungal rhinosinusitis is a chronic disease in cats (Barrs et al., 2012). A limitation to 
this type of research is that most cats have advanced disease at diagnosis and many were 
deceased at the time of environmental sampling, so the source of infection may have been long 
since removed from their environment. This makes identification of control measures for 
disease prevention difficult to determine. Since Aspergillus conidia are dispersed widely 
through air, prevention measures may be difficult. Suggesting pre-disposed cat breeds be indoor 
only would be unlikely to prevent disease as isolates of A. felis have been sampled from indoor 
environments (Barrs et al., 2013). Clearly A. felis resides in soil and is dispersed through the 
air (Nováková et al., 2014, Barrs et al., 2013). It is likely that one way cats are exposed to this 
fungus is when they interact with soils, such as scratching and digging associated with toileting 
behaviours. It is sensible to suggest that when removing soil and laying down new soil, mulches 
or composts, that feline access to these areas be restricted, especially in breeds that are 
predisposed to fungal infection, to avoid increased environmental exposure to fungal spores. 
 
This publication demonstrated the AVSC members A. felis, A. parafelis and A. pseudofelis are 
all closely related and likely the same species, and it was suggested the name A. felis-clade be 
used when referring to these species until further taxonomic analysis resolves this. Preliminary 
published results by another research group also support these findings, and additionally this 
work has identified another likely new species within the complex, previously identified as A. 
aureolus species and temporarily called A. acrensis (Lyskova et al., 2018). Further taxonomic 
analysis being undertaken with Vit Hubka, a mycology taxonomist and PhD candidate in the 
Department of Botany at Charles University, Prague, includes the isolates from this chapter. 
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Interestingly, we isolated A. felis-clade species from woodland soil from a nature reserve in 
Frankston where the founding species of the Aspergillus viridinutans species complex, A. 
viridinutans sensu stricto, was isolated in the 1950s (McLennan et al., 1954). We also found a 
new A. viridinutans species complex member, A. frankstonensis in the same location, and this 
species is most closely related to A. viridinutans. It appears that the environment at Frankston 
has offered a good ecological niche for members of the 
A. viridinutans species complex for a considerable time. Another study found A. felis associated 
with rocks in the Atacama Desert in Chile, offering a contrasting ecology to Frankston 
(Gonçalves et al., 2016). A. viridinutans species complex members thrive best at temperatures 
between 37- 45 ° Celsius on Malt Extract Agar (McLennan et al., 1954, Fennell and Raper, 
1955, Horie et al., 1995, Samson et al., 2007, Barrs et al., 2013, Eamvijarn et al., 2013, Howard 
SJ, 2014, Samson et al., 2014, Nováková et al., 2014, Matsuzawa et al., 2015) but their 
ascospore form can withstand more extreme temperatures (Barrs et al., 2013, Nováková et al., 
2014, Sugui et al., 2014). Their special requirements for growth in the laboratory may support 
their predilection for a particular ecological niche. 
 
This publication isolated many environmental A. fumigatus isolates. Considering the growing 
global prevalence of ARAf, I was interested in further examining the antifungal susceptibility 
of these environmental isolates, and this is the subject of Chapter 6. I was also interested in 
further investigating the antifungal susceptibilities and cyp51A sequences of environmental 
versus clinical AVSC isolates to determine if higher MICs for azoles, generally observed 
amongst members of this species complex, could be attributed to mutations in this gene, 
commonly observed amongst azole-resistant A. fumigatus, and this is further explored in a 
subsequent chapter (Chapter 7). 
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Chapter 4. Agents of avian aspergillosis amongst captive birds in 
Australia 
 
4.1 Introduction 
 
Birds in captive settings are particularly susceptible to developing aspergillosis. Having 
performed an Australian environmental investigation for Aspergillus felis-clade species, I 
wanted to next investigate isolates of Aspergillus species sampled from birds in Australia, to 
determine if, in addition to domestic small animals (cat and dogs), these or other cryptic 
Aspergillus species were causing disease in birds. 
 
4.2 Premise 
 
The publication in this chapter includes a prospective investigation of the species causing 
aspergillosis in captive birds in Australia. This research was undertaken to determine if cryptic 
and/or common Aspergillus species were causing avian disease, as captive birds are highly 
susceptible to aspergillosis, commonly attributed to high environmental fungal burden and host 
stress/ immunosuppression. If birds were being infected with cryptic species, then it was highly 
likely these fungi would be readily isolated from their environment, possibly shedding further 
light on disease pathogenesis. 
 
Global surveillance studies using multi-locus identification of avian Aspergillus isolates were 
lacking in the literature, with existing molecular studies from Europe, the USA, South America, 
China and Australia only performing genotyping A. fumigatus sensu stricto using specific 
microsatellite markers, or one gene (Katz et al., 1996, Lair-Fulleringer et al., 2003, Beernaert 
et al., 2009, Thierry et al., 2010, Lança et al., 2010, Olias et al., 2011, Van Waeyenberghe et 
al., 2011, Burco et al., 2012, Wang et al., 2014, Li et al., 2015, de Oca et al., 2017). 
 
The publication in this chapter demonstrates the fungal species causing disease in captive birds 
in Australia are similar to those of humans and dogs where infection due to A. fumigatus is 
most common (Balajee et al., 2009, Alastruey-Izquierdo et al., 2013, Negri et al., 2014, Sabino 
et al., 2014, Talbot et al., 2014), contrasting with Australian cats with sino-orbital aspergillosis, 
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where cryptic Aspergillus species are commonly the cause of infection (Kano et al., 2008, Barrs 
et al., 2012, Barrs et al., 2013, Kano et al., 2013, Barrs et al., 2014, Barrs and Talbot, 2014). 
 
To perform the study, isolates were collected and processed over a three year period (2014 to 
2017). Included fungal cultures had been identified phenotypically as Aspergillus species by 
veterinary microbiologists prior to submission to the study. Molecular identification was 
performed for each sample, as is recommended for identification of clinical isolates to genus 
and species level (Balajee et al., 2007), including amplification of the ITS region (White et al., 
1990) and partial beta-tubulin gene (Glass and Donaldson, 1995). All sequences were deposited 
in GenBank (National Center for Biotechnology Information, 2016). Where available, clinical 
history and post mortem and histopathology reports were forwarded to me for analysis of 
infection type. Selected isolates were deposited into the Mycobank private collection of Prof. 
Vanessa Barrs at the University of Sydney, with some studied further in Chapter 6. 
 
4.3 Publication 
 
The following publication has been re-formatted here to suit the style of this thesis. The 
publication’s in-text references remain in the style required by the journal (superscript number 
form) and the publication associated tables, figures, references and supplementary data follow 
the main text. This research is presented in its original publication form in Appendix 3. A list 
of all other references referred to in this chapter outside of section 4.3 Publication can be found 
at the chapter’s end (see 4.5 References). 
 
Talbot JJ, Thompson P, Vogelnest L, Barrs VR. Identification of pathogenic Aspergillus 
isolates from captive birds in Australia. Medical Mycology. 2017; myx137, 
https://doi.org/10.1093/mmy/myx137. 
 
Abstract 
 
Aspergillosis is a major cause of severe respiratory disease in birds. The prevalence of cryptic 
section Fumigati and other non–Aspergillus fumigatus species as causative agents is unknown. 
Species identity was determined in 30 isolates from affected birds from zoos, pet birds and 
poultry by PCR of the ITS1-5.8S-ITS2 and partial β-tubulin genes. The most prevalent isolate 
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was A. fumigatus sens. str. in 87% (26) cases. Other Aspergillus species were identified in 13% 
(4) cases, including A. restrictus (1), A. flavus sens. str. (2), and A. nidulans-clade (1). This is 
the first report of A. restrictus causing avian disease. 
 
Introduction 
 
Avian aspergillosis, first reported in the 1800s,1 is a significant cause of mortality among 
captive birds worldwide. It most commonly causes disease within the respiratory tract, and can 
progress to disseminated invasive aspergillosis. Two forms of lesions have been described; a 
granulomatous deep nodular form affecting non-aerated parenchyma, and a pyogranulomatous 
nonencapsulated superficial diffuse form involving lungs and serosae.2 
 
Captive birds are highly susceptible to aspergillosis due to environmental factors (increased 
burden of fungal spores), host immune factors (immunosuppression from disease, stress, or 
therapeutics), and unique respiratory anatomy.1,2 Anatomical differences to mammals that 
enable unique airflow in birds include nonexpansile and unlobed lungs with no pleural cavity, 
looped parabronchi with bi-directional air flow capillaries instead of terminal ending alveoli, 
and cranial and caudal air sacs that extend the bronchial system beyond the lung to pneumatize 
bones and enable fresh airflow during inspiration and expiration.3 Infection occurs when innate 
defenses cannot eliminate spores in parabronchial air capillaries, resulting in fungal plaques 
that can penetrate surrounding tissues.2 Despite a range of antifungal therapeutic treatment 
options, infections are often fatal.2 
 
The clinical importance of fungal molecular identification techniques has been demonstrated 
for human and nonavian animal species with aspergillosis, with cryptic section Fumigati 
species increasingly identified, prompting epidemiological studies.4–9 We previously identified 
isolates causing respiratory aspergillosis in cats and dogs and found that disease in dogs, like 
humans is predominantly caused by A. fumigatus sens. str.,8 while in cats, infections with 
cryptic species in section Fumigati including A. felis, A. udagawae, and A. thermomutatus are 
most prevalent.9 We performed environmental sampling for Aspergillus section Fumigati in 
homes of cats previously diagnosed with aspergillosis and in a recreational nature reserve and 
found that cryptic species reported to cause disease in humans or animals were common, 
comprising 25% of isolates overall.10 
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Aspergillus fumigatus sens. str. has been most commonly associated with avian infections 
based on phenotypic identification techniques, with A. flavus, A. niger, A. glaucus, and A. 
nidulans also reported.2 Thus, cryptic species may have been overlooked as a cause of avian 
aspergillosis. 
 
This study aimed to definitively identify fungal pathogens causing avian aspergillosis and to 
determine the prevalence of cryptic A. section Fumigati species. A secondary aim was to 
determine the form of aspergillosis present. 
 
Methods 
 
Australian avian veterinarians were contacted to recruit isolates from clinical cases of avian 
aspergillosis between 2013 and 2017. Aspergillus isolates cultured from lesions in captive birds 
consistent with aspergillosis, including fungal plaques or granulomas observed within the 
respiratory tract or other parenchyma during diagnostic investigation or at post mortem were 
included for study. Morphological identification of Aspergillus species was performed by 
microbiologists, based on consistent macroscopic and microscopic features including 
identification of smooth or rough walled conidia stemming from radiate or columnar conidial 
heads with globose or subclavate vesicles, stipe and a foot cell.11 Thirty isolates were received 
from Australian native and exotic avian species (Table 1), including 26 from zoos (New South 
Wales [n = 23, Taronga Conservation Society approved opportunistic sampling request 
R14B178], South Australia [n = 3]), one from private practice (Queensland) and three from 
commercial poultry producers (NSW). Histopathology post-mortem reports were available for 
review in 20 zoological cases. 
 
All isolates were subcultured onto malt extract agar and grown in the dark at 25°C for up to 7 
days until sporulation occurred. DNA was extracted using the MoBio DNA isolation kit 
(QIAGEN MO BIO, Carlsbad, USA). Conventional polymerase chain reaction (PCR) was 
performed targeting the rDNA gene cluster, including the ITS1, 5.8S gene, and ITS2 regions 
using primers ITS1 and ITS4.12 Amplification of the partial β-tubulin (BenA) gene was 
performed using primers bt2a and bt2b.13 PCR product was sent to an external laboratory for 
purification and Sanger sequencing (Macrogen, Seoul, South Korea). Generated sequences 
were edited using BioEdit version 7.2.5.14 Species identification was determined using NCBI- 
BLAST tool and sequence homology of ≥99% (ITS) and ≥99.5% (BenA) with type strains 
215 
 
 
sequences.15 If BenA homology was <99.5%, a separate alignment and phylogenetic analysis 
was performed in Mega 6.0616 with sequences of all section type-strains to confirm the closest 
type-strain match using the maximum likelihood method based on the Tamura-Nei model with 
gamma distribution and 1000 bootstrap replicates. Sequences were deposited in GenBank 
(MF540250-MF540309). 
 
Results 
 
Twenty-six of 30 (87%) isolates were identified as A. fumigatus sens. str., and the remaining 
four (13%) were other Aspergillus species, including A. restrictus (n = 1), A. flavus sens. str. 
(n = 2), and A. nidulans-clade (n = 1) (Table 1). The latter isolate had 99.1% BenA homology 
with A. nidulans sens. str. Phylogenetic analysis with section Nidulantes type-strains placed 
this isolate in the A. nidulans-clade, where it was most closely related to A. pachychristatus 
and A. latilabiatus. 
 
Affected avian species were 70% native and 30% exotic to Australia; passerines were most 
commonly affected (30%). Five A. fumigatus sens. str. isolates were from IUCN listed critically 
endangered native species (http://www.iucnredlist.org/search) including Plains Wanderer 
(Pedionomus torquatus) (3), Regent Honeyeater (Anthochaera Phrygia) (1), and Swift Parrot 
(Lathamus discolor) (1). 
 
Histopathology findings are summarized in supplementary Table 1. Seventeen of 20 cases had 
invasive aspergillosis, which was disseminated in 12 and focal in five (respiratory). There were 
three cases of noninvasive localized infection, involving conjunctiva, air sacs, and a coelomic 
cavity mass. All six respiratory cases (5 invasive, 1 noninvasive) involved the lower respiratory 
tract; localized to the air sacs (1), the lungs (4), or both air sacs and lungs (1). In four cases, a 
primary nonfungal disease process was identified including mycobacteriosis, egg yolk 
peritonitis, metastatic pancreatic adenocarcinoma and chronic liver disease. 
 
Discussion 
 
Aspergillus fumigatus sens. str. was the most common isolate amongst our study population 
(87%), similar to prevalence studies in humans, dogs, and the environment.4–8 While other 
Aspergillus species were identified in 13% of cases, no cryptic section Fumigati species were 
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identified. This is in contrast to prevalence studies in humans (0.75–3.7% of cases)4–6 and 
reports on cats, in which invasive fungal rhinosinusitis is the most common form and is caused 
by cryptic species in section Fumigati.9 Although our sample size was small, we found a similar 
prevalence for A. flavus sens. str. (6%) and A. nidulans-clade (3%) as is reported in humans (A. 
flavus 8–13%; A. nidulans 0.5–2.5%).4–6 
 
Our study is the first to our knowledge to report aspergillosis in birds due to A. restrictus. This 
case was in a Java Finch (Lonchura oryzivora) with chronic liver disease and disseminated 
invasive aspergillosis affecting air sacs, lung, and gizzard. Aspergillus restrictus has also been 
isolated from humans with disseminated infection following a heart valve replacement, 
although only phenotypic identification was performed.17,18 Our findings support an 
opportunistic pathogen role for this fungal species. 
 
This study demonstrates the value of molecular characterization of avian fungal isolates. 
Aspergillus species other than A. fumigatus sens. str. should also be considered as potential 
agents of this disease and may have important implications for patient management as seen in 
humans and other animals. Different Aspergillus species isolated from birds have been shown 
to have different susceptibilities to commonly used antifungal therapies, including itraconazole 
and amphotericin B.19 This information could prove invaluable in management of a disease that 
is already challenged by lack of knowledge in avian pharmacokinetics and late-stage clinical 
presentation.2 
 
We investigated avian aspergillosis amongst captive birds including several critically 
endangered native Australian species. The pathogenesis of avian disease has been associated 
with an increased environmental load of filamentous fungi in captive/rehabilitation settings 
(5.7% of fungal isolates grown) compared to natural avian habitats (0.03%),20 with an A. 
fumigatus average air count nine times greater than natural habitats reported from rehabilitation 
centres.21 Furthermore, genotyping of clinical and environmental isolates has demonstrated that 
the rehabilitation setting is a source of clinical disease in captive birds, likely due to this 
increased fungal burden and the presence of existing disease and/or stress.21 This highlights the 
importance of environmental control strategies to reduce the risk of aspergillosis in captivity, 
and the importance of fungal load monitoring. 
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Overall, the diversity of Aspergillus genus species causing infection in captive Australian birds 
was limited. Surveillance of wild birds may also be important for both human and animal 
health, as wild animal populations can be sentinels for infectious disease.22 
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Publication Table 
 
Table 1. Fungal molecular identification (internal transcribed spacer (ITS), partial beta-tubulin [BenA] gene), avian species and origin details 
for fungal isolates used in this study (n= 30), collected from 2013 to 2017. Molecular identification is based on homology percentage matches 
of ≥99% (ITS) and ≥99.5% (BenA) using NCBI-BLAST tool. 
 
 
Fungal 
species 
Genbank accession 
number (ITS; BenA) 
Avian species 
(native/exotic) 
Organ 
isolated from 
Location 
A. fumigatus sens.st. MF540280; MF540250 Pacific Black Duck (n) Lung Zoo, NSW 
MF540281; MF540251 Domestic Turkey (e) Ocular Zoo, NSW 
MF540282; MF540252 Diamond Firetail Finch (n) Lung Zoo, NSW 
MF540303; MF540273 Red-browed finch (n) Liver Zoo, NSW 
MF540284; MF540254 Crimson Finch (n) Lung Zoo, NSW 
MF540283; MF540253 Metallic Starling (n) Lung Zoo, NSW 
MF540287; MF540257 Metallic Starling (n) Liver Zoo, NSW 
MF540294; MF540264 Metallic Starling (n) Lung Zoo, NSW 
MF540285; MF540255 Olive-backed Oriole (n) Air sac Zoo, NSW 
MF540288; MF540258 Red Jungle Fowl (e) Lung Zoo, NSW 
MF540296; MF540266 Red Jungle Fowl (e) Abdominal mass Zoo, NSW 
MF540289; MF540259 Little Penguin (n) Lung Zoo, NSW 
MF540292; MF540262 Domestic Chicken (e) Lung Poultry producer, NSW 
MF540293; MF540263 Rufous Owl (n) Ocular Zoo, NSW 
MF540295; MF540265 Regent Honeyeater (n) Lung Zoo, NSW 
MF540297; MF540267 Scaly-breasted Lorikeet (n) Pericardium Zoo, NSW 
MF540298; MF540268 Hardhead Duck (n) Air sac Zoo, NSW 
MF540299; MF540269 Blue Fronted Amazon Parrot (e) Lung Veterinarian, QLD 
MF540300; MF540270 Crimson Rosella (n) Lung Zoo, NSW 
MF540301; MF540271 Plains Wanderer (n) Lung Zoo, NSW 
MF540307; MF540277 Plains Wanderer (n) Lung Zoo, NSW 
MF540309; MF540279 Plains Wanderer (n) Air sac Zoo, NSW 
219 
 
 
 MF540305; MF540275 Swift Parrot (n) Kidney Zoo, SA 
MF540306; MF540276 Sacred Ibis (n) Lung Zoo, NSW 
MF540308; MF540278 Mandarin Duck (e) Air sac Zoo, SA 
MF540302; MF540272 Black-faced Cockatoo (n) Air sac Zoo, NSW 
A. restrictus MF540286; MF540256 Java Finch (e) Lung Zoo, NSW 
A. flavus sens. str. MF540290; MF540260 Domestic Chicken (e) Lung Poultry producer, NSW 
MF540291; MF540261 Domestic Chicken (e) Lung Poultry producer, NSW 
A. nidulans-clade MF540304; MF540274 Palm Cockatoo (n) Tracheal mass Zoo, SA 
Abbreviations: e, exotic; n, native. 
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Publication Supplementary Material 
 
Table 2. Histopathology information for 20 cases of avian aspergillosis used in this study. 
 
 
Avian species Sample site 
for culture 
Histopathological 
diagnosis 
Form of 
aspergillosis 
Histopathology of fungal lesions 
Pacific Black Duck Lung Tuberculosis 
(Mycobacterium avium) with 
secondary pulmonary 
aspergillosis 
Pulmonary 
aspergillomas 
(invasive, secondary 
to another disease 
process) 
Multifocal necroinflammatory 
nodules with fungal hyphae and 
acid fast bacteria effacing lung 
parenchyma 
Domestic Turkey Ocular Fungal conjunctivitis, 
enteric coccidiosis, 
metabolic bone disease 
Conjunctivitis 
(localised, non- 
invasive) 
Right side ocular and periocular 
inflammatory reaction extending 
from the conjunctiva with associated 
septate fungal hyphae in serocellular 
discharge 
Diamond Firetail Finch Lung Invasive aspergillosis 
causing air sacculitis and 
coleomitis; hepatitis; 
enteritis due to 
  microsporidia  
Disseminated, 
invasive 
Fibrin, inflammatory cells, fungal 
hyphae, necrotic debris in air sac, 
proventriculus and ventriculus 
Metallic Starling Lung Invasive aspergillosis with 
associated pneumonia and 
encephalitis 
Disseminated, 
invasive 
Multifocal aspergillomas in lung 
and brain tissue (necrotic, 
inflammatory   lesions with 
associated fungal hyphae); 
malacia of the brain 
Crimson Finch Lung Invasive aspergillosis; 
ventricular yeasts; duodenal 
parasitism (cestodes) 
Disseminated, 
invasive 
Fibrin layer with fungal hyphae 
and inflammatory cells in lungs, 
kidneys, testis, ventriculus 
Olive Backed Oriole Air sac Egg yolk peritonitis with 
secondary invasive 
aspergillosis 
Disseminated, 
invasive, secondary to 
another disease 
  process  
Fibrin layer with fungal hyphae 
and inflammatory cells in air sacs 
and ventriculus 
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Java Finch Lung Chronic liver disease with 
secondary aspergillosis 
Disseminated, 
invasive 
Inflammatory and proliferative 
changes in air sacs, gizzard serosa 
consistent with aspergillosis 
Metallic Starling Liver Invasive aspergillosis with 
secondary Mycobacterium 
genevense liver infection 
Disseminated, 
invasive, secondary to 
another disease process 
Multifocal necroinflammatory 
aspergillomas in lungs with 
associated fungal hyphae; fungal 
hyphae in liver; cerebellum focal 
malacia with inflammation and 
fungal hyphae 
Jungle Fowl Air sac Mycotic air sacculitis Granulomatous air 
sacculitis (diffuse, non- 
invasive) 
Granulomatous inflammation 
with fungal hyphae 
Little Penguin Lung Invasive aspergillosis Disseminated, 
invasive 
Multisystemic granulomas 
containing branching, septate 
fungal hyphae invading the 
parenchyma of the liver, the air 
sacs and peri-renal tissue 
Rufous owl Ocular orbit 
tissue 
Intra-ocular and retrobulbar 
mycosis (right orbit) and 
severe mycotic pneumonia 
with secondary ovarian, 
splenic and renal glomeruli 
amyloidosis and hepatopathy 
Disseminated, 
invasive 
Lung parenchyma replaced by 
multiple cavitated, 
necroinflammatory nodules 
surrounded by fungal hyphae; 
multifocal necrotising 
panophthalmitis with multifocal 
thrombosis and 
  intralesional fungal hyphae  
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Metallic Starling Lung Invasive aspergillosis Pulmonary 
aspergillomas (diffuse, 
invasive) 
Lung parenchyma replaced by 
multiple necroinflammatory 
nodules with central acute 
branching septate fungal hyphae; 
fungal hyphae in lumen of large 
blood vessels of lungs but no 
evidence of dissemination to 
other organs 
Regent Honeyeater Lung Mycotic pneumonia with 
secondary hepatopathy 
Pulmonary 
aspergillomas (diffuse, 
invasive) 
Multifocal necroinflammatory 
nodules with fungal hyphae 
causing destruction of lung 
parenchyma 
Jungle Fowl Coelomic 
mass 
Metastatic pancreatic 
adenocarcinoma with 
secondary coelomic 
aspergillosis 
Focal, non- 
invasive, secondary to 
another disease process 
Free coelomic mass with 
calcification, fibrin and 
haemorrhage 
Scaly-breasted Lorikeet Pericardium Invasive aspergillosis Disseminated, 
invasive 
Pericardium and epicardium 
necrosis, inflammation and fibrin 
with fungal hyphae also invading 
into the superficial myocardium; 
lung parenchyma destruction by a 
focal necroinflammatory nodule 
with fungal hyphae present in 
nearby airways 
Plains wanderer Air sac Invasive aspergillosis Disseminated, 
invasive 
Necroinflammatory foci with 
fungal hyphae invading the 
parenchyma of the lungs, 
proventriculus, spleen, liver and 
ovary 
Crimson Rosella Lung Mycotic bronchopneumonia, 
hepatic amyloidosis, 
myositis 
Pulmonary 
aspergillosis (diffuse, 
invasive) 
Necroinflammatory foci with 
acute branching fungal hyphae in 
the parabronchi and alveoli and 
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Plains Wanderer Lung Multicentric aspergillosis, 
endometriosis, arteritis, air 
sacculitis, polyserositis, 
biliary hyperplasia, hepatic 
necrosis, proventricular 
necrosis 
Swift Parrot Kidney Fungal nephritis, 
myocarditis, pericarditis 
 
 
Disseminated, 
invasive 
 
 
 
Aspergilloma 
(diffuse, invasive) 
 
necrosis of alveolar walls 
Paraovarian aspergilloma with 
invasion of adjacent small 
intestine; multifocal fungal 
hyphae infiltration of lung 
parenchyma with associated 
tissue necrosis and inflammation 
Multifocal nodular 
necroinflammatory lesions with 
associated fungal hyphae in the 
kidney 
Mandarin Duck Air sac Mycotic air sacculitis Aspergilloma 
(diffuse, invasive) 
Severe, subacute to chronic 
multifocal air sacculitis with 
intralesional fungal hyphae; 
multifocal pulmonary granulomas 
containing acute branching 
  septate fungal hyphae  
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4.4 Conclusions 
 
This chapter demonstrates that similar to humans and dogs, A. fumigatus is the most common 
cause of aspergillosis in captive birds in Australia (Balajee et al., 2009, Alastruey-Izquierdo et 
al., 2013, Negri et al., 2014, Sabino et al., 2014, Talbot et al., 2014), contrasting with Australian 
cats with sino-orbital aspergillosis, where cryptic Aspergillus species are most commonly 
identified (Kano et al., 2008, Barrs et al., 2012, Kano et al., 2013, Barrs et al., 2013, Barrs et 
al., 2014, Barrs and Talbot, 2014). No members of the Aspergillus viridinutans species complex 
(AVSC) were isolated in the study. However, another Aspergillus section Fumigati species, A. 
restrictus, which was identified is a previously unknown avian pathogen. 
 
Avian aspergillosis is thought to arise when an immunocompromised bird encounters a high 
environmental load of Aspergillus spores, most commonly associated with poor husbandry. 
Thus, finding A. fumigatus is the most commonly isolated species is not surprising as this is 
the most readily isolated fungus in the environment (Sabino et al., 2014). This is similar to the 
findings of Chapter 3, where A. fumigatus was the most common Aspergillus species recovered 
from Australian domestic environments. Avian aspergillosis has predominantly been reported 
in captive birds, including wildlife undergoing rehabilitation, 
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production and sporting birds (e.g. racing pigeons, falconry) (Balseiro et al., 2005, Beernaert 
et al., 2010, Burco et al., 2012, Neumann, 2016). The pathogenesis involves increased 
environmental burdens of fungal spores due to facility location (region, climate), and / or poor 
husbandry (poor ventilation, poor hygiene and sanitation, animal stocking densities, vegetation 
build-up, substrate removal and contaminated feed), plus host factors, including impaired 
immunity (disease or therapeutic induced) and/ or stress (Balseiro et al., 2005, Beernaert et al., 
2010, Burco et al., 2012). 
 
Including zoos allowed the collection of isolates from a diverse range of avian species, 
including ducks, estrildid finches, owls, parrots, orioles, penguins, pheasants, poultry, ground-
dwelling pedianomids, honeyeaters, songbirds, starlings and wading ibis. Importantly, the 
reporting of confirmed disease in several critically endangered native Australian birds 
highlights the importance of strategies to reduce the risk of aspergillosis in captive breeding 
recovery programs for these species. 
 
Aspergillosis cases included in this study were mostly invasive, fatal disease with most cases 
diagnosed post-mortem. Given avian infection is usually associated with high environmental 
burdens of fungal spores, determining the species of Aspergillus causing infection may not only 
be important for managing patients diagnosed ante-mortem. Additionally, birds can act as 
sentinels for human disease so knowing the pathogens causing infection can be vital in disease 
surveillance (Reif, 2011). Finally, for treating cases, identifying the pathogen can be crucial to 
selecting the most appropriate treatment (Balajee et al., 2009, Zbinden et al., 2012, Alastruey-
Izquierdo et al., 2013, Negri et al., 2014, Gautier et al., 2016). 
 
This investigation identified a high proportion of clinical A. fumigatus sens. str. isolates, and a 
selection of these will be examined for azole resistance in Chapter 6. 
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Chapter 5. Azole resistance amongst canine and feline sino-nasal 
aspergillosis isolates 
 
5.1 Introduction 
 
Aspergillus fumigatus is the most common cause of sino-nasal aspergillosis (SNA) in dogs. As 
with human aspergillosis, azole therapeutics are also the mainstay for treating veterinary 
aspergillosis. Surgical debridement of fungal plaques and application of topical azole antifungal 
drugs (clotrimazole or enilconazole) is the recommended treatment for canine SNA, and where 
topical treatment is not possible, systemic antifungal azole drugs are recommended (e.g. 
itraconazole) (Zonderland et al., 2002, Claeys et al., 2006, Billen et al., 2010, Stengel, 2017). 
Multiple treatments are often required and a mortality rate up to 13% is reported in dogs 
following one treatment with fungal plaque debridement and topical application of either 
clotrimazole or enilconazole (Sharman et al., 2010). Additionally, in vitro antifungal 
susceptibility testing data for isolates in the literature are limited (Lanthier and Chalifoux, 1991, 
Sharp et al., 1993). This chapter investigates if azole- resistant A. fumigatus (ARAf) are a cause 
of treatment failure in dogs, as in human patients throughout the world. This was investigated 
through microbroth dilution antifungal susceptibility testing and cyp51A sequencing. 
 
5.2 Premise 
 
Antifungal susceptibility is often tested using in vitro microbroth dilution to determine the 
susceptibility of A. fumigatus to antifungal drugs. It is employed for epidemiological research 
as well as management of human clinical cases where results can be used to predict the in vivo 
response to therapy and recognise resistant isolates. Epidemiological cut-off values (ECVs) and 
EUCAST proposed breakpoints have been reported for most antifungal therapies used to treat 
aspergillosis in people (Rodriguez-Tudela et al., 2008, Verweij et al., 2009, Pfaller et al., 2009, 
Espinell-Ingroff et al., 2010, Espinel-Ingroff et al., 2013, Wiederhold et al., 2016, Clinical 
Laboartory Standards Institute (CLSI), 2017, EUCAST, 2017, Clinical and Laboratory 
Standards Institute (CLSI), 2018). These are used to interpret minimum inhibitory 
concentration (MIC) values by distinguishing between wild-type (susceptible) and resistant 
phenotypes. 
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This chapter builds on an investigation I commenced during my undergraduate BSc(vet)(hons) 
degree where I identified 88 isolates of A. fumigatus from dogs with clinically confirmed cases 
of SNA in Australia, the USA and Belgium (Talbot et al., 2014) and learnt antifungal 
susceptibility testing techniques based on CLSI methodology (Rex et al., 2008). This chapter 
further investigates the in vitro antifungal susceptibility profiles of a selection of these isolates 
from 46 dogs (29 from Australia, 7 from Belgium, 10 from the USA) plus isolates from four 
Australian cats also with sino-nasal aspergillosis against azole antifungal therapeutics, 
including clotrimazole and enilconazole. This was achieved via the CLSI microbroth dilution 
method M38-A2 standard method (for clotrimazole and enilconazole susceptibility), (Rex et al., 
2008) and the colorimetric microbroth dilution in house commercial testing kit Sensititre™ 
YeastOne™ (Thermo Scientific Trek Diagnostic Systems, USA) to test itraconazole, 
voriconazole, posaconazole, ketoconazole, fluconazole, amphotericin B, caspofungin and 5-
flucytosine C. I identified one canine isolate from Australia with in vitro resistance to 
itraconazole and ketoconazole, and elevated MICs for voriconazole and posaconazole. 
 
This chapter also examines the cyp51A gene for isolates with in vitro resistance. Because 
mutations in the cyp51A gene have been identified as the most common cause of azole 
resistance in human and environmental A. fumigatus isolates, I performed cyp51A sequencing 
to determine if mutations known to cause resistance in human and environmental A. fumigatus 
isolates were also present amongst veterinary ARAf isolates using previously published primers 
(Chen et al., 2005). 
 
While clotrimazole and enilconazole are the topical treatment of choice for dogs and cats with 
SNA (Goodall et al., 1984, Zonderland et al., 2002, Tomsa et al., 2003, Claeys et al., 2006, 
Furrow and Groman, 2009, Billen et al., 2010, Barrs et al., 2012, Tamborini et al., 2016, 
Stengel, 2017), they are not used for treatment of aspergillosis in people, and no ECVs or 
proposed breakpoints have been established for these against A. fumigatus. Antifungal 
susceptibility reports for these drugs in the canine SNA literature are largely lacking. Therefore, 
this chapter investigates the prevalence of ARAf in canine and feline SNA isolates and provides 
the largest dataset of MIC ranges of clotrimazole and enilconazole against canine isolates of A. 
fumigatus. 
 
5.3 Publication 
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The following publication was re-formatted to suit the style of this thesis. The publication’s in-
text references remain in the style required by the journal (number brackets form) and the 
publication associated tables and references follow the main text. This research is presented in 
its original publication form in Appendix 4. A list of all other references referred to in this 
chapter outside of section 5.3 Publication can be found at the chapter’s end (see 5.5 
References). 
 
Talbot JJ., Kidd SE., Martin P., Beatty JA., Barrs VR. Azole resistance in canine and feline 
isolates of Aspergillus fumigatus. Comparative Immunology, Microbiology and Infectious 
Diseases.2015; 42: 37-41. 
 
Abstract 
 
Azole resistance is an emerging cause of treatment failure in humans with aspergillosis. The 
aim of this study was to determine if azole resistance is emerging in Aspergillus fumigatus 
isolates from canine and feline sino-nasal aspergillosis cases. Susceptibilities of isolates 
collected between 1988 and 2014 from 46 dogs and 4 cats to itraconazole, posaconazole, 
voriconazole, fluconazole and ketoconazole were assessed using Sensititre YeastOne 
microdilution trays; and to enilconazole and clotrimazole, following the CLSI M38-A2 
standard. For the majority of isolates MICs were high for ketoconazole, low for enilconazole 
and clotrimazole, and less than established epidemiological cut-off values for itraconazole, 
posaconazole and voriconazole. One canine isolate from 1992 had multiazole resistance and 
on Cyp51A gene sequencing a mutation associated with azole resistance (F46Y) was detected. 
There is no evidence of emerging azole resistance among A. fumigatus isolates from dogs and 
cats and topical azole therapy should be effective against most isolates. 
 
Introduction 
 
Azole antifungal drugs are pillars of treatment for aspergillosis in humans and animals. Since 
1997, there has been an increasing number of reports of azole resistance amongst isolates of 
Aspergillus fumigatus from human patients with both invasive and non-invasive forms of 
aspergillosis. Azole resistance is associated with treatment failures and increased mortality [1– 
3]. Resistance to itraconazole alone or multiazole or panazole resistance has been reported 
globally [4–7]. 
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Fungal azole resistance can be intrinsic or acquired. Intrinsic resistance is reported for cryptic 
Aspergillus species, whereas acquired resistance is increasingly described for A. fumigatus 
sensu stricto isolates [8,9]. Resistant strains have been identified in the environment and in 
human patients naïve to and previously exposed to azole therapy [10]. Resistance is associated 
with mutations in the cyp51A gene which encodes lanosterol 14α-demethylase, a component 
of the ergosterol synthesis pathway targeted by triazole drugs [9,11]. Emergence of resistance 
in Europe has been linked to triazole fungicide use in agriculture causing altered gene 
expression [12]. 
 
Clinical antifungal resistance is defined as persistence of infection despite treatment with an 
antifungal with proven in vitro activity against the infecting fungus [13]. In vitro resistance is 
difficult to define as although standardised methods of anti-fungal susceptibility testing have 
been developed [14–16], clinical breakpoints based on minimum inhibitory concentrations 
(MICs), pharmacological parameters, animal data and clinical outcomes, have not yet been 
established for Aspergillus species. Instead, epidemiological cut-off values (ECVs) of wild- 
type A. fumigatus isolates are used to evaluate clinical isolate minimum inhibitory 
concentrations (MICs). Correlation between in vitro and clinical outcomes is reported from 
invasive and non-invasive human aspergillosis cases [1–3]. 
 
Canine and feline sino-nasal aspergillosis (SNA) is most commonly caused by members of 
Aspergillus section Fumigati. Canine SNA is usually caused by A. fumigatus [17] while feline 
SNA is most commonly caused by A. fumigatus and Aspergillus niger [18]. These infections 
present therapeutic challenges for veterinarians, and involve the use of endosurgical procedures 
and topical and/or systemic antifungal azole administration. Topical clotrimazole (CLO) or 
enilconazole (ENL) are the mainstays of therapy, although there are limited in vitro studies to 
support the use of these drugs [19,20]. Response rates to treatment vary [18,21,22]. Whether 
emerging azole resistance contributes to treatment failures is unknown. To date no studies have 
systematically investigated the prevalence of azole resistance amongst A. fumigatus isolates 
from dogs and cats. To determine whether azole resistance is emerging amongst A. fumigatus 
isolates from dogs and cats susceptibilities to a panel of antifungal drugs were assessed in a 
retrospective surveillance study. 
 
Materials and Methods 
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Isolates 
 
 
Fifty archived isolates of A. fumigatus from dogs (n = 46) and cats (n = 4) with confirmed SNA 
were retrieved from the fungal culture biobank of the Small Animal Infectious Diseases 
Clinical Research Group at the University of Sydney [17,21,23]. Isolates originated from 
Australia (n = 33), United States of America (n = 10) and Belgium (n = 7). Collection dates 
ranged from 1988 to 2013 inclusive [1988 (n = 1); 1992 (n = 1); 1994  (n = 1); 2000 (n =  1); 
2004 (n = 1); 2005 (n = 1); 2006 (n = 1); 2007 (n = 5); 2008 (n = 7); 2009 (n = 5); 2010 (n = 6); 
2011 (n = 3); 2012 (n = 14); 2013 (n = 3)]. 
 
Antifungal susceptibility testing 
 
 
Isolates were sub-cultured onto malt extract agar and grown in the dark at 25 °C until 
sporulation occurred (7–14 days), then inoculum was prepared according to the Clinical 
Laboratory Standards Institute (CLSI) M38-A2 standard for filamentous fungi [16]. 
 
Susceptibility (n = 50) to ENL and CLO (BOVA Compounding Chemist, St Marys, Australia) 
was assessed following the recommendations for drug preparation, dilution, inoculum 
preparation, incubation and endpoint reading stipulated by the CLSI M38-A2 standard [16]. 
Final concentrations tested were two fold dilutions within the range 0.03–16 μg/mL for both 
compounds. The concentrations selected were based on in vitro susceptibilities of A. fumigatus 
to other azole drugs [16,24,25] and are lower than concentrations of 1–2% (10–20 mg/mL) 
used in topical preparations of clotrimazole and enilconazole for treatment of canine and feline 
SNA [19–21,24,25]. Quality control strains used as a standard to assess repeatability and 
accuracy of testing procedures were reference strains of Candida parapsilosis (ATCC 22019) 
and A. fumigatus (ATCC MYA-3626), according to the CLSI M38-A2 standard. 
 
Susceptibility to amphotericin B (AMB), itraconazole (ITZ), ketoconazole (KCZ), 
voriconazole (VCZ) (range 0.008–16 μg/mL for all four compounds), posaconazole (POS) 
(range 0.008–8 μg/mL), fluconazole (FLU) (0.12–256 μg/mL) and 5-flucytosine (5-FC) (0.03– 
64 μg/mL) was assessed using Sensititre YeastOne YO8 microdilution trays according to the 
manufacturer's instructions. Susceptibility to caspofungin (CSP) (range 0.008–16 μg/mL) was 
assessed using the CLSI M38-A2 standard [16]. For those drugs for which pharmacokinetic 
data are available in dogs and/or cats including itraconazole, fluconazole, ketoconazole and 
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posaconazole, reported CMAX in serum or plasma after therapeutic dosing were within the range 
of drug concentrations tested in this study [26–31]. C. parapsilosis (ATCC 22019) was used as 
the quality control strain (Trek Diagnostic Systems, Thermo Fisher Scientific, Scoresby, 
Australia). 
 
For all isolates and both tray types, 10 μL from the growth control well was spread onto a 
Sabouraud's agar plate immediately after plate inoculation as a purity and inoculum density 
check. All trays were incubated at 35 °C for 72 h ± 2 h in an ambient air incubator. Endpoints 
for all drugs were determined after 72 h incubation. For CLO and ENL the endpoint was the 
lowest two-fold dilution revealing 100% growth inhibition (MIC). For AMB, ITZ, POS, VCZ, 
FLU, KCZ and 5-FC, the endpoints were as per the manufacturer's instructions (Trek 
Diagnostic Systems, Thermo Fisher Scientific, Scoresby, Australia). For CSP endpoints were 
read as MECs at the lowest dilution of round compact hyphal forms as per CLSI M38A2 [16]. 
Geometric mean, MIC50 and MIC90 values were calculated using Windows Excel (Microsoft 
Office, 2007, Redmond, United States of America). 
 
In vitro azole resistance was defined as the absence of endpoint antifungal activity in the range 
of drug concentrations tested, except for FLU and 5-FC, as most filamentous fungi have 
intrinsic resistance to these drugs [16]. Multiazole resistance was defined as resistance to more 
than one antifungal azole. Decreased susceptibility was defined as MICs greater than 
established ECVs for wild-type A. fumigatus, established using CLSI standards [16]. 
 
Cyp51A gene sequencing 
 
 
DNA was extracted from those isolates with possible ITZ resistance (i.e. MICs > 1 μg/mL) 
using the Roche High Pure PCR Template Preparation Kit (Castle Hill, Australia), with an 
additional bead beating step [32]. The coding region of cyp51A was sequenced as described 
previously [11]. Sequences were aligned with cyp51A A. fumigatus reference strain, GenBank 
reference AF338659 [33] and sequence from a reference laboratory isolate with a L98H cyp51A 
resistance mutation (obtained from National Mycology Reference Centre, SA Pathology, 
Adelaide, South Australia, 2014). 
 
Results 
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Antifungal susceptibility results for all 50 A. fumigatus isolates from clinical specimens from 
dogs and cats with sino-nasal aspergillosis are listed in Table 1 and compared to established 
epidemiological cut-off values (ECVs) where these have been established. All isolates had high 
MICs for KCZ. As expected, there was no observed activity of FLU or 5-FC against any isolate. 
Forty-nine of the 50 isolates had low MICs for ITZ, VCZ, POS and low MECs for CSP. Seven 
isolates had MICs higher than the ECV for AMB. The C. parapsilosis (ATCC 22019) quality 
control strain had MIC values within the manufacturer's defined range defined within the 
YeastOne YO8 product insert. 
 
The majority of A. fumigatus isolates had low MICs for ENL and CLO. The A. fumigatus 
(ATCC MYA-3626) quality control strain had a MIC value of 1 μg/mL for CLO and 
0.25 μg/mL for ENL. The C. parapsilosis (ATCC 22019) quality control strain had a MIC 
value of 0.125 μg/mL for CLO and 0.25 μg/mL for ENL. 
 
There was no activity of ITZ and KCZ against one Australian canine A. fumigatus isolate 
collected in 1992. The same isolate also showed high MICs of VCZ and POS (Table 2). Cyp51A 
sequencing revealed non-synonymous mutations at nucleotide positions 137 (F46Y), 267 
(G89E), 1279 (E427K) and a synonymous mutation at nucleotide 1362 (C454). 
 
Discussion 
 
In this study azole resistance was rare amongst A. fumigatus isolates from dogs and cats. ITZ 
resistance in Aspergillus species was first reported in 1997 from Californian isolates sampled 
from human patients in the late 1980s [34]. Since the late 1990s, there has been an increase in 
the number of reports of and surveillance programs for azole resistance in human A. fumigatus 
isolates [35]. Azole resistance in environmental and human clinical isolates has been reported 
in Europe, Asia, North and South America, Australia and the Middle East [2,4,5,7,36]. 
Emergence of resistance in Europe has been linked to triazole fungicide use on crops causing 
altered gene expression and this has prompted a number of surveillance programs that have 
continued to identify azole resistance in the region, predominantly amongst isolates of A. 
fumigatus [10,12]. 
 
The only isolate in this study to demonstrate in vitro azole resistance was collected from a dog 
in Australia in 1992. This isolate exhibited multiazole resistance, with no observed activity of 
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ITZ/KCZ in the range tested (MIC > 16 μg/mL) (Table 2). Itraconazole MIC values >8 μg/mL 
in A. fumigatus isolates from humans with invasive aspergillosis have been associated with 
clinical resistance [14,34]. Correlations between in vitro and clinical activity of KCZ and A. 
fumigatus isolates from humans have also been reported [37]. A limitation of the current study 
was the lack of detailed treatment histories for affected dogs and cats. 
 
This is the first study to systematically confirm in vitro susceptibility of canine and feline 
isolates of A. fumigatus to ENL and CLO using standardized methods. Pharmaceutical 
company MIC values for ENL against 77 Aspergillus spp. canine isolates were reported by a 
pharmaceutical company previously and were ≤1 μg/mL in  62%  of  these  (range  ≤0.1–  10 
μg/mL) [19]. However, isolates were not identified to species level, and the method for 
antifungal susceptibility testing was not described. Another study on the use of ENL to treat 
canine SNA reported a MIC value for A. fumigatus to ENL of 1 μg/mL [20]. However, the 
number of isolates tested and the method of testing was not reported. 
 
We found that canine and feline isolates of A. fumigatus are susceptible to ENL and CLO. A. 
fumigatus isolates had MIC values for CLO between 0.25 and 4 μg/mL and for ENL between 
0.06 and 2 μg/mL. Therefore, assuming that in vitro MICs correlate with clinical response, 
currently used concentrations (10 mg/mL) of topical azole therapy should be effective against 
A. fumigatus isolates causing SNA in dogs and cats, and azole resistance is unlikely to be a 
cause of treatment failure at this time. One percent solutions of CLO and ENL are standard for 
the treatment of canine SNA, with approximately 50 mL of 10 mg/mL solution infused into the 
sino-nasal cavities of large breed dogs to ensure that high concentrations of the drug contact 
fungal plaques [24,25]. Additional treatment with at least 20 g of CLO 10 mg/g cream has also 
been used following infusion therapy [24]. CLO infusions have also been used in cats with 
SNA [18]. 
 
A recent study by the authors to determine the molecular identification of canine SNA isolates 
confirmed the most common aetiological agent as A. fumigatus (88/91 isolates), thus different 
aetiological agents are not the cause of the varied clinical response to treatment reported in 
dogs [17]. CLO and ENL were found to have in vitro activity against all isolates in this study. 
A likely impediment to disease resolution is the inability of azoles to adequately penetrate into 
mucosal fungal plaques. Endoscopic debridement of all visible plaques is considered essential 
to achieve disease resolution in both dogs and cats with SNA [18,38]. In human fungal 
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rhinosinusitis due to A. fumigatus, fungal balls are endosurgically removed and usually no 
topical antifungal therapy is applied or required to achieve therapeutic success [39,40]. Another 
possible cause of treatment failure in canine and feline SNA is a lack of adequate drug 
distribution to the affected areas of the nasal cavity and frontal sinus when applying topical 
preparations of azoles [38,41,42]. 
 
Topical azole therapy is contraindicated in the presence of cribriform plate breaches in dogs 
and cats with SNA due to the potential for chemical meningoencephalitis. In these cases 
systemic antifungal therapy is offered in addition to topical fungal plaque debridement. We 
recommend that in vitro antifungal susceptibility testing be performed to determine resistant 
phenotypes. The seven isolates with high MICs for AMB (>2 μg/mL) in this study highlight 
the importance of performing in vitro susceptibility in cases where systemic therapy is being 
considered. In human studies, MIC values >2 μg/mL have been associated with treatment 
failure, while values <2 μg/mL have been associated with treatment success in patients with 
invasive A. fumigatus infections [43]. The significance of these MIC values has not yet been 
determined dogs and cats with sino-nasal aspergillosis. 
 
High KCZ MIC results (≥MIC90 8 μg/mL) were present in 38% (19/50) of A. fumigatus isolates 
in this study, suggesting that KCZ is unsuitable for treatment of canine or feline SNA. These 
MICs are similar to those reported for human clinical A. fumigatus isolates [44,45]. 
 
Combinations of topical azoles and systemic antifungals have also been used to treat canine 
and feline SNA. Previously KCZ and topical ENL were used for canine SNA treatment [19]. 
More recently combination therapy with oral ITZ and topical therapy has been employed [46]. 
Feline SNA has also been treated with a combination of systemic and topical intranasal 
infusions or topical intranasal infusions only. Therapeutic success of systemic (ITZ or  POS ± 
AMB), topical (CLO) and combined antifungal therapies has been reported in 14 cases of feline 
SNA, with a success rate of 79% [18]. 
 
Epidemiological cut-off values (ECVs) for wild type A. fumigatus isolates to AMB, ITZ, POS, 
VCZ and CSP have been established using CLSI standards for broth microdilution testing. 
These ECVs may be useful for identifying resistant phenotypes with non-wild type MICs. For 
AMB 3988 wild type A. fumigatus isolates were tested and 95% had MICs of 2 μg/mL [47]. In 
the current study, 86% (n = 43) of the A. fumigatus isolates were found to have 
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MICs ≤ 2 μg/mL. The remaining 14% of isolates (n = 7) had higher MIC values (4 μg/mL). Of 
1684–2815 wild type, A. fumigatus isolates tested for susceptibility to ITZ, POS and VCZ, 
98.8% had MIC values of 1 μg/mL for ITZ; 99.2% had MICs of 0.5 μg/mL for POS; and 97.7% 
had MICs of 1 μg/mL for VCZ [48].  In  the  current  study  all  isolates  had  MICs  for  POS 
≤ 0.5 μg/mL and only one isolate had ITZ MIC > 1 μg/mL (16 μg/mL). The same isolate and 
one USA isolate from 2008 had VCZ MICs > 1 μg/mL (4 μg/mL and 2 μg/mL, respectively). 
Of 1691 wild type A. fumigatus isolates tested for susceptibility to CSP, 99% had MECs of 1 
μg/mL [49]. In the current study all isolates had MECs for CSP <1 μg/mL. These results imply 
that compared to the ECVs for wild type A. fumigatus isolates, resistant phenotypes were rare 
amongst this cohort of isolates, although resistance for AMB (n = 7), ITZ (n = 1) and VCZ (n = 
2) was observed. 
 
The most common cyp51A mutations associated with azole resistance in A. fumigatus are a 
SNP (L98H) in combination with a 34 bp tandem repeat in the gene promoter region 
(TR34/L98H) or a 46 bp tandem repeat in the same region and two separate SNPs 
(TR46/Y156F/T289A) [4]. In this study the cyp51A amino acid substitutions found in the 1992 
azole resistant canine isolate mostly occurred in regions outside the coding region and are 
therefore unlikely to contribute to resistance [50,51]. However, the F46Y mutation we detected, 
has been previously associated with reduced susceptibility to triazoles [7]. Azole resistant 
isolates lacking mutations in the cyp51A gene have been previously reported [50]. Other 
proposed resistance mechanisms include upregulation of efflux pumps, expression levels of 
transporters and multidrug resistance proteins or other undiscovered mechanisms [50]. 
 
Conclusions 
 
This study determined that azole resistance is not emerging in A. fumigatus isolates from dogs 
and cats with SNA. In general, MICs were similar to those reported for wild type isolates for 
ITZ, POS, VCZ, AMB and CSP, implying that canine and feline isolates of A. fumigatus are 
generally susceptible to these antifungals. MICs of A. fumigatus isolates to ENL and CLO were 
relatively low and concentrations currently used for topical therapy should be effective. Further 
studies would be useful to investigate in vitro versus clinical outcomes in a greater number of 
cases to help develop interpretive guidelines for antifungal susceptibility testing. 
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Publication Tables 
 
Table 1. Antifungal susceptibility results for 50 A. fumigatus isolates from clinical specimens from dogs and cats and comparison with 
epidemiological cut-off values.* MIC/MEC (μg/mL) values reflect the number of isolates within the specific cut-off value. 
 
Drug   MIC/MEC (μg/mL) distribution among tested isolates GM MIC50 MIC90 ECV(μg/mL) 
 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 >16  
AMB      1 8 34 7    1.92 2 4 2 
ITZ 
 
2 13 16 17 1 
     
1 0.13 0.12 0.25 1 
VCZ 
  
2 3 24 16 3 1 1 
   
0.34 0.25 0.5 1 
POS 5 13 20 8 3 1 
      
0.06 0.06 0.12 0.5 
KCZ 
      
1 2 28 15 3 1 5.09 4 8 – 
CSP† 16 25 8 1 
        
0.03 0.03 0.06 1 
CLO 
    
2 31 15 1 1 
   
0.64 0.5 1 – 
ENL 
  
7 27 11 4 
 
1 
    
0.15 0.12 0.25 – 
 
* ECV, epidemiological cut off value [46–48]; MIC, minimum inhibitory concentration; MEC, minimum effective concentration (†); AMB, 
amphotericin-B; ITZ, itraconazole; VCZ, voriconazole; POS, posaconazole; KCZ, ketoconazole; CSP, caspofungin; CLO, clotrimazole; ENL, 
enilconazole; GM, geometric mean; MIC50, minimum inhibitory concentration at which ≥50% of isolates in the group were inhibited; MIC90, 
minimum inhibitory concentration at which ≥90% of isolates in the group were inhibited. 
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Table 2. Antifungal susceptibility results for an Australian canine clinical isolate of A. fumigatus from 1992 compared to group GM, MIC50 and 
MIC90 results*. 
 
 
Drug MIC/MEC (μg/mL) GM MIC50 MIC90 ECV (μg/mL) 
AMB 1 1.97 2 4 2 
ITZ >16 0.14 0.12 0.25 1 
VCZ 4 0.37 0.25 0.5 1 
POS 0.5 0.06 0.06 0.12 0.5 
KCZ >16 5.52 4 8 – 
CSP† 0.03 0.03 0.06 0.03 1 
CLO 4 0.39 0.5 0.5 – 
ENL 2 0.15 0.125 0.5 – 
* ECV, epidemiological cut-off values from [46–48]; MIC, minimum inhibitory concentration; MEC, minimum effective concentration (†); AMB, 
amphotericin-B; ITZ, itraconazole; VCZ, voriconazole; POS, posaconazole; KCZ, ketoconazole; CSP, caspofungin; CLO, clotrimazole; ENL, 
enilconazole. 
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5.4 Conclusions 
 
This publication identified only one isolate with azole resistance amongst 53 veterinary clinical 
isolates of A. fumigatus from different global locations. The resistant isolate taken from an 
Australian sample from 1992 had the cyp51A mutations F46Y, G89E and E427K (GenBank 
Accession number KT366018). The mutation F46Y is associated with azole resistant and azole 
susceptible isolates of A. fumigatus. Where resistance has been observed, it has only been noted 
combined with other mutations, including M172V and E427K (itraconazole resistance) 
(Howard et al., 2009, Meneau et al., 2016); M172V, N248T, D255E (itraconazole and 
posaconazole resistance) (Prigitano et al., 2014); TR34/ L98H, M172V, N248T, D255E, 
E427K (itraconazole, posaconazole and isavuconazole resistance) (Abdolrasouli et al., 2015); 
and TR34/L98H, M172V, N248T, D255E, S297T, E427K, F495I (Abdolrasouli et al., 2015). 
It is also reported with isolates susceptible to azole antifungals (Snelders et al., 2010, Escribano 
et al., 2011, Alanio A et al., 2012, Buied et al., 2013, Abdolrasouli et al., 2015, Lavergne et al., 
2015). Interestingly, some combinations of mutations associated with resistance have also been 
associated with susceptibility, including F46Y, M172V and E427K (Howard et al., 2009, 
Snelders et al., 2010, Escribano et al., 2011, Alanio A et al., 2012, Buied et al., 2013, Meneau 
et al., 2016). Following this publication, the F46Y and E427K mutations were also reported in 
a study researching in vitro resistance in human derived isolates of A. fumigatus in Australia 
using the EUCAST antifungal susceptibility microbroth dilution testing method 
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(Kidd et al., 2015). The isolate demonstrated intermediate susceptibility to itraconazole (2 
µg/mL) and susceptibility to posaconazole (0.03 µg/mL) and voriconazole (0.25 µg/mL), with 
the cyp51A mutations F46Y, M172V and E427K. Based on cyp51A protein homology 
modelling using the crystal structure of the fungus Saccharomyces cerevisiae, the F46Y 
mutation has since been demonstrated to be at the cyp51A protein periphery and therefore is 
not considered important regarding the docking of azole molecules or the protein’s structural 
integrity (Liu et al., 2016). It is most likely that non-cyp51A associated mechanisms contributed 
to the azole resistance in this isolate. The mutation G89E has not been reported for A. fumigatus. 
 
This publication showed that azole resistance is not emerging amongst veterinary clinical 
isolates from Australia, the USA and Belgium. However, as this research detected azole 
resistance in an Australian canine isolate from the early 1990s and Kidd et al. (2015) detected 
ARAf in Australian human isolates, further investigation into ARAf in Australia was prompted, 
presented in Chapter 6 in an Australian focused study investigating azole resistance amongst 
environmental and clinical (human and additional veterinary) isolates of A. fumigatus. 
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Chapter 6. Investigation for cyp51A resistance in Australian 
environmental and clinical isolates of Aspergillus fumigatus sensu 
stricto 
 
6.1 Introduction 
 
Azole-resistant Aspergillus fumigatus (ARAf) have been identified worldwide as a major threat 
to the treatment of aspergillosis in people. Studies have demonstrated the relationship between 
the use of triazole fungicides in agricultural practice and the development of resistance in 
clinical patients treated with triazole therapeutics. Additionally, resistance can develop 
following prolonged use of azole therapeutics. The most common cause of ARAf are tandem 
repeats and/or single point mutations in the cyp51A gene, which is the target gene of triazole 
drugs. Although ARAf is recognised globally in human derived and environmental isolates, few 
studies investigated human clinical isolates from Australian, with one study identifying 
occasional ARAf in isolates from human patients, and reporting the TR34/L98H mechanism or 
cyp51A point mutations in these isolates (Kidd et al., 2015). Chapter 5 presented the first study 
investigating ARAf in veterinary clinical isolates (dogs and cats) of Australian origin, finding 
in vitro azole resistance in a dog isolate from 1992. There are no reported Australian 
environmental investigations for ARAf. This chapter investigates the prevalence of ARAf 
amongst many clinical (human and veterinary) and environmental isolates in Australia, and 
utilises cyp51A sequencing and protein homology modelling to investigate resistant 
mechanisms. 
 
6.2 Premise 
 
This study from 2016 to 2017 was a collaboration with the Centre for Infectious Diseases and 
Microbiology Laboratory Services, ICPMR, New South Wales Health Pathology at Westmead 
Hospital. Given the limited number of Australian A. fumigatus isolates screened for ARAf 
(Kidd et al., 2015), and following my work in Chapter 5, I was keen to screen my collection 
of Australian isolates for ARAf. 
 
This chapter presents findings on azole resistance in Australian environmental (azole-exposed 
and azole-naïve) and clinical (human and veterinary) isolates. A random selection of A. 
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fumigatus environmental isolates from Chapter 3, avian clinical isolates from Chapter 4 and 
clinical veterinary samples of A. fumigatus from dogs and cats are included. I collected 69 soil 
samples from public hospital grounds and New South Wales agricultural lands (viticulture and 
fruit crops). I received 25 soil samples from viticulture sites in Western Australia and four from 
Tasmania from Dr Fran Lopez and Dr Lincoln Harper (School of Science, Faculty of Science 
and Engineering, Curtin University), and three soil samples from agricultural crops in New 
South Wales from Dr Will Cuddy (NSW Department of Primary Industries) and Professor 
Robert Park (Faculty of Agriculture & Environment, University of Sydney). 
 
A. fumigatus was isolated from soil using two methods. The first used a simple dilution 
technique (Snelders et al., 2009) and the second the heat activation method described in Chapter 
3 (Nováková et al., 2014, Houbraken and Samson, 2006) to activate any A. fumigatus 
ascospores in the soil. A. fumigatus strains were isolated from azole-naive and azole-exposed 
soil by Prof Vanessa Barrs and myself. I analysed the macroscopic and microscopic 
morphologies of resulting cultures to confirm isolates were Aspergillus species (Samson et al., 
2010) which were then sub-cultured for molecular identification using the partial beta-tubulin 
gene, to confirm their identity to species level as A. fumigatus (Glass and Donaldson, 1995). I 
identified all environmental and veterinary clinical isolates by amplifying the partial beta-
tubulin gene. 
 
The azole susceptibility screening test VIPcheck™ (AMT Plates, Balis Laboratorium V.O.F., 
Boven Leeuwen, the Netherlands) was used to examine all isolates for azole resistance. This 
test has high sensitivity (99%) and specificity (99%) for detecting ARAf amongst isolates of 
A. fumigatus (van der Linden et al., 2013, Arendrup et al., 2017). Environmental and veterinary 
A. fumigatus isolates were screened for azole resistance using the VIPcheck™ test by myself 
and Prof Vanessa Barrs. Any isolates demonstrating growth in drug wells on VIPcheck™ 
testing were further assessed by the colorimetric microbroth dilution antifungal susceptibility 
test Sensititre™ YeastOne™ YO10 assay (TREK Diagnostic Systems Ltd., OH, USA) to 
confirm or disprove resistant phenotype, based on recommended epidemiological cut-off 
values (ECVs) for A. fumigatus (Espinell-Ingroff et al., 2010, Clinical and Laboratory 
Standards Institute (CLSI), 2018). 
 
Cyp51A sequencing was repeated for the presence of mutations in the gene for any isolates with 
ARAf or high MICs for voriconazole itraconazole or posaconazole (Chen et al., 2005). I 
performed cyp51A sequencing on an environmental isolate with high MIC against 
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voriconazole. 
 
All human isolate DNA sequencing (partial beta-tubulin and cyp51A), VIPcheck™ testing, and 
all Sensititre™ YeastOne™ YO10 microbroth dilution antifungal testing included in this study 
were processed by our Westmead Hospital collaborators, Dr Shradha Subedi, Dr Catriona 
Halliday and Associate Professor Sharon Chen. 
 
This research identified the resistant cyp51A genotype amongst isolates of A. fumigatus with 
azole resistant phenotypes. To demonstrate the cyp51A mutations could produce the resistant 
phenotype, a crystal structure homology model was designed by Prof David Hibbs and Ms 
Felcia Lai (Faculty of Pharmacy, the University of Sydney) based on published homology 
models for A. fumigatus cyp51A with the closest percentage match (Saccharomyces cerevisiae 
cyp51A and the A. fumigatus cyp51B model) (Liu et al., 2016, Hargrove et al., 2015). 
 
6.3 Publication 
 
The following publication has been re-formatted here to suit the style of this thesis. The 
publication’s in-text references remain in the style required by the journal (superscript number 
form) and the publication associated tables, figures, references and supplementary data follow 
the main text. This research is presented in its original publication form in Appendix 5. A list 
of all other references referred to in this chapter outside of section 6.3 Publication can be found 
at the chapter’s end (see 6.5 References). 
 
Talbot J.J., Subedi S., Halliday C., Hibbs D., Lai F., Lopez-Ruiz F.J., Harper L., Park R.F., 
Cuddy W.S., Biswas C., Cooley L., Carter D., Sorrell T.C., Barrs V.R., Chen S.C-A. 
Surveillance for azole resistance in clinical and environmental isolates of Aspergillus 
fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates. Journal of 
Antimicrobial Chemotherapy. 2018, dky187, https://doi.org/10.1093/jac/dky187. 
 
Abstract 
 
Background: The prevalence of azole resistance in Aspergillus fumigatus is uncertain in 
Australia. Azole exposure may select for resistance. We investigated the frequency of azole 
resistance in a large number of clinical and environmental isolates. 
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Methods: A. fumigatus isolates [148 human, 21 animal and 185 environmental strains from air 
(n = 6) and azole-exposed (n = 64) or azole-naive (n = 115) environments] were screened for 
azole resistance using the VIPcheck™ system. MICs were determined using the Sensititre™ 
YeastOne YO10 assay. Sequencing of The Aspergillus cyp51A gene and promoter region was 
performed for azole-resistant isolates, and cyp51A homology protein modelling undertaken. 
 
Results: Non-WT MICs/MICs at the epidemiological cut-off value of one or more azoles were 
observed for 3/148 (2%) human isolates but not amongst animal, or environmental, isolates. 
All three isolates grew on at least one azole-supplemented well based on VIPcheck™ 
screening. For isolates 9 and 32, the itraconazole and posaconazole MICs were 1 mg/L 
(voriconazole MICs 0.12 mg/L); isolate 129 had itraconazole, posaconazole and voriconazole 
MICs of >16, 1 and 8 mg/L, respectively. Soil isolates from azole-exposed and azole-naive 
environments had similar geometric mean MICs of itraconazole, posaconazole and 
voriconazole (P > 0.05). A G54R mutation was identified in the isolates exhibiting itraconazole 
and posaconazole resistance, and the TR34/L98H mutation in the pan-azole-resistant isolate. 
cyp51A modelling predicted that the G54R mutation would prevent binding of itraconazole and 
posaconazole to the haem complex. 
 
Conclusions: Azole resistance is uncommon in Australian clinical and environmental A. 
fumigatus isolates; further surveillance is indicated. 
 
Introduction 
 
Aspergillus fumigatus causes aspergillosis in humans and animals ranging from chronic forms 
to acute invasive aspergillosis (IA). IA, in particular, presents significant problems for 
haematological patients, with mortalities of >50%.1,2 Antifungal triazoles are first-line agents 
for managing these infections and preventing fungal diseases in agriculture and construction.3 
The emergence of azole-resistant strains of A. fumigatus (ARAf) is thus concerning, being 
associated with treatment failure and resistance, and may be particularly relevant in 
haematology patients, many of whom have prior exposure to azoles.2,4–6 Selection pressure for 
ARAf has also been linked to exposure to agricultural azole-based fungicides, the 
demethylation inhibitors (DMIs).5–7 Major mechanisms of azole resistance in ARAf include 
SNPs in the A. fumigatus cyp51A gene, alone or combined with tandem repeats (TRs) in the 
promoter region.8–10 
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The prevalence of ARAf varies with geographical region and is highest in Europe (3%– 
26%).5,8,10 In Australia, while ARAf isolates have been identified,11 their prevalence is 
uncertain. To better understand the burden of ARAf, we investigated the frequency of 
resistance to itraconazole, voriconazole and posaconazole among clinical and environmental 
A. fumigatus isolates. 
 
Methods 
 
Human isolates of A. fumigatus (n = 148) were obtained from culture collections at Westmead 
and Royal Hobart Hospitals from 2015 to 2017 (Table S1, available as Supplementary data at 
JAC Online). Of these, 35 isolates were from patients with physician-ascribed IA using 
established criteria where appropriate (see Table S1).12 Twenty-one animal isolates (School of 
Veterinary Science, University of Sydney, 2013–17; Table S1) and 185 environmental isolates 
from azole-naive (n = 115) or azole-exposed (n = 64) habitats and ambient air (n = 6) (2013– 
17; Table S2) were also studied. 
 
For isolation of A. fumigatus, soil samples were stored at 4°C and processed within 1 week 
(method 1),13 with 100 μL of soil suspension incubated at 45°C on malt extract agar containing 
chloramphenicol (MEASC). Early experiments showed that for azole-treated soils, A. 
fumigatus yields were low and samples were reprocessed using ‘method 2’ as previously 
described.14 Briefly, two sets of 5× serial 1:10 dilutions of soil were analysed. One set was heat 
treated at 75°C for 30 min and 100 μL from each dilution was incubated at 37°C on MEASC 
for 21 days. Colonies were identified as A. fumigatus species complex by standard 
morphological methods.15 Identity was confirmed as A. fumigatus sensu stricto by β-tubulin 
gene sequencing.16 
 
To screen for azole resistance, Aspergillus isolates were inoculated onto 4-well VIPcheck™ 
plates (Balis Laboratorium VOF, Boven Leeuwen, The Netherlands) with wells supplemented 
with itraconazole (4 mg/L), voriconazole (2 mg/L) or posaconazole (0.5 mg/L), or 
unsupplemented.17 Isolates growing only in the control well were considered azole susceptible. 
Isolates that grew on any azole-containing well underwent re-examination and susceptibility 
testing using the Sensititre™ YeastOne YO10 system (TREK Diagnostics Systems Ltd, OH, 
USA).18 Both SensititreTM and VIPcheckTM testing was repeated for isolates that grew on azole- 
supplemented wells. 
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Susceptibility testing was performed on all human isolates and randomly selected animal 
(n = 11, 52%) and environmental (n = 41, 22%) isolates according to the manufacturer’s 
instructions and following CLSI methodology (Third Edition: M38).18 MICs or minimum 
effective concentrations (MECs) were read after 48 h of incubation and determined by visual 
inspection. Candida parapsilosis ATCC 22019 (GenBank reference NRRL Y-12969) was the 
quality control, and A. fumigatus ATCC 204305 (GenBank reference KC689329, KU729126 
and KU897017) was the reference strain.18 MICs or MECs were assessed using established 
criteria, with MICs read at 100% inhibition, i.e. no signs of visual growth.18 Interpretative 
criteria based on epidemiological cut-off values (ECVs) were: for itraconazole and 
voriconazole, an MIC of ≤1 mg/L was WT and ≥2 mg/L was non-WT (NWT); and for 
posaconazole, an MIC of ≤0.25 mg/L was WT and >0.5 mg/L was NWT.19,20 Geometric mean 
(GM) MICs/MECs were calculated for WT isolates. Standard deviations and t-scores compared 
GM MICs for groups of isolates with significance set at P ≤ 0.05. For isolates with NWT MICs, 
the Aspergillus cyp51A gene and promoter region were amplified and sequenced.21 Sequences 
were aligned with GenBank reference sequence AF222068.21 
 
The A. fumigatus cyp51A sequence AF33865922 was obtained from the universal protein 
resource (http://www.uniprot.org). Homology modelling was inter alia cyp51B-based with the 
crystal structure of A. fumigatus cyp51B retrieved from the Research Collaboratory for 
Structural Bioinformatics Protein Data Bank (http://www.rcsb.org) as it returned the highest 
sequence identity and BLAST score (identification no. 5FRB: resolution 2.99 Å, max score 
660, total score 660, query cover 92%, identity 65%). Of five homology models of the cyp51A 
gene built using Schrödinger’s Prime,23 the best model (data not shown) was prepared for 
molecular docking (see below). 
 
The single-residue mutation G54R was tested with 2D structures of itraconazole, posaconazole 
and voriconazole and drawn (Schrödinger Release 2017-3; LigPrep LLC, New York). Docking 
of the three triazoles was carried out via Glide with extra precision (XP),24 and the potential 
energy in different conformations with an open and closed binding cavity was calculated via 
MacroModel (Schrödinger Release 2017-3). 
 
Results 
 
Environmental sampling 
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In addition to culture collection isolates included in this study [ambient air (n = 6) and soil 
(n = 20)] a further 159 A. fumigatus environmental cultures were isolated from soil. Method 1 
yielded 91 A. fumigatus isolates from azole-naive soils (n = 90) and azole-exposed soils (n = 1). 
Method 2 yielded an additional 68 isolates from azole-naive soils (n = 5) and azole-exposed 
soils (n = 63). 
 
Resistance screening 
 
 
Five isolates (one avian and four from azole-exposed soil) grew on the itraconazole-containing 
well of the VIPcheck™ plate. Of 148 human isolates, isolate 129 grew on all azole-
supplemented wells, and isolates 9 and 32 grew on posaconazole- and itraconazole-containing 
wells. Isolates 32 and 129 were from patients who had received prior fluconazole as antifungal 
prophylaxis during the preceding 6 month period, whilst isolate 9 was from an azole-naive 
patient. All three patients had invasive pulmonary aspergillosis.12 
 
Susceptibility testing 
 
 
Table 1 summarizes the MIC/MEC values for the study isolates (see Tables S1 and S2 for 
individual isolate results). Of 148 human isolates, 145 had WT MICs below the ECV for the 
drugs tested with GM MICs of itraconazole, posaconazole, voriconazole and amphotericin B 
of 0.12, 0.06, 0.23 and 1.04 mg/L, respectively (MIC90 values were 0.25, 0.12, 0.5 and 
2.0 mg/L, respectively). Of three isolates that had MICs at the ECV or NWT MICs (Table S1), 
isolates 9 and 32 had an MIC of 1 mg/L of posaconazole and itraconazole (voriconazole MIC 
0.12 mg/L). Isolate 129 had MICs of >16, 8 and 1 mg/L of itraconazole, voriconazole and 
posaconazole, respectively. However, the avian isolate that grew on the itraconazole- 
containing well of the VIPcheck™ plate had a WT itraconazole MIC (0.06 mg/L). The 
assignment of MIC results as WT or NWT/MIC at the ECV of clinical isolates was concordant 
with results obtained by VIPcheck™ screening for 99% of clinical isolates. 
 
All 41 environmental isolates had WT MIC values of the azoles (Table 1); GM MICs of 
itraconazole, posaconazole and voriconazole were 0.13, 0.05 and 0.29 mg/L, respectively 
(MIC90 0.25, 0.12 and 0.5 mg/L). All four isolates that grew on the itraconazole-containing 
agar well of the VIPcheck™ plate had WT MICs of itraconazole [0.06 (n = 3) and 0.12 (n = 1) 
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mg/L]. Comparison of GM MICs, MIC50 values and MIC90 values between ‘azole-exposed’ 
and ‘azole-naive’ isolates showed these were not statistically different (data not shown: 
posaconazole, P > 0.05–0.1; and itraconazole and voriconazole, P > 0.2). 
 
Cyp51A sequencing and modelling 
 
 
Cyp51A mutations were identified in the three isolates with NWT MICs or MICs at the ECV 
(see Table S1) (GenBank accession numbers MG687254–MG687257). Isolates 9 and 32 had 
SNPs present at nucleotide position 160 (GGG to AGG and CGG, respectively), resulting in a 
G54R substitution. Isolate 32 had another SNP at nucleotide position 744 (AAT to AAA), 
resulting in N248K. Isolate 129 carried a TR34/L98H mutation at nucleotide position 323. 
Modelling G54R indicated that replacing the short side-chain glycine (G) with arginine (R) 
allowed the formation of hydrogen bonds with T50 and S493, which closes off binding channel 
access (Figure 1). This closed conformation stabilized the model by 84.47 kcal/mol with high 
likelihood that the large triazole structures (itraconazole and posaconazole but not 
voriconazole) would be prevented from entering the channel. 
 
Discussion 
 
This large study found isolates with NWT MICs to be uncommon in Australian human clinical 
isolates (2.0%), and at the lower end of that seen globally (0%–26%), contrasting particularly 
with that in the Netherlands.5,8,10 Of note, ARAf was absent amongst animal isolates. These 
data suggest that treatment guidelines currently recommending azoles as preferred therapy for 
IA remain appropriate in Australia.3 
 
Also notable was the apparent absence of ARAf in the environment, including azole-exposed 
habitats. Environmental studies have reported a broad range of prevalence of ARAf (0%–91%), 
with the highest prevalence in the Netherlands, where most resistant isolates carry the 
TR34/L98H mechanism.
7 The implications of our results for agricultural practice, although 
uncertain, raise questions regarding the impact of different agricultural practices between 
Australia and Europe including percentage of crop area treated, number and amount of 
applications/crop, and type and rotation of DMIs used. Composts, which have yielded a high 
percentage of environmental ARAf in Europe,25 are not used in broad-acre farming in Australia. 
Additionally, compared with Western Europe, the Australian climate has prolonged periods of 
dryness or drought, where the need for DMIs is greatly reduced. In Australia, the most 
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commonly used azole fungicides for grape crops include difenoconazole, myclobutanil, 
penconazole, tebuconazole and tetraconazole and for grain crops cyproconazole, 
epoxiconazole, propiconazole, prothioconazole and tebuconazole.26 Azole fungicide and 
medical practices of different locations worldwide should be compared to further our 
understanding of the variation in ARAf prevalence rates between regions. 
 
The agar-based VIPcheck™ screening test is well established to have sufficiently high 
sensitivity and specificity for predicting azole resistance.27 In the present study, the test proved 
useful in screening for resistance with no false ‘susceptible’ results; all isolates with NWT 
MICs or with MICs at the ECV were observed to grow on the plates. The VIPcheck™ plates 
overcalled ‘resistance’ for five isolates (5/8 isolates, specificity 97.5%). This is reasonable for 
a screening test which must have a high negative predictive value. As the VIPcheckTM test does 
not measure MICs, all isolates that grow on azole-supplemented agar should be tested for 
antifungal susceptibility. 
 
The G54R mutation, identified here in two isolates, is known to confer differential azole 
resistance in A. fumigatus.9 One of our isolates with the G54R mutation had a second mutation 
leading to amino acid substitution N248K; however, this also occurs in azole-susceptible A. 
fumigatus isolates with no documented link to resistance.9 Pan-resistance in isolate 129 was 
through the TR34/L98H mutation, consistent with existing literature.
10 Of note, both TR34/L98H 
and G54R mutations have been linked to environmental acquisition,7,10 and were identified 
previously in three other Australian clinical isolates.11 
 
Our homology modelling results using a cyp51B A. fumigatus model are consistent with 
previous observations in non-Aspergillus cyp51A models that the G54R mutation can prevent 
docking of the long-tailed azoles itraconazole and posaconazole but not of the more compact 
voriconazole molecule.28 
 
Recovery of A. fumigatus from soil found that method 2, which uses heat-shock to inactivate 
asexual spores, gave a higher yield of isolates from azole-treated soils. Although no ARAf was 
found, the survival of sexual spores in azole-treated soil could serve as a potential reservoir for 
resistance development; in the laboratory setting, sexual reproduction has been implicated in 
the development of cyp51A-mediated azole resistance.25 
 
A limitation of the present study was that clinical data were not collected. This prevented more 
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precise determination of ARAf incidence amongst different groups of azole-exposed or azole- 
naive patients. About half of the cystic fibrosis patients in the Centre for Infectious Diseases 
and Microbiology Laboratory Services receive intermittent azole therapy (usually itraconazole) 
(S. C.-A. Chen, unpublished data). Other isolates were recovered from disparate groups of 
patients with unknown azole exposure. Whilst it is possible that the low prevalence observed 
is related to potential inhomogeneity in the patient population, the fact that we only observed 
three ‘azole-resistant’ isolates would limit any statistically meaningful data. We acknowledge 
the importance of prospective studies to investigate azole resistance amongst specific patient 
groups. 
 
In conclusion, ARAf appears to be uncommon in Australia, which indicates that the preferred 
therapy for aspergillosis does not need to be changed. However, continued surveillance is 
warranted to pre-empt the emergence of ARAf strains and to inform management strategies. 
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Publication Figures 
 
 
 
Figure 1. A. fumigatus cyp51B model demonstrating binding to the active site of cyp51A and 
the H-bond interaction. Itraconazole (blue) binding in the active site of cyp51A: (a) amino acid 
G54 (red) and (b) mutated G54R (purple). (c) Hydrogen bonding (yellow dashed lines) between 
T50, G54R and S493 (H-bond length: T50 and G54R, 1.99 Å; and S493 and G54R, 2.28 Å). 
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(d) Voriconazole (orange), posaconazole (green) and itraconazole (blue) in the binding cavity; 
residue G54R (purple) and the haem group (yellow) are shown. 
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Publication Tables 
 
Table 1. Antifungal susceptibilities [MIC or MECa values (mg/L)] of 147 human,b 11 animal and 41 environmental isolates of A. fumigatus, 
according to origin of isolates  
 
 AMB ANF CAS FLC ITC MIF POS VRC 
GM MIC/MEC 
human, invasive (35) 
 
1.2 
 
0.02 
 
0.04 
 
184.35 
 
0.22 
 
0.01 
 
0.11 
 
0.28 
human, colonization (112) 0.99 0.02 0.03 195.85 0.12 0.01 0.05 0.22 
animal (11) 1.13 0.02 0.04 256 0.12 0.02 0.04 0.34 
azole-exposed soil (23)c 1.2 0.02 0.04 246 0.13 0.01 0.06 0.27 
azole-naive soil (12) 1.06 0.02 0.04 256 0.12 0.02 0.04 0.31 
air (6) 2 0.015 0.04 228 0.15 0.01 0.05 0.25 
MIC/MEC90 
human, invasive (35) 
 
2 
 
0.03 
 
0.12 
 
>256 
 
0.5 
 
0.015 
 
0.5 
 
0.5 
human, colonization (112) 2 0.03 0.06 >256 0.25 0.03 0.12 0.5 
animal (11) 2 0.03 0.06 >256 0.25 0.03 0.12 0.5 
azole exposed soil (23)c 2 0.03 0.06 256 0.25 0.015 0.12 0.5 
azole-naive soil (12) 1 0.03 0.06 >256 0.25 0.03 0.12 0.5 
air (6) 2 0.015 0.06 256 0.25 0.015 0.06 0.5 
MIC/MEC range 
human, invasive (35) 
 
0.25–8 
 
<0.015–0.06 
 
0.008–0.5 
 
64 to >256 
 
0.06 to .16 
 
<0.008–0.03 
 
0.015–1 
 
0.06–8 
human, colonization (112) 0.25–2 <0.015–0.12 <0.008–0.12 64 to >256 <0.015–0.5 <0.008–0.03 <0.008–0.25 0.03–1 
animal (11) 0.5–2 0.015–0.03 0.015–0.06 256 to >256 0.03–0.5 0.008–0.03 0.015–0.25 0.25–0.5 
azole-exposed soil (23)c 0.5–2 0.015–0.06 0.015–0.06 128 to >256 0.03–0.5 0.008–0.03 0.015–0.25 0.12–1.0 
azole-naive soil (12) 1–2 0.015–0.06 0.03–0.06 256 to >256 0.03–0.25 0.008–0.03 0.015–0.12 0.25–0.5 
air (6) 2 0.015 0.03–0.06 128–256 0.12–0.25 0.008–0.015 0.03–0.06 0.06–0.5 
AMB, amphotericin B; ANF, anidulafungin; CAS, caspofungin; FLC, fluconazole; ITC, itraconazole; MIF, micafungin; POS, posaconazole; VRC, voriconazole. Numbers in brackets refer to the 
numbers of isolates tested. a MECs are reported for echinocandin drugs (anidulafungin, caspofungin and micafungin). b Disease state information was not available for one human isolate (isolate 
number 24). MICs for this isolate were (in mg/L): amphotericin B, 1; anidulafungin, 0.015; caspofungin, 0.06; fluconazole, 256; itraconazole, 0.25; micafungin, 0.008; posaconazole, 0.12; and 
voriconazole, 0.25. c DMIs used on azole-exposed soil isolates included cyproconazole (n=3), myclobutanil (n=4), tebuconazole and epoxiconazole (n=10), tebuconazole and myclobutanil (n=1), 
tebuconazole and penconazole (n=3), and tetraconazole and myclobutanil (n=2). 
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Publication Supplementary Data 
 
Table S1. Isolate details for human (n=148) and animal (n=21) patients from whom Aspergillus fumigatus was cultured. MIC, or minimum effective 
concentration (for echinocandins), values are provided for 159 isolates. 
 
 
Isolate 
Number 
Source 
isolate 
Disease state 
(site of 
infection)* 
MICs or MECs^ (mg/L) 
AMB ANF CAS FLC 5FC ITC MIF POS VRC 
Human 
isolates 
1 Sputum I (lung) 1 <0.015 0.015 256 0.5 0.12 <0.008 0.03 0.12 
2 Pleural fluid C 1 0.015 0.015 128 32 0.12 0.015 0.06 0.25 
3 Lung tissue I (lung) 0.5 0.015 0.015 128 2 0.06 <0.008 0.03 0.12 
4 BAL fluid I (lung) 1 0.015 0.015 128 1 0.06 0.008 0.03 0.12 
5 BAL fluid I (lung) 1 0.015 0.008 >256 16 0.12 0.008 0.03 0.25 
6 BAL fluid I (lung) 0.25 <0.015 0.015 256 1 0.12 <0.008 0.06 0.12 
 
7 
Parotid 
gland 
I (soft tissue 
and parotid) 
 
2 
 
0.015 
 
0.015 
 
>256 
 
2 
 
0.12 
 
0.008 
 
0.06 
 
0.25 
 
8 
Bronchial 
tissue 
 
I (lung) 
 
0.25 
 
0.015 
 
0.008 
 
128 
 
1 
 
0.06 
 
<0.008 
 
0.03 
 
0.06 
9# BAL fluid I (lung) 1 0.03 0.06 64 32 1 0.015 1 0.12 
10 Sputum I (lung) 0.5 0.03 0.015 128 0.5 0.12 0.015 0.06 0.12 
 
11 
Bronchial 
tissue 
 
I (lung) 
 
0.5 
 
0.015 
 
0.03 
 
256 
 
2 
 
0.12 
 
0.008 
 
0.06 
 
0.25 
12 Lung tissue I (lung) 0.5 0.015 0.03 256 32 0.06 <0.008 0.015 0.12 
13 Sinus tissue I (sinus, bone) 2 0.03 0.03 >256 32 0.5 0.015 0.25 0.5 
14 Lung tissue I (lung) 1 0.015 0.06 >256 32 0.5 0.015 0.25 0.5 
15 Sputum I (lung) 2 0.03 0.03 >256 16 0.25 0.015 0.12 0.25 
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16 
Mastoid 
tissue 
I (bone, sinus, 
ear) 
 
8 
 
0.015 
 
0.015 
 
>256 
 
16 
 
0.12 
 
0.015 
 
0.06 
 
0.25 
17 Sputum I (lung) 2 0.03 0.03 >256 16 0.25 0.008 0.12 0.25 
18 BAL fluid I (lung) 2 0.015 0.06 >256 16 0.25 0.008 0.12 0.25 
19 BAL fluid I (lung) 4 0.06 0.06 >256 64 0.5 0.015 0.25 0.5 
 
20 
Mastoid 
tissue 
 
I (ear, bone) 
 
2 
 
0.03 
 
0.06 
 
256 
 
8 
 
0.12 
 
0.015 
 
0.03 
 
0.25 
21 Sputum I (lung) 2 0.03 0.06 >256 4 0.5 <0.008 0.25 0.5 
22 Pleural fluid I (lung) 1 <0.015 0.015 256 16 0.5 0.008 0.5 1 
23 Lung Tissue I (lung) 2 0.015 0.06 256 8 0.25 0.008 0.12 0.5 
24 NA NA 1 0.015 0.06 256 32 0.25 0.008 0.12 0.25 
25 Lung tissue I (lung) 1 0.015 0.03 64 32 0.25 0.008 0.12 0.25 
26 Sputum C 1 0.03 0.06 256 16 0.12 0.015 0.03 0.25 
 
27 
Abdominal 
wall tissue 
I (soft tissue, 
muscle) 
 
1 
 
0.015 
 
0.12 
 
256 
 
32 
 
0.12 
 
0.015 
 
0.03 
 
0.25 
28 Cornea I (eye) 2 0.015 0.06 256 32 0.25 0.015 0.12 0.25 
29 Sputum I (lung) 1 0.015 0.06 >256 64 0.25 0.015 0.12 0.5 
30 BAL fluid I (lung) 4 0.03 0.25 >256 64 0.5 0.015 0.25 0.25 
31 Sputum I (lung) 1 0.06 0.5 >256 >64 0.5 0.03 0.25 0.5 
32# Sputum I (lung) 1 0.03 0.03 256 32 1 0.015 1 0.12 
33 Sputum C 1 <0.015 0.015 256 4 0.03 <0.008 0.015 0.12 
34 Sputum C 0.5 <0.015 0.015 256 0.5 <0.015 <0.008 <0.008 0.06 
35 Sputum C 0.5 <0.015 0.015 256 1 0.03 <0.008 0.015 0.12 
36 Sputum C 0.5 <0.015 0.015 256 2 0.03 <0.008 0.015 0.12 
37 Sputum C 0.5 <0.015 0.015 128 128 0.015 <0.008 <0.008 0.06 
38 Sputum C 0.5 <0.015 0.008 256 0.5 0.03 <0.008 0.015 0.06 
39 Sputum C 0.5 <0.015 0.008 128 1 0.03 <0.008 0.015 0.06 
40 Sputum C 0.5 <0.015 0.008 128 0.5 0.06 <0.008 0.015 0.06 
41 Sputum C 0.25 <0.015 0.008 128 0.25 0.015 <0.008 0.008 0.03 
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42 Sputum C 0.5 <0.015 0.008 256 1 0.06 <0.008 0.03 0.12 
43 Sputum C 0.25 <0.015 0.015 128 0.5 0.03 <0.008 0.015 0.06 
44 Sputum C 0.25 <0.015 0.015 128 0.5 0.03 <0.008 0.015 0.06 
45 Sputum C 0.5 0.015 0.015 256 1 0.12 <0.008 0.03 0.12 
46 Sputum C 0.25 0.015 0.015 64 1 0.03 <0.008 0.015 0.06 
47 Sputum C 1 0.015 0.06 256 16 0.06 0.015 0.03 0.12 
48 Sputum C 0.25 <0.015 <0.008 256 0.25 0.06 <0.008 0.03 0.06 
49 Sputum C 0.5 0.015 <0.008 256 0.5 0.12 <0.008 0.06 0.12 
50 Sputum C 0.5 0.015 0.03 256 0.5 0.06 <0.015 0.03 0.12 
51 Sputum C 0.5 <0.015 0.015 128 0.25 0.03 <0.008 0.015 0.06 
52 Sputum C 0.25 <0.015 0.015 256 0.25 0.06 <0.008 0.03 0.06 
53 Sputum C 0.25 <0.015 <0.008 128 1 0.06 <0.008 0.03 0.06 
54 Sputum C 0.25 <0.015 <0.008 128 0.25 0.06 <0.008 0.03 0.06 
55 Sputum C 0.5 <0.015 0.008 256 0.5 0.12 <0.008 0.015 0.25 
56 Sputum C 1 0.015 0.12 256 4 0.25 0.015 0.12 0.25 
57 Sputum C 0.25 <0.015 0.015 256 4 0.12 <0.008 0.06 0.12 
58 Sputum C 0.25 <0.015 <0.008 64 0.25 0.06 <0.008 0.03 0.06 
59 Sputum C 0.25 <0.015 <0.008 256 0.5 0.03 <0.008 0.015 0.06 
60 Sputum C 0.5 <0.015 0.015 256 4 0.03 <0.008 0.03 0.12 
61 Sputum C 1 0.015 0.008 256 32 0.03 <0.008 0.03 0.25 
62 Sputum C 0.5 0.015 0.015 256 4 0.25 0.015 0.12 0.25 
63 Sputum C 1 <0.015 0.015 256 32 0.25 <0.008 0.12 0.25 
64 Sputum C 1 0.03 0.015 256 64 0.12 <0.008 0.12 0.25 
65 Sputum C 2 0.015 0.03 256 1 0.25 <0.008 0.12 0.25 
66 Sputum C 1 0.015 0.015 256 32 0.25 <0.008 0.12 0.25 
67 Sputum C 1 <0.015 <0.0008 256 32 0.25 <0.008 0.12 0.25 
68 Sputum C 1 0.015 0.015 256 4 0.25 0.008 0.12 0.5 
69 Sputum C 1 0.015 0.015 256 4 0.25 0.008 0.12 0.25 
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70 Sputum C 1 0.03 0.03 256 32 0.5 0.008 0.12 0.5 
71 Sputum C 1 0.015 0.03 128 16 0.25 0.008 0.25 0.25 
72 Sputum C 1 0.015 0.015 128 32 0.25 0.008 0.12 0.25 
73 Sputum C 2 0.015 0.03 256 16 0.25 0.008 0.12 0.5 
74 Sputum C 1 0.015 0.03 256 16 0.25 0.008 0.12 0.25 
75 Sputum C 1 0.015 0.03 128 16 0.25 0.008 0.12 0.25 
76 Sputum C 0.25 0.015 0.015 128 1 0.25 0.008 0.06 0.12 
77 Sputum C 1 0.015 0.03 128 32 0.25 0.008 0.06 0.25 
78 Sputum C 1 0.015 0.03 128 16 0.25 0.008 0.12 0.5 
79 Sputum C 0.25 0.015 0.015 128 1 0.12 0.008 0.06 0.12 
80 Sputum C 0.25 0.015 0.015 128 0.5 0.12 0.008 0.06 0.12 
81 Sputum C 1 0.12 0.06 256 2 0.25 0.015 0.06 0.25 
82 Sputum C 2 0.03 0.015 256 32 0.25 0.008 0.12 0.25 
83 Sputum C 0.25 0.06 0.03 256 1 0.12 0.008 0.06 0.12 
84 Sputum C 0.5 0.015 0.03 64 1 0.25 0.008 0.12 0.25 
85 Sputum C 2 0.03 0.06 256 16 0.25 0.008 0.12 0.25 
86 Sputum C 0.5 0.015 0.015 128 4 0.25 0.008 0.06 0.12 
87 Sputum C 1 0.03 0.03 128 2 0.25 0.008 0.12 0.25 
88 Sputum C 2 0.03 0.012 >256 32 0.12 0.03 0.06 0.25 
89 Sputum C 1 0.015 0.03 >256 8 0.12 0.03 0.03 1 
90 Sputum C 2 0.015 0.03 >256 64 0.12 0.03 0.06 0.5 
91 Sputum C 2 0.03 0.03 >256 64 0.12 0.03 0.06 0.5 
92 Sputum C 2 0.015 0.03 >256 64 0.12 0.03 0.03 0.5 
93 Sputum C 2 0.03 0.06 256 64 0.12 0.03 0.03 0.5 
94 Sputum C 2 0.015 0.03 >256 16 0.12 0.015 0.06 0.5 
95 Sputum C 2 0.015 0.06 >256 64 0.12 0.03 0.06 0.5 
96 Sputum C 2 0.015 0.015 >256 64 0.12 0.015 0.06 0.25 
97 Sputum C 2 0.03 0.06 256 32 0.06 0.03 0.015 0.25 
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98 Sputum C 2 0.03 0.06 >256 32 0.12 0.03 0.03 0.5 
99 Sputum C 2 0.015 0.06 256 32 0.12 0.015 0.03 0.25 
100 Sputum C 2 0.015 0.06 256 32 0.12 0.03 0.03 0.5 
101 Sputum C 2 0.015 0.03 >256 16 0.12 0.015 0.06 0.5 
102 Sputum C 2 0.03 0.06 256 32 0.25 0.03 0.06 0.25 
103 Sputum C 2 0.015 0.03 >256 64 0.25 0.015 0.12 1 
104 Sputum C 2 0.03 0.06 256 64 0.16 0.03 0.06 0.25 
105 Sputum C 2 0.015 0.06 256 8 0.25 0.03 0.06 0.25 
106 Sputum C 2 0.015 0.015 256 16 0.12 0.008 0.03 0.5 
107 Sputum C 2 0.015 0.03 128 32 0.06 0.015 0.03 0.25 
108 Sputum C 2 0.015 0.015 256 4 0.12 0.008 0.03 0.25 
109 Sputum C 2 0.015 0.03 >256 32 0.12 0.015 0.03 0.25 
110 Sputum C 2 0.015 0.015 128 32 0.06 0.008 0.03 0.25 
111 Sputum C 2 0.015 0.03 256 64 0.12 0.008 0.03 0.25 
112 Sputum C 2 0.015 0.03 256 32 0.06 0.008 0.03 0.25 
113 Sputum C 2 0.015 0.015 128 16 0.03 0.015 0.03 0.25 
114 Sputum C 2 0.015 0.03 256 32 0.12 0.015 0.03 0.12 
115 Sputum C 2 0.015 0.03 >256 32 0.12 0.008 0.03 0.12 
116 Sputum C 2 0.015 0.015 256 32 0.06 <0.008 0.015 0.25 
117 Sputum C 2 0.015 0.015 256 64 0.03 0.008 0.015 0.25 
118 Sputum C 2 0.015 0.008 >256 32 0.06 0.008 0.03 0.25 
119 Sputum C 1 0.015 0.015 256 64 0.03 0.015 0.015 0.25 
120 Sputum C 2 0.03 0.008 >256 64 0.06 0.008 0.03 0.25 
121 Sputum C 2 0.015 0.03 256 32 0.25 0.008 0.12 0.25 
122 Sputum C 2 0.03 0.06 256 32 0.25 0.015 0.12 0.5 
123 Sputum C 2 0.015 0.06 128 32 0.12 0.015 0.06 0.25 
124 Sputum C 2 0.015 0.015 256 32 0.12 0.008 0.03 0.5 
125 Sputum C 2 0.015 0.03 256 32 0.25 0.008 0.12 0.5 
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126 Sputum C 1 0.03 0.06 256 32 0.25 0.015 0.12 0.5 
127 Sputum C 2 0.015 0.06 128 16 0.12 0.008 0.03 0.25 
128 Sputum I (lung) 2 0.015 0.06 128 32 0.12 0.008 0.06 0.5 
 
129# 
Pus from 
lung 
 
I (lung) 
 
2 
 
0.015 
 
0.03 
 
>256 
 
16 
 
>16 
 
0.015 
 
1 
 
8 
130 Sputum I (lung) 1 0.015 0.008 >256 4 0.25 0.008 0.12 0.5 
131 Sputum C 1 0.015 0.03 >256 4 0.25 0.015 0.06 0.25 
132 Sputum C 2 0.015 0.03 >256 32 0.25 0.008 0.12 0.5 
133 Sputum C 2 0.015 0.06 128 64 0.25 0.015 0.06 0.25 
134 Sputum C 2 0.015 0.06 256 64 0.25 0.008 0.12 0.5 
135 Sputum C 0.5 0.015 0.03 >256 4 0.25 0.008 0.12 0.25 
136 Sputum C 1 0.015 0.03 256 32 0.06 0.008 0.03 0.25 
137 Sputum C 1 0.015 0.015 >256 64 0.25 0.008 0.12 0.5 
138 Sputum C 0.5 0.015 0.03 128 2 0.12 0.008 0.06 0.25 
139 Sputum I (lung) 0.5 0.015 0.015 256 2 0.25 0.008 0.06 0.25 
140 Sputum C 1 0.015 0.015 >256 64 0.5 0.008 0.25 0.5 
141 Sputum C 2 0.015 0.015 128 64 0.12 0.008 0.03 0.25 
142 Sputum C 1 0.03 0.12 >256 32 0.5 0.015 0.25 0.25 
143 Sputum C 2 0.06 0.06 256 64 0.5 0.03 0.25 0.5 
144 Sputum C 2 0.03 0.12 >256 64 0.5 0.03 0.25 0.5 
145 Sputum C 2 0.06 0.12 >256 32 0.5 0.03 0.12 0.25 
146 Soft tissue I (soft tissue) 1 0.03 0.12 >256 64 0.5 0.03 0.25 0.25 
147 Sputum I (lung) 1 0.03 0.12 256 8 0.25 0.015 0.12 0.25 
148 Sputum C 1 0.03 0.12 >256 64 0.25 0.015 0.12 0.5 
Veterinary 
isolates 
 
 
149 
Canine, 
sinus tissue 
 
C 
 
2 
 
0.03 
 
0.03 
 
>256 
 
32 
 
0.12 
 
0.015 
 
0.03 
 
0.5 
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150 
Canine, 
sinus tissue 
C  
1 
 
0.015 
 
0.03 
 
>256 
 
32 
 
0.5 
 
0.015 
 
0.25 
 
0.5 
 
151 
Canine, 
sinus tissue 
C  
1 
 
0.03 
 
0.03 
 
256 
 
64 
 
0.03 
 
0.015 
 
0.015 
 
0.25 
 
152 
Feline, sinus 
tissue 
C  
1 
 
0.015 
 
0.06 
 
>256 
 
32 
 
0.12 
 
0.015 
 
0.03 
 
0.25 
 
153 
Avian, lung 
 
C 
 
1 
 
0.03 
 
0.06 
 
>256 
 
32 
 
0.25 
 
0.03 
 
0.06 
 
0.25 
 
154 
Avian, air 
sac 
I 
(respiratory) 
 
1 
 
0.03 
 
0.03 
 
>256 
 
64 
 
0.12 
 
0.015 
 
0.03 
 
0.5 
 
 
155 
Avian, 
coelom 
tissue 
 
 
C 
 
 
0.5 
 
 
0.015 
 
 
0.015 
 
 
256 
 
 
8 
 
 
0.25 
 
 
0.015 
 
 
0.12 
 
 
0.25 
 
156 
Avian, lung I 
(lung) 
 
1 
 
0.03 
 
0.06 
 
>256 
 
64 
 
0.06 
 
0.015 
 
0.015 
 
0.25 
 
157 
Avian, 
pericardium 
I  
2 
 
0.03 
 
0.06 
 
256 
 
64 
 
0.12 
 
0.03 
 
0.06 
 
0.25 
 
 
158† 
Avian, air 
sac 
 
 
I (respiratory) 
 
 
2 
 
 
0.015 
 
 
0.06 
 
 
>256 
 
 
64 
 
 
0.06 
 
 
0.015 
 
 
0.03 
 
 
0.5 
 
159 
Avian, 
ocular tissue 
I 
(disseminated) 
 
1 
 
0.015 
 
0.03 
 
>256 
 
>64 
 
0.12 
 
0.008 
 
0.06 
 
0.5 
 
 
160 
Avian, 
conjunctival 
swab 
 
I 
(disseminated) 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
161 
Avian, lung 
 
I (lung) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
162 
Avian, lung I 
(disseminated) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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163 
Avian, air 
sac 
I 
(disseminated) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
164 
Avian, 
kidney 
I 
(disseminated) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
165 
Avian, lung I 
(lung) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
166 
Avian, air 
sac 
 
I (respiratory) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
167 
Feline, nasal 
plaque 
 
C 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
168 
Canine, 
nasal plaque 
 
C 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
169 
Canine, 
sinus plaque 
 
C 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Abbreviations: AMB, amphotericin B; ANF, anidulafungin; BAL, bronchoalveolar lavage; CAS, caspofungin; C, colonisation; FLC, fluconazole; 
5FC, 5-flucytosine-C; I, invasive; ITC, itraconazole; MIF, micafungin; POS, posaconazole; VRC, voriconazole. 
* Disease state: For the purposes of this study human and animal patients were assigned as having invasive disease if fungal hyphae with evidence 
of invasion were seen on histological sections of affected tissue or body sties as well as being cultured, or were isolated from a normally sterile 
body site e.g. eye; or who had host risk factors, a positive A. fumigatus culture and radiological evidence consistent with invasive fungal disease.13 
Colonisation was defined as the isolation of A. fumigatus from non-sterile sites, and in human patients, where there was no clinical radiological 
evidence of infection. 
^ Minimum effective concentrations (MECs) are reported for echinocandin drugs, anidulafungin, caspofungin and micafungin. 
# azole –resistant isolates. 
† isolates that had discordant results of VIPcheckTM testing and SensititreTM antifungal susceptibility testing 
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Table S2. Isolate details for 185 environmental isolates from azole-exposed (n=64) and azole naïve (n=121) sources. Sensititre™ YeastOne 
YO10 assay (TREK Diagnostics, USA) MIC/ minimum effective concentration (for echinocandins) values are provided for isolates tested 
(n=41). 
 
 
 
Isolate 
No 
 
 
Jurisdiction 
 
Azole status 
(exposed/naïve) 
DMI 
fungicide 
used 
 
 
Substrate 
 
 
MIC/ MEC^ values (mg/L) 
     AMB ANI CAS FLU 5-FC ITC MIF POS VRC 
 
1 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
1 
 
0.03 
 
0.06 
 
>256 
 
32 
 
0.12 
 
0.03 
 
0.03 
 
0.25 
 
2 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
1 
 
0.015 
 
0.06 
 
256 
 
32 
 
0.06 
 
0.015 
 
0.015 
 
0.25 
 
3 
 
WA 
 
naïve 
 
- 
soil, 
viticulture 
 
2 
 
0.03 
 
0.03 
 
256 
 
2 
 
0.12 
 
0.015 
 
0.03 
 
0.25 
 
4 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
1 
 
0.03 
 
0.06 
 
256 
 
16 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
5 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
1 
 
0.015 
 
0.03 
 
>256 
 
4 
 
0.12 
 
0.015 
 
0.03 
 
0.5 
 
6 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
1 
 
0.03 
 
0.03 
 
>256 
 
16 
 
0.12 
 
0.03 
 
0.06 
 
0.25 
 
7 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
1 
 
0.03 
 
0.06 
 
256 
 
16 
 
0.25 
 
0.03 
 
0.06 
 
0.25 
8 
 
NSW 
 
naïve 
 
- 
soil, fig 
crop 
 
1 
 
0.015 
 
0.03 
 
>256 
 
32 
 
0.06 
 
0.008 
 
0.015 
 
0.5 
 
 
9 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
1 
 
 
0.03 
 
 
0.06 
 
 
256 
 
 
32 
 
 
0.25 
 
 
0.015 
 
 
0.06 
 
 
0.25 
 
 
10 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
1 
 
 
0.015 
 
 
0.03 
 
 
>256 
 
 
32 
 
 
0.03 
 
 
0.015 
 
 
0.015 
 
 
0.5 
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11 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
1 
 
 
0.015 
 
 
0.03 
 
 
>256 
 
 
64 
 
 
0.25 
 
 
0.008 
 
 
0.06 
 
 
0.5 
 
12 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
1 
 
0.03 
 
0.06 
 
256 
 
16 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
13 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
1 
 
0.06 
 
0.06 
 
256 
 
8 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
14 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.015 
 
0.03 
 
256 
 
8 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
15 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.03 
 
0.06 
 
256 
 
8 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
16 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.03 
 
0.06 
 
256 
 
16 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
17 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.015 
 
0.06 
 
>256 
 
64 
 
0.06 
 
0.015 
 
0.015 
 
0.25 
 
18 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.03 
 
0.06 
 
256 
 
16 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
19 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.03 
 
0.03 
 
256 
 
32 
 
0.03 
 
0.015 
 
0.015 
 
0.25 
 
20 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.015 
 
0.06 
 
256 
 
4 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
21 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.03 
 
0.06 
 
>256 
 
>64 
 
0.5 
 
0.015 
 
0.25 
 
0.25 
 
22 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.015 
 
0.015 
 
256 
 
64 
 
0.06 
 
0.008 
 
0.03 
 
0.5 
 
23 
 
TAS 
 
exposed 
tebuconazole, 
epoxiconazole 
soil, cereal 
crop 
 
1 
 
0.03 
 
0.03 
 
256 
 
4 
 
0.25 
 
0.03 
 
0.12 
 
0.25 
 
24 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
1 
 
0.015 
 
0.06 
 
256 
 
2 
 
0.25 
 
0.008 
 
0.12 
 
0.25 
 
25 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
2 
 
0.03 
 
0.06 
 
256 
 
64 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
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26 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
2 
 
0.015 
 
0.03 
 
256 
 
64 
 
0.03 
 
0.015 
 
0.015 
 
0.25 
 
27 
 
WA 
 
naïve 
 
- 
soil, 
viticulture 
 
1 
 
0.06 
 
0.06 
 
256 
 
2 
 
0.25 
 
0.03 
 
0.12 
 
0.25 
 
28 
 
WA 
 
naïve 
 
- 
soil, 
viticulture 
 
1 
 
0.015 
 
0.03 
 
256 
 
32 
 
0.03 
 
0.008 
 
0.015 
 
0.25 
 
29 
 
WA 
 
exposed 
tebuconazole, 
penconazole 
soil, 
viticulture 
 
0.5 
 
0.03 
 
0.03 
 
256 
 
4 
 
0.25 
 
0.015 
 
0.12 
 
0.25 
 
30 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
2 
 
0.015 
 
0.03 
 
256 
 
64 
 
0.03 
 
0.015 
 
0.015 
 
0.25 
 
31 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
1 
 
0.03 
 
0.06 
 
128 
 
2 
 
0.25 
 
0.015 
 
0.12 
 
0.12 
 
32† 
 
WA 
 
exposed 
tebuconazole, 
penconazole 
soil, 
viticulture 
 
2 
 
0.015 
 
0.03 
 
>256 
 
>64 
 
0.06 
 
0.015 
 
0.03 
 
0.25 
 
33† 
 
WA 
 
exposed 
tebuconazole, 
myclobutanil 
soil, 
viticulture 
 
2 
 
0.015 
 
0.03 
 
>256 
 
>64 
 
0.06 
 
0.015 
 
0.03 
 
0.25 
 
34† 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
2 
 
0.015 
 
0.06 
 
>256 
 
64 
 
0.12 
 
0.015 
 
0.06 
 
1 
 
35† 
 
WA 
 
exposed 
tebuconazole, 
penconazole 
soil, 
viticulture 
 
2 
 
0.015 
 
0.015 
 
>256 
 
>64 
 
0.06 
 
0.008 
 
0.03 
 
0.5 
 
 
36 
 
 
NSW 
 
 
naïve 
 
 
- 
air, 
hospital 
indoors 
 
 
2 
 
 
0.015 
 
 
0.03 
 
 
256 
 
 
16 
 
 
0.12 
 
 
0.008 
 
 
0.06 
 
 
0.5 
 
 
37 
 
 
NSW 
 
 
naïve 
 
 
- 
air, 
hospital 
indoors 
 
 
2 
 
 
0.015 
 
 
0.03 
 
 
256 
 
 
16 
 
 
0.12 
 
 
0.008 
 
 
0.03 
 
 
0.25 
 
 
38 
 
 
NSW 
 
 
naïve 
 
 
- 
air, 
hospital 
indoors 
 
 
2 
 
 
0.015 
 
 
0.06 
 
 
256 
 
 
16 
 
 
0.25 
 
 
0.015 
 
 
0.06 
 
 
0.25 
 
 
39 
 
 
NSW 
 
 
naïve 
 
 
- 
air, 
hospital 
indoors 
 
 
2 
 
 
0.015 
 
 
0.03 
 
 
256 
 
 
32 
 
 
0.12 
 
 
0.008 
 
 
0.03 
 
 
0.25 
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40 
 
 
NSW 
 
 
naïve 
 
 
- 
air, 
hospital 
indoors 
 
 
2 
 
 
0.015 
 
 
0.03 
 
 
256 
 
 
32 
 
 
0.25 
 
 
0.015 
 
 
0.06 
 
 
0.25 
 
 
41 
 
 
NSW 
 
 
naïve 
 
 
- 
air, 
hospital 
indoors 
 
 
2 
 
 
0.015 
 
 
0.06 
 
 
128 
 
 
32 
 
 
0.12 
 
 
0.008 
 
 
0.06 
 
 
0.5 
 
42 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
43 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
44 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
45 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
46 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
47 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
48 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
49 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
50 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
51 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
52 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
53 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
54 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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55 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
56 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
57 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
58 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
59 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
60 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
61 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
62 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
63 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
64 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
65 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
66 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
67 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
68 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
69 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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70 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
71 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
72 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
73 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
74 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
75 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
76 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
77 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
78 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
79 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
80 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
81 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
82 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
83 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
84 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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85 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
86 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
87 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
88 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
89 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
90 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
91 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
92 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
93 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
94 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
95 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
96 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
97 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
98 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
99 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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100 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
101 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
102 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
103 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
104 
 
NSW 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
105 NSW naïve - soil, figs - - - - - - - - - 
 
 
106 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
107 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
108 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
109 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
110 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
111 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
112 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 289  
 
 
 
113 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
114 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
115 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
116 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
117 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
118 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
119 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
120 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
121 
 
 
NSW 
 
 
naïve 
 
 
- 
soil, 
hospital 
grounds 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
122 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
123 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
124 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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125 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
126 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
127 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
128 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
129 
 
WA 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
130 
 
WA 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
131 
 
WA 
 
naïve 
 
- 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
132 
 
WA 
 
exposed 
tebuconazole, 
penconazole 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
133 
 
WA 
 
exposed 
tebuconazole, 
penconazole 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
134 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
135 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
136 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
137 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
138 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
139 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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140 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
141 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
142 
 
WA 
 
exposed 
 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
143 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
144 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
145 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
146 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
147 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
148 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
149 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
150 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
151 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
152 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
153 
 
NSW 
 
exposed 
 
cyproconazole 
soil, oats 
crop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
154 
 
WA 
 
exposed 
tebuconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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155 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
156 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
157 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
158 
 
NSW 
 
exposed 
 
cyproconazole 
soil, wheat 
crop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
159 
 
WA 
 
exposed 
tebuconazole, 
penconazole 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
160 
 
WA 
 
exposed 
tebuconazole, 
penconazole 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
161 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
162 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
163 
 
WA 
 
exposed 
tebuconazole, 
penconazole 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
164 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
165 
 
WA 
 
exposed 
tetraconazole, 
myclobutanil 
soil, 
viticulture 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
166* 
 
VIC 
 
naïve 
 
- 
air, nature 
reserve 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
167* 
 
VIC 
 
naïve 
 
- 
air, nature 
reserve 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
168* 
 
 
VIC 
 
 
naïve 
 
 
- 
soil, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
169* 
 
VIC 
 
naïve 
 
- 
air, nature 
reserve 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
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170* 
 
 
VIC 
 
 
naïve 
 
 
- 
soil, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
171* 
 
VIC 
 
naïve 
 
- 
air, nature 
reserve 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
172* 
 
 
VIC 
 
 
naïve 
 
 
- 
soil, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
173* 
 
 
VIC 
 
 
naïve 
 
 
- 
soil, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
174* 
 
 
VIC 
 
 
naïve 
 
 
- 
air, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
175* 
 
 
VIC 
 
 
naïve 
 
 
- 
air, 
domestic 
barn 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
176* 
 
 
VIC 
 
 
naïve 
 
 
- 
air, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
177* 
 
VIC 
 
naïve 
 
- 
air, nature 
reserve 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
178* 
 
VIC 
 
naïve 
 
- 
air, nature 
reserve 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
179* 
 
 
VIC 
 
 
naïve 
 
 
- 
air, 
domestic 
barn 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
180* 
 
 
VIC 
 
 
naïve 
 
 
- 
soil, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
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181* 
 
 
VIC 
 
 
naïve 
 
 
- 
soil, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
182* 
 
 
VIC 
 
 
naïve 
 
 
- 
air, 
domestic 
indoor 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
183* 
 
VIC 
 
naïve 
 
- 
air, nature 
reserve 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
184* 
 
VIC 
 
naïve 
 
- 
air, nature 
reserve 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
185* 
 
 
VIC 
 
 
naïve 
 
 
- 
soil, 
domestic 
garden 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
Abbreviations: AMB, amphotericin B; ANF, anidulafungin; CAS, caspofungin; FLC, fluconazole; ITC, itraconazole; MIF, micafungin; MEC, 
minimum effective concentration; NA, not available; POS, posaconazole; VRC, voriconazole. 
^ Minimum effective concentrations (MECs) are reported for echinocandin drugs, including anidulafungin, caspofungin and micafungin. 
† isolates that had discordant results of VIPcheckTM testing and SensititreTM antifungal susceptibility testing. 
* isolates obtained from culture collection (Talbot JJ, Houbraken J, Frisvad C et al. Discovery of Aspergillus frankstonensis sp. nov. during 
environmental sampling for animal and human fungal pathogens. PLoS ONE 2017; 12: e0181660). 
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6.4 Conclusions 
 
This large study showed a low prevalence of azole resistance amongst A. fumigatus clinical 
and environmental isolates in Australia (2.0%). Azole resistance was only detected amongst 
human patients, not environmental and veterinary isolates. A low prevalence is welcome news 
in an antimicrobial resistance era, where azole resistance has spread globally with high 
prevalence reported out of some regions, including up to 26% in human (van der Linden et al., 
2015) and 91% in environmental isolates (Zhang et al., 2017) in western Europe. 
 
The azole resistant isolates in this study had cyp51A mutations associated with environmental 
development (TR34/L98H and G54). If environmental evidence of ARAf was confirmed in 
Australia, whole genome sequencing could help determine the relatedness between clinical 
isolates to determine the effects of DMI fungicide use. Although ARAf prevalence was low in 
this study, continued surveillance is recommended for monitoring and selection of treatment 
regimens. 
 
This study also demonstrated the usefulness of heat treatment for recovering isolates of A. 
fumigatus from soil (method 2) (Nováková et al., 2014) (Houbraken and Samson, 2006) which 
targets the activation of ascospores and was particularly useful for isolating A. fumigatus from 
azole-exposed soils. 
 
The cyp51A A. fumigatus homology model highlights the usefulness of such models for 
predicting the significance of cyp51A mutation; their potential to interfere with azole drug 
binding to the protein and complex stability. This model was based on the most recently 
published A. fumigatus cyp51B model (Hargrove et al., 2015). Thus this research also further 
highlights the usefulness of the A. fumigatus cyp51B as a homology model for the crystal 
structure of A. fumigatus cyp51A by demonstrating how the G54R mutation prevents docking 
of large azole molecules but permits docking of smaller molecules to the cyp51A haem 
complex, leading to resistance to voriconazole and susceptibility to itraconazole and 
posaconazole. 
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A selection of full genome sequences from this study will undergo further examination by 
Professor Matthew Fisher’s group at the Imperial College London to determine their genetic 
relatedness amongst global populations of A. fumigatus isolates. 
 
Interestingly, members of the A. viridinutans species complex (AVSC) causing clinical disease 
have high azole MICs (Balajee et al., 2006, Alcazar-Fuoli et al., 2008, Vinh et al., 2009, 
Posteraro et al., 2011, Coelho et al., 2011, Gyotoku et al., 2012, Barrs et al., 2013, Peláez et 
al., 2013, Sugui et al., 2014, Alvarez-Pérez et al., 2014); however the cyp51A gene has not been 
sequenced for these species, so it is unknown if their resistance is inherent or acquired and 
possibly attributed to cyp51A mutations as in ARAf isolates. This will be further examined in 
Chapter 7. 
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Chapter 7. Antifungal susceptibility testing and cyp51A analysis of 
Aspergillus viridinutans species complex isolates of environmental 
and clinical origin. 
 
7.1 Introduction 
 
Reports of aspergillosis due to Aspergillus viridinutans species complex (AVSC) generally 
describe high minimum inhibitory concentration (MIC) of azole antifungals compared to MICs 
for wild-type A. fumigatus (Balajee et al., 2006, Alcazar- Fuoli et al., 2008, Vinh et al., 2009, 
Posteraro et al., 2011, Coelho et al., 2011, Gyotoku et al., 2012, Barrs et al., 2013, Peláez et 
al., 2013, Sugui et al., 2014, Alvarez-Pérez et al., 2014). It is assumed this is an inherent feature 
of these complex members; however no studies have investigated the possibility of cyp51A 
mutations, the main cause of azole resistance in other Aspergillus species (A. fumigatus). This 
chapter investigates antifungal susceptibility testing and sequencing of the cyp51A gene in 
clinical and environmental AVSC isolates. 
 
7.2 Premise 
 
Azole therapeutics are the first line of defence when treating aspergillosis. Azoles bind to the 
active site of the cyp51A protein, preventing demethylation of lanosterol to ergosterol, required 
for maintaining fungal cell walls (Hargrove et al., 2015). Alterations to this gene (tandem 
repeats and single point mutations) are the main cause of azole resistance in A. fumigatus 
isolates, generally identified in vitro via microbroth dilution antifungal susceptibility testing and 
sequencing of the cyp51A gene. 
 
This research aimed to characterise and determine the prevalence of 
cyp51A  mutations  amongst  AVSC  members  to  establish  if  these  are  a  minor  or major 
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mechanism of azole resistance.  
 
I performed cyp51A sequencing under the supervision of Dr Jos Houbraken at the Westerdijk 
Institute, Utrecht, the Netherlands, while undertaking my Australian Government Endeavour 
Research Fellowship. Primers were based on published primers for the cyp51A gene in A. 
fumigatus species (Chen et al., 2005). Degenerate primer sets were developed by searching for 
the cyp51A region in the A. udagawae whole genome sequence (Kusuya et al., 2015). 
Sequencing included all AVSC isolates available in the Westerdijk Institute collection and 
those described in Chapter 3, including at least one representative isolate from every species in 
the AVSC. Following PCR optimisation, Sanger sequencing was performed in-house. The 
FunResDB online database was used to determine mutation positions and for comparison with 
wild-type A. fumigatus cyp51A sequences (Weber et al., 2017). 
 
Antifungal susceptibility testing initially used the  testing kit Sensititre™ YeastOneYO8 system 
(TREK Diagnostic Systems Ltd., OH, USA) (n=48), with MIC, or minimum effective 
concentration (MEC) values (for echinocandins) determined as published (Talbot et al., 2015, 
Arendrup et al., 2017). As no ECVs have been established for the AVSC, the end-point for 
determining MIC/MEC values was read at 72 hours, and azole MIC value interpretation was 
based on epidemiological cut-off values for A. fumigatus (for itraconazole and voriconazole, a 
MIC of <1 mg/L was WT and ≥2 mg/L was non-WT (NWT); for posaconazole, a MIC of ≤0.25 
mg/L was WT, and of >0.5 mg/L was NWT) (Espinell- Ingroff et al., 2010, Clinical and 
Laboratory Standards Institute (CLSI), 2018). Forty-eight isolates sporulated adequately for 
Sensititre™ testing (see Supplementary Table 3). Of these, 38 (79%) demonstrated non-WT 
MICs to at least  one  azole  drug,  including  10  (21%)  to  itraconazole  (>2  mg/L),  37  (77  
%) to voriconazole (>2 mg/L) and 7 (15%) to posaconazole (>0.5 mg/L). Five (10%; 2 clinical, 
3 environmental) isolates demonstrated non-susceptibility to itraconazole (>16 μg/mL). 
Twenty isolates had MICs at or above the epidemiological cut-off value, but were not non-WT, 
including nine (19%) to itraconazole, 11 (23%) to posaconazole and four (8 
 %) to voriconazole. 
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Unexpectedly only five isolates demonstrated resistance to itraconazole. Shortly after this, Prof 
Vanessa Barrs shared the results of an international study on antifungal susceptibility testing 
in the AVSC with me prior to publication. In their study (later published as Lyskova et al. 2018), 
comparing Sensititre™ testing and EUCAST antifungal susceptibility testing (Arendrup et al., 
2017) revealed a discrepancy between the two for AVSC isolates (Lyskova et al. 2018). Thus, 
I further investigated my results with another globally accepted technique, the Clinical 
Laboratory Standards Institute (CLSI) method of antifungal susceptibility testing (Clinical 
Laboartory Standards Institute (CLSI), 2017). For moulds, CLSI and EUCAST testing 
produces comparable MICs (Mirchevska and Bosshard, 2012). Australian mycology reference 
laboratories routinely use the Sensititre™ method. Although this involves the same sample 
spore density as the CLSI method, the microbroth dilution technique differs. Thus the testing 
must be external which my colleagues in the Netherlands, Dr Jacques Meis (Department of 
Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital (CWZ), 
Nijmegen, the Netherlands and Center of Expertise in Mycology Radboudumc/CWZ, 
Nijmegen, the Netherlands) and Dr Ferry Hagen (Department of Medical Microbiology and 
Infectious Diseases, Canisius Wilhelmina Hospital (CWZ), Nijmegen, the Netherlands and 
Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands) arranged at their national 
Aspergillus reference laboratory. They obtained data from 37/56 isolates that sporulated 
enough to satisfy testing requirements, returning strikingly different results compared to my 
Sensititre™ testing, with many more isolates returning high MICs or non-susceptibility azole 
phenotypes. This was consistent with the findings of Lyskova et al. (2018) who reported an 
overall agreement between EUCAST and Sensititre™ of 67% when Sensititre™ plates were 
read at 48 hours and 82% at 72 hours (Lyskova et al., 2018). Comparing my Sensititre™ results 
to those obtained via CLSI for 31 isolates tested using both methods, concordant results for 
detecting high and low MICs were 55% for itraconazole, and 87% for voriconazole and 
posaconazole. These results are also consistent with the Lyskova et al. (2018) findings of a 
lower agreement between EUCAST and Sensititre™ for itraconazole, with a much lower 
detection rate for resistance or high MIC to itraconazole detection using the Sensititre™ 
method (Lyskova et al., 2018). 
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While performing CLSI testing, Dr Meis and Dr Hagen also tested the 37 AVSC isolates against 
luliconazole (an imidazole), currently being tested as an alternative first-line triazole for 
aspergillosis, showing promise for treating azole resistant Aspergillus isolates (Abastabar et al., 
2016). 
 
To further investigate the significance of the cyp51A mutations sequenced, homology was 
modelled in collaboration with Prof David Hibbs and Ms Felcia Lai (Faculty of Pharmacy, the 
University of Sydney). These models were based on published homology models for A. 
fumigatus cyp51A with the closest percentage match (Saccharomyces cerevisiae cyp51A) (Liu 
et al., 2016). Additional AVSC models were developed using the amino acid profiles from a 
selection of cyp51A sequences amplified in this study, to compare and determine the 
significance of susceptible and non-susceptible isolate profiles. 
 
7.3 Unpublished Manuscript 
 
The following manuscript has not been submitted to a journal. 
 
Talbot J. J., Samson R. A., Kidd S. E., Meis J. F., Hagen F, Hibbs D. E., Lai F., Verweij P. 
E., Barrs, V. R., Houbraken J. Cyp51A mutations in clinical and environmental isolates of the 
Aspergillus viridinutans species complex. 
 
Abstract 
 
Over the past decade reports of aspergillosis in humans and other animals due to the Aspergillus 
viridinutans species complex (AVSC) have increased. Azole resistance is common among 
AVSC infections, carrying a poor prognosis. Cyp51A gene mutations are recognized as the 
most common cause of acquired azole resistance in Aspergillus fumigatus isolates. This study 
aimed to determine if cyp51A mutations in ASVC members are associated with an azole 
resistant phenotype through amplification of cyp51A amongst 56 AVSC members (clinical and 
environmental isolates) and antifungal susceptibility testing (CLSI [n=37]). CLSI testing 
detected very high minimum inhibitory concentrations (MICs) to azoles in 84% (31/37) of 
isolates. MICs for the imidazole antifungal luliconazole were low for all isolates. Cyp51A was 
amplified using novel degenerate primers, and sequences compared 
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to A. fumigatus, with a total of 113 non-synonymous mutations. Three cyp51A mutations 
(M172A, M172V and D255G) previously reported in association with azole resistance in A. 
fumigatus were common amongst all AVSC members (high and low MICs). Two 
environmental isolates with non-susceptibility to itraconazole at the highest drug concentration, 
and high MICs to voriconazole and isavuconazole, harboured the G138C mutation, previously 
associated with azole resistance in A. fumigatus. Some mutations were only identified amongst 
AVSC members with high azole MICs; however no other known acquired cyp51A alterations 
reported for A. fumigatus were identified. Cyp51A homology modelling did not change the 
overall protein structure significantly to confer resistance. Cyp51A mutations are not a major 
mechanism of antifungal resistance among AVSC isolates. The imidazole antifungal 
luliconazole shows promise for treating infections caused by azole-resistant AVSC. 
 
Introduction 
 
Aspergillosis, usually due to Aspergillus fumigatus, can cause invasive fatal disease. Triazole 
antifungal drugs target fungal ergosterol synthesis (itraconazole, voriconazole, posaconazole 
and more recently isavuconazole) and are the mainstay of treatment (Ullmann et al., 2018). 
Since the late 1990s aspergillosis treatment in humans has been complicated by azole resistance, 
most commonly reported in A. fumigatus isolates (Verweij et al., 2016). Poor clinical outcomes 
are also associated with increased reports of infection by other species in Aspergillus section 
Fumigati with decreased antifungal susceptibility in vitro and in vivo, including members of 
the Aspergillus viridinutans species complex (AVSC) (Talbot and Barrs, 2018). 
 
Azole drug resistance can be innate or acquired (van der Linden et al., 2011). Acquired 
resistance in A. fumigatus clinical and environmental isolates is mostly associated with tandem 
repeats in the promoter region and single point mutations of the cyp51A gene. Acquired 
antifungal resistance was first reported in isolates from human patients in the United States 
(Denning et al., 1997), then the Netherlands where it was associated with the use of triazole 
fungicides in agriculture (Chowdhary et al., 2013). Azole resistance due to cyp51A mutations 
has since been reported globally among clinical and environmental isolates (Chowdhary et al., 
2017), reinforcing the concept of a one-health approach also in fungal diseases (Talbot and 
Barrs, 2018, Chowdhary and Meis, 2018). 
 
More than 50 mutations and tandem repeat combinations in the cyp51A gene have been 
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detected among A. fumigatus isolates (Weber et al., 2017). TR34/L98H and TR46/Y121F/T289 
are most frequently associated with environmentally acquired azole resistance (van der Linden 
et al., 2013), while other mutations have been associated with therapeutic azole drugs (G54, 
G138, G448, M220) (Howard and Arendrup, 2011). 
 
The AVSC contains nine species (A. arcoverdensis, A. aureolus, A. felis, A. frankstonensis, A. 
pseudoviridinutans, A. siamensis, A. udagawae, A. viridinutans, A. wyomingensis). In 2014, A. 
parafelis and A. pseudofelis were described as novel species closely related to A. felis; however, 
analysis of more strains indicates they are A. felis (Talbot JJ et al., 2017, Lyskova et al., 2018, 
Hubka et al., 2018). Since 2005, A. felis, A. pseudoviridinutans, A. udagawae, and A. 
wyomingensis, have been increasingly associated with localized or disseminated infections that 
are difficult to treat and often have high minimum inhibitory concentrations (MICs) of triazole 
antifungals (Talbot and Barrs, 2018). Innate resistance is thought to be responsible for the high 
intrinsic resistance among these species (van der Linden et al., 2011). However, whether 
mutations of the cyp51A gene could be involved has not been investigated. 
 
This study investigated correlations between azole resistant phenotype and cyp51A genotype 
among clinical and environmental AVSC isolates (n=56, see Supplementary Table 1) by 
amplifying the cyp51A gene, antifungal susceptibility testing and cyp51A protein homology 
modelling. 
 
Materials and Methods 
 
Isolates 
 
 
The 56 archived AVSC isolates retrieved from the fungal culture biobank (CBS) of the 
Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands (n=55) and one from South 
Australia Pathology, Adelaide, South Australia included 6 human isolates, 20 animal isolates, 
25 environmental isolates and 5 isolates of unknown origin (see Supplementary Table 1). 
 
Antifungal susceptibility testing 
 
 
Testing for susceptibility to azole antifungal drugs was performed using the CLSI microbroth 
dilution antifungal susceptibility method (n=37) with MIC, or minimum effective 
concentration (MEC) values (for echinocandins) determined as previously described (Clinical 
307 
 
 
Laboartory Standards Institute (CLSI), 2017). As clinical breakpoints have not been assigned 
to AVSC species, MIC interpretation did not designate isolates as susceptible or resistant but 
as high or low (Lyskova et al., 2018), based on epidemiological cut-off values (ECVs) for 
Aspergillus fumigatus (ECV of itraconazole, voriconazole and isavuconazole of 1 mg/L; for 
posaconazole 0.5 mg/L) (Espinell-Ingroff et al., 2010, Clinical and Laboratory Standards 
Institute (CLSI), 2018). Luliconazole MIC values were reported but not assigned as susceptible 
or resistant as clinical breakpoints have not been determined for Aspergillus species. 
 
Geometric mean values, range, MIC50 and MIC90 values were calculated in Excel. Standard 
deviations and t-scores were calculated to determine if triazole MICs for clinical isolates were 
higher than those of environmental isolates with significance set at P<0.05 using a two- tailed 
test (data not shown). 
 
Cyp51A gene targeting 
 
 
DNA was extracted from all isolates using the MoBio DNA isolation kit (QIAGEN Pty Ltd, 
Chadstone Centre, Australia and Venlo, the Netherlands). Multiple primer pairs were designed 
to amplify the cyp51A gene. 
 
Primer design was based on 3 primer pairs of cyp51A gene primer pairs developed by Chen et 
al 2005: CYP1-L, CYP 1-R, CYP 2-L, CYP 2-R, CYP 3-L and CYP 3-R. Using these, 
degenerate primers were developed from the whole genome sequence for A. udagawae IFM 
46973 (Kusuya et al., 2015) available on GenBank (http://blast.ncbi.nlm.nih.gov/Blast.cgi.) 
(849273732:670000-675000, contig:Aud0040) using MEGA6 (Tamura et al., 2013). In total 
eight primer pairs were developed (see Table 3) and synthesized by Integrated DNA 
Technologies (Iowa, United States). 
 
Conventional PCR was performed in a Life Technologies Applied Biosystems, 2720 Thermal 
Cycler for 5 minutes at 94°C; 35 cycles of 30 seconds at 94°C, 30 seconds at 52°C, 1 minute 
at 72°C; then 5 minutes at 72°C and hold at 10°C. PCR product was purified in-house in a 
Sensoquest Lab cycler and Sanger sequencing on a Hitachi/Applied Biosystems 3730xL 
Genetic Analyzer. 
 
Sequences were analysed using Seqman Pro, DNAstar, Version 12.1.0. Sequences were 
aligned in MEGA v6 using MUSCLE alignment. Phylogenetic trees were constructed in 
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MEGA v6 using the Kimura 2 + gamma distribution, maximum likelihood discrete data method 
(tree searching method of 1,000 replicate trees) and bootstrapping. All sequences were 
submitted to GenBank (accession numbers MF178327-MF178401; see Supplementary Table 
1). 
 
Data were analysed for mutations using the FunResDB, comparing Cyp51A sequences of AVSC 
isolates with A. fumigatus reference strain ATCC36607 (Weber et al., 2017). Mutations in 
isolates with high MICs were compared to other isolates of the same species and all isolates in 
the complex. 
 
Cyp51A homology modelling 
 
 
A. fumigatus cyp51A sequence (GenBank accession no. AF338659) was retrieved from the 
universal protein resources (http:// www.uniprot.org) and a NCBI BLAST (blastp) search was 
performed to identify a suitable template. The crystal structure of Sacchyromyces cerevisiae 
cyp51A (PDB ID: 5EQB) was selected as the template for homology modelling as it is the 
cyp51A protein that returned the highest sequence identity in blastp search (resolution 2.19 Å, 
max and total score 506, query cover 94 %, identity 51 %). Five homology models were 
produced based on the template using Schrödinger’s Prime (Jacobson et al., 2002, Jacobson et 
al., 2004), and the best model (model B) was selected after testing their quality with Verify 3D 
(84.66 % of residues scored a 3D-1D score >=0.2, see Supplementary Table 4) (Bowie et al., 
1991, Luthy et al., 1992). Homology models of A. felis clade species A. felis (model F), A. 
viridinutans (model G) and A. aureolus (model H) were built based on model B using the 
cyp51A amino acid sequences of isolates DTO 131-G1, DTO 050-F1 and DTO 278-B7, 
respectively (see Supplementary Table 1 [GenBank accession numbers] and Supplementary 
Table 4 [Verify 3D results]). The models were verified with Verify 3D. Additionally, model F, 
the low azole MICs A. felis azole homology model, was subjected to mutations present in three 
A. felis clade isolates demonstrating high azole MICs (mutations T215S/G138C [model I] and 
S197C/ Q340R [model J], see Table 2 for isolate details). Finally, for models containing 
mutations at positions previously associated with azole resistance in A. fumigatus isolates 
(models H [V101] and I [G138]), mutations were added to A. fumigatus model B, producing 
model K (mutations from model I, G138C/T215S) and model L (mutations from model H, 
V101L/A103T/A234V/I360V/V428I/G505R/Q423D/F478V). 
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Molecular docking and Molecular Mechanics-Generalised Born Surface Area 
 
 
Models F to L were prepared for molecular docking using Protein Preparation Wizard (Sastry 
et al., 2013). 2D structures of itraconazole, posaconazole and voriconazole were first drawn 
using 2D sketcher then prepared with Ligprep (Schrödinger Release 2017-3: LigPrep). Docking 
studies for the three triazoles with these models was carried out via Glide with standard 
prevision (SP) (Halgren et al., 2004, Friesner et al., 2004, Friesner et al., 2006) to determine 
the binding affinity between the ligand and the receptor. For each model, conformers of the 
triazoles that interact with the protein with the expected binding mode in SP study were chosen 
for the next step. They were subjected to minimisation via Macromodel (Schrödinger Release 
2017-3: MacroModel), followed by ConfGen (Watts et al., 2010) to generate alternative low 
energy conformations. Docking study for these conformers was then carried out via Glide with 
extra precision (XP) (Halgren et al., 2004, Friesner et al., 2004, Friesner et al., 2006). Only the 
conformers with the best docking score in XP analysis were considered. Docking scores from 
Glide XP of each azole-resistant receptor-ligand interaction were compared to their azole-
susceptible counterparts. Since model G and H, which are based on A. viridinutans and A. 
aureolus respectively, do not have corresponding low azole MIC models, they were also 
compared with model F. Results were interpreted as the more negative the docking score, the 
better the binding affinity. Molecular Mechanics-Generalised Born Surface Area (MMGBSA) 
binding free energy (ΔG(binding)), ligand strain energy and receptor strain energy of the 
ligand-receptor calculations were also performed using Prime (Li et al., 2011) based on XP 
docking studies; residues within 20 Å from the ligand were set flexible. Default settings were 
used for all calculations. ΔG(binding) indicated how strong the binding was between the ligand 
and receptor, and ligand and receptor strain energy indicated how much energy the ligand and 
protein required to distort themselves into the appropriate binding pose respectively. 
 
Root-mean-square deviation scores 
 
 
The differences between model F and azole-resistant models G-J were measured via 
superimposition and determination of root-mean-square deviation (RMSD) scores for 
comparison of structural similarity. 
 
Results 
 
Antifungal susceptibility testing 
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Clinical Laboratory Standards Institute (CLSI) antifungal susceptibility testing was performed 
to differentiate isolates with high MIC from those with low MIC phenotype. 
 
Thirty-seven AVSC isolates sporulated adequately for antifungal susceptibility testing 
(Supplementary Table 2). Of these, 31 (84%) were defined as having high MICs to at least one 
azole, including 20 (54%) to itraconazole (>1 mg/L), 31 (84%) to voriconazole (>1 mg/L), 30 
(81%) to isavuconazole (>1 mg/L) and one to posaconazole (>0.5 mg/L). Of these isolates, 15 
were environmental, 14 were clinical, and two were of unknown origin. Comparisons of MIC 
geometric mean, MIC ranges, MIC50 and MIC90 results for environmental versus clinical 
AVSC isolates are presented in Table 1. Environmental isolates had higher MICs than clinical 
isolates but this was not statistically significant (isavuconazole, itraconazole and posaconazole 
P=>0.2; voriconazole P=0.1-0.2). All isolates were inhibited by luliconazole (geometric mean 
0.002 mg/L, MIC90 0.002 mg/L, range 0.001- 1 mg/L). Six AVSC isolates (four clinical, two 
environmental and one unknown) had low MICs for all azole drugs tested. Poor sporulation in 
19 isolates precluded CLSI testing. 
 
Cyp51A sequencing 
 
 
A total of 204 synonymous and 113 non-synonymous mutations were identified amongst the 
56 AVSC isolates (see Supplementary Table 3). Of the non-synonymous mutations, all AVSC 
isolates tested, regardless of azole phenotype, had the mutations W6L, V15M, K80R, D255G, 
C270S, I367L, H403Y and L464I. At amino acid position M172, all isolates had a mutation of 
either M172V (n=55) or M172A (n=1). 
 
Isolates demonstrating high azole MICs had 15 unique mutations not present in isolates with 
low MICs (see Table 2). This included G138C, found in two environmental A. felis-clade 
isolates that were non-susceptible to itraconazole at the highest concentration tested, had high 
MICs to voriconazole and isavuconazole, with one also demonstrating MICs at the A. fumigatus 
ECV to posaconazole, and the other an intermediate MIC to posaconazole (Table 2). Both 
isolates also harboured a unique SNP, T215S (see Table 2). Two A. aureolus environmental 
isolates harboured the non-synonymous mutation V101L; isolate DTO 278-B7 had a MIC at 
the A. fumigatus ECV to posaconazole only, while DTO 331-G6 did not sporulate to be used 
in antifungal susceptibility testing. Both isolates also harboured unique cyp51A SNPs A103T, 
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A234V, I360V, V428I, Q423D, F478V, G505R (see Table 2). 
 
A phylogenetic tree for cyp51A sequences groups isolates of the same species (see Figure 1). 
 
Cyp51A homology modelling 
 
 
Five AVSC cyp51A homology models (models F to J) compared amino acid profiles of low 
azole MIC value (model F A. felis-clade, DTO 131-G1) with high azole MIC value isolates 
(model G A. viridinutans, DTO 050-F1; model H A. aureolus, DTO 278-B7; model I A. felis 
clade, DTO 341-E5; model J A. felis-clade, DTO 131-E6) (see Figure 2). Docking scores and 
MMGBSA analysis results are presented in Table 4. Compared to model F, there were no 
significant changes to the overall protein structure to confer resistance in models G to J. For 
itraconazole, the most negative value docking score was with model I (-11.03 kcal/mol) and 
most negative ΔG(binding) value was with low azole MIC model F (-148.403 kcal/mol), with 
a higher potential for azole binding in model F compared to models G to J. For posaconazole’s 
interactions the most negative docking score was with model I (-11.54 kcal/mol) and the most 
negative ΔG(binding) value was with model G (-148.061 kcal/mol). Results for voriconazole 
were inconsistent, with model H having the most negative docking score (-7.881 kcal/mol) and 
ΔG(binding) value (-64.09 kcal/mol) the highest potential for azole binding (see Table 4). 
RMSD scores demonstrated high similarity between models compared to the susceptible A. 
felis (model F), a difference of less than 0.2 Å for all models (model I= 0.2004 Å; model J= 
0.1929 Å; model G=0.0613 Å; model H= 0.0570 Å). Two A. fumigatus cyp51A homology 
models (models K and L) were constructed to determine whether mutations reported in 
association with azole resistance in A. fumigatus (positions G138 and V101) altered the protein 
structure like the AVSC based models H and I. This confirmed the results of AVSC models H 
and I, with no major difference for docking and MMGBSA analysis with these mutations in 
the A. fumigatus model (see Table 4 and Supplementary Figure 1). 
 
Discussion 
 
There were nine cyp51A mutations amongst all AVSC isolates compared to A. fumigatus wild-
type (see Supplementary Table 3). As these were found in isolates with high and low MICs, 
they are likely non-functional in relation to azole resistance. Also, species specific amino acid 
substitutions were observed. Those positions could be interesting targets for identification 
(either on species or complex level) or for diagnostics, and the degenerate primers developed 
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could have clinical application for other pathogenic, non-A. fumigatus Aspergillus species. 
Further, phylogenetic analysis of the cyp51A gene sequences resolved all AVSC species. 
 
Of the cyp51A SNPs identified in isolates with high MICs only, none shared the same 
susceptibility phenotype (see Table 2). Cyp51A modelling was used to determine the 
significance of these mutations. Interactions in high azole MIC value models (model G to J) 
were proposed to have weaker binding affinity and less azole binding in mutated models G to J, 
hence these models might confer resistance. However, the resulting homology models varied. 
Itraconazole interactions were most consistent, with model F having the strongest binding 
affinity to this drug. This trend was also observed in posaconazole’s interactions and 
voriconazole demonstrated conflicting results, most likely due to its smaller size, as it requires 
little energy to position itself to the correct binding mode. These results and the similarity 
between the protein structures demonstrated via RMSD score calculations suggests that the 
cyp51A mutations in these isolates do not significantly change the overall protein structure and 
thus do not directly interfere with azole drug binding to confer resistance. Future work 
investigating genome sequences of AVSC susceptible and resistant isolates could clarify these 
amino acid profile differences, potentially determining strain lineage as well as identifying other 
genetic causes of azole resistance. Aspergillus felis is heterothallic and progeny, from directed 
mating of susceptible and resistant A. felis isolates, could be used in segregate analyses. 
 
Although non-synonymous mutations at sites previously associated with azole resistance in A. 
fumigatus were found (M172A, M172V and D255G), these were in AVSC isolates with both 
high and low azole MICs, and so are unlikely to confer azole resistance, as reported for A. 
fumigatus WT isolates (Howard et al., 2006, Garcia-Effron et al., 2008, Howard et al., 2009, 
Snelders et al., 2010, Albarrag et al., 2011, Escribano et al., 2011, Mortensen et al., 2011, Buied 
et al., 2013, Abdolrasouli et al., 2015, Kidd et al., 2015, Lavergne et al., 2015, Mavridou et al., 
2015, van Ingen et al., 2015, Meneau et al., 2016, Wiederhold et al., 2016). However, specific 
combinations of single point mutations may also be important when determining ability to 
cause azole resistance, as recently demonstrated with A. fumigatus isolates harbouring 
mutations at these positions (M172V and D255E) in combination with either F46Y, G89G, 
L358L and C454C or F46Y, G89G, N248T, L358L, E427K and C454C were shown to have 
elevated azole MICs, were pathogenic in Galleria mellonella host virulence studies and of a 
different cluster/lineage to strains of WT A. fumigatus (Garcia-Rubio et al., 2018). However, 
this was not the case for isolates in our study with high azole MIC values that underwent 
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cyp51A homology modelling. 
 
We identified the azole-resistance associated mutation G138C in two environmental isolates of 
the A. felis clade (DTO 341-E4, DTO 341-E5) from woodland soil in Australia. Interestingly, this 
mutation was reported in clinical A. fumigatus isolates and is thought to be acquired following 
azole therapy conferring resistance to itraconazole, voriconazole, posaconazole and 
isavuconazole (Wiederhold et al., 2016), similar to our phenotype results. However, this is not 
clear, as other single point mutations associated with in-host development have been found in 
the environment also (e.g. M220 and G54) (Sharma et al., 2015, Bader et al., 2015). These two 
strains also harboured the T215S mutation, not previously reported for A. fumigatus, and not 
identified in any other isolates in this study. This mutation, in combination with G138C, may 
also contribute to acquired resistance, however this was not supported by our cyp51A homology 
modelling of AVSC or A. fumigatus species. Like our finding, it has been demonstrated via A. 
fumigatus cyp51A homology modelling that while G138C is closely positioned to the protein 
access channel opening, the mutation can increase stability for azole docking (Liu et al., 2016). 
 
The mutation V101L was found in two A. aureolus isolates; however only one sporulated 
adequately for antifungal susceptibility testing, demonstrating a MIC at the A. fumigatus ECV 
of posaconazole. Mutations at this position in A. fumigatus have led to the change V101F, 
which in association with M220I confers multi-azole resistance (itraconazole and posaconazole 
resistance with variable voriconazole resistance) (Mortensen et al., 2010). Mutations at M220 
were not present in these or any other AVSC isolates. Cyp51A homology modelling of these 
mutations in AVSC and A. fumigatus models did not confer azole resistance. 
 
Poor clinical outcomes and high in vitro MICs are common amongst patients with aspergillosis 
due to AVSC member species. We tested AVSC isolate susceptibility to a newer antifungal 
drug, luliconazole, using the CLSI method. Luliconazole is a cytochrome P450 2C19 inhibitor 
imidazole antifungal commercially available in a topical 1% cream for treating fungal skin 
infections. Although there is limited efficacy data for its use in treating aspergillosis, in vitro 
antifungal susceptibility testing on A. fumigatus and A. terreus isolates and in vivo animal 
models demonstrated a promising treatment alternative to current antifungals, with much lower 
MIC values and improved survival rates with oral treatments for models of invasive 
aspergillosis in mice, and intravenous preparation for rat models of pulmonary aspergillosis 
(Niwano et al., 1999, Abastabar et al., 2016, Zargaran et al., 2017). All but one of our AVSC 
isolates had MICs in the same range reported for azole susceptible A. fumigatus isolates against 
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luliconazole (0.001 – 0.008 mg/L) (Abastabar et al., 2016). The remaining isolate (A. 
udagawae, soil, USA, pan-azole high MIC phenotype) had a MIC of 1 mg/L, which is higher 
than the reported range for azole susceptible and resistant A. fumigatus isolates (Abastabar et 
al., 2016). Reference ranges were generally lower than other azoles tested, consistent with the 
literature for other Aspergillus species (Niwano et al., 1999, Zargaran et al., 2017). Although 
further evaluation is required, this antifungal drug has promising potential as an alternative to 
current azole therapeutics for in vivo therapeutic use on AVSC species. 
 
In this study, high azole MIC values were common in AVSC clinical and environmental 
isolates. High isavuconazole MICs were most frequent, followed by voriconazole and 
itraconazole, while high MICs to posaconazole were uncommon. These results are consistent 
with a recent study of AVSC isolates which found high MICs to voriconazole and itraconazole, 
with generally low MICs to posaconazole; the study did not test isavuconazole susceptibility 
(Lyskova et al., 2018). Reference susceptibility testing relies on standardized spore densities 
for inoculation. This can be difficult in slowly sporulating organisms of the AVSC and 19 
isolates failed to sporulate well enough to test. Although cyp51A sequences were still determined 
in these isolates, genotype interpretation is limited without phenotype results. 
 
Other mechanisms of innate and acquired azole resistance should be further investigated as 
possible causes of AVSC resistance. This could include investigating alterations to other genes 
related to the development of azole resistance in A. fumigatus species, including cyp51B, the 
P88L mutation in the hapE gene, afyap1, aldA, alga and AfCox10 genes, multidrug resistant 
efflux pump genes (AfuMDR3 and AfuMDR4) and the transcriptional regulator SrbA 
(Nascimento et al., 2003, Willger et al., 2008, Camps et al., 2012). Extrolite production could 
also account for innate resistance profiles in some species and this should be examined. Extrolite 
products in a limited number of isolates from the complex demonstrated unique properties, 
including antibacterial and anti-cancer (Lillehoj and Ciegler, 1972, Lillehoj and Milburn, 1973, 
Mendes et al., 2016, Gonçalves et al., 2016, Frisvad and Larsen, 2016). Examples of AVSC 
extrolites include viriditoxin, which is produced by all AVSC member species; pyriopyropene 
A, aspochalasin E and cytochalasins produced by A. felis; fumigaclavine C, helvolic acid, 
methyl-sulochrin, pyripyropene A and E and trypacidin production by A. udagawae and A. 
viridinutans sensu stricto; fumigaclavine A and fumiquinazoline F/G in A. udagawae; and 
fumagillin, fumitremorgins A and C, and pyripyropenes O and S (Lillehoj and Ciegler, 1972, 
Naruse et al., 1993, Xiao et al., 2013, Mendes et al., 2016). 
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Amplification of cyp51A in members of the AVSC identified several non-synonymous 
mutations within the group compared to the reference sequence for A. fumigatus; however, 
mutations related to environmentally acquired resistance in A. fumigatus were not identified. 
The single point mutation G138C, identified to confer multi and pan azole resistance in A. 
fumigatus clinical isolates associated with therapeutic exposure to azoles, was found in two 
environmental A. felis isolates (woodland soil, Australia). No other mutations commonly 
associated with azole resistance in A. fumigatus were identified in azole resistant AVSC isolates 
alone. All members of the AVSC (both high and low MICs) had the mutations W6L, V15M, 
K80R, D255G, C270S, I367L, H403Y, L464I and M172V/A. A total of 13 single point 
mutations were identified amongst isolates with high azole MICs absent from isolates with low 
azole MICs; however, none conferred the same resistant phenotype. Cyp51A homology 
modelling of mutations found only in isolates with high azole MICs compared to a low azole 
MIC isolate model did not significantly change the overall protein structure or directly interfere 
with azole drug binding to confer resistance. The cyp51A gene confers good phylogenetic 
analysis for the AVSC but is unlikely to enable azole resistance in isolates with high MICs to 
one or more azole drugs (95 % of AVSC isolates tested). Mechanisms of innate and other 
causes of acquired azole resistance should be further investigated for the AVSC. Luliconazole 
showed promise as a therapeutic option by inhibiting the growth of all AVSC isolates on CLSI 
antifungal susceptibility testing. 
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Tables 
 
Table 1. Comparison of CLSI testing results for clinical (n=17) versus environmental (n=17) AVSC isolates. 
 
 
Parameter (mg/L) ITC POS VRC ISA LUL 
MIC range 
Clinical 
Environmental 
 
0.125->16.00 
0.5->16.00 
 
0.031-0.25 
0.125-0.50 
 
0.25-8.00 
2.00-16.00 
 
0.50-4.00 
2.00-8.00 
 
0.001-0.004 
0.001-1.00 
GM MIC 
Clinical 
Environmental 
 
2.76 
5.5 
 
0.16 
0.26 
 
2.40 
4.69 
 
2.40 
3.79 
 
0.002 
0.003 
MIC50 
Clinical 
Environmental 
 
1.00 
>16.00 
 
0.25 
0.25 
 
2.00 
4.00 
 
2.00 
4.00 
 
0.002 
0.002 
MIC90 
Clinical 
Environmental 
 
>16.00 
>16.00 
 
0.25 
0.50 
 
4.00 
8.00 
 
4.00 
8.00 
 
0.002 
0.004 
Note: Three isolates with unknown origin (DTO 019-D8, DTO 316-F9 and DTO 342-I3) were excluded from this table. Abbreviations: ITC, 
itraconazole; POS, posaconazole; VRC, voriconazole; ISA, isavuconazole; LUL, luliconazole; MIC, minimum inhibitory concentration. 
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Table 2. Cyp51A mutations observed in high azole minimum inhibitory concentration phenotype Aspergillus viridinutans species complex isolates 
(determined by CLSI testing) that were not found in low azole MIC isolates (see Supplementary Table 3 for a list of all mutations found). 
 
 
 
Azole resistant phenotype 
 
Species (isolate number) 
cyp51A 
mutations 
 
High multi-azole MICs (ITC, ISA, 
VRC) 
 
A. felis clade (DTO 341-E5) 
 
T215S 
G138C 
High multi-azole MICs (ITC, ISA, 
VRC) 
A. felis clade (DTO 341-E4) 
T215S 
G138C 
High multi-azole MICs (ITC, ISA, 
VRC) 
A. felis clade (DTO 131-E6) 
S197C 
Q340R 
 
High multi-azole MICs (ITC, ISA, 
VRC) 
 
A. viridinutans (DTO 050-F1) 
 
A63S 
L327P 
V396A 
 
 
Single azole MIC at the ECV for A. 
fumigatus (POS) 
 
 
 
A. aureolus (DTO 278-B7) 
A103T 
V101L 
A234V 
I360V 
V428I 
G505R 
Q423D 
F478V 
Abbreviations: MICs, minimum inhibitory concentrations; ISA isavuconazole; ITC itraconazole; VRC voriconazole; POS posaconazole; ECV, 
epidemiological cut-off value. 
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Table 3. Primers used to target the cyp51A gene in AVSC members in this study. 
 
 
Primer Sets for cyp51A Primer Pairs used Sequence (5’ to 3’) 
Aspergillus udagawae   
Forward 1 CYP0-F_uda ¥ GACTTTCATATCTTGCTCAGC 
Reverse 1 CYP1-R_uda ¥ AGCCTTGAAAGTTCGGCGAG 
Forward 2 CYP2-L* CATGTGCCACTTATTGAGAAGG 
Reverse 2 CYP2-R_uda ¥ CCTTGCGCATGAGCGAGTGA 
Forward 3 CYP3-L _uda ¥ TTCCTCCGCTCCAGTACGAG 
Reverse 3 CYP3-R_uda ¥ CCTTTGATGTCCTCGATGAAA 
Forward 4 CYP3-L _uda ¥ TTCCTCCGCTCCAGTACGAG 
Reverse 4 CYP4-R_uda ¥ GATCGCACCGTGTCCTTTG 
Degenerate Primers   
Forward 5 CYP0-F_deg± GRCKTTCAWATSTTGCTCAGC 
Reverse 5 CYP1-R_deg± AGCCTTGAAARTTCGGYGAR 
Forward 6 CYP2-L_deg± CATGTGCCACTYATYGAGAAGG 
Reverse 6 CYP2-R_deg± CCTTGCGCATGAKMGAGTGA 
Forward 7 CYP0-F_deg± GRCKTTCAWATSTTGCTCAGC 
Reverse 7 CYP2-R_deg± CCTTGCGCATGAKMGAGTGA 
Forward 8 CYP3-L* TTCCTCCGCTCCAGTACAAG 
Reverse 8 CYP4-R_deg± GATCRCACCRWRTCCTTTG 
¥ primers identified from contig:Aud0040 of A. udagawae (IFM 46973) (Kusuya et al., 2015) corresponding with primers developed by Chen et 
al., 2005; * primers used by Chen et al., 2005; ± degenerate primers developed for this study. 
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Table 4. Docking scores of the best conformers of posaconazole, itraconazole and 
voriconazole, and corresponding MMGBSA study values. Models F to J are Aspergillus 
viridinutans species complex member based models and models B, K and L are A. fumigatus 
based models. 
 
Model (species) Ligand Docking 
score 
(kcal/mol) 
Ligand 
strain 
energy 
(kcal/mol) 
Receptor 
strain 
energy 
(kcal/mol) 
ΔG(binding) 
(kcal/mol) 
F 
(A. felis clade) 
posaconazole 
#2 
-9.549 20.174 43.264 -145.031 
itraconazole #2 -10.348 10.148 61.584 -148.403 
voriconazole -7.284 2.101 18.284 -56.913 
G 
(A. viridinutans) 
posaconazole 
#2 
-9.457 17.582 20.2 -148.061 
itraconazole #1 -7.972 11.809 48.485 -117.783 
voriconazole -7.13 2.618 23.192 -51.94 
H 
(A. aureolus) 
posaconazole 
#2 
-10.21 11.18 62.408 -117.291 
itraconazole #4 -8.732 8.419 29.881 -134.629 
voriconazole -7.881 10.41 16.574 -64.09 
I 
(A. felis clade 
mutations 
T215S/G138C) 
posaconazole 
#2 
-11.541 13.355 34.947 -140.137 
itraconazole #1 -11.031 10.476 36.487 -122.160 
voriconazole -7.220 6.929 20.331 -50.546 
J 
(A. felis clade 
mutations 
S197C/Q340R) 
posaconazole 
#2 
-10.275 16.779 36.947 -141.408 
itraconazole #3 -10.318 14.646 36.402 -112.306 
voriconazole -7.461 6.916 24.457 -50.255 
B 
(A. fumigatus) 
posaconazole 
#2 
-10.385 11.936 34.031 -133.210 
itraconazole #4 -9.543 11.503 10.276 -128.252 
voriconazole -6.991 2.048 -0.416 -49.793 
K 
(A. fumigatus model of 
model I mutations) 
posaconazole 
#2 
-9.859 12.880 30.784 -145.495 
itraconazole #4 -9.002 11.412 52.439 -131.727 
voriconazole -7.570 11.101 -0.489 -72.311 
L 
(A. fumigatus model of 
V101L/A103T/A234V 
/I360V/V428I/G505R 
`/Q423D/F478V ) 
posaconazole 
#1 
-10.530 12.928 29.622 -122.594 
itraconazole #2 -10.764 10.357 49.188 -148.968 
voriconazole -7.098 2.482 31.636 -49.211 
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Figures 
Figure 1. Phylogenetic tree of cyp51A sequences 
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Figure 2. Voriconazole (red), itraconazole (blue) and posaconazole (purple) binding to the haem 
group (grey) of cyp51A homology models F (A. felis clade [A]), G (A. viridinutans [B]), H (A. 
aureolus [C]), I and J (A. felis clade [D and E]). 
 
Supplementary data 
 
 
 
Supplementary Figure 1. Voriconazole (red), itraconazole (blue) and posaconazole (purple) 
binding to the haem group (grey) of cyp51A homology models B (A. fumigatus wild-type [A]), K 
(A. fumigatus [B], and L (A. fumigatus [C]). 
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Supplementary Tables 
 
Supplementary Table 1. All isolates used in this study, their associated cyp51A GenBank accession number and antifungal susceptibility testing 
method used. 
 
Strain number Species Source Location GenBank 
accession 
number 
Antifungal 
susceptibility 
testing 
DTO 019-F2 A. arcoverdensis soil Australia MF178320 - 
DTO 316-F7 (= CBS 139187 (T)) A. arcoverdensis semi-desert soil Brazil MF178321 - 
DTO 316-F9 (= CBS 139188) A. arcoverdensis unknown Brazil MF178322 CLSI 
DTO 278-B7 (= CBS 137453) A. aureolus soil Brazil MF178323 CLSI 
DTO 331-G6 (= CBS 105.55 (T) = DTO 052-C8 = NRRL 
2244) 
A. aureolus soil Ghana MF178324 - 
CBS 143249 A. felis-clade human Australia MF178299 CLSI 
DTO 131-E3 A. felis-clade cat, RBM Australia MF178286 - 
DTO 131-E4 A. felis-clade cat, RBM Australia MF178301 CLSI 
DTO 131-E5 A. felis-clade cat, RBM Australia MF178302 CLSI 
DTO 131-E6 (= CBS 130244) A. felis-clade cat, RBM Australia MF178292 CLSI 
DTO 131-E9 A. felis-clade cat, RBM Australia MF178287 - 
DTO 131-F1 A. felis-clade cat, RBM Australia MF178288 CLSI 
DTO 131-F2 A. felis-clade cat, RBM Australia MF178289 - 
DTO 131-F3 A. felis-clade cat, RBM Australia MF178290 CLSI 
DTO 131-F4 (= CBS 130245 (T)) A. felis-clade cat, RBM Australia MF178296 - 
DTO 131-F6 A. felis-clade cat, RBM Australia MF178291 CLSI 
DTO 131-F9 (= CBS 130246) A. felis-clade cat, SNC Australia MF178297 - 
DTO 131-G1 A. felis-clade cat, RBM Australia MF178303 CLSI 
DTO 131-G2 (= CBS 130247) A. felis-clade cat, RBM Australia MF178293 - 
DTO 131-G3 (= CBS 130248) A. felis-clade cat, RBM Australia MF178294 CLSI 
DTO 155-G3 (= CBS 130249) A. felis-clade dog, VH Australia MF178295 CLSI 
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DTO 159-C9 (= CBS 130250) A. felis-clade cat, RBM United Kingdom MF178317 - 
DTO 175-H3 A. felis-clade surface water Portugal MF178304 CLSI 
DTO 176-F1 A. felis-clade air Germany MF178305 CLSI 
DTO 316-C8 A. felis-clade CBS culture contaminant The Netherlands MF178316 CLSI 
DTO 327-G4 A. felis-clade human patient The Netherlands MF178315 CLSI 
DTO 341-E4 A. felis-clade woodland soil Frankston, Australia MF178306 CLSI 
DTO 341-E5 (= CBS 142232) A. felis-clade woodland soil Frankston, Australia MF178307 CLSI 
DTO 341-E6 A. felis-clade woodland soil Frankston, Australia MF178308 - 
DTO 341-E8 A. felis-clade woodland soil Frankston, Australia MF178309 CLSI 
DTO 341-E9 A. felis-clade woodland soil Frankston, Australia MF178310 CLSI 
DTO 341-F1 A. felis-clade woodland soil Frankston, Australia MF178311 - 
DTO 341-F2 A. felis-clade woodland soil Frankston, Australia MF178312 CLSI 
DTO 342-I4 (= NRRL 62900 = CM-3147 = DTO 342-I4 = 
CBS 140762 (T)) 
A. felis-clade human, OPE Spain MF178313 CLSI 
DTO 342-I5 (= NRRL 62901 = CM-5623 = DTO 342-I5 = 
CBS 140765) 
A. felis-clade human, lungs Portugal MF178314 CLSI 
DTO 342-I6 (= NRRL 62902 = CM-4518 = DTO 342-I6 = 
CBS 140766) 
A. felis-clade human, nail Spain MF178318 CLSI 
DTO 342-I7 (= NRRL 62903 = CM-6087 = DTO 342-I7 = 
CBS 140763 (T)) 
A. felis-clade human, sputum Spain MF178319 CLSI 
DTO 341-E7 (= CBS 142233 = IBT 34172 (T)) A. frankstonensis woodland soil Frankston, Australia MF178271 - 
DTO 341-F3 (= CBS 142234 = IBT 34204) A. frankstonensis woodland soil Frankston, Australia MF178272 CLSI 
DTO 153-A1 (= CBS 458.75) A. pseudoviridinutans soil India MF178276 - 
DTO 303-A1 A. pseudoviridinutans Pinus caribea (pine tree) Sri Lanka MF178273 CLSI 
DTO 304-I5 (= NRRL 62904 = NIHAV1 = DTO 304-I5 = 
CBS 140396 (T)) 
A. pseudoviridinutans human, lung USA MF178275 - 
DTO 342-I3 (= NRRL 6106 = DTO 342-I3 = CBS 140764) A. pseudoviridinutans unknown unknown MF178274 CLSI 
DTO 278-B6 (= CBS 137452 (T)) A. siamensis soil Thailand MF178325 - 
DTO 006-A3 A. udagawae soil USA MF178277 CLSI 
DTO 019-D7 A. udagawae unknown unknown MF178280 - 
DTO 019-D8 A. udagawae unknown unknown MF178281 CLSI 
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DTO 157-D7 (= CBS 114217 (T)) A. udagawae soil Brazil MF178278 CLSI 
DTO 157-D8 (= CBS 114218) A. udagawae soil Brazil MF178279 CLSI 
DTO 166-D6 A. udagawae cat Australia MF178282 CLSI 
DTO 283-D3 A. udagawae soil Thailand MF178283 - 
DTO 308-H6 A. udagawae soil Turkey MF178284 CLSI 
DTO 341-E3 (= CBS 142231) A. udagawae cat, RBM Kealba, Australia MF178285 CLSI 
DTO 050-F1 (= CBS 127.56 (T) = NRRL 4365) A. viridinutans rabbit dung Australia MF178270 CLSI 
DTO 155-G2 A. wyomingensis cat, RBM Australia MF178298 - 
DTO 332-B1 (= CBS 135456 (T)) A. wyomingensis coal mine reclamation 
site soil 
Glenrock, USA MF178326 CLSI 
Abbreviations: (T), type strain; CLSI, Clinical Laboratory Standards Institute; - = isolate did not sporulate for testing. 
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Supplementary Table 2. CLSI antifungal susceptibility testing results for 37 Aspergillus viridinutans species complex isolates included in this 
study. 
 
Drug Species MIC/MEC (μg/mL) distribution among tested isolates 
  0.001 0.002 0.004 0.008 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 >16 GM 
 
 
 
 
ITZ* 
A. arcoverdensis         
 
1 
1   
 
1 
    
 
1 
 0.25 
A. aureolus 1   0.25 
A. felis 2 4 14 4.38 
A. frankstonensis   1 >16 
A. pseudoviridinutans 1  1 4 
A. udagawae 1 5 1 1.26 
A. viridinutans   1 >16 
A. wyomingensis   1 >16 
 
 
 
 
VCZ* 
A. arcoverdensis          
 
1 
1      
 
 
 
 
 
1 
 0.5 
A. aureolus 1    0.5 
A. felis 2 4 13 3 2.87 
A. frankstonensis    1 8 
A. pseudoviridinutans 1  1  1.41 
A. udagawae  5 1  2.97 
A. viridinutans   1  4 
A. wyomingensis   1  4 
 
 
 
POS* 
A. arcoverdensis       
 
2 
1          
 
 
 
 
 
1 
0.06 
A. aureolus    1 0.5 
A. felis  4 15 2 0.2 
A. frankstonensis    1 0.5 
A. pseudoviridinutans 1  1  0.25 
A. udagawae  3 3  0.34 
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 A. viridinutans         1        0.25 
A. wyomingensis 1 0.25 
 
 
 
 
ISA* 
A. arcoverdensis         
1 
  1      1 
A. aureolus      0.13 
A. felis 2 1 6 12 2 2.79 
A. frankstonensis     1 8 
A. pseudoviridinutans 1   1  1.41 
A. udagawae  1 5  1 2.21 
A. viridinutans    1  4 
A. wyomingensis     1 8 
 
 
 
 
AMB* 
A. arcoverdensis        1  
 
2 
       0.13 
A. aureolus   1  1 
A. felis  1 14 6 1.03 
A. frankstonensis    1 2 
A. pseudoviridinutans 1  1  0.35 
A. udagawae  1 3 3 1.22 
A. viridinutans  1   0.5 
A. wyomingensis   1  1 
 
 
 
 
MIF† 
A. arcoverdensis       
 
4 
 1     
 
 
 
 
 
1 
  
 
1 
  0.13 
A. aureolus     1  1 
A. felis 5 3 2 1 1 6 0.44 
A. frankstonensis 1      0.06 
A. pseudoviridinutans 2      0.06 
A. udagawae 3 1 1 1   0.19 
A. viridinutans  1     0.125 
A. wyomingensis      1 >16 
LUL* 
A. arcoverdensis 1   
1 
             0 
A. aureolus 0 
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 A. felis 7 15 1         
 
 
 
1 
     0 
A. frankstonensis  1  0 
A. pseudoviridinutans 1 1  0 
A. udagawae 3 3  0 
A. viridinutans  1  0 
A. wyomingensis   1 0 
Abbreviations: ITZ, itraconazole; VCZ, voriconazole; POS, posaconazole; ISA, isavuconazole; AMB, amphotericin B; MIF, micafungin; LUL, 
luliconazole. *minimum inhibitory concentration values calculated; † minimum effective concentration calculated. 
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Supplementary Table 3. All AVSC cyp51A mutations found in this study compared to A. fumigatus wild-type cyp51A. 
 
 
Mutation present Isolate ID/ Species 
 
P3S, V13G 
6 A. felis-clade isolates (DTO 341-E4, DTO 341-E5, DTO 341-E6, DTO 341-E8, DTO 341-E9, DTO 
341-F1) 
L5V 1 A. wyomingensis isolate (DTO 155-G2) 
M11L, S493T All 4 A. pseudoviridinutans and 32 A. felis-clade isolates 
A12V, L31H, T35A, Y137F, I151V, P376S, C409R, E488K, N512V All 1 A. siamensis isolates (DTO 278-B6) 
A18V 
All 1 A. viridinutans, 2 A. frankstonensis, 9 A. udagawae, 3 A. arcoverdensis, 2 A. aureolus, 1 A. 
siamensis and 2 A. wyomingensis isolates 
I19T, V44F, A177V All 2 A. frankstonensis isolates 
 
I19V, L316P 
6 A. felis-clade isolates (DTO 131-E3, DTO 327-G4, DTO 316-C8, DTO 159-C9, DTO 342-I6, DTO 
342-I7) 
F28L, D253G, M499V 1 A. pseudoviridinutans isolate (DTO 153-A1) 
F29Y, P109A, N512E All 3 A. arcoverdensis isolates 
T35I, S117T, A330T 1 A. udagawae isolate (DTO 283-D3) 
M39T, V480M 3 A. felis-clade isolates (DTO 131-E4, DTO 131-E5, DTO 131-G1) 
V44I, E317D, M383L, Q423H All 9 A.udagawae isolates 
T50A All 4 A. pseudoviridinutans isolates 
K59R All 1 A. viridinutans and 2 A. frankstonensis isolates 
A63S, L327P, V396A All 1 A. viridinutans isolates 
I71V 1 A. arcoverdensis isolate (DTO 019-F2) 
V101L, A103T, A234V, I360V, V428I, G505R, Q423D, F478V All 2 A. aureolus isolates 
T215S, G138C 2 A. felis-clade isolates (DTO 341-E4, DTO 341-E5) 
D161N All AVSC isolates (except 2 A. udagawae isolates [DTO 283-D3 and DTO 341-E3]) 
R171H All 2 A. frankstonensis and 3 A. arcoverdensis isolates 
 
R171K 
6 A. felis-clade isolates (CBS 143249, DTO 327-G4, DTO 316-C8, DTO 159-C9, DTO 342-I6, DTO 
342-I7) 
 
R171Q 
All 1 A. siamensis, 2 A. wyomingensis and 31A. felis-clade isolates (all A. felis-clade except CBS 
143249) 
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M172A 1 A. udagawae isolate (DTO 308-H6) 
A189V 1 A. pseudoviridinutans isolate (DTO 342-I3) 
S197C, Q340R 1 A. felis-clade isolate (DTO 131-E6) 
A234T, S241A 3 A. pseudoviridinutans isolates (DTO 303-A1, DTO 342-I3, DTO 304-I5) 
K256N All 2 A. aureolus and 1 A. arcoverdensis (DTO 019-F2) isolates 
K256R, L390P, H474Y 1 A. pseudoviridinutans isolate (DTO 304-I5) 
D257E, K346R All 1 A. viridinutans, 2 A. frankstonensis and 3 A. arcoverdensis isolates 
 
 
N274S 
19 A. felis-clade isolates (DTO 327-G4, DTO 316-C8, DTO 159-C9, DTO 342-I6, DTO 342-I7, CBS 
143249, DTO 131-E3, DTO 131-E9, DTO 131-G3, DTO 131-F4, DTO 131-F1, DTO 131-F2, DTO 
131-F3, DTO 131-G2, DTO 155-G3, DTO 131-F9, DTO 131-F6, DTO 131-E6, DTO 155-G2) 
K281H All 4 A. pseudoviridinutans isolates 
K281N, K314D All 32 A. felis-clade isolates 
 
S302G 
All 4 A. pseudoviridinutans, 9 A. udagawae, 1 A. siamensis, 2 A. wyomingensis, and 31 A. felis-clade 
isolates (all A. felis-clade isolates except CBS 143249) 
 
K314E 
All 1 A. viridinutans, 2 A. frankstonensis, 4 A. pseudoviridinutans, 9 A. udagawae, 3 A. arcoverdensis, 
2 A. aureolus, 1 A. siamensis and 2 A. wyomingensis isolates 
Q321R, L344I 1 A. felis-clade isolate (DTO 341-F2) 
 
N326S 
10 A. felis-clade isolates (DTO 131-E3, DTO 131-E9, DTO 131-G3, DTO 131-F4, CBS 143249, DTO 
327-G4, DTO 316-C8, DTO 159-C9, DTO 342-I6, DTO 342-I7) 
A330I All AVSC isolates (except 1 A. pseudoviridinutans [DTO 303-A1] and 1 A. udagawae [DTO 283-D3]) 
 
K342E 
8 A. udagawae isolates (DTO 006-A3, DTO 019-D7, DTO 019-D8, DTO 157-D8, DTO 166-D6, DTO 
283-D3, DTO 308-H6, DTO 341-E3) 
I354V, M383V All AVSC isolates (except all 9 A. udagawae isolates) 
I360L, V462L All AVSC isolates (except all 2 A. aureolus isolates) 
 
S373N 
All 4 A. pseudoviridinutans, 2 A. wyomingensis and 31 A. felis-clade isolates (all A. felis-clade isolates 
except DTO 131-F6) 
S373R 2 A. arcoverdensis isolates (DTO 316-F7 and DTO 316-F9) 
L375F, C409Y, A419D 1 A. udagawae isolate (DTO 166-D6) 
I384V 1 A. udagawae isolate DTO 341-E3, all 3 A. arcoverdensis isolates 
P386S, M499K 1 A. pseudoviridinutans isolate (DTO 303-A1) 
N406S All 4 A. pseudoviridinutans, 2 A. wyomingensis and 32 A. felis-clade isolates 
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T420A 
All 1 A. viridinutans, 4 A. pseudoviridinutans, 2 A. aureolus, 1 A. siamensis, 2 A. wyomingensis, and 
32 A. felis-clade isolates, and 3 A. udagawae isolates (DTO 166-D6, DTO 308-H6, DTO 341-E3) 
T420S 5 A. udagawae isolates (DTO 157-D7, DTO 157-D8, DTO 019-D7, DTO 019-D8, DTO 283-D3) 
T420V All 2 A. frankstonensis and 3 A. arcoverdensis isolates 
N425S 31 A. felis-clade isolates (all A. felis-clade isolates except DTO 341-E5) 
 
 
V428F 
17 A. felis-clade isolates (DTO 131-E3, DTO 131-E6, DTO 131-E9, DTO 131-F1, DTO 131-F2, DTO 
131-F4, DTO 131-F6, DTO 131-F9, DTO 131-G2 DTO 131-G3, DTO 155-G3, DTO 159-C9, DTO 
316-C9, DTO 327-G4, DTO 342-I6, DTO 342-I7, CBS 143249) 
 
V428L 
1 A. pseudoviridinutans isolate (DTO 153-A1), 3 A. udagawae isolates (DTO 157-D7, DTO 019-D7, 
DTO 019-D8) 
I471F 1 A. aureolus isolate (DTO 331-G6 ) 
 
I471V 
All AVC isolates (except 2 A. arcoverdensis [DTO 316-F7 and DTO 316-F9] and one A. aureolus 
[DTO 331-G6] isolates) 
V480A All 2 A. wyomingensis isolates 
G482E All 9 A. udagawae and 2 A. wyomingensis isolates 
M499I 5 A. felis-clade isolates (DTO 327-G4, DTO 316-C8, DTO 159-C9, DTO 342-I6, DTO 342-I7) 
N512D All AVSC isolates (except all 3 A. arcoverdensis and 1 A. siamensis isolates) 
T513V All 9 A. udagawae, 2 A. aureolus and 2 A. wyomingensis isolates 
W6L, V15M, K80R, M172V¥, D255G, C270S, I367L, H403Y, L464I 
All 56 AVSC isolates 
¥55/56 AVSC isolates tested had this mutation, and the remaining isolate (DTO 308-H6 [A. udagawae]) had a mutation at this position of M172A. 
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Supplementary Table 4. Verify3D results of the five A. fumigatus homology models (Model A-E) and three AVSC homology models (Model F-H). 
 
 
Model Species (isolate number) % of residues that have scored a 3D-1D score >=0.2 
A A. fumigatus (AF338659) 83.11 
B A. fumigatus (AF338659) 84.66 
C A. fumigatus (AF338659) 84.47 
D A. fumigatus (AF338659) 84.08 
E A. fumigatus (AF338659) 84.65 
F A. felis (DTO 131-F6) 85.41 
G A. viridinutans (DTO 050-F1) 83.50 
H A. aureolus (DTO 278-B7) 82.91 
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7.4 Conclusions 
 
This investigation showed that while most AVSC members have high MICs of one or more 
triazole antifungal drugs and contain many single point mutations in the cyp51A gene compared 
to the A. fumigatus wild genotype, these mutations are unlikely to confer the observed azole 
resistance. Very few known azole resistance mechanisms were identified, and comparison of 
azole susceptible and resistant isolates showed few mutations were only associated with 
isolates considered resistant and these could not be confirmed to confer azole resistance on 
cyp51A homology modelling. On CLSI testing, 84% of isolates demonstrated high MIC values 
against azole drugs that are considered resistant phenotype in A. fumigatus species, and 
resistance was observed in clinical and environmental isolates, with no statistically significant 
differences between these groups. Thus, this research highlights the need to further investigate 
inherent defence mechanisms in this species complex and novel antifungal drug alternatives to 
available therapies. 
 
During my PhD I also performed secondary metabolite extraction and HPLC analysis on these 
AVSC isolates under the supervision and expertise of Prof Jens Frisvad at the Technical 
University of Denmark. We are still investigating the information collected and will continue 
to examine post this thesis. 
 
This research also highlighted differences in the susceptibility testing results between CLSI 
and Sensititre™ antifungal susceptibility testing methods, like the findings of Lyskova et al. 
(2018) who compared EUCAST and Sensititre™ testing methods. In their study Sensititre™ 
could not detect elevated itraconazole MICs (Lyskova et al., 2018), and this was also true for 
most isolates in our study. In Australia Sensititre™ commercial testing is used by the Australian 
National Reference Laboratory in Medical Mycology following the preparation standards set 
for moulds in the CLSI M38 method, as EUCAST and CLSI methods are not routinely 
available in the region (Ellis, 2017, Kidd et al., 2017, Clinical Laboartory Standards Institute 
(CLSI), 2017). While Sensititre™ has been demonstrated to provide comparable results with 
the CLSI method for A. fumigatus, the results of this research show they are not comparable 
for AVSC species, and it is recommended Sensititre™ is not used for antifungal susceptibility 
testing for these species where CLSI or EUCAST testing can be performed. 
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Chapter 8. General Discussion 
 
8.1 Introduction 
 
The research in this thesis examined two threats to successful treatment of aspergillosis – 
infections with cryptic Aspergillus species and azole-resistant Aspergillus fumigatus (ARAf) 
isolates. It has investigated the prevalence of and certain virulence factors of pathogenic 
Aspergillus species causing disease in animals, including humans, examining both 
environmental and clinical isolates from Australia. This body of research further investigated 
the virulence factors of important one-health cryptic Aspergillus species in the Aspergillus 
viridinutans species complex (AVSC), and also investigated the prevalence of azole resistant 
A. fumigatus isolates in Australia. 
 
8.2 Summary of Results 
 
The work in this thesis produced the following novel findings: 
 
1. Pathogenic, cryptic Aspergillus sect. Fumigati species are commonly isolated from 
residential environments in Australia. 
2. There is an environmental niche for AVSC members, including pathogenic species (A. 
felis-clade), in natural habitats (soil) in Frankston, Victoria, Australia. 
3. A novel species in section Fumigati, A. frankstonensis, belonging to the AVSC isolated 
from Frankston, Victoria. 
4. Unique secondary metabolite profiles for A. frankstonensis environmental isolates 
including novel secondary metabolites, temporarily named DOLD, RAIMO and CALBO. 
5. A. fumigatus is the most common cause of aspergillosis in captive birds in Australia. 
6. A. restrictus is an aetiological agent of avian aspergillosis. 
7. There is a low prevalence of azole resistance amongst environmental, veterinary and 
human isolates of A. fumigatus in Australia. 
8. The cyp51A mutation F46Y in an azole resistant canine clinical A. fumigatus isolate 
from Australia from 1992. 
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9. The cyp51A mutations TR34/L98H and G54R in azole resistant human clinical A. 
fumigatus isolates from Australia from 2015-2017. 
10. Unique cyp51A gene DNA sequences of AVSC member species and that cyp51A is a 
useful gene for species’ delimitation 
11. Cyp51A gene mutations are not an important mechanism of azole resistance amongst 
AVSC member species. 
12. In vitro antifungal susceptibility profiles of AVSC member species using CLSI and 
Sensititre™ YeastOne microbroth dilution testing. 
13. Luliconazole (imidazole antifungal agent) returned low MIC values on CLSI antifungal 
susceptibility testing for AVSC isolates and is promising for treatment of triazole-resistant 
AVSC species infections. 
14. Protein models for cyp51A single point mutations in Aspergillus species. 
 
8.3 Further discussion 
 
This thesis examined the prevalence of clinically relevant Aspergillus species in clinical (human 
and veterinary) and environmental (soil and air) samples from Australia. Notably, it further 
examined members of A. section Fumigati, and within this section, the AVSC and A. fumigatus 
sensu stricto. This led to the discovery of a new fungal species within the AVSC, a further 
understanding of the prevalence of pathogenic A. sect. Fumigati species in Australian 
environments and genus Aspergillus species in captive birds in Australia, the prevalence of 
ARAf in Australian environmental and clinical samples (human and veterinary) and reporting 
of AVSC antifungal susceptibilities and cyp51A amplification. Most AVSC species are known 
pathogens of humans and other animals (Vinh et al., 2009, Posteraro et al., 2011, Coelho et al., 
2011, Gyotoku et al., 2012, Barrs et al., 2013, Peláez et al., 2013, Alvarez-Pérez et al., 2014, 
Sugui et al., 2014), so the discovery of another species is potentially clinically relevant. While 
the pathogenicity of this new species was not identified, its environmental discovery enhanced 
understanding of the niche of AVSC members. Additionally, CLSI in vitro antifungal 
susceptibility testing demonstrated high MICs to multiple azoles (itraconazole, voriconazole 
and isavuconazole) in A. frankstonensis, highlighting the potential for pathogenicity in this new 
species. Interestingly, A. frankstonensis was found with other known pathogenic AVSC 
members which also demonstrated high CLSI MICs of triazole therapeutics (Clinical and 
Laboratory Standards Institute (CLSI), 2018). The secondary metabolites of A. felis were also 
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examined, demonstrating potential pathogenicity in one isolate producing aszonapyrones, and 
both isolates producing chrysogine precursors (alkaloids). Several novel compounds also 
discovered will be examined in future work. 
 
This study describes the cyp51A gene of AVSC species. Previously, AVSC clinical isolates 
were recognised as having higher MIC values of triazole antifungals than wild-type A. 
fumigatus isolates (Vinh et al., 2009, Posteraro et al., 2011, Gyotoku et al., 2012, Barrs et al., 
2013, Peláez et al., 2013, Alvarez-Pérez et al., 2014, Sugui et al., 2014), and it was assumed 
this was an inherent mechanism of resistance rather than adaptive resistance due to cyp51A 
mutations as in ARAf, although no studies had investigated this. Additionally, previously the 
cyp51A gene had only been sequenced for two cryptic species in section Fumigati, A. lentulus 
and A. udagawae (Alcazar-Fuoli et al., 2011, Mellado et al., 2011, Kusuya et al., 2015). For A. 
lentulus, a similarity of 95% to wild-type A. fumigatus cyp51A was reported with 26 different 
amino acids observed between the two species, although no mutations were identified in the 
protein conserved regions (Alcazar-Fuoli et al., 2011, Mellado et al., 2011). For A. udagawae, 
the gene was sequenced as part of a draft genome project for this species and is not yet analysed 
(Kusuya et al., 2015). It was important to investigate this gene in other cryptic species. High 
MIC values of azole antifungals were found in most AVSC isolates tested, including 
environmental isolates. In comparison to the cyp51A gene of A. fumigatus species, many single 
point mutations were identified; however, the most common tandem repeat and polymorphisms 
associated with acquired ARAf were not identified. Difficulties in this process were 
deciphering between mutations that were non- functional that could be used as phylogenetic 
markers versus mutations conferring azole resistance. Very few mutations in the AVSC species 
were previously reported amongst ARAf isolates, with most being new mutations. This was 
overcome via an invaluable collaboration with pharmacists involving cyp51A protein modelling 
of the mutations unique to isolates with high MICs to azoles. This helped determine that these 
mutations were unlikely to confer azole resistance as they did not produce changes in the 
protein structure that would interfere with triazole drug binding to the haem. Thus, we 
identified that cyp51A mutations are not important in resistance in AVSC species. Instead, 
resistance may be innate in many AVSC isolates; or secondary, non-cyp51A mediated 
mechanisms, might confer resistance. 
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Although cyp51A mutations are most commonly reported in ARAf, they are not the only 
mechanism of azole resistance and it has been estimated that 10% of acquired azole resistance 
in A. fumigatus isolates is due to non-cyp51A mechanisms (Meis et al., 2016). Other 
mechanisms associated with resistance include the mutation P88L in the HapE gene, mutations 
and deletions in afyap1, aldA, alga and AfCox10 genes, biofilm development, overexpression 
of adenosine triphosphate-binding cassette transporter (which has been linked to the 
TR34/L98H mutation), cholesterol import mechanisms, overexpression of multidrug resistant 
efflux pump genes (AfuMDR3 and AfuMDR4) and the transcriptional regulator SrbA 
(Nascimento et al., 2003, Willger et al., 2008, Camps et al., 2012, Paul et al., 2017). Mutations 
in cyp51b of A. fumigatus have also been investigated in connection with azole resistance 
(Mellado et al., 2001, Diaz-Guerra et al., 2003, Mellado et al., 2007, Buied et al., 2013). The 
two cyp51A genes in Aspergillus fumigatus, cyp51A and cyp51B both function in the 
biosynthesis of ergosterol and can be inhibited by azoles (Mellado et al., 2001, Mellado et al., 
2007, Buied et al., 2013). An initial study looking at cyp51A and cyp51B sequence analysis in 
a few itraconazole resistant and susceptible isolates determined cyp51B mutations were less 
likely to play a role in azole resistance (Diaz-Guerra et al., 2003). The researchers discovered 
cyp51A and cyp51B single point mutations in three resistant isolates that led to amino acid 
changes, including G54E in cyp51A in all three isolates, Q42L and M236V in cyp51B in two 
of the isolates and D387E in cyp51B in one of the isolate. As the G54E mutation was common 
to all isolates and led to azole resistance when inserted into a wild-type isolate, it was concluded 
the cyp51A mutation was likely to be causing resistance in these isolates (Diaz-Guerra et al., 
2003). Both cyp51A and cyp51B genes were amplified in a study examining resistance 
mechanisms in 14 azole resistant clinical isolates of A. fumigatus from human patients (Mellado 
et al., 2007). The TR34/L98H mechanism was identified in all itraconazole resistant isolates. 
Additionally, two isolates also had cyp51A mutations S297T and F495I. No non-synonymous 
mutations were detected in the cyp51B gene in this study (Mellado et al., 2007). Another study 
examining 12 ARAf isolates with no cyp51A mutations found one isolate showed over 
induction of cyp51B following itraconazole exposure and another isolate had high cyp51B 
expression (Buied et al., 2013). No single point mutations were identified. The remaining 10 
isolates had a similar induction of cyp51B to control wild-type isolates. It was proposed that 
overexpression and induction of cyp51B in the two isolates could cause azole resistance (Buied 
et al., 2013). 
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The commercially available Sensititre™ method is a reliable antifungal susceptibility test for 
determining MIC values in A. fumigatus species; however this thesis showed this method was 
less reliable at detecting azole resistance in AVSC isolates compared to the CLSI reference 
method. This is consistent with another recent study that also investigated EUCAST and 
Sensititre™ antifungal susceptibility testing on A. hiratsukae, A. thermomutatus and the AVSC 
member, A. udagawae, observing a low essential agreement for posaconazole of 67%; however 
for voriconazole and itraconazole the essential agreement for these three species was 100 % 
(Mello et al., 2017). 
 
This thesis also examined AVSC susceptibility to the triazole drug isavuconazole. 
Isavuconazole is the most recently approved triazole drug for treatment of invasive 
aspergillosis. It has been recently tested for non-AVSC Aspergillus species isolates, with 
clinical breakpoints defined as 1 mg/L for A. fumigatus and A. terreus, and 0.25 mg/L for A. 
nidulans. The geometric mean MIC to isavuconazole for AVSC members tested in Chapter 7 
(n=37) was higher than both these breakpoints for Aspergillus species at 2.96 mg/L (range 0.5- 
8.0 mg/L) (Denis et al., 2018). One previous study reported lower MICs to isavuconazole in 
10 isolates of A. udagawae (geometric mean MIC 0.66 mg/L [range 0.25-1.0 mg/L] (Datta et 
al., 2013) compared to the seven A. udagawae isolates tested in this thesis (geometric mean 
MIC 2.21 mg/L [range 1.0-8.0 mg/L]); however the high MICs to isavuconazole amongst many 
AVSC isolates tested in this thesis suggests drugs with lower MIC values, such as luliconazole, 
should be further evaluated as better treatment options for AVSC member species. 
 
This thesis also demonstrated close phylogenetic relationships between three species within the 
AVSC – A. felis, A. pseudofelis and A. parafelis (Barrs et al., 2013, Sugui et al., 2014). The 
preliminary work using multi-locus DNA phylogenetic analysis indicated that these three 
species are conspecific and may all be more appropriately designated A. felis. We suggested 
the use of felis-clade as an umbrella for A. felis, A. parafelis and A. pseudofelis while this was 
being resolved. A subsequent analysis of the AVSC preliminary results in support of the 
findings of this thesis were discussed in a recent publication (Lyskova et al., 2018). The 
phylogenetic status of A. felis, A. parafelis and A. pseudofelis as conspecific was confirmed in 
a comprehensive taxonomic study by Dr Vit Hubka at Charles University, Prague, which 
resolved A. pseudofelis and A. parafelis to be designated as A. 
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felis. My AVSC environmental isolates contributed to this collaborative investigation (Hubka 
et al., 2018). 
 
While it was disappointing I did not find A. felis, the major pathogen of cats with sino-orbital 
aspergillosis, in the environment where infected cats resided, valuable information about the 
niche of these species in Australia was discovered, contributing to understanding the 
pathogenesis. It was shown that A. felis complex species could be isolated from surface soil in 
Frankston, Victoria, along with other closely related species, including the novel species 
discovered through my work, A. frankstonensis. This research and previous studies that isolated 
A. felis in the environment demonstrated these organisms are present in soil and dispersed 
through air (Barrs et al., 2013, Nováková et al., 2014). If samples were collected from domiciles 
with active infection a reservoir might have been located; however this could still be 
problematic as cats usually present with advanced chronic infection. Importantly, home 
environments were shown to be sources of other pathogenic Aspergillus species. 
 
A lack of an environmental reservoir for A. felis when sampling may have been due to the 
following: 
 
1. The soil reservoir that initiated infection was no longer present  
2. The fungus was carried in by a mechanical vector e.g. insect or other animal species 
3. The cats ( all except one roamed their neighbourhoods) were exposed to the pathogen 
when roaming nearby 
4. The cats were infected from an external source such as contaminated food or litter 
5. The cats were infected elsewhere such as a boarding facility, veterinary hospital, 
breeder or other residence. 
 
No common source of infection was identified when cat owners were surveyed regarding their 
cat’s habits and husbandry. Properties of affected cats varied from rural, to semi-rural to urban 
and the cats varied from free-roaming to supervised outdoor access. Various litter substrates 
and food products were used with none common amongst infected cats. My initial testing 
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of food and litter types demonstrated A. fumigatus can grow on recycled paper pellets, so this 
could be a source of infection although A. felis was not isolated directly from this substrate, 
and not all cats used this type of litter. This research highlighted soil as a source of these fungal 
pathogens. 
 
Previously, multi-locus molecular studies had not been undertaken on the cause of avian 
aspergillosis in Australia. Investigating this was interesting as captive birds are particularly 
susceptible to aspergillosis, usually due to high environmental burdens. It was important to 
investigate the aetiological agent given the high prevalence of cryptic Aspergillus species 
infecting other animals in Australia (Barrs et al., 2012, Barrs et al., 2013). From the avian study 
in this thesis, my previous undergraduate honours research on canine aspergillosis, 
investigations on feline aspergillosis and the various human epidemiology studies investigating 
molecular identification of pathogenic Aspergillus samples, it appears that cryptic Aspergillus 
species from the AVSC are only a common cause of aspergillosis in felines, only occasionally 
causing disease in other species, including dogs and humans. Interestingly this raises the 
question why are AVSC species infections so prevalent in felines compared to other species; 
is this due to increased environmental interactions between cats and the fungus, or 
immunological disorders of fungal clearance being more prevalent in cats, or a combination of 
these? Do cats have closer contact with a vector for fungal spores e.g. predation of 
contaminated hosts? Continued investigation into these aspects of host-pathogen-environment 
interactions is required. Immunological responses are being studied by my fellow University 
of Sydney PhD candidate, Dr Joanna Whitney, with differences observed between white blood 
cell populations in the nasal mucosa of affected cats compared to healthy controls, and observed 
differences in the inflammatory cell profile of affected cats compared to those produced by 
dogs and murine infection models mounting a protective acquired immunological response to 
invasive aspergillosis (Whitney et al., 2016). 
 
This thesis demonstrates that in vitro testing of clotrimazole and enilconazole against A. 
fumigatus was effective at concentrations used for in vivo treatment of dogs with non-invasive 
SNA. As azole resistance was shown to be uncommon amongst canine isolates from Australia, 
Belgium and the USA from 1988 to 2014, topical and systemic therapies should be effective; 
however ongoing surveillance to detect ARAf is required. Treatment efficacy may be impacted 
by the technique used for application of topical treatment therapies, the number of treatments 
performed, and drug selection, dosage and length 
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of systemic treatments. While topical clotrimazole and enilconazole are the mainstays of 
therapy in dogs with SNA, with a higher success rate than systemic treatments (Sissener et al., 
2006), topical therapy is contraindicated in dogs with evidence of cribriform plate lysis on 
computed tomography. However, a recent study of a few dogs (n=5) with sino-nasal 
aspergillosis and cribriform plate lysis with no neurological abnormalities, reported no adverse 
effects when the dogs were treated with topical clotrimazole, so this may not exclude this cohort 
from topical treatment. Four of the five dogs were followed up 2 years after treatment and 
owners reported no clinical signs of either SNA (e.g. nasal discharge, epistaxis) or neurological 
signs, although follow-up consultation with a veterinarian and diagnostic testing such as 
imaging was not performed (Stanton et al., 2018). 
 
The investigation into azole resistance amongst canine isolates of A. fumigatus revealed a 
resistant phenotype in one Australian isolate which also harboured the cyp51A F46Y, G89E 
and E427K mutations. The F46Y and E427K have been reported in ARAf in humans and in 
susceptible A. fumigatus human derived isolates (Kidd et al., 2015). Investigating the F46Y 
mutation via cyp51A protein homology modelling in a model based on the A. fumigatus cyp51B 
crystal structure found this mutation was positioned at the substrate channel entrance 
concluding this could contribute to higher azole MIC values in isolates with these mutations, 
possibly by blocking the inhibitor entrance. The authors concluded this is likely a partial 
mechanism based on F46Y expression mutant modelling changes to azole susceptibility 
profiles (Garcia-Rubio et al., 2018). The same study found the E427K mutation resided in a 
non-conserved region at the protein surface, and thus had no interaction with azoles and no 
effect on the protein structure (Garcia- Rubio et al., 2018). 
 
This thesis further investigated the prevalence of ARAf in Australia looking at the largest 
number of clinical and environmental isolates for the country. Previously there was little 
information on the prevalence of cryptic and pathogenic Aspergillus species in Australian 
environments, and ARAf in Australia (Kidd et al., 2015), with no environmental or veterinary 
ARAf studies. This was important to assess as ARAf is a major threat to effective treatment of 
aspergillosis in many other regions of the world, and where it has high prevalence, changes to 
treatment protocols are recommended (Verweij et al., 2015). Thus, appropriate disease 
management in Australia required more information on prevalence. These investigations 
revealed a low prevalence of ARAf amongst human and veterinary clinical isolates, with no 
evidence of ARAf amongst environmental isolates. Known cyp51A mutations were found in 
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three human clinical isolates, leading to the observed resistant phenotype. The Australian 
prevalence of ARAf of 2% among human clinical isolates is much lower than ARAf prevalence 
reports from Western Europe of up to 26%, and those reported from other Asia-Pacific member 
countries, including China, Japan, Pakistan and Taiwan of between 4.5% to 7.8% (Lockhart et 
al., 2011, Tashiro et al., 2012, Toyotome et al., 2016, Wu et al., 2015, Perveen et al., 2016). 
Importantly, this research indicates current international recommendations regarding the use of 
medical azoles in Australia do not need to be modified; however continued surveillance is 
recommended. 
 
8.4 Future directions 
 
Aspergillosis is a global health concern for humans and other animals. The Global Action Fund 
for Fungal Infections (GAFFI) estimates the global impact of fungal disease on humans. Based 
on data from 2005 to 2007, GAFFI estimates 1.37 million people are affected by chronic 
pulmonary aspergillosis, and that each year over 30 million people on corticosteroid therapy 
are at risk of invasive aspergillosis. GAFFI also reported that invasive aspergillosis has an 
annual infection rate of 300,000 people, with almost half in patients with chronic obstructive 
pulmonary disease, and in 2016, 56,000 AIDs patients died from aspergillosis (Global Action 
Fund for Fungal Infections (GAFFI), 2018). Thus, medical mycology is an important 
expanding scientific field with many opportunities for further research and collaboration. Since 
mycology employed polyphasic taxonomy, new Aspergillus species are discovered regularly, 
including opportunistic pathogens and isolates only discovered in the environment. Future 
studies could investigate the following: 
 
1. Ongoing prospective multicentre surveillance of ARAf in clinical and environmental 
isolates in Australia. 
2. A. fumigatus cyp51A crystal structure development for modelling of cyp51A gene 
alterations. 
3. Sequencing of the cyp51B gene in AVSC member species to determine if mutations in 
this gene contribute to azole resistance in AVSC species. 
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4. Further analysis of secondary metabolites produced by AVSC species to further 
understand their potential pathogenicity. 
5. Antifungal susceptibility testing and cyp51 gene sequencing of a range of Genus 
Aspergillus species, including clinical and environmental isolates, to further understand the 
significance of mutations and the potential pathogenicity of newly discovered species 
6. Development of novel antifungal therapies to circumvent azole resistance in Aspergillus 
species. 
7. Further investigation of the potential for luliconazole treatment of AVSC infections. 
8. Review agricultural industry practices regarding the application of antifungal drugs of 
the same class as medical antifungal therapies i.e. azole class drugs. 
9. Regular screening for azole resistance amongst A. fumigatus environmental isolates 
where fungicidal azoles are used. 
10. Environmental surveillance for AVSC members in cases of active infection in cats with 
aspergillosis due to these species. 
 
8.5 Summary 
 
Aspergillosis is a one-health infectious disease requiring input from multiple disciplines and 
collaborative studies to achieve better outcomes for human and veterinary patients. Continued 
research in this field will further our knowledge on the adaptability, virulence and niche living 
requirements of fungi, to better understand why they are such successful opportunistic 
pathogens and to exploit these factors to improve therapeutics. Globally, fungal pathogens 
affect millions of people annually. Antifungal resistance can no longer be ignored as the poor 
cousin of antibacterial resistance. I hope this thesis has demonstrated why fungi should not be 
ignored as a major player in the antimicrobial resistance threat to one health and the importance 
of correct fungal identification, antifungal susceptibility testing and cyp51A analysis of clinical 
and environmental isolates. This work reflects the importance of screening for both cryptic and 
azole-resistant Aspergillus species; one-health surveillance for both should continue. 
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Chapter 9. Appendices 
Appendix 1: One-health pathogens in the Aspergillus viridinutans 
complex 
This is a pre-copy edited, author-produced version of an article accepted for publication in 
Medical Mycology following peer review. The version of record Talbot JJ, Barrs VR. One- 
health pathogens in the Aspergillus viridinutans complex, Medical Mycology, volume 56, issue 
1, 1 January 2018, Pages 1–12, is available online at https://doi.org/10.1093/mmy/myx016. 
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Appendix 2: Discovery of Aspergillus frankstonensis sp. nov. 
during environmental sampling for human and animal fungal 
pathogens 
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Appendix 3: Identification of pathogenic Aspergillus isolates from 
captive birds in Australia 
This is a pre-copy edited, author-produced version of an article accepted for publication in 
Medical Mycology following peer review. The version of record Talbot JJ, Thompson P, 
Vogelnest L, Barrs VR. Identification of pathogenic Aspergillus isolates from captive birds in 
Australia. Medical Mycology, 2017; myx137, is available online at 
https://doi.org/10.1093/mmy/myx137. 
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Appendix 4: Azole resistance in canine and feline isolates of 
Aspergillus fumigatus 
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https://doi.org/10.1093/jac/dky187. 
Appendix 5: Surveillance for azole resistance in clinical and 
environmental isolates of Aspergillus fumigatus in Australia and 
cyp51A homology modelling of azole-resistant isolates 
This is a pre-copy edited, author-produced version of an article accepted for publication in 
Medical Mycology following peer review. The version of record Talbot J.J., Subedi S., 
Halliday C., et al., Surveillance for azole resistance in clinical and environmental isolates of 
Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates, 
Journal of Antimicrobial Chemotherapy, 2018, dky187, is available online at 
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Appendix 6: Disseminated Scedosporium prolificans infection in a 
Labrador retriever with immune mediated haemolytic anaemia 
 
 
6.1 Introduction 
 
The following appendix contains a publication by Taylor et al., 2014 
(http://dx.doi.org/10.1016/j.mmcr.2014.10.001). This publication details a clinical case of 
disseminated scedosporiosis in a dog (Labrador retriever) that presented to the University 
Veterinary Teaching Hospital Sydney for diagnosis and treatment. The case was managed by 
Dr A. Taylor under the supervision of Prof. V.R. Barrs and Dr P. Bennett. 
 
I performed the molecular identification on the clinical samples, identifying the agent of disease 
as Scedosporium prolificans, and assisted in drafting and finalising the manuscript. 
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6.2 Main article 
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Appendix 7 Gastrointestinal granuloma due to Candida albicans 
in an immunocompetent cat 
 
7.1 Introduction 
 
The following appendix contains a publication by Duchaussoy et al., 2015 
(http://dx.doi.org/10.1016/j.mmcr.2015.12.002). This publication details a clinical case of 
focal intestinal candidiasis in a cat (domestic shorthair) that presented to the University of 
Melbourne Veterinary Teaching Hospital for diagnosis and treatment. 
 
I performed the molecular identification on the clinical samples, identifying the agent of disease 
as Candida albicans, and assisted in drafting and finalising the manuscript. 
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Appendix 8: Detection of Aspergillus-specific antibodies by agar 
gel immunodiffusion and IgG ELISA for diagnosis of feline upper 
respiratory tract aspergillosis 
 
 
8.1 Introduction 
 
The following appendix contains a publication by Barrs et al., 2015 
(http://dx.doi.org/10.1016/j.tvjl.2014.12.020). This publication investigates the use of 
Aspergillus specific antibodies as a diagnostic tool for feline upper respiratory tract 
aspergillosis. 
 
I performed molecular identification on fungal cultures grown from some of the new clinical 
samples included in this study, identifying the agent of disease as Aspergillus viridinutans 
species complex members, and assisted in drafting and finalising the manuscript. 
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Appendix 9: Sinonasal aspergillosis in a British shorthair cat in 
the United Kingdom 
 
 
9.1 Introduction 
 
The following appendix contains a publication by Tamborini et al., 2016 
(https://doi.org/10.1177/2055116916653775). This publication details a clinical case of sino- 
nasal aspergillosis in a cat (British shorthair) that presented to the VRCC, Laindon, UK for 
diagnosis and treatment. This is the first reported case of SNA in a cat in the United Kingdom. 
 
I performed the molecular identification on the clinical samples, identifying the agent of 
disease as Aspergillus fumigatus, and assisted in drafting and finalising the manuscript. 
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